



(22) Date de dépôt/Filing Date: 1994/04/26

(41) Mise à la disp. pub./Open to Public Insp.: 1994/10/29

(45) Date de délivrance/Issue Date: 2007/02/13


(30) Priorités/Priorities: 1993/04/28 (GB9308804.5);
1993/09/13 (GB9318929.8)

(51) Cl.Int./Int.Cl. *C07D 413/12* (2006.01),
A61K 31/47 (2006.01), *A61K 31/495* (2006.01),
A61K 31/535 (2006.01), *C07D 215/26* (2006.01),
C07D 237/28 (2006.01), *C07D 239/74* (2006.01),
C07D 241/42 (2006.01), *C07D 253/08* (2006.01),
C07D 253/10 (2006.01), *C07D 257/12* (2006.01),
C07D 401/12 (2006.01), ...

(72) Inventeurs/Inventors:
OKU, TERUO, JP;
KAYAKIRI, HIROSHI, JP;
SATO, SHIGEKI, JP;
ABE, YOSHITO, JP;
SAWADA, YUKI, JP;
...

(54) Titre : COMPOSES HETEROCYCLIQUES

(54) Title: QUINOLINES AND THEIR ANALOGS



(57) Abrégé/Abstract:

Compounds of the formula: (See above formula) wherein X^1 is N or C- R^6 , X^2 is N or C- R^7 , X^3 is N or C- R^8 , R^1 is hydrogen or halogen, R^2 is halogen, R^3 is hydrogen, nitro, amino optionally having suitable substituent(s) or a heterocyclic group optionally having suitable substituent(s), R^4 and R^5 are each hydrogen or halogen, R^6 and R^8 are each hydrogen, halogen, lower alkyl, hydroxy, lower alkylthio, amino optionally substituted with lower alkyl, or lower alkoxy optionally substituted with a substituent selected from the group consisting of hydroxy, lower alkoxy, amino, lower alkylamino and aryl optionally substituted with lower alkoxy, R^7 is hydrogen or lower alkyl, A is lower alkylene, and Q is O or N- R^9 , in which R^9 is hydrogen or acyl, provided that R^3 is not hydrogen when X^1 is C- R^6 , in which R^6 is hydrogen, and pharmaceutically acceptable salts thereof. These compounds are active as, bradykinin antagonists. Processes for preparation therein, pharmaceutical compositions containing same and methods of using them in the prevention and/or the treatment bradykinin and its analogs mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like in humans or animals are also disclosed.

(51) Cl.Int./Int.Cl. (suite/continued) *C07D 401/14* (2006.01), *C07D 403/12* (2006.01), *C07D 405/12* (2006.01),
C07D 409/12 (2006.01), *C07F 7/18* (2006.01), *C07K 5/062* (2006.01)


(72) Inventeurs(suite)/Inventors(continued): INOUE, TAKAYUKI, JP; TANAKA, HIROKAZU, JP

(73) Propriétaires(suite)/Owners(continued):ASTELLAS PHARMA INC., JP

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L.,S.R.L.

ABSTRACT OF THE DISCLOSURE

Compounds of the formula:



wherein X^1 is N or C- R^6 , X^2 is N or C- R^7 , X^3 is N or C- R^8 , R^1 is hydrogen or halogen, R^2 is halogen, R^3 is hydrogen, nitro, amino optionally having suitable substituent(s) or a heterocyclic group optionally having suitable substituent(s), R^4 and R^5 are each hydrogen or halogen, R^6 and R^8 are each hydrogen, halogen, lower alkyl, hydroxy, lower alkylthio, amino optionally substituted with lower alkyl, or lower alkoxy optionally substituted with a substituent selected from the group consisting of hydroxy, lower alkoxy, amino, lower alkylamino and aryl optionally substituted with lower alkoxy, R^7 is hydrogen or lower alkyl, A is lower alkylene, and Q is O or N- R^9 , in which R^9 is hydrogen or acyl, provided that R^3 is not hydrogen when X^1 is C- R^6 , in which R^6 is hydrogen, and pharmaceutically acceptable salts thereof. These compounds are active as bradykinin antagonists. Processes for preparation therein, pharmaceutical compositions containing same and methods of using them in the prevention and/or the treatment bradykinin and its analogs mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like in humans or animals are also disclosed.

- 1 -

QUINOLINES AND THEIR ANALOGS

This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof.

More particularly, it relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof which have activities as bradykinin antagonists, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human being or animals.

One object of this invention is to provide new and useful heterocyclic compounds and pharmaceutically acceptable salts thereof which possess activities as bradykinin antagonists.

Another object of this invention is to provide processes for the preparation of said compounds and salts thereof.


A further object of this invention is to provide a

pharmaceutical composition comprising, as an active ingredient, said heterocyclic compounds and pharmaceutically acceptable salts thereof.

Still further object of this invention is to provide a therapeutical method for the prevention and/or the treatment of bradykinin or its analogues mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, using said heterocyclic compounds and pharmaceutically acceptable salts thereof.

Some heterocyclic compounds have been known as described, for example, in EP-A-224,086, EP-A-261,539, Chemical Abstracts 90:34849g (1979), or Chemical Abstracts 97:18948c (1982). However, it is not known that said compounds have activities as bradykinin antagonists.

The object heterocyclic compounds of this invention are new and can be represented by the following general formula [I] :



[I]

wherein X¹ is N or C-R⁶,
X² is N or C-R⁷,
X³ is N or C-R⁸,
R¹ is hydrogen or halogen,
R² is halogen,
R³ is hydrogen, nitro, amino optionally having

2122236

suitable substituent(s) or a heterocyclic group optionally having suitable substituent(s),

R^4 and R^5 are each hydrogen or halogen,

R^6 and R^8 are each hydrogen, halogen, lower alkyl, hydroxy, lower alkylthio, amino optionally substituted with lower alkyl, or lower alkoxy optionally substituted with a substituent selected from the group consisting of hydroxy, lower alkoxy, amino, lower alkylamino and aryl optionally substituted with lower alkoxy,


R^7 is hydrogen or lower alkyl,

A is lower alkylene, and


Q is O or $N-R^9$, in which R^9 is hydrogen or acyl, provided that R^3 is not hydrogen when X^1 is $C-R^6$, in which R^6 is hydrogen.

The object compound [I] or its salt can be prepared by processes as illustrated in the following reaction schemes.

Process 1




2122236




[I]

or its salt

Process 2



Acylation



[Ia]


or its salt

[Ib]


or its salt

2122236


Process 3



Process 4



2122236



[If]

or its salt

wherein R^{10} is hydrogen or lower alkyl,

R^{11} is acyl,

R_a^{11} is acyl having amino,

R_b^{11} is acyl having acylamino,

R^{12} is hydrogen, lower alkyl, lower

alkoxy(lower)alkyl, lower

alkylamino(lower)alkyl,

heterocyclic(lower)alkyl, a heterocyclic

group, lower alkenyl, lower alkynyl, lower

alkylcarbamoyloxy(lower)alkyl, lower

alkoxycarbonyl(lower)alkyl,

carboxy(lower)alkyl, lower

alkylcarbamoyl(lower)alkyl, lower

alkoxycarbonyl-ar(lower)alkyl,

carboxy-ar(lower)alkyl, lower

alkylcarbamoyl-ar(lower)alkyl, protected or

unprotected hydroxy(lower)alkyl or aryl

optionally substituted with lower

alkylamino, and

2122236

R^{13} is hydrogen, lower alkyl, lower
alkoxy(lower)alkyl or protected or
unprotected hydroxy(lower)alkyl, or
 R^{12} and R^{13} are taken together with the attached
nitrogen atom to form a heterocyclic group
optionally having suitable substituent(s),
(AA) is amino acid residue,
X is a leaving group,
Y is NH or lower alkenylene,
Z is CH or N, and
 R^1 , R^2 , R^3 , R^4 , R^5 , X^1 , X^2 , X^3 , Q and A are each
as defined above.

In the above and subsequent description of the
present specification, suitable examples of the various
definitions to be included within the scope of the
invention are explained in detail in the following.

The term "lower" is intended to mean a group having 1
to 6 carbon atom(s), unless otherwise provided.

In this respect, the term "lower" in lower alkenyl
moiety, lower alkynyl moiety and ar(lower)alkenyl moiety
in the various definitions is intended to mean a group
having 2 to 6 carbon atoms.

Further, the term "lower" in lower alkenoyl moiety,
lower alkynoyl moiety, cyclo(lower)alkyl moiety,
cyclo(lower)alkenyl moiety, ar(lower)alkenoyl moiety,
ar(lower)alkynoyl moiety and heterocyclic(lower)alkenoyl
moiety in the various definitions is intended to mean a
group having 3 to 6 carbon atoms.

Suitable "halogen" may be fluorine, chlorine, bromine
and iodine.

Suitable "aryl" and aryl moiety in the term
"ar(lower)alkenoyl" may be phenyl, naphthyl, phenyl
substituted with lower alkyl [e.g. tolyl, xylyl, mesityl,
cumenyl, di(tert-butyl)phenyl, etc.] and the like, in

2122236

which preferable one is phenyl, naphthyl and tolyl.

Suitable "lower alkyl" and lower alkyl moiety in the terms "heterocyclic(lower)alkyl", "lower alkylthio" and "lower alkylamino" may be straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl or the like, in which preferable one is C_1-C_4 alkyl such as methyl, ethyl, propyl, isobutyl or tert-butyl.

Suitable "lower alkylene" may be a straight or branched one such as methylene, ethylene, trimethylene, methylenemethylene, tetramethylene, ethylethylene, propylene, pentamethylene, hexamethylene or the like, in which the most preferable one is methylene.

Suitable "lower alkoxy" may be straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy or the like, in which preferable one is C_1-C_4 alkoxy such as methoxy, ethoxy or isopropoxy.

Suitable "lower alkenylene" may be a straight or branched C_2-C_6 alkenylene such as vinylene, methylvinylene, propenylene, 1,3-butadienylene or the like, in which the most preferable one is vinylene.

Suitable "acyl" may be substituted or unsubstituted alkanoyl such as alkanoyl [e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, 3,3-dimethylbutyryl, etc.], halo(lower)alkanoyl [e.g. chloroacetyl, trifluoroacetyl, bromoacetyl, bromobutyryl, heptafluorobutyryl, etc.], hydroxy(lower)alkanoyl [e.g. glycoloyl, lactoyl, 3-hydroxypropionyl, glyceroyl, etc.], lower alkylsulfonyloxy(lower)alkanoyl [e.g. mesyloxyacetyl, ethylsulfonyloxyacetyl, mesyloxypropionyl, etc.], lower alkoxy(lower)alkanoyl [e.g. methoxyacetyl, ethoxyacetyl, methoxypropionyl, ethoxypropionyl, propoxypropionyl, methoxybutyryl, etc.], lower

2122236

alkylthio(lower)alkanoyl [e.g. methylthioacetyl,
ethylthioacetyl, methylthiopropionyl, ethylthiopropionyl,
propylthiopropionyl, methylthiobutyryl, etc.], lower
alkanoyloxy(lower)alkanoyl [e.g. acetyloxyacetyl,
5 acetyloxypropionyl, propionyloxyacetyl, etc.],
aryloxy(lower)alkanoyl [e.g. phenyloxyacetyl,
phenyloxypropionyl, tolyloxyacetyl, naphthyloxyacetyl,
etc.], aroyl(lower)alkanoyl [e.g. phenyloxalyl,
benzoylacetyl, benzoylpropionyl, etc.],
10 carboxy(lower)alkanoyl [e.g. oxalo, carboxyacetyl,
3-carboxypropionyl, 3-carboxybutyryl, 4-carboxybutyryl,
4-carboxyvaleryl, etc.], esterified
carboxy(lower)alkanoyl, for example, lower
alkoxycarbonyl(lower)alkanoyl [e.g. methoxycarbonylacetyl,
15 ethoxycarbonylacetyl, methoxycarbonylpropionyl,
ethoxycarbonylpropionyl, etc.], carbamoyl(lower)alkanoyl
[e.g. carbamoylacetyl, carbamoylpropionyl, etc.], lower
alkylcarbamoyl(lower)alkanoyl [e.g. methylcarbamoylacetyl,
methylcarbamoylpropionyl, ethylcarbamoylpropionyl,
20 dimethylcarbamoylpropionyl, (N-methyl-N-ethylcarbamoyl)-
propionyl, etc.], ar(lower)alkanoyl [e.g. phenylacetyl,
tolylacetyl, naphthylacetyl, 2-phenylpropionyl,
3-phenylpropionyl, 4-phenylbutyryl, tritylcarbonyl, etc.],
optionally substituted heterocyclic(lower)alkanoyl [e.g.
25 morpholinoacetyl, thiomorpholinoacetyl,
morpholinopropionyl, thiomorpholinopropionyl,
piperidinopropionyl, piperazinylpropionyl, pyridylacetyl,
pyrrolidinylpropionyl, imidazolidinylpropionyl,
piperidinoacetyl, pyrrolidinylacetyl,
30 hexamethyleneiminoacetyl, hexamethyleneiminopropionyl,
imidazolylacetyl, furylacetyl, thienylacetyl,
methylpiperazinylacetyl, pyridylpiperazinylacetyl, etc.],
heterocyclicthio(lower)alkanoyl [e.g. pyridylthioacetyl,
pyrimidinylthioacetyl, imidazolylthiopropionyl, etc.],
35 etc., lower alkenoyl [e.g. acryloyl, crotonoyl,

2122236

isocrotonoyl, 3-butenoyl, 3-pentenoyl, 4-pentenoyl,
methacryloyl, etc.], lower alkynoyl [e.g. propioloyl,
2-butyneoyl, 3-butyneoyl, etc.], cyclo(lower)alkylcarbonyl
[e.g. cyclopropylcarbonyl, cyclobutylcarbonyl,
5 cyclopentylcarbonyl, cyclohexylcarbonyl, etc.],
cyclo(lower)alkenylcarbonyl [e.g. cyclopentenylcarbonyl,
cyclohexenylcarbonyl, etc.], carboxy, esterified carboxy
such as lower alkoxycarbonyl [e.g. methoxycarbonyl,
ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl,
10 butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
pentyloxycarbonyl, hexyloxycarbonyl, etc.],
aryloxycarbonyl [e.g. phenoxycarbonyl, etc.], etc.,
substituted or unsubstituted aroyl such as aroyl [e.g.
benzoyl, toluoyl, xyloyl, naphthoyl, etc.], lower
15 alkoxylaroyl [e.g. methoxybenzoyl, etc.], haloaroyl [e.g.
chlorobenzoyl, fluorobenzoyl, etc.], acylaroyl, for
example, lower alkoxycarbonylaroyl [e.g.
methoxycarbonylbenzoyl, etc.], etc., substituted or
unsubstituted ar(lower)alkenoyl such as ar(lower)alkenoyl
20 [e.g. cinnamoyl, allocinnamoyl, α -methylcinnamoyl,
4-methylcinnamoyl, etc.], lower alkoxy-ar(lower)alkenoyl
[e.g. methoxycinnamoyl, ethoxycinnamoyl,
dimethoxycinnamoyl, etc.], lower
alkylenedioxy-ar(lower)alkenoyl [e.g.
25 methylenedioxcinnamoyl, ethylenedioxcinnamoyl, etc.],
nitro-ar(lower)alkenoyl [e.g. nitrocinnamoyl, etc.],
cyano-ar(lower)alkenoyl [e.g. cyanocinnamoyl, etc.],
halo-ar(lower)alkenoyl [e.g. chlorocinnamoyl,
fluorocinnamoyl, etc.], hydroxy-ar(lower)alkenoyl [e.g.
30 hydroxycinnamoyl, etc.],
hydroxy(lower)alkoxy-ar(lower)alkenoyl [e.g.
hydroxymethoxycinnamoyl, hydroxyethoxycinnamoyl, etc.],
amino(lower)alkoxy-ar(lower)alkenoyl [e.g.
aminoethoxycinnamoyl, etc.], lower alkylamino(lower)-
35 alkoxy-ar(lower)alkenoyl [e.g.

2122236

methyaminomethoxycinnamoyl, dimethylaminoethoxycinnamoyl,
etc.], heterocyclic(lower)alkoxy-ar(lower)alkenoyl [e.g.
pyridylmethoxycinnamoyl, etc.], optionally substituted
heterocyclic-ar(lower)alkenoyl [e.g. morpholinocinnamoyl,
5 methyloperazinylcinnamoyl, pyrrolidinylcinnamoyl,
oxopyrrolidinylcinnamoyl, oxopiperidinocinnamoyl,
dioxopyrrolidinylcinnamoyl, oxooxazolidinylcinnamoyl,
pyrrolylcinnamoyl, tetrazolylcinnamoyl, etc.],
amino-ar(lower)alkenoyl [e.g. aminocinnamoyl, etc.], lower
10 alkylamino-ar(lower)alkenoyl [e.g. methylaminocinnamoyl,
dimethylaminocinnamoyl, etc.],
acylamino-ar(lower)alkenoyl, for example, lower
alkanoylamino-ar(lower)alkenoyl [e.g.
acetylaminocinnamoyl, propionylaminocinnamoyl,
15 isobutyrylamino-cinnamoyl, etc.],
cycloalkyl(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
cyclopentylacetylaminocinnamoyl,
cyclohexylacetylaminocinnamoyl,
adamantylacetylaminocinnamoyl, etc.],
20 cycloalkylcarbonylamino-ar(lower)alkenoyl [e.g.
cyclopropylcarbonylamino-cinnamoyl,
cyclopentylcarbonylamino-cinnamoyl,
cyclohexylcarbonylamino-cinnamoyl,
adamantylcarbonylamino-cinnamoyl, etc.], lower
25 alkenoylamino-ar(lower)alkenoyl [e.g.
acryloylamino-cinnamoyl, crotonoylamino-cinnamoyl, etc.],
lower alkoxycarbonylamino-ar(lower)alkenoyl [e.g.
methoxycarbonylamino-cinnamoyl,
ethoxycarbonylamino-cinnamoyl, etc.],
30 hydroxy(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
hydroxyacetylaminocinnamoyl,
hydroxypropionylaminocinnamoyl, etc.], lower
alkoxy(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
methoxyacetylaminocinnamoyl,
35 methoxypropionylaminocinnamoyl, etc.],

2122236

halo(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
chloroacetylaminocinnamoyl, bromobutyrylamino-cinnamoyl,
trifluoroacetylaminocinnamoyl, etc.],
amino(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
5 aminoacetylaminocinnamoyl, aminopropionylaminocinnamoyl,
etc.], lower alkylamino(lower)alkanoylamino-ar(lower)-
alkenoyl [e.g. methylaminoacetylaminocinnamoyl,
dimethylaminoacetylaminocinnamoyl, etc.], lower
alkanoylamino(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
10 acetylaminocinnamoyl,
acetylaminopropionylaminocinnamoyl, etc.],
carboxy(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
carboxyacetylaminocinnamoyl,
carboxypropionylaminocinnamoyl, etc.], lower
15 alkoxycarbonyl(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
ethoxycarbonylacetylaminocinnamoyl,
ethoxycarbonylpropionylaminocinnamoyl, etc.], lower
alkoxycarbonyl(lower)alkenoylamino-ar(lower)alkenoyl [e.g.
ethoxycarbonylacryloylamino-cinnamoyl, etc.],
20 halo(lower)alkoxycarbonylamino-ar(lower)alkenoyl [e.g.
chloroethoxycarbonylamino-cinnamoyl, etc.], optionally
substituted heterocyclic(lower)alkanoylamino-ar(lower)-
alkenoyl [e.g. pyridylacetylaminocinnamoyl,
thienylacetylaminocinnamoyl,
25 methylpyrrolylacetylaminocinnamoyl, etc.],
aroylamino-ar(lower)alkenoyl [e.g. benzoylamino-cinnamoyl,
etc.], optionally substituted
heterocycliccarbonylamino-ar(lower)alkenoyl [e.g.
pyridylcarbonylamino-cinnamoyl,
30 morpholinocarbonylamino-cinnamoyl,
furylcarbonylamino-cinnamoyl,
thienylcarbonylamino-cinnamoyl,
oxazolylcarbonylamino-cinnamoyl,
methyloxazolylcarbonylamino-cinnamoyl,
35 dimethylisoxazolylcarbonylamino-cinnamoyl,

2122236

imidazolylcarbonylaminocinnamoyl,
methylimidazolylcarbonylaminocinnamoyl,
piperidylcarbonylaminocinnamoyl,
ethylpiperidylcarbonylaminocinnamoyl,
5 acetylpiperidylcarbonylaminocinnamoyl,
pyrrolidinylcarbonylaminocinnamoyl,
acetylpyrrolidinylcarbonylaminocinnamoyl,
tert-butoxycarbonylpyrrolidinylcarbonylaminocinnamoyl,
etc.], lower alkylsulfonylamino-ar(lower)alkenoyl [e.g.
10 mesylaminocinnamoyl, ethylsulfonylamino-cinnamoyl, etc.],
etc., N-(lower alkanoyl)-N-(lower alkyl)amino-
ar(lower)alkenoyl [e.g. N-acetyl-N-methylaminocinnamoyl,
N-acetyl-N-ethylaminocinnamoyl, N-propionyl-N-
methylaminocinnamoyl, etc.], N-[lower alkoxy(lower)-
15 alkanoyl]-N-(lower alkyl)amino-ar(lower)alkenoyl [e.g.
N-methoxyacetyl-N-methylaminocinnamoyl,
N-methoxypropionyl-N-methylaminocinnamoyl, etc.],
N-(lower alkanoyl)-N-[heterocyclic(lower)alkyl]amino-
ar(lower)alkenoyl [e.g. N-acetyl-N-pyridylmethylamino-
20 cinnamoyl, etc.], N-(lower alkanoyl)-N-[lower
alkoxy(lower)alkyl]amino-ar(lower)alkenoyl [e.g.
N-acetyl-N-methoxyethylaminocinnamoyl,
N-acetyl-N-methoxymethylaminocinnamoyl,
N-propionyl-N-methoxyethylaminocinnamoyl, etc.],
25 N-(lower alkanoyl)-N-[lower alkoxycarbonyl(lower)alkyl]-
amino-ar(lower)alkenoyl [e.g.
N-acetyl-N-tert-butoxycarbonylmethylaminocinnamoyl,
N-acetyl—N-tert-butoxycarbonylethylaminocinnamoyl,
N-propionyl-N-tert-butoxycarbonylmethylaminocinnamoyl,
etc.], N-(lower alkanoyl)-N-[carboxy(lower)alkyl]amino-
30 ar(lower)alkenoyl [e.g.
N-acetyl-N-carboxymethylaminocinnamoyl,
N-acetyl-N-carboxyethylaminocinnamoyl,
N-propionyl-N-carboxymethylaminocinnamoyl, etc.], N-[lower
35 alkoxy(lower)alkanol]-N-[heterocyclic(lower)alkyl]amino-

2122236

- ar(lower)alkenoyl [e.g.
N-methoxyacetyl-N-pyridylmethylaminocinnamoyl,
N-methoxypropionyl-N-pyridylmethylaminocinnamoyl, etc.],
N-[heterocycliccarbonyl]-N-[lower
5 alkoxy(lower)alkyl]amino-ar(lower)alkenoyl [e.g.
N-pyridylcarbonyl-N-methoxymethylaminocinnamoyl,
N-pyridylcarbonyl-N-methoxyethylaminocinnamoyl,
N-thienylcarbonyl-N-methoxyethylaminocinnamoyl, etc.],
ureido-ar(lower)alkenoyl [e.g. ureidocinnamoyl, etc.],
10 lower alkylureido-ar(lower)alkenoyl [e.g.
methylureidocinnamoyl, ethylureidocinnamoyl,
dimethylureidocinnamoyl, etc.],
heterocyclicureido-ar(lower)alkenoyl [e.g.
pyridylureidocinnamoyl, pyrimidinylureidocinnamoyl,
15 thienylureidocinnamoyl, etc.],
acyl-ar(lower)alkenoyl, for example, lower
alkanoyl-ar(lower)alkenoyl [e.g. formylcinnamoyl,
acetylcinnamoyl, propionylcinnamoyl, etc.],
carboxy-ar(lower)alkenoyl [e.g. carboxycinnamoyl, etc.],
20 lower alkoxycarbonyl-ar(lower)alkenoyl [e.g.
methoxycarbonylcinnamoyl, ethoxycarbonylcinnamoyl, etc.],
carbamoyl-ar(lower)alkenoyl [e.g. carbamoylcinnamoyl,
etc.], lower alkylcarbamoyl-ar(lower)alkenoyl [e.g.
methylcarbamoylcinnamoyl, ethylcarbamoylcinnamoyl,
25 dimethylcarbamoylcinnamoyl, propylcarbamoylcinnamoyl,
isopropylcarbamoylcinnamoyl, diethylcarbamoylcinnamoyl,
N-methyl-N-ethylcarbamoylcinnamoyl, etc.],
hydroxy(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
hydroxyethylcarbamoylcinnamoyl,
30 bis(hydroxyethyl)carbamoylcinnamoyl, etc.],
N-[hydroxy(lower)alkyl]-N-(lower alkyl)carbamoyl-
ar(lower)alkenoyl [e.g. N-hydroxyethyl-N-
methylcarbamoylcinnamoyl, etc.],
lower alkoxy(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
35 methoxymethylcarbamoylcinnamoyl,

2122236

methoxyethylcarbamoylcinnamoyl,
bis(methoxyethyl)carbamoylcinnamoyl,
ethoxyethylcarbamoylcinnamoyl,
methoxypropylcarbamoylcinnamoyl,
5 bis(ethoxyethyl)carbamoylcinnamoyl, etc.], N-[lower
alkoxy(lower)alkyl]-N-(lower
alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
N-methoxyethyl-N-methylcarbamoylcinnamoyl,
N-ethoxyethyl-N-methylcarbamoylcinnamoyl, etc.],
10 heterocyclic(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
pyridylmethylcarbamoylcinnamoyl,
furylmethylcarbamoylcinnamoyl,
thienylmethylcarbamoylcinnamoyl, etc.],
N-[heterocyclic(lower)alkyl]-N-(lower
15 alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
N-pyridylmethyl-N-methylcarbamoylcinnamoyl, etc.],
heterocycliccarbamoyl-ar(lower)alkenoyl [e.g.
morpholinylcarbamoylcinnamoyl, thienylcarbamoylcinnamoyl,
pyridylcarbamoylcinnamoyl, pyrimidinylcarbamoylcinnamoyl,
20 tetrazolylcarbamoylcinnamoyl, etc.], optionally
substituted heterocycliccarbonyl-ar(lower)alkenoyl [e.g.
morpholinocarbonylcinnamoyl,
pyrrolidinylcarbonylcinnamoyl,
piperidinocarbonylcinnamoyl,
25 tetrahydropyridylcarbonylcinnamoyl,
methylpiperazinylcarbonylcinnamoyl, etc.],
lower alkenylcarbamoyl-ar(lower)alkenoyl [e.g.
vinylcarbamoylcinnamoyl, allylcarbamoylcinnamoyl,
methylpropenylcarbamoylcinnamoyl, etc.], lower
30 alkynylcarbamoyl-ar(lower)alkenoyl [e.g.
ethynylcarbamoylcinnamoyl, propynylcarbamoylcinnamoyl,
etc.], amino(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
aminomethylcarbamoylcinnamoyl,
aminoethylcarbamoylcinnamoyl, etc.], lower
35 alkylamino(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.

2122236

methyaminomethylcarbamoylecinnamoyl,
methyaminomethylcarbamoylecinnamoyl,
ethylaminomethylcarbamoylecinnamoyl,
dimethylaminomethylcarbamoylecinnamoyl, etc.], lower
5 alkylcarbamoyleoxy(lower)alkylcarbamoyle-ar(lower)alkenoyl
[e.g. methylcarbamoyleoxymethylcarbamoylecinnamoyl,
methylcarbamoyleoxyethylcarbamoylecinnamoyl,
ethylcarbamoyleoxyethylcarbamoylecinnamoyl,
dimethylcarbamoyleoxyethylcarbamoylecinnamoyl, etc.], lower
10 alkylcarbamoyle(lower)alkylcarbamoyle-ar(lower)alkenoyl
[e.g. methylcarbamoylemethylcarbamoylecinnamoyl,
methylcarbamoyleethylcarbamoylecinnamoyl,
ethylcarbamoyleethylcarbamoylecinnamoyl,
dimethylcarbamoyleethylcarbamoylecinnamoyl, etc.], lower
15 alkoxycarbonyl(lower)alkylcarbamoyle-ar(lower)alkenoyl
[e.g. methoxycarbonylmethylcarbamoylecinnamoyl,
methoxycarbonylethylcarbamoylecinnamoyl,
ethoxycarbonylmethylcarbamoylecinnamoyl,
ethoxycarbonylethylcarbamoylecinnamoyl, etc.],
20 carboxy(lower)alkylcarbamoyle-ar(lower)alkenoyl [e.g.
carboxymethylcarbamoylecinnamoyl,
carboxyethylcarbamoylecinnamoyl, etc.], [lower
alkylcarbamoyle-ar(lower)alkyl]carbamoyle-ar(lower)alkenoyl
[e.g. (methylcarbamoyle-phenethyl)carbamoylecinnamoyl,
25 (ethylcarbamoyle-phenethyl)carbamoylecinnamoyl, etc.],
[lower alkoxycarbonyl-ar(lower)alkyl]carbamoyle-
ar(lower)alkenoyl [e.g. (methoxycarbonyl-phenethyl)-
carbamoylecinnamoyl, (ethoxycarbonyl-phenethyl)-
carbamoylecinnamoyl, etc.],
30 [carboxy-ar(lower)alkyl]carbamoyle-ar(lower)alkenoyl [e.g.
carboxy-phenethyl)carbamoylecinnamoyl, etc.], N-[lower
alkylcarbamoyle(lower)alkyl]-N-(lower
alkyl)carbamoyle-ar(lower)alkenoyl [e.g.
N-(methylcarbamoylemethyl)-N-methylcarbamoylecinnamoyl,
35 N-(methylcarbamoyleethyl)-N-methylcarbamoylecinnamoyl,

2122236

N-(ethylcarbamoylethyl)-N-methylcarbamoylcinnamoyl,
N-(dimethylcarbamoylethyl)-N-methylcarbamoylcinnamoyl,
etc.], N-[lower alkoxy carbonyl(lower)alkyl]-N-(lower
alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
5 N-methoxycarbonylmethyl-N-methylcarbamoylcinnamoyl,
N-methoxycarbonylethyl-N-methylcarbamoylcinnamoyl,
N-ethoxycarbonylmethyl-N-methylcarbamoylcinnamoyl,
N-ethoxycarbonylethyl-N-methylcarbamoylcinnamoyl, etc.],
N-[carboxy(lower)alkyl]-N-(lower
10 alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
N-carboxymethyl-N-methylcarbamoylcinnamoyl,
N-carboxyethyl-N-methylcarbamoylcinnamoyl, etc.],
arylcarbamoyl-ar(lower)alkenoyl [e.g.
phenylcarbamoylcinnamoyl, naphthylcarbamoylcinnamoyl,
15 etc.], etc., etc., ar(lower)alkynoyl [e.g.
phenylpropioloyl, etc.], substituted or unsubstituted
heterocyclic(lower)alkenoyl such as
heterocyclic(lower)alkenoyl [e.g. morpholinylacryloyl,
pyridylacryloyl, thienylacryloyl, etc.],
20 amino-heterocyclic(lower)alkenoyl [e.g.
aminopyridylacryloyl, etc.], lower
alkylamino-heterocyclic(lower)alkenoyl [e.g.
methylaminopyridylacryloyl, dimethylaminopyridylacryloyl,
etc.], acylamino-heterocyclic(lower)alkenoyl, for example,
25 lower alkanoylamino-heterocyclic(lower)alkenoyl [e.g.
acetylaminopyridylacryloyl, propionylaminopyridylacryloyl,
etc.], lower alkenoylamino-heterocyclic(lower)alkenoyl
[e.g. acryloylamino-pyridylacryloyl,
crotonoylamino-pyridylacryloyl, etc.],
30 heterocyclic(lower)alkanoylamino-heterocyclic(lower)-
alkenoyl [e.g. pyridylacetylaminopyridylacryloyl,
thienylacetylaminopyridylacryloyl, etc.],
heterocyclic carbonylamino-heterocyclic(lower)alkenoyl
[e.g. pyridylcarbonylamino-pyridylacryloyl,
35 furylcarbonylamino-pyridylacryloyl, etc.], lower

2122236

alkanoylamino(lower)alkanoylamino-heterocyclic(lower)-
alkenoyl [e.g. acetylaminoacetylaminopyridylacryloyl,
acetylaminopropionylaminopyridylacryloyl, etc.], lower
alkoxycarbonyl(lower)alkanoylamino-heterocyclic(lower)-
5 alkenoyl [e.g. ethoxycarbonylacetylaminopyridylacryloyl,
ethoxycarbonylpropionylaminopyridylacryloyl, etc.], lower
alkoxy(lower)alkanoylamino-heterocyclic(lower)alkenoyl
[e.g. methoxyacetylaminopyridylacryloyl, methoxypropionyl-
aminopyridylacryloyl, ethoxypropionylaminopyridylacryloyl,
10 etc.], etc., lower alkylureido-heterocyclic(lower)alkenoyl
[e.g. methylureidopyridylacryloyl, etc.],
acyl-heterocyclic(lower)alkenoyl, for example, carboxy-
heterocyclic(lower)alkenoyl [e.g. carboxypyridylacryloyl,
etc.], lower alkoxycarbonyl-heterocyclic(lower)alkenoyl
15 [e.g. ethoxycarbonylpyridylacryloyl, etc.],
lower alkylcarbamoyl-heterocyclic(lower)alkenoyl [e.g.
methylcarbamoylpyridylacryloyl,
ethylcarbamoylpyridylacryloyl,
dimethylcarbamoylpyridylacryloyl,
20 diethylcarbamoylpyridylacryloyl,
isopropylcarbamoylpyridylacryloyl,
N-ethyl-N-methylcarbamoylpyridylacryloyl, etc.], lower
alkoxy(lower)alkylcarbamoyl-heterocyclic(lower)alkenoyl
[e.g. methoxymethylcarbamoylpyridylacryloyl,
25 methoxyethylcarbamoylpyridylacryloyl,
methoxypropylcarbamoylpyridylacryloyl,
ethoxyethylcarbamoylpyridylacryloyl,
bis(methoxyethyl)carbamoylpyridylacryloyl, etc.],
hydroxy(lower)alkylcarbamoyl-heterocyclic(lower)alkenoyl
30 [e.g. hydroxymethylcarbamoylpyridylacryloyl,
hydroxyethylcarbamoylpyridylacryloyl,
bis(hydroxyethyl)carbamoylpyridylacryloyl, etc.],
heterocycliccarbamoyl-heterocyclic(lower)alkenoyl [e.g.
pyridylcarbamoylpyridylacryloyl,
35 morpholinylcarbamoylpyridylacryloyl,

2122236

thienylcarbamoylepyridylacryloyl,
pyrimidinylcarbamoylepyridylacryloyl, etc.],
heterocyclic(lower)alkylcarbamoyleheterocyclic(lower)-
alkenoyl [e.g. pyridylmethylcarbamoylepyridylacryloyl,
5 furylmethylcarbamoylepyridylacryloyl,
thienylmethylcarbamoylepyridylacryloyl, etc.],
heterocycliccarbonyl-heterocyclic(lower)alkenoyl [e.g.
morpholinocarbonylpyridylacryloyl,
pyrrolidinylcarbonylpyridylacryloyl,
10 piperidinocarbonylpyridylacryloyl, etc.], lower
alkenylcarbamoyleheterocyclic(lower)alkenoyl [e.g.
vinylcarbamoylepyridylacryloyl,
allylcarbamoylepyridylacryloyl, etc.], lower
alkynylcarbamoyleheterocyclic(lower)alkenoyl [e.g.
15 ethynylcarbamoylepyridylacryloyl,
propynylcarbamoylepyridylacryloyl, etc.], etc., etc.,
heterocycliccarbonyl which may be substituted with
substituent [e.g. furoyl, thenoyl, nicotinoyl,
isonicotinoyl, morpholinocarbonyl, piperidinocarbonyl,
20 4-methyl-1-piperazinylcarbonyl,
4-ethyl-1-piperazinylcarbonyl,
dimethylaminopiperidinocarbonyl,
4-methylcarbamoyle-1-piperazinylcarbonyl,
1,2,3,6-tetrahydropyridylcarbonyl, pyrrolidinylcarbonyl,
25 indolylcarbonyl, etc.], aryloxy carbonyl which may be
substituted with nitro [e.g. phenyloxy carbonyl,
nitrophenyloxy carbonyl, etc.], ar(lower)alkoxy carbonyl
which may be substituted with nitro [e.g.
benzyloxy carbonyl, nitrobenzyloxy carbonyl, etc.],
30 substituted or unsubstituted carbamoyle or thiocarbamoyle
such as carbamoyle, lower alkylcarbamoyle [e.g.
methylcarbamoyle, ethylcarbamoyle, propylcarbamoyle,
isopropylcarbamoyle, butylcarbamoyle, isobutylcarbamoyle,
tert-butylcarbamoyle, pentylcarbamoyle, dimethylcarbamoyle,
35 diethylcarbamoyle, N-ethyl-N-methylcarbamoyle, etc.],

2122236

carboxy(lower)alkylcarbamoyl [e.g. carboxymethylcarbamoyl,
carboxyethylcarbamoyl, etc.], esterified
carboxy(lower)alkylcarbamoyl, for example, lower
alkoxycarbonyl(lower)alkylcarbamoyl [e.g.
5 methoxycarbonylmethylcarbamoyl,
ethoxycarbonylmethylcarbamoyl,
ethoxycarbonylethylcarbamoyl, etc.], lower
alkenylcarbamoyl [e.g. vinylcarbamoyl, allylcarbamoyl,
etc.], cyclo(lower)alkylcarbamoyl [e.g.
10 cyclopropylcarbamoyl, cyclobutylcarbamoyl,
cyclopentylcarbamoyl, cyclohexylcarbamoyl, etc.],
halo(lower)alkanoylcarbamoyl [e.g.
trichloroacetylcarbamoyl, etc.],
substituted or unsubstituted arylcarbamoyl, for example,
15 arylcarbamoyl [e.g. phenylcarbamoyl, tolylcarbamoyl,
xylylcarbamoyl, naphthylcarbamoyl, ethylphenylcarbamoyl,
etc.], arylthiocarbamoyl [e.g. phenylthiocarbamoyl, etc.],
lower alkoxy-arylcarbamoyl [e.g. methoxyphenylcarbamoyl,
etc.], halo-arylcarbamoyl [e.g. fluorophenylcarbamoyl,
20 chlorophenylcarbamoyl, etc.], halo(lower)alkyl-
arylcarbamoyl [e.g. trifluoromethylphenylcarbamoyl, etc.],
nitro-arylcarbamoyl [e.g. nitrophenylcarbamoyl, etc.],
cyano-arylcarbamoyl [e.g. cyanophenylcarbamoyl, etc.],
hydroxy(lower)alkyl-arylcarbamoyl [e.g. hydroxymethyl-
25 phenylcarbamoyl, hydroxyethylphenylcarbamoyl, etc.],
amino-arylcarbamoyl [e.g. aminophenylcarbamoyl, etc.],
lower alkylamino-arylcarbamoyl [e.g.
methylaminophenylcarbamoyl, ethylaminophenylcarbamoyl,
dimethylaminophenylcarbamoyl, etc.], lower alkanoylamino-
30 arylcarbamoyl [e.g. acetylamino-phenylcarbamoyl,
propionylaminophenylcarbamoyl, etc.], N-(lower
alkanoyl)-N-(lower alkyl)amino-arylcarbamoyl [e.g.
N-acetyl-N-methylaminophenylcarbamoyl,
N-propionyl-N-methylaminophenylcarbamoyl, etc.],
35 lower alkoxy(lower)alkanoylamino-arylcarbamoyl [e.g.

2122236

methoxyacetylaminophenylcarbamoyle,
methoxypropionylaminophenylcarbamoyle, etc.], lower
alkoxycarbonyl(lower)alkanoylamino-arylcarbamoyle [e.g.
ethoxycarbonylacetylaminophenylcarbamoyle,
5 methoxycarbonylpropionylaminophenylcarbamoyle, etc.],
carboxyamino-arylcarbamoyle [e.g.
carboxyamino-phenylcarbamoyle, etc.], lower
alkoxycarbonylamino-arylcarbamoyle [e.g.
ethoxycarbonylamino-phenylcarbamoyle, etc.],
10 aroylamino-arylcarbamoyle [e.g.
benzoylamino-phenylcarbamoyle, etc.],
heterocycliccarbonylamino-arylcarbamoyle [e.g.
pyridylcarbonylamino-phenylcarbamoyle,
furylcarbonylamino-phenylcarbamoyle,
15 morpholinocarbonylamino-phenylcarbamoyle, etc.],
heterocyclic(lower)alkanoylamino-arylcarbamoyle [e.g.
pyridylacetylaminophenylcarbamoyle,
thienylacetylaminophenylcarbamoyle, etc.],
ureido-arylcarbamoyle [e.g. ureidophenylcarbamoyle, etc.],
20 lower alkylureido-arylcarbamoyle [e.g.
methylureidophenylcarbamoyle, ethylureidophenylcarbamoyle,
etc.], hydroxyimino(lower)alkyl-arylcarbamoyle [e.g.
hydroxyiminoethylphenylcarbamoyle, etc.], lower
alkoxyimino(lower)alkyl-arylcarbamoyle [e.g.
25 methoxyiminoethylphenylcarbamoyle, etc.], lower
alkylhydrazono(lower)alkyl-arylcarbamoyle [e.g.
methylhydrazonoethylphenylcarbamoyle,
dimethylhydrazonoethylphenylcarbamoyle, etc.],
optionally substituted heterocyclic-arylcarbamoyle [e.g.
30 oxopyrrolidinylphenylcarbamoyle,
oxopiperidinophenylcarbamoyle,
dioxopyrrolidinylphenylcarbamoyle,
oxooxazolidinylphenylcarbamoyle, pyrrolylphenylcarbamoyle,
etc.], acyl-arylcarbamoyle, for example,
35 carboxy-arylcarbamoyle [e.g. carboxyphenylcarbamoyle, etc.],

2122236

- lower alkoxycarbonyl-arylcarbamoyl [e.g. ethoxycarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl [e.g. morpholinocarbonylphenylcarbamoyl, pyrrolidinylcarbonylphenylcarbamoyl, piperidinocarbonylphenylcarbamoyl, 1,2,3,6-tetrahydropyridylcarbonylphenylcarbamoyl, piperazinylcarbonylphenylcarbamoyl, thiomorpholinocarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl substituted with lower alkyl [e.g. methylpiperazinylcarbonylphenylcarbamoyl, ethylpiperazinylcarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl substituted with aryl [e.g. phenylpiperazinylcarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl substituted with a heterocyclic group [e.g. pyridylpiperazinylcarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl substituted with lower alkanoyl [e.g. acetyl piperazinylcarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl substituted with lower alkoxycarbonyl [e.g. ethoxycarbonylpiperazinylcarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl substituted with lower alkylamino [e.g. methylaminopiperazinylcarbonylphenylcarbamoyl, dimethylaminopiperidinocarbonylphenylcarbamoyl, etc.], heterocycliccarbonyl-arylcarbamoyl substituted with lower alkylcarbamoyl [e.g. methylcarbamoylpiperazinylcarbonylphenylcarbamoyl, etc.], carbamoyl-arylcarbamoyl [e.g. carbamoylphenylcarbamoyl, etc.], lower alkylcarbamoyl-arylcarbamoyl [e.g. methylcarbamoylphenylcarbamoyl, ethylcarbamoylphenylcarbamoyl, propylcarbamoylphenylcarbamoyl, dimethylcarbamoylphenylcarbamoyl, diethylcarbamoylphenylcarbamoyl, N-ethyl-N-methylcarbamoylphenylcarbamoyl, N-isopropyl-N-methylcarbamoylphenylcarbamoyl, etc.],

2122236

hydroxy(lower)alkylcarbamoyl-arylcarbamoyl [e.g.
hydroxymethylcarbamoylphenylcarbamoyl,
hydroxyethylcarbamoylphenylcarbamoyl,
bis(hydroxyethyl)carbamoylphenylcarbamoyl, etc.],
5 N-[hydroxy(lower)alkyl]-N-(lower
alkyl)carbamoyl-arylcarbamoyl [e.g. N-(hydroxyethyl)-N-
methylcarbamoylphenylcarbamoyl, etc.],
lower alkoxy(lower)alkylcarbamoyl-arylcarbamoyl [e.g.
methoxymethylcarbamoylphenylcarbamoyl,
10 methoxyethylcarbamoylphenylcarbamoyl,
ethoxyethylcarbamoylphenylcarbamoyl,
bis(methoxyethyl)carbamoylphenylcarbamoyl,
bis(ethoxyethyl)carbamoylphenylcarbamoyl, etc.],
N-[lower alkoxy(lower)alkyl]-N-(lower
15 alkyl)carbamoyl-arylcarbamoyl [e.g.
N-(methoxyethyl)-N-methylcarbamoylphenylcarbamoyl,
N-(methoxypropyl)-N-methylcarbamoylphenylcarbamoyl, etc.],
lower alkylamino(lower)alkylcarbamoyl-arylcarbamoyl [e.g.
methylaminoethylcarbamoylphenylcarbamoyl,
20 dimethylaminoethylcarbamoylphenylcarbamoyl, etc.],
N-[lower alkylamino(lower)alkyl]-N-(lower alkyl)carbamoyl-
arylcarbamoyl [e.g. N-(dimethylaminoethyl)-N-methyl-
carbamoylphenylcarbamoyl,
N-(dimethylaminopropyl)-N-methylcarbamoylphenylcarbamoyl,
25 etc.], heterocycliccarbamoyl-arylcarbamoyl [e.g.
morpholinylcarbamoylphenylcarbamoyl,
thienylcarbamoylphenylcarbamoyl,
pyridylcarbamoylphenylcarbamoyl,
pyrimidinylcarbamoylphenylcarbamoyl, etc.],
30 N-(heterocyclic)-N-(lower alkyl)carbamoyl-arylcarbamoyl
[e.g. N-pyridyl-N-methylcarbamoylphenylcarbamoyl, etc.],
heterocyclic(lower)alkylcarbamoyl-arylcarbamoyl [e.g.
pyridylmethylcarbamoylphenylcarbamoyl,
pyridylethylcarbamoylphenylcarbamoyl,
35 thienylmethylcarbamoylphenylcarbamoyl, etc.],

2122236

N-[heterocyclic(lower)alkyl]-N-(lower
alkyl)carbamoyl-arylcarbamoyl [e.g.
N-pyridylmethyl-N-methylcarbamoylphenylcarbamoyl, etc.],
N-[heterocyclic(lower)alkyl]-N-[lower alkoxy(lower)alkyl]-
5 carbamoyl-arylcarbamoyl [e.g.
N-pyridylmethyl-N-methoxyethylcarbamoylphenylcarbamoyl,
etc.] arylcarbamoyl-arylcarbamoyl [e.g.
phenylcarbamoylphenylcarbamoyl, etc.], lower
alkylamino-arylcarbamoyl-arylcarbamoyl [e.g.
10 dimethylaminophenylcarbamoylphenylcarbamoyl, etc.],
lower alkanoyl-arylcarbamoyl [e.g. acetylphenylcarbamoyl,
propionylphenylcarbamoyl, etc.], etc., etc.,
ar(lower)alkylcarbamoyl [e.g. benzylcarbamoyl,
phenethylcarbamoyl, etc.], heterocycliccarbamoyl [e.g.
15 furylcarbamoyl, thienylcarbamoyl, pyridylcarbamoyl,
quinolylcarbamoyl, isoquinolylcarbamoyl,
pyrimidinylcarbamoyl, pyrazolylcarbamoyl, etc.],
heterocyclic(lower)alkylcarbamoyl [e.g.
pyridylmethylcarbamoyl, pyridylethylcarbamoyl,
20 furylmethylcarbamoyl, thienylmethylcarbamoyl, etc.],
arylaminocarbamoyl [e.g. phenylaminocarbamoyl, etc.],
aroylcarbamoyl [e.g. benzoylcarbamoyl, etc.], etc., lower
alkylsulfonyl [e.g. mesyl, ethylsulfonyl, propylsulfonyl,
isopropylsulfonyl, tert-butylsulfonyl, pentylsulfonyl,
25 etc.], arylsulfonyl [e.g. tosyl, phenylsulfonyl, etc.],
ar(lower)alkylsulfonyl [e.g. benzylsulfonyl,
phenethylsulfonyl, etc.], ar(lower)alkenylsulfonyl [e.g.
styrylsulfonyl, cinnamoylsulfonyl, etc.], phthaloyl,
substituted or unsubstituted amino acid residue mentioned
30 below, or the like.

Suitable "amino acid residue" may include natural or
artificial ones, and such amino acid may be glycine,
sarcosine, alanine, β -alanine, valine, norvaline, leucine,
isoleucine, norleucine, serine, threonine, cysteine,
35 methionine, phenylalanine, phenylglycine, tryptophan,

2122236

tyrosine, proline, hydroxyproline, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, histidine, ornithine, or the like, in which more preferable one is glycine, sarcosine, alanine, β -alanine and proline, and the most preferable one is glycine. And said amino acid residue may be substituted with suitable substituent(s) such as the above-mentioned lower alkyl, the above-mentioned aryl, the above-mentioned acyl, ar(lower)alkyl [e.g. benzyl, phenethyl, trityl, etc.], cycloalkyl [e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, etc.], a heterocyclic group mentioned below, heterocyclic(lower)alkyl [e.g. pyridylmethyl, pyridylethyl, imidazolylmethyl, furylmethyl, thienylmethyl, morpholinomethyl, piperidinomethyl, etc.], substituted or unsubstituted amidino [e.g. amidino, methylamidino, N-ethyl-N'-cyanoamidino, etc.], or the like.

Preferred example of said amino acid residue substituted with suitable substituent(s) may be amino acid residue substituted with lower alkyl [e.g. ethylglycyl, isopropylglycyl, dimethylglycyl, diethylglycyl, ethylsarcosyl, isopropylsarcosyl, methylalanyl, methyl- β -alanyl, dimethyl- β -alanyl, etc.], amino acid residue substituted with aryl [e.g. N-phenylglycyl, N-tolylglycyl, N-phenylalanyl, N-phenylsarcosyl, etc.], amino acid residue substituted with ar(lower)alkyl [e.g. benzylglycyl, tritylglycyl, phenethylglycyl, benzylsarcosyl, benzylalanyl, etc.], amino acid residue substituted with a heterocyclic group [e.g. morpholinoglycyl, piperidinoglycyl, pyridylglycyl, etc.], amino acid residue substituted with heterocyclic(lower)alkyl [e.g. pyridylmethylglycyl, imidazolylmethylglycyl, furylmethylglycyl, thienylmethylglycyl, etc.], amino acid residue substituted

2122236

with cycloalkyl [e.g. cyclopropylglycyl, cyclobutylglycyl, cyclopentylglycyl, cyclohexylglycyl, cycloheptylglycyl, cyclooctylglycyl, adamantylglycyl, cyclohexylsarcosyl, cycloheptylsarcosyl, cyclohexylalanyl, etc.], amino acid
5 residue substituted with optionally substituted amidino [e.g. amidinoglycyl, methylamidinoglycyl, N-ethyl-N'-cyanoamidinoglycyl, etc.], amino acid residue substituted with acyl such as amino acid residue substituted with alkanoyl [e.g. formylglycyl,
10 acetylglycyl, acetylsarcosyl, acetylalanyl, acetyl- β -alanyl, propionylglycyl, butyrylglycyl, isobutyrylglycyl, valerylglycyl, isovalerylglycyl, pivaloylglycyl, hexanoylglycyl, heptanoylglycyl, etc.], amino acid residue substituted with halo(lower)alkanoyl
15 [e.g. trifluoroacetylglycyl, trifluoroacetylsarcosyl, trifluoroacetylalanyl, bromoacetylglycyl, heptafluorobutyrylglycyl, etc.], amino acid residue substituted with hydroxy(lower)alkanoyl [e.g. glycoloylglycyl, glycoloylsarcosyl, lactoylglycyl,
20 lactoylalanyl, etc.], amino acid residue substituted with lower alkylsulfonyloxy(lower)alkanoyl [e.g. mesyloxyacetylglycyl, ethylsulfonyloxyacetylglycyl, mesyloxyacetylsarcosyl, etc.], amino acid residue substituted with lower alkoxy(lower)alkanoyl [e.g.
25 methoxyacetylglycyl, ethoxyacetylglycyl, methoxyacetylsarcosyl, methoxypropionylalanyl, etc.], amino acid residue substituted with aryloxy(lower)alkanoyl [e.g. phenyloxyacetylglycyl, phenyloxypropionylglycyl, phenyloxyacetylsarcosyl, etc.], amino acid residue
30 substituted with lower alkylthio(lower)alkanoyl [e.g. methylthioacetylglycyl, methylthiopropionylglycyl, etc.], amino acid residue substituted with lower alkylcarbamoyl-(lower)alkanoyl [e.g. methylcarbamoylpropionylglycyl, methylcarbamoylpropionylalanyl, etc.], amino acid residue
35 substituted with lower alkanoyloxy(lower)alkanoyl [e.g.

2122236

acetyloxyacetylglucyl, acetyloxyacetylsarcosyl,
propionyloxyacetylglucyl, acetyloxypropionylalanyl, etc.],
amino acid residue substituted with carboxy(lower)alkanoyl
[e.g. carboxyacetylglucyl, carboxypropionylglucyl,
5 carboxypropionylsarcosyl, carboxyacetylalanyl, etc.],
amino acid residue substituted with lower
alkoxycarbonyl(lower)alkanoyl [e.g. methoxycarbonylacetyl-
glucyl, ethoxycarbonylpropionylglucyl,
methoxycarbonylacetylsarcosyl, etc.], amino acid residue
10 substituted with ar(lower)alkanoyl [e.g.
phenylacetylglucyl, phenylacetylsarcosyl,
phenylpropionylalanyl, phenylpropionylglucyl,
naphthylacetylglucyl, phenylbutyrylglucyl, etc.], amino
acid residue substituted with optionally substituted
15 heterocyclic(lower)alkanoyl [e.g. morpholinoacetylglucyl,
thiomorpholinoacetylglucyl, its oxide or dioxide,
pyridylacetylglucyl, morpholinopropionylalanyl,
imidazolylacetylglucyl, piperidinoacetylglucyl,
pyrrolidinylacetylglucyl, hexamethyleneiminoacetylglucyl,
20 methylpiperazinylacetylglucyl,
pyridylpiperazinylacetylglucyl, etc.], amino acid residue
substituted with lower alkenoyl [e.g. acryloylglucyl,
crotonoylglucyl, 3-pentenoylglucyl, 3-butenoylglucyl,
4-pentenoylglucyl, 3-butenoylsarcosyl, etc.], amino acid
25 residue substituted with ar(lower)alkenoyl [e.g.
cinnamoylglucyl, allocinnamoylglucyl,
 α -methylcinnamoylglucyl, 4-methylcinnamoylglucyl,
cinnamoylsarcosyl, etc.], amino acid residue substituted
with lower alkoxy-ar(lower)alkenoyl [e.g.
30 methoxycinnamoylglucyl, ethoxycinnamoylglucyl,
dimethoxycinnamoylglucyl, etc.], amino acid residue
substituted with lower alkylenedioxy-ar(lower)alkenoyl
[e.g. methylenedioxcinnamoylglucyl,
ethylenedioxcinnamoylglucyl, etc.],
35 amino acid residue substituted with

2122236

nitro-ar(lower)alkenoyl [e.g. nitrocinnamoylglycyl, etc.],
amino acid residue substituted with
cyano-ar(lower)alkenoyl [e.g. cyanocinnamoylglycyl, etc.],
amino acid residue substituted with halo-ar(lower)alkenoyl
5 [e.g. chlorocinnamoylglycyl, fluorocinnamoylglycyl, etc.],
amino acid residue substituted with hydroxy-
ar(lower)alkenoyl [e.g. hydroxycinnamoylglycyl, etc.],
amino acid residue substituted with hydroxy(lower)alkoxy-
ar(lower)alkenoyl [e.g. hydroxymethoxycinnamoylglycyl,
10 hydroxyethoxycinnamoylglycyl, etc.],
amino acid residue substituted with amino(lower)alkoxy-
ar(lower)alkenoyl [e.g. aminoethoxycinnamoylglycyl, etc.],
amino acid residue substituted with lower
alkylamino(lower)alkoxy-ar(lower)alkenoyl [e.g.
15 methylaminomethoxycinnamoylglycyl,
dimethylaminoethoxycinnamoylglycyl, etc.],
amino acid residue substituted with
heterocyclic(lower)alkoxy-ar(lower)alkenoyl [e.g.
pyridylmethoxycinnamoylglycyl, etc.],
20 amino acid residue substituted with optionally substituted
heterocyclic-ar(lower)alkenoyl [e.g. morpholinocinnamoyl-
glycyl, methylpiperazinylcinnamoylglycyl, pyrrolidinyl-
cinnamoylglycyl, oxopyrrolidinylcinnamoylglycyl,
oxopiperidinocinnamoylglycyl, dioxopyrrolidinyl-
25 cinnamoylglycyl, oxooxazolidinylcinnamoylglycyl,
pyrrolylcinnamoylglycyl, tetrazolylcinnamoylglycyl, etc.],
amino acid residue substituted with
amino-ar(lower)alkenoyl [e.g. aminocinnamoylglycyl, etc.],
amino acid residue substituted with lower
30 alkylamino-ar(lower)alkenoyl [e.g. methylaminocinnamoyl-
glycyl, dimethylaminocinnamoylglycyl, etc.],
amino acid residue substituted with
acylamino-ar(lower)alkenoyl, for example,
amino acid residue substituted with lower alkanoylamino-
35 ar(lower)alkenoyl [e.g. acetylaminocinnamoylglycyl,

2122236

propionylaminocinnamoylglycyl, isobutyrylamino-cinnamoyl-
glycyl, etc.], amino acid residue substituted with
cycloalkyl(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
cyclopentylacetylaminocinnamoylglycyl,
5 cyclohexylacetylaminocinnamoylglycyl,
adamantylacetylaminocinnamoylglycyl, etc.], amino acid
residue substituted with
cycloalkylcarbonylamino-ar(lower)alkenoyl [e.g.
cyclopropylcarbonylamino-cinnamoylglycyl,
10 cyclopentylcarbonylamino-cinnamoylglycyl,
cyclohexylcarbonylamino-cinnamoylglycyl,
adamantylcarbonylamino-cinnamoylglycyl, etc.], amino acid
residue substituted with lower
alkenoylamino-ar(lower)alkenoyl [e.g.
15 acryloylamino-cinnamoylglycyl,
crotonoylamino-cinnamoylglycyl, etc.], amino acid residue
substituted with lower alkoxycarbonylamino-ar(lower)-
alkenoyl [e.g. methoxycarbonylamino-cinnamoylglycyl,
ethoxycarbonylamino-cinnamoylglycyl, etc.],
20 amino acid residue substituted with
hydroxy(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
hydroxyacetylaminocinnamoylglycyl,
hydroxypropionylaminocinnamoylglycyl, etc.],
amino acid residue substituted with lower
25 alkoxy(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
methoxyacetylaminocinnamoylglycyl,
methoxypropionylaminocinnamoylglycyl, etc.],
amino acid residue substituted with
halo(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
30 chloroacetylaminocinnamoylglycyl,
trifluoroacetylaminocinnamoylglycyl,
bromobutyrylamino-cinnamoylglycyl, etc.],
amino acid residue substituted with
amino(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
35 aminoacetylaminocinnamoylglycyl,

2122236

aminopropionylaminocinnamoylglycyl, etc.],
amino acid residue substituted with lower
alkylamino(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
methylaminoacetylaminocinnamoylglycyl,
5 dimethylaminoacetylaminocinnamoylglycyl, etc.],
amino acid residue substituted with lower
alkanoylamino(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
acetylaminopropionylaminocinnamoylglycyl,
acetylaminopropionylaminocinnamoylglycyl, etc.],
10 amino acid residue substituted with
carboxy(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
carboxyacetylaminocinnamoylglycyl,
carboxypropionylaminocinnamoylglycyl, etc.],
amino acid residue substituted with lower
15 alkoxycarbonyl(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
ethoxycarbonylacetylaminocinnamoylglycyl,
ethoxycarbonylpropionylaminocinnamoylglycyl, etc.],
amino acid residue substituted with lower
alkoxycarbonyl(lower)alkenoylamino-ar(lower)alkenoyl [e.g.
20 ethoxycarbonylacryloylaminocinnamoylglycyl, etc.],
amino acid residue substituted with
halo(lower)alkoxycarbonylamino-ar(lower)alkenoyl [e.g.
chloroethoxycarbonylaminocinnamoylglycyl, etc.],
amino acid residue substituted with optionally substituted
25 heterocyclic(lower)alkanoylamino-ar(lower)alkenoyl [e.g.
pyridylacetylaminocinnamoylglycyl,
thienylacetylaminocinnamoylglycyl,
methylpyrrolylacetylaminocinnamoylglycyl, etc.],
amino acid residue substituted with
30 aroylamino-ar(lower)alkenoyl [e.g.
benzoylaminoacetylaminocinnamoylglycyl, etc.],
amino acid residue substituted with optionally substituted
heterocycliccarbonylamino-ar(lower)alkenoyl [e.g.
pyridylcarbonylaminocinnamoylglycyl,
35 morpholinocarbonylaminocinnamoylglycyl,

furylcarbonylaminocinnamoylglycyl,
thienylcarbonylaminocinnamoylglycyl,
oxazolylcarbonylaminocinnamoylglycyl,
methyloxazolylcarbonylaminocinnamoylglycyl,
5 dimethylisoxazolylcarbonylaminocinnamoylglycyl,
imidazolylcarbonylaminocinnamoylglycyl,
methylimidazolylcarbonylaminocinnamoylglycyl,
piperidylcarbonylaminocinnamoylglycyl,
ethylpiperidylcarbonylaminocinnamoylglycyl,
10 acetylpiperidylcarbonylaminocinnamoylglycyl,
pyrrolidinylcarbonylaminocinnamoylglycyl,
acetylpyrrolidinylcarbonylaminocinnamoylglycyl,
tert-butoxycarbonylpyrrolidinylcarbonylaminocinnamoyl-
glycyl, etc.], amino acid residue substituted with lower
15 alkylsulfonylamino-ar(lower)alkenoyl [e.g.
mesylaminocinnamoylglycyl,
ethylsulfonylamino-cinnamoylglycyl, etc.], etc.,
amino acid residue substituted with N-(lower
alkanoyl)-N-(lower alkyl)amino-ar(lower)alkenoyl [e.g.
20 N-acetyl-N-methylaminocinnamoylglycyl,
N-acetyl-N-ethylaminocinnamoylglycyl,
N-propionyl-N-methylaminocinnamoylglycyl, etc.],
amino acid residue substituted with N-[lower
alkoxy(lower)alkanoyl]-N-(lower alkyl)amino-
25 ar(lower)alkenoyl [e.g. N-methoxyacetyl-N-
methylaminocinnamoylglycyl, N-methoxypropionyl-N-
methylaminocinnamoylglycyl, etc.], amino acid residue
substituted with N-(lower alkanoyl)-N-
[heterocyclic(lower)alkyl]amino-ar(lower)alkenoyl [e.g.
30 N-acetyl-N-pyridylmethylaminocinnamoylglycyl, etc.],
amino acid residue substituted with N-(lower alkanoyl)-N-
[lower alkoxy(lower)alkyl]amino-ar(lower)alkenoyl [e.g.
N-acetyl-N-methoxyethylaminocinnamoylglycyl,
N-acetyl-N-methoxymethylaminocinnamoylglycyl, N-propionyl-
35 N-methoxyethylaminocinnamoylglycyl, etc.], amino acid

2122236

residue substituted with N-(lower alkanoyl)-N-[lower
alkoxycarbonyl(lower)alkyl]amino-ar(lower)alkenoyl [e.g.
N-acetyl-N-tert-butoxycarbonylmethylaminocinnamoylglycyl,
N-acetyl-N-tert-butoxycarbonylethylaminocinnamoylglycyl,
5 N-propionyl-N-tert-butoxycarbonylmethylaminocinnamoyl-
glycyl, etc.], amino acid residue substituted with
N-(lower alkanoyl)-N-[carboxy(lower)alkyl]amino-ar(lower)-
alkenoyl [e.g. N-acetyl-N-carboxymethylaminocinnamoyl-
glycyl, N-acetyl-N-carboxyethylaminocinnamoylglycyl,
10 N-propionyl-N-carboxymethylaminocinnamoylglycyl, etc.],
amino acid residue substituted with N-[lower
alkoxy(lower)alkanoyl]-N-[heterocyclic(lower)alkyl]amino-
ar(lower)alkenoyl [e.g.
N-methoxyacetyl-N-pyridylmethylaminocinnamoylglycyl,
15 N-methoxypropionyl-N-pyridylmethylaminocinnamoylglycyl,
etc.], amino acid residue substituted with
N-[heterocycliccarbonyl]-N-[lower
alkoxy(lower)alkyl]amino-ar(lower)alkenoyl [e.g.
N-pyridylcarbonyl-N-methoxymethylaminocinnamoylglycyl,
20 N-pyridylcarbonyl-N-methoxyethylaminocinnamoylglycyl,
N-thienylcarbonyl-N-methoxyethylaminocinnamoylglycyl,
etc.], amino acid residue substituted with ureido-
ar(lower)alkenoyl [e.g. ureidocinnamoylglycyl, etc.],
amino acid residue substituted with lower
25 alkylureido-ar(lower)alkenoyl [e.g.
methylureidocinnamoylglycyl, ethylureidocinnamoylglycyl,
dimethylureidocinnamoylglycyl, etc.],
amino acid residue substituted with
heterocyclicureido-ar(lower)alkenoyl [e.g.
30 pyridylureidocinnamoylglycyl,
pyrimidinylureidocinnamoylglycyl,
thienylureidocinnamoylglycyl, etc.],
amino acid residue substituted with acyl-ar(lower)-
alkenoyl, for example, amino acid residue substituted with
35 lower alkanoyl-ar(lower)alkenoyl [e.g.

2122236

- formylcinnamoylglycyl, acetylcinnamoylglycyl,
propionylcinnamoylglycyl, etc.],
amino acid residue substituted with carboxy-ar(lower)-
alkenoyl [e.g. carboxycinnamoylglycyl, etc.],
5 amino acid residue substituted with lower
alkoxycarbonyl-ar(lower)alkenoyl [e.g.
methoxycarbonylcinnamoylglycyl,
ethoxycarbonylcinnamoylglycyl, etc.],
amino acid residue substituted with carbamoyl-ar(lower)-
10 alkenoyl [e.g. carbamoylcinnamoylglycyl, etc.],
amino acid residue substituted with lower
alkylcarbamoyl-ar(lower)alkenoyl [e.g.
methylcarbamoylcinnamoylglycyl,
ethylcarbamoylcinnamoylglycyl,
15 dimethylcarbamoylcinnamoylglycyl,
propylcarbamoylcinnamoylglycyl,
isopropylcarbamoylcinnamoylglycyl,
diethylcarbamoylcinnamoylglycyl,
N-methyl-N-ethylcarbamoylcinnamoylglycyl, etc.],
20 amino acid residue substituted with
hydroxy(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
hydroxyethylcarbamoylcinnamoylglycyl,
bis(hydroxyethyl)carbamoylcinnamoylglycyl, etc.],
amino acid residue substituted with
25 N-[hydroxy(lower)alkyl]-N-(lower
alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
N-hydroxyethyl-N-methylcarbamoylcinnamoylglycyl, etc.],
amino acid residue substituted with lower
alkoxy(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
30 methoxymethylcarbamoylcinnamoylglycyl,
methoxyethylcarbamoylcinnamoylglycyl, bis(methoxyethyl)-
carbamoylcinnamoylglycyl,
ethoxyethylcarbamoylcinnamoylglycyl,
methoxypropylcarbamoylcinnamoylglycyl,
35 bis(ethoxyethyl)carbamoylcinnamoylglycyl, etc.],

2122236

amino acid residue substituted with N-[lower
alkoxy(lower)alkyl]-N-(lower alkyl)carbamoyl-ar(lower)-
alkenoyl [e.g. N-methoxyethyl-N-methylcarbamoylcinnamoyl-
glycyl, N-ethoxyethyl-N-methylcarbamoylcinnamoylglycyl,
5 etc.], amino acid residue substituted with
heterocyclic(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
pyridylmethylcarbamoylcinnamoylglycyl,
furylmethylcarbamoylcinnamoylglycyl,
thienylmethylcarbamoylcinnamoylglycyl, etc.], amino acid
10 residue substituted with N-[heterocyclic(lower)alkyl]-
N-(lower alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
N-pyridylmethyl-N-methylcarbamoylcinnamoylglycyl, etc.],
amino acid residue substituted with
heterocycliccarbamoyl-ar(lower)alkenoyl [e.g. morpholinyl-
15 carbamoylcinnamoylglycyl, thienylcarbamoylcinnamoylglycyl,
pyridylcarbamoylcinnamoylglycyl, pyrimidinylcarbamoyl-
cinnamoylglycyl, tetrazolylcarbamoylcinnamoylglycyl,
etc.], amino acid residue substituted with optionally
substituted heterocycliccarbonyl-ar(lower)alkenoyl [e.g.
20 morpholinocarbonylcinnamoylglycyl, pyrrolidinyl-
carbonylcinnamoylglycyl, piperidinocarbonylcinnamoyl-
glycyl, tetrahydropyridylcarbonylcinnamoylglycyl,
methylpiperazinylcarbonylcinnamoylglycyl, etc.],
amino acid residue substituted with lower
25 alkenylcarbamoyl-ar(lower)alkenoyl [e.g.
vinylcarbamoylcinnamoylglycyl,
allylcarbamoylcinnamoylglycyl,
methylpropenylcarbamoylcinnamoylglycyl, etc.], amino acid
residue substituted with lower
30 alkynylcarbamoyl-ar(lower)alkenoyl [e.g.
ethynylcarbamoylcinnamoylglycyl,
propynylcarbamoylcinnamoylglycyl, etc.], amino acid
residue substituted with
amino(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
35 aminomethylcarbamoylcinnamoylglycyl,

2122236

aminoethylcarbamoylcinnamoylglycyl, etc.], amino acid
residue substituted with lower
alkylamino(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
methylaminomethylcarbamoylcinnamoylglycyl,
5 methylaminoethylcarbamoylcinnamoylglycyl,
ethylaminoethylcarbamoylcinnamoylglycyl,
dimethylaminoethylcarbamoylcinnamoylglycyl, etc.], amino
acid residue substituted with lower
alkylcarbamoyloxy(lower)alkylcarbamoyl-ar(lower)alkenoyl
10 [e.g. methylcarbamoyloxymethylcarbamoylcinnamoylglycyl,
methylcarbamoyloxyethylcarbamoylcinnamoylglycyl,
ethylcarbamoyloxyethylcarbamoylcinnamoylglycyl,
dimethylcarbamoyloxyethylcarbamoylcinnamoylglycyl, etc.],
amino acid residue substituted with lower
15 alkylcarbamoyl(lower)alkylcarbamoyl-ar(lower)alkenoyl
[e.g. methylcarbamoylmethylcarbamoylcinnamoylglycyl,
methylcarbamoylethylcarbamoylcinnamoylglycyl,
ethylcarbamoylethylcarbamoylcinnamoylglycyl,
dimethylcarbamoylethylcarbamoylcinnamoylglycyl, etc.],
20 amino acid residue substituted with lower
alkoxycarbonyl(lower)alkylcarbamoyl-ar(lower)alkenoyl
[e.g. methoxycarbonylmethylcarbamoylcinnamoylglycyl,
methoxycarbonylethylcarbamoylcinnamoylglycyl,
ethoxycarbonylmethylcarbamoylcinnamoylglycyl,
25 ethoxycarbonylethylcarbamoylcinnamoylglycyl, etc.], amino
acid residue substituted with
carboxy(lower)alkylcarbamoyl-ar(lower)alkenoyl [e.g.
carboxymethylcarbamoylcinnamoylglycyl,
carboxyethylcarbamoylcinnamoylglycyl, etc.], amino acid
30 residue substituted with [lower
alkylcarbamoyl-ar(lower)alkyl]carbamoyl-ar(lower)alkenoyl
[e.g. (methylcarbamoyl-phenethyl)carbamoylcinnamoylglycyl,
(ethylcarbamoyl-phenethyl)carbamoylcinnamoylglycyl, etc.],
amino acid residue substituted with [lower
35 alkoxycarbonyl-ar(lower)alkyl]carbamoyl-ar(lower)alkenoyl

2122236

[e.g. (methoxycarbonyl-phenethyl)carbamoylcinnamoylglycyl,
(ethoxycarbonyl-phenethyl)carbamoylcinnamoylglycyl, etc.],
amino acid residue substituted with
[carboxy-ar(lower)alkyl]carbamoyl-ar(lower)alkenoyl [e.g.
5 (carboxy-phenethyl)carbamoylcinnamoylglycyl, etc.], amino
acid residue substituted with N-[lower
alkylcarbamoyl(lower)alkyl]-N-(lower
alkyl)carbamoyl-ar(lower)alkenoyl [e.g. N-(methyl-
carbamoylmethyl)-N-methylcarbamoylcinnamoylglycyl,
10 N-(methylcarbamoylethyl)-N-methylcarbamoylcinnamoylglycyl,
N-(ethylcarbamoylethyl)-N-methylcarbamoylcinnamoylglycyl,
N-(dimethylcarbamoylethyl)-N-methylcarbamoylcinnamoyl-
glycyl, etc.], amino acid residue substituted with
N-[lower alkoxycarbonyl(lower)alkyl]-N-(lower
15 alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
N-methoxycarbonylmethyl-N-methylcarbamoylcinnamoylglycyl,
N-methoxycarbonylethyl-N-methylcarbamoylcinnamoylglycyl,
N-ethoxycarbonylmethyl-N-methylcarbamoylcinnamoylglycyl,
N-ethoxycarbonylethyl-N-methylcarbamoylcinnamoylglycyl,
20 etc.], amino acid residue substituted with
N-[carboxy(lower)alkyl]-N-(lower
alkyl)carbamoyl-ar(lower)alkenoyl [e.g.
N-carboxymethyl-N-methylcarbamoylcinnamoylglycyl,
N-carboxyethyl-N-methylcarbamoylcinnamoylglycyl, etc.],
25 amino acid residue substituted with
arylcarbamoyl-ar(lower)alkenoyl [e.g.
phenylcarbamoylcinnamoylglycyl,
naphthylcarbamoylcinnamoylglycyl, etc.], etc., amino acid
residue substituted with ar(lower)alkynoyl [e.g.
30 phenylpropioloylglycyl, etc.],
amino acid residue substituted with heterocyclic(lower)-
alkenoyl [e.g. morpholinylacryloylglycyl,
pyridylacryloylglycyl, thienylacryloylglycyl, etc.],
amino acid residue substituted with
35 amino-heterocyclic(lower)alkenoyl [e.g.

2122236

aminopyridylacryloylglycyl, etc.],
amino acid residue substituted with lower
alkylamino-heterocyclic(lower)alkenoyl [e.g.
methylaminopyridylacryloylglycyl,
5 dimethylaminopyridylacryloylglycyl, etc.],
amino acid residue substituted with
acylamino-heterocyclic(lower)alkenoyl, for example,
amino acid residue substituted with lower
alkanoylamino-heterocyclic(lower)alkenoyl [e.g.
10 acetylaminopyridylacryloylglycyl,
propionylaminopyridylacryloylglycyl, etc.], amino acid
residue substituted with lower
alkenoylamino-heterocyclic(lower)alkenoyl [e.g.
acryloylamino-pyridylacryloylglycyl,
15 crotonoylamino-pyridylacryloylglycyl, etc.], amino acid
residue substituted with
heterocyclic(lower)alkanoylamino-heterocyclic(lower)-
alkenoyl [e.g. pyridylacetylaminopyridylacryloylglycyl,
thienylacetylaminopyridylacryloylglycyl, etc.], amino acid
20 residue substituted with
heterocycliccarbonylamino-heterocyclic(lower)alkenoyl
[e.g. pyridylcarbonylamino-pyridylacryloylglycyl,
furylcarbonylamino-pyridylacryloylglycyl, etc.], amino
acid residue substituted with lower alkanoylamino-
25 (lower)alkanoylamino-heterocyclic(lower)alkenoyl [e.g.
acetylaminopropionylaminopyridylacryloylglycyl,
acetylaminopropionylaminopyridylacryloylglycyl, etc.],
amino acid residue substituted with lower alkoxycarbonyl-
(lower)alkanoylamino-heterocyclic(lower)alkenoyl [e.g.
30 ethoxycarbonylacetylaminopyridylacryloylglycyl,
ethoxycarbonylpropionylaminopyridylacryloylglycyl, etc.],
amino acid residue substituted with lower
alkoxy(lower)alkanoylamino-heterocyclic(lower)alkenoyl
[e.g. methoxyacetylaminopyridylacryloylglycyl,
35 methoxypropionylaminopyridylacryloylglycyl,

2122236

- ethoxypropionylaminopyridylacryloylglycyl, etc.], etc.,
amino acid residue substituted with lower
alkylureido-heterocyclic(lower)alkenoyl [e.g.
methylureidopyridylacryloylglycyl, etc.],
5 amino acid residue substituted with
acyl-heterocyclic(lower)alkenoyl, for example,
amino acid residue substituted with
carboxy-heterocyclic(lower)alkenoyl [e.g.
carboxypyridylacryloylglycyl, etc.],
10 amino acid residue substituted with lower
alkoxycarbonyl-heterocyclic(lower)alkenoyl [e.g.
ethoxycarbonylpyridylacryloylglycyl, etc.],
amino acid residue substituted with lower
alkylcarbamoyl-heterocyclic(lower)alkenoyl [e.g.
15 methylcarbamoylpyridylacryloylglycyl,
ethylcarbamoylpyridylacryloylglycyl,
dimethylcarbamoylpyridylacryloylglycyl,
diethylcarbamoylpyridylacryloylglycyl,
isopropylcarbamoylpyridylacryloylglycyl,
20 N-ethyl-N-methylcarbamoylpyridylacryloylglycyl, etc.],
amino acid residue substituted with lower
alkoxy(lower)alkylcarbamoyl-heterocyclic(lower)alkenoyl
[e.g. methoxymethylcarbamoylpyridylacryloylglycyl,
methoxyethylcarbamoylpyridylacryloylglycyl,
25 methoxypropylcarbamoylpyridylacryloylglycyl,
ethoxyethylcarbamoylpyridylacryloylglycyl, bis(methoxy-
ethyl)carbamoylpyridylacryloylglycyl, etc.],
amino acid residue substituted with
hydroxy(lower)alkylcarbamoyl-heterocyclic(lower)alkenoyl
30 [e.g. hydroxymethylcarbamoylpyridylacryloylglycyl,
hydroxyethylcarbamoylpyridylacryloylglycyl, bis(hydroxy-
ethyl)carbamoylpyridylacryloylglycyl, etc.],
amino acid residue substituted with heterocycliccarbamoyl-
heterocyclic(lower)alkenoyl [e.g.
35 pyridylcarbamoylpyridylacryloylglycyl,

2122236

morpholinylcarbamoylepyridylacryloyl-glycyl,
thienylcarbamoylepyridylacryloylglycyl,
pyrimidinylcarbamoylepyridylacryloylglycyl, etc.],
amino acid residue substituted with heterocyclic-
5 (lower)alkylcarbamoyle-heterocyclic(lower)alkenoyl [e.g.
pyridylmethylcarbamoylepyridylacryloylglycyl,
furylmethylcarbamoylepyridylacryloylglycyl,
thienylmethylcarbamoylepyridylacryloylglycyl, etc.],
amino acid residue substituted with heterocycliccarbonyl-
10 heterocyclic(lower)alkenoyl [e.g.
morpholinocarbonylpyridylacryloylglycyl,
pyrrolidinylcarbonylpyridylacryloylglycyl,
piperidinocarbonylpyridylacryloylglycyl, etc.], amino acid
residue substituted with lower
15 alkenylcarbamoyle-heterocyclic(lower)alkenoyl [e.g.
vinylcarbamoylepyridylacryloylglycyl,
allylcarbamoylepyridylacryloylglycyl, etc.], amino acid
residue substituted with lower alkynylcarbamoyle-
heterocyclic(lower)alkenoyl [e.g.
20 ethynylcarbamoylepyridylacryloylglycyl,
propynylcarbamoylepyridylacryloylglycyl, etc.], etc.,
amino acid residue substituted with
heterocyclicthio(lower)alkanoyl [e.g.
pyridylthioacetyl-glycyl, pyrimidinylthioacetyl-glycyl,
25 imidazolylthiopropionyl-glycyl, etc.], amino acid residue
substituted with optionally substituted
heterocycliccarbonyl [e.g. morpholinocarbonylglycyl,
indolylcarbonylglycyl, 4-methyl-1-piperazinyl-
carbonylglycyl, etc.], amino acid residue substituted with
30 cyclo(lower)alkylcarbonyl [e.g. cyclopropylcarbonylglycyl,
cyclopentylcarbonylglycyl, cyclohexylcarbonylglycyl,
cyclohexylcarbonylsarcosyl, etc.], amino acid residue
substituted with lower alkoxycarbonyl [e.g.
methoxycarbonylglycyl, tert-butoxycarbonylglycyl,
35 tert-butoxycarbonylsarcosyl, tert-butoxycarbonylalanyl,

2122236

etc.], amino acid residue substituted with
aryloxycarbonyl [e.g. phenoxycarbonylglycyl, etc.], amino
acid residue substituted with aroyl(lower)alkanoyl [e.g.
phenyloxalylglycyl, benzoylpropionylglycyl, etc.], amino
5 acid residue substituted with aroyl [e.g. benzoylglycyl,
naphthoylglycyl, benzoylsarcosyl, benzoylalanyl, etc.],
amino acid residue substituted with nitro-aryloxycarbonyl
[e.g. nitrophenyloxycarbonylglycyl, etc.], amino acid
residue substituted with carbamoyl [e.g. carbamoylglycyl,
10 carbamoylalanyl, carbamoylsarcosyl, carbamoyl- β -alanyl,
etc.], amino acid residue substituted with lower
alkylcarbamoyl [e.g. methylcarbamoylglycyl,
ethylcarbamoylglycyl, propylcarbamoylglycyl,
isopropylcarbamoylglycyl, methylcarbamoylsarcosyl,
15 ethylcarbamoylalanyl, isopropylcarbamoyl- β -alanyl,
pentylcarbamoylglycyl, etc.], amino acid residue
substituted with lower alkoxycarbonyl(lower)alkylcarbamoyl
[e.g. methoxycarbonylmethylcarbamoylglycyl,
ethoxycarbonylmethylcarbamoylglycyl, etc.], amino acid
20 residue substituted with lower alkenylcarbamoyl [e.g.
vinylcarbamoylglycyl, allylcarbamoylglycyl,
allylcarbamoylsarcosyl, etc.], amino acid residue
substituted with cyclo(lower)alkylcarbamoyl [e.g.
cyclopropylcarbamoylglycyl, cyclohexylcarbamoylglycyl,
25 cyclohexylcarbamoylsarcosyl, etc.], amino acid residue
substituted with arylcarbamoyl [e.g.
phenylcarbamoylglycyl, naphthylcarbamoylglycyl,
tolylcarbamoylglycyl, ethylphenylcarbamoylglycyl,
phenylcarbamoylalanyl, phenylcarbamoylsarcosyl, etc.],
30 amino acid residue substituted with lower
alkoxy-arylcarbamoyl [e.g. methoxyphenylcarbamoylglycyl,
ethoxyphenylcarbamoylglycyl, methoxyphenylcarbamoylalanyl,
etc.], amino acid residue substituted with
halo(lower)alkyl-arylcarbamoyl [e.g.
35 trifluoromethylphenylcarbamoylglycyl,

2122236

trifluoromethylphenylcarbamoylalanyl,
trifluoromethylphenylcarbamoylsarcosyl, etc.], amino acid
residue substituted with halo-arylcarbamoyl [e.g.
chlorophenylcarbamoylglycyl, fluorophenylcarbamoylglycyl,
5 fluorophenylcarbamoylalanyl, etc.], amino acid residue
substituted with hydroxy(lower)alkyl-arylcarbamoyl [e.g.
hydroxymethylphenylcarbamoylglycyl,
hydroxyethylphenylcarbamoylglycyl,
hydroxyethylphenylcarbamoylalanyl, etc.],
10 amino acid residue substituted with nitro-arylcarbamoyl
[e.g. nitrophenylcarbamoylglycyl, etc.], amino acid
residue substituted with cyano-arylcarbamoyl [e.g.
cyanophenylcarbamoylglycyl, etc.], amino acid residue
substituted with amino-arylcarbamoyl [e.g.
15 aminophenylcarbamoylglycyl, etc.], amino acid residue
substituted with lower alkylamino-arylcarbamoyl [e.g.
methylaminophenylcarbamoylglycyl,
ethylaminophenylcarbamoylglycyl,
dimethylaminophenylcarbamoylglycyl, etc.], amino acid
20 residue substituted with lower alkanoylamino-arylcarbamoyl
[e.g. acetylaminophenylcarbamoylglycyl,
propionylaminophenylcarbamoylglycyl, etc.], amino acid
residue substituted with N-(lower alkanoyl)-N-(lower
alkyl)amino-arylcarbamoyl [e.g.
25 N-acetyl-N-methylaminophenylcarbamoylglycyl,
N-propionyl-N-methylaminophenylcarbamoylglycyl, etc.],
amino acid residue substituted with lower
alkoxy(lower)alkanoylamino-arylcarbamoyl [e.g.
methoxyacetylaminophenylcarbamoylglycyl,
30 methoxypropionylaminophenylcarbamoylglycyl, etc.],
amino acid residue substituted with lower
alkoxycarbonyl(lower)alkanoylamino-arylcarbamoyl [e.g.
ethoxycarbonylacetylaminophenylcarbamoylglycyl,
methoxycarbonylpropionylaminophenylcarbamoylglycyl, etc.],
35 amino acid residue substituted with

2122236

carboxyamino-arylcarbamoyle [e.g.
carboxyaminophenylcarbamoyleglycyl, etc.], amino acid
residue substituted with lower alkoxycarbonyl-
amino-arylcarbamoyle [e.g. ethoxycarbonylamino-phenyl-
5 carbamoyleglycyl, etc.], amino acid residue substituted
with aroylamino-arylcarbamoyle [e.g.
benzoylamino-phenylcarbamoyleglycyl, etc.], amino acid
residue substituted with heterocycliccarbonylamino-
arylcarbamoyle [e.g. pyridylcarbonylamino-phenylcarbamoyle-
10 glycyl, furylcarbonylamino-phenylcarbamoyleglycyl,
morpholinocarbonylamino-phenylcarbamoyleglycyl, etc.], amino
acid residue substituted with
heterocyclic(lower)alkanoylamino-arylcarbamoyle [e.g.
pyridylacetylamino-phenylcarbamoyleglycyl,
15 thienylacetylamino-phenylcarbamoyleglycyl, etc.],
amino acid residue substituted with ureido-arylcarbamoyle
[e.g. ureidophenylcarbamoyleglycyl, etc.], amino acid
residue substituted with lower alkylureido-arylcarbamoyle
[e.g. methylureidophenylcarbamoyleglycyl,
20 ethylureidophenylcarbamoyleglycyl, etc.], amino acid
residue substituted with
hydroxyimino(lower)alkyl-arylcarbamoyle [e.g.
hydroxyiminoethylphenylcarbamoyleglycyl, etc.], amino acid
residue substituted with lower alkoxyimino(lower)alkyl-
25 arylcarbamoyle [e.g. methoxyiminoethylphenylcarbamoyle-
glycyl, etc.], amino acid residue substituted with lower
alkylhydrazono(lower)alkyl-arylcarbamoyle [e.g.
methylhydrazonoethylphenylcarbamoyleglycyl,
dimethylhydrazonoethylphenylcarbamoyleglycyl, etc.],
30 amino acid residue substituted with optionally substituted
heterocyclic-arylcarbamoyle [e.g.
oxopyrrolidinylphenylcarbamoyleglycyl,
oxopiperidinophenylcarbamoyleglycyl,
dioxopyrrolidinylphenylcarbamoyleglycyl,
35 oxooxazolidinylphenylcarbamoyleglycyl,

2122236

pyrrolylphenylcarbamoyleglycyl, etc.],
amino acid residue substituted with acyl-arylcarbamoyle,
for example, amino acid residue substituted with lower
alkanoyl-arylcarbamoyle [e.g. acetylphenylcarbamoyleglycyl,
5 propionylphenylcarbamoyleglycyl, etc.],
amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyle [e.g.
morpholinocarbonylphenylcarbamoyleglycyl,
piperidinocarbonylphenylcarbamoyleglycyl,
10 piperazinylcarbonylphenylcarbamoyleglycyl,
thiomorpholinocarbonylphenylcarbamoylealanyl,
pyrrolidinylcarbonylphenylcarbamoyleglycyl,
1,2,3,6-tetrahydropyridylcarbonylphenylcarbamoyleglycyl,
etc.], amino acid residue substituted with
15 carboxy-arylcarbamoyle [e.g. carboxyphenylcarbamoyleglycyl,
etc.], amino acid residue substituted with lower
alkoxycarbonyl-arylcarbamoyle [e.g.
methoxycarbonylphenylcarbamoyleglycyl, ethoxycarbonyl-
phenylcarbamoyleglycyl, etc.], amino acid residue
20 substituted with carbamoyle-arylcarbamoyle [e.g.
carbamoylephenylcarbamoyleglycyl, etc.], amino acid residue
substituted with lower alkylcarbamoyle-arylcarbamoyle [e.g.
methylcarbamoylephenylcarbamoyleglycyl,
ethylcarbamoylephenylcarbamoyleglycyl,
25 propylcarbamoylephenylcarbamoyleglycyl,
dimethylcarbamoylephenylcarbamoyleglycyl,
diethylcarbamoylephenylcarbamoyleglycyl,
N-ethyl-N-methylcarbamoylephenylcarbamoyleglycyl,
N-isopropyl-N-methylcarbamoylephenylcarbamoyleglycyl, etc.],
30 amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyle having lower alkyl
[e.g. methylpiperazinylcarbonylphenylcarbamoyleglycyl,
ethylpiperazinylcarbonylphenylcarbamoyleglycyl, etc.],
amino acid residue substituted with
35 heterocycliccarbonyl-arylcarbamoyle having aryl [e.g.

2122236

phenylpiperazinylcarbonylphenylcarbamoyleglycyl, etc.],
amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyle having a heterocyclic
group [e.g. pyridylpiperazinylcarbonylphenylcarbamoyle-
5 glycyl, etc.], amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyle having lower alkanoyl
[e.g. acetyl piperazinylcarbonylphenylcarbamoyleglycyl,
etc.], amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyle having lower
10 alkoxycarbonyl [e.g. ethoxycarbonylpiperazinylcarbonyl-
phenylcarbamoyleglycyl, etc.], amino acid residue
substituted with heterocycliccarbonyl-arylcarbamoyle having
lower alkylamino [e.g. methylaminopiperazinylcarbonyl-
phenylcarbamoyleglycyl, dimethylaminopiperidinocarbonyl-
15 phenylcarbamoyleglycyl, etc.],
amino acid residue substituted with heterocycliccarbonyl-
arylcarbamoyle having lower alkylcarbamoyle [e.g. methyl-
carbamoylepiperazinylcarbonylphenylcarbamoyleglycyl, etc.],
amino acid residue substituted with
20 hydroxy(lower)alkylcarbamoyle-arylcarbamoyle [e.g.
hydroxymethylcarbamoylephenylcarbamoyleglycyl,
hydroxyethylcarbamoylephenylcarbamoyleglycyl,
bis(hydroxyethyl)carbamoylephenylcarbamoyleglycyl, etc.],
amino acid residue substituted with
25 N-[hydroxy(lower)alkyl]-N-(lower alkyl)carbamoyle-
arylcarbamoyle [e.g. N-(hydroxyethyl)-N-methylcarbamoyle-
phenylcarbamoyleglycyl, etc.], amino acid residue
substituted with lower alkoxy(lower)alkylcarbamoyle-aryl-
carbamoyle [e.g. methoxymethylcarbamoylephenylcarbamoyle-
30 glycyl, methoxyethylcarbamoylephenylcarbamoyleglycyl,
ethoxyethylcarbamoylephenylcarbamoyleglycyl,
bis(methoxyethyl)carbamoylephenylcarbamoyleglycyl,
bis(ethoxyethyl)carbamoylephenylcarbamoyleglycyl, etc.],
amino acid residue substituted with N-[lower alkoxy-
35 (lower)alkyl]-N-(lower alkyl)carbamoyle-arylcarbamoyle [e.g.

2122236

N-(methoxyethyl)-N-methylcarbamoylphenylcarbamoylglycyl,
N-(methoxypropyl)-N-methylcarbamoylphenylcarbamoylglycyl,
etc.], amino acid residue substituted with lower
alkylamino(lower)alkylcarbamoyl-arylcarbamoyl [e.g.
5 methylaminoethylcarbamoylphenylcarbamoylglycyl,
dimethylaminoethylcarbamoylphenylcarbamoylglycyl, etc.],
amino acid residue substituted with N-[lower
alkylamino(lower)alkyl]-N-(lower alkyl)carbamoyl-
arylcarbamoyl [e.g. N-(dimethylaminoethyl)-N-
10 methylcarbamoylphenylcarbamoylglycyl,
N-(dimethylaminopropyl)-N-methylcarbamoylphenylcarbamoyl-
glycyl, etc.], amino acid residue substituted with
heterocycliccarbamoyl-arylcarbamoyl [e.g.
morpholinylcarbamoylphenylcarbamoylglycyl,
15 thienylcarbamoylphenylcarbamoylglycyl,
pyridylcarbamoylphenylcarbamoylglycyl,
pyrimidinylcarbamoylphenylcarbamoylglycyl, etc.],
amino acid residue substituted with N-(heterocyclic)-
N-(lower alkyl)carbamoyl-arylcarbamoyl [e.g.
20 N-pyridyl-N-methylcarbamoylphenylcarbamoylglycyl, etc.],
amino acid residue substituted with
heterocyclic(lower)alkylcarbamoyl-arylcarbamoyl [e.g.
pyridylmethylcarbamoylphenylcarbamoylglycyl,
pyridylethylcarbamoylphenylcarbamoylglycyl,
25 thienylmethylcarbamoylphenylcarbamoylglycyl, etc.],
amino acid residue substituted with
N-[heterocyclic(lower)alkyl]-N-(lower alkyl)carbamoyl-
arylcarbamoyl [e.g. N-pyridylmethyl-N-methylcarbamoyl-
phenylcarbamoylglycyl, etc.],
30 amino acid residue substituted with
N-[heterocyclic(lower)alkyl]-N-[lower alkoxy(lower)alkyl]-
carbamoyl-arylcarbamoyl [e.g. N-pyridylmethyl-N-
methoxyethylcarbamoylphenylcarbamoylglycyl, etc.],
amino acid residue substituted with
35 arylcarbamoyl-arylcarbamoyl [e.g.

2122236

- phenylcarbamoylphenylcarbamoylglycyl, etc.],
amino acid residue substituted with lower
alkylaminoarylcarbamoyl-arylcarbamoyl [e.g. dimethylamino-
phenylcarbamoylphenylcarbamoylglycyl, etc.], etc.,
5 amino acid residue substituted with arylthiocarbamoyl
[e.g. phenylthiocarbamoylglycyl,
naphthylthiocarbamoylglycyl, phenylthiocarbamoylalanyl,
phenylthiocarbamoylsarcosyl, etc.], amino acid residue
substituted with ar(lower)alkylcarbamoyl [e.g.
10 benzylcarbamoylglycyl, benzylcarbamoylsarcosyl,
benzylcarbamoylalanyl, etc.], amino acid residue
substituted with aroylcarbamoyl [e.g.
benzoylcarbamoylglycyl, etc.], amino acid residue
substituted with heterocycliccarbamoyl [e.g.
15 pyridylcarbamoylglycyl, pyridylcarbamoylalanyl,
pyridylcarbamoylsarcosyl, thienylcarbamoylglycyl,
pyrazolylcarbamoylglycyl, pyrimidinylcarbamoylglycyl,
quinolylcarbamoylglycyl, isoquinolylcarbamoylglycyl,
etc.], amino acid residue substituted with
20 heterocyclic(lower)alkylcarbamoyl [e.g.
pyridylmethylcarbamoylglycyl, pyridylethylcarbamoylglycyl,
thienylmethylcarbamoylglycyl, etc.],
amino acid residue substituted with arylaminocarbamoyl
[e.g. phenylaminocarbamoylglycyl, etc.], amino acid
25 residue substituted with ar(lower)alkenylsulfonyl [e.g.
styrylsulfonylglycyl, cinnamoylsulfonylglycyl, etc.],
amino acid residue substituted with lower alkylsulfonyl
[e.g. mesylglycyl, ethylsulfonylglycyl, mesylsarcosyl,
mesylalanyl, etc.], amino acid residue substituted with
30 phthaloyl [e.g. phthaloylglycyl, phthaloylalanyl,
phthaloyl- β -alanyl, etc.], amino acid residue having
unsubstituted amino acid residue [e.g. glycylglycyl,
alanylglycyl, sarcosylglycyl, prolylglycyl,
glycylsarcosyl, prolylsarcosyl, etc.], amino acid residue
35 having substituted amino acid residue [e.g. amino acid


2122236

residue having amino acid residue substituted with lower
alkyl (e.g. dimethylglycylglycyl, diethylglycylglycyl,
dimethylglycylsarcosyl, ethylsarcosylglycyl,
isopropylsarcosylglycyl, ethylglycylglycyl,
5 propylglycylglycyl, isopropylglycylglycyl,
ethylglycylalanyl, dimethylglycylalanyl,
dimethylalanylglycyl, dimethyl- β -alanylglycyl, etc.),
amino acid residue having amino acid residue substituted
with a heterocyclic group (e.g. morpholinoglycylglycyl,
10 piperidinoglycylglycyl, pyridylglycylglycyl,
piperidinosarcosylglycyl, etc.), amino acid residue having
amino acid residue substituted with
heterocyclic(lower)alkyl (e.g. pyridylmethylglycylglycyl,
imidazolylmethylglycylglycyl, furylmethylglycylglycyl,
15 thienylmethylsarcosylglycyl, etc.), amino acid residue
having amino acid residue substituted with cycloalkyl
(e.g. cyclopropylglycylglycyl, cyclobutylglycylglycyl,
cyclopentylglycylglycyl, cyclohexylglycylglycyl,
cycloheptylglycylglycyl, cyclooctylglycylglycyl,
20 adamantylglycylglycyl, cyclohexylsarcosylglycyl,
cycloheptylsarcosylglycyl, cyclohexylglycylsarcosyl,
cyclohexylglycylalanyl, etc.), amino acid residue having
amino acid residue substituted with aryl (e.g.
phenylglycylglycyl, phenylsarcosylglycyl, etc.), amino
25 acid residue having amino acid residue substituted with
acyl {e.g. amino acid residue having amino acid residue
substituted with alkanoyl (e.g. acetylglycylglycyl,
acetylprolylglycyl, propionylglycylglycyl,
acetylalanylglycyl, etc.), amino acid residue having amino
30 acid residue substituted with lower alkoxycarbonyl (e.g.
tert-butoxycarbonylglycylglycyl,
tert-butoxycarbonylprolylglycyl, etc.), amino acid residue
having amino acid residue substituted with phthaloyl (e.g.
phthaloylglycylglycyl, etc.), etc.}, amino acid residue
35 having amino acid residue substituted with ar(lower)alkyl

2122236

(e.g. benzylglycylglycyl, etc.), etc.], etc., or the like.

Groups of the formulas of the compounds [Ie] and [If] :



10 wherein R^{12} , R^{13} , (AA), Y and Z are each as defined above, are also included within "acyl".

15 Suitable "acyl having amino" may be unsubstituted amino acid residue, amino acid residue having unsubstituted amino acid residue, or the like, and preferred examples thereof can be referred to those exemplified above.

20 Suitable "acyl having acylamino" may be amino acid residue substituted with acyl, amino acid residue having amino acid residue substituted with acyl, or the like, and preferred examples thereof can be referred to those exemplified above.

25 Suitable substituents in the term "amino optionally having suitable substituent(s)" may be the above-mentioned lower alkyl, the above-mentioned acyl, ar(lower)alkyl [e.g. benzyl, phenethyl, trityl, etc.], carboxy(lower)alkyl [e.g. carboxymethyl, carboxyethyl, carboxypropyl, etc.], lower alkoxycarbonyl(lower)alkyl
30 [e.g. methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylpropyl, etc.], heterocyclic(lower)alkyl [e.g. pyridylmethyl, pyridylethyl, etc.], or the like.

35 Suitable "protected or unprotected hydroxy(lower)alkyl" may be hydroxymethyl, hydroxyethyl,

2122236

hydroxypropyl, benzyloxymethyl,
tert-butyldiphenylsilyloxyethyl or the like.

5 Suitable "lower alkoxy(lower)alkyl" may be
methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl,
ethoxyethyl, or the like.

 Suitable "lower alkylamino(lower)alkyl" may be
methylaminomethyl, methylaminoethyl, methylaminopropyl,
dimethylaminomethyl, dimethylaminoethyl,
dimethylaminopropyl, diethylaminoethyl, or the like.

10 Suitable "lower alkenyl" may be vinyl, allyl,
methylpropenyl, butenyl, pentenyl or the like.

 Suitable "lower alkynyl" may be ethynyl, propynyl,
butynyl, pentynyl or the like.

15 Suitable "lower alkylcarbamoyloxy(lower)alkyl" may be
methylcarbamoyloxymethyl, methylcarbamoyloxyethyl,
ethylcarbamoyloxyethyl, dimethylcarbamoyloxyethyl or the
like.

20 Suitable "lower alkoxycarbonyl(lower)alkyl" may be
methoxycarbonylmethyl, methoxycarbonylethyl,
ethoxycarbonylmethyl, ethoxycarbonylethyl or the like.

 Suitable "carboxy(lower)alkyl" may be carboxymethyl,
carboxyethyl, carboxypropyl or the like.

25 Suitable "lower alkylcarbamoyl(lower)alkyl" may be
methylcarbamoylmethyl, methylcarbamoylethyl,
ethylcarbamoylethyl, dimethylcarbamoylethyl or the like.

 Suitable "lower alkoxycarbonyl-ar(lower)alkyl" may be
methoxycarbonyl-benzyl, methoxycarbonyl-phenethyl,
ethoxycarbonyl-phenethyl or the like.

30 Suitable "carboxy-ar(lower)alkyl" may be
carboxy-benzyl, carboxy-phenethyl or the like.

 Suitable "lower alkylcarbamoyl-ar(lower)alkyl" may be
methylcarbamoyl-benzyl, methylcarbamoyl-phenethyl,
ethylcarbamoyl-phenethyl or the like.

35 Suitable "heterocyclic group" and all heterocyclic
moieties in the various definitions mentioned in this

2122236

specification and claims such as in the term
"heterocyclic(lower)alkyl", "heterocyclic(lower)alkenoyl",
etc., may include saturated or unsaturated, monocyclic or
polycyclic one containing at least one hetero atom such as
5 nitrogen atom, oxygen atom or sulfur atom, preferably N, O
and/or S containing 5 or 6 membered heterocyclic group, in
which preferable ones may be morpholinyl, piperazinyl,
pyridyl, tetrahydropyridyl, pyrimidinyl, piperidyl,
thienyl, furyl, oxazolyl, isoxazolyl, thiazolyl,
10 tetrazolyl, imidazolyl, pyrrolidinyl, pyrrolyl, or the
like.

Suitable substituents in the term "heterocyclic group
optionally having suitable substituent(s)" may be the
above-mentioned halogen, the above-mentioned lower alkyl,
15 the above-mentioned acyl, the above-mentioned aryl, oxo,
nitro, amino, ar(lower)alkyl [e.g. benzyl, phenethyl,
trityl, etc.], lower alkoxycarbonyl(lower)alkyl [e.g.
methoxycarbonylmethyl, ethoxycarbonylmethyl,
methoxycarbonylethyl, ethoxycarbonylpropyl, etc.], or the
20 like.






Suitable "heterocyclic group" formed by R^{12} , R^{13} and
the attached nitrogen atom may be morpholino,
thiomorpholino, pyrrolidin-1-yl, piperidino,
1,2,3,6-tetrahydropyridin-1-yl, piperazin-1-yl, or the
25 like. And said heterocyclic group may be substituted with
suitable substituent(s) such as the above-mentioned lower
alkyl, the above-mentioned heterocyclic group, the
above-mentioned acyl, lower alkylamino, the
above-mentioned aryl, or the like.

30 Preferred examples of "heterocyclic(lower)alkyl" may
be morpholinomethyl, morpholinoethyl, pyridylmethyl,
pyridylethyl, thienylmethyl, piperidinomethyl,
pyrrolylmethyl, imidazolylmethyl, furylmethyl, or the
like.

2122236

Particularly, the preferred embodiments of x^1 , x^2 , x^3 , R^1 , R^2 , R^3 , R^4 , R^5 , Q and A are as follows :

5 A group of the formula : $-x^3=x^2-x^1=N-$ is a group of the formula :



in which

25 R^6 and R^8 are each hydrogen; halogen such as fluorine, chlorine, bromine and iodine; lower alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl and hexyl; hydroxy; lower alkylthio such as methylthio, ethylthio, propylthio, isopropylthio and butylthio; amino; lower alkylamino such as methylamino, ethylamino, propylamino, dimethylamino and diethylamino; lower alkoxy such as methoxy, ethoxy, propoxy, isopropoxy and butoxy; lower alkoxy(lower)alkoxy such as methoxymethoxy and methoxyethoxy; lower alkylamino(lower)alkoxy such as

30

35

2122236

methylaminoethoxy and dimethylaminoethoxy; or
ar(lower)alkoxy substituted with lower alkoxy such as
dimethoxybenzyloxy;


R^7 is hydrogen; or lower alkyl such as methyl, ethyl,
propyl, isopropyl and butyl;

R^1 is hydrogen; or halogen such as fluorine, chlorine,
bromine and iodine;

R^2 is halogen such as fluorine, chlorine, bromine and
iodine;

R^3 is hydrogen; nitro;

a group of the formula :



in which

R_a^{10} is hydrogen; lower alkyl such as methyl, ethyl,
propyl and butyl; carboxy(lower)alkyl such as
carboxymethyl and carboxyethyl; lower
alkoxycarbonyl(lower)alkyl such as
methoxycarbonylmethyl, methoxycarbonylethyl and
ethoxycarbonylmethyl; ar(lower)alkyl such as
benzyl and phenethyl; and acyl such as lower
alkanoyl [e.g. formyl, acetyl, propionyl, etc.],
carboxy and esterified carboxy [e.g. lower
alkoxycarbonyl (e.g. methoxycarbonyl,
ethoxycarbonyl, tert-butoxycarbonyl, etc.), etc.],

R_c^{11} is hydrogen; lower alkyl such as methyl, ethyl,
propyl, isopropyl and butyl; ar(lower)alkyl such
as benzyl; heterocyclic(lower)alkyl such as
pyridyl(lower)alkyl [e.g. pyridylmethyl,
pyridylethyl, etc.]; and acyl such as lower
alkanoyl [e.g. formyl, acetyl, propionyl,
butyryl, isobutyryl, etc.], halo(lower)alkanoyl
[e.g. trifluoroacetyl, etc.], carboxy,
esterified carboxy [e.g. lower alkoxycarbonyl

2122236

(e.g. methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), etc.], hydroxy(lower)alkanoyl [e.g. glycoloyl, lactoyl, 3-hydroxypropionyl, etc.], lower alkanoyloxy(lower)alkanoyl [e.g. acetyloxyacetyl, acetyloxypropionyl, etc.], lower alkoxy(lower)alkanoyl [e.g. methoxyacetyl, methoxypropionyl, etc.], benzoyl, toluoyl, benzoyl substituted with lower alkoxy [e.g. methoxybenzoyl, etc.], benzoyl substituted with esterified carboxy [e.g. lower alkoxycarbonylbenzoyl (e.g. methoxycarbonylbenzoyl, tert-butoxycarbonylbenzoyl, etc.), etc.], benzoyl substituted with halogen [e.g. chlorobenzoyl, fluorobenzoyl, etc.], phenoxycarbonyl optionally substituted with nitro, lower alkylsulfonyl [e.g. mesyl, ethylsulfonyl, etc.], carbamoyl, lower alkylcarbamoyl [e.g. methylcarbamoyl, ethylcarbamoyl, isopropylcarbamoyl, etc.], halo(lower)alkanoylcarbamoyl [e.g. trichloroacetylcarbamoyl, etc.], phenylcarbamoyl, unsubstituted amino acid residue [e.g. glycyl, sarcosyl, alanyl, β -alanyl, etc.] and substituted amino acid residue [e.g. amino acid residue substituted with lower alkyl (e.g. ethylglycyl, isopropylglycyl, dimethylglycyl, diethylglycyl, ethylsarcosyl, isopropylsarcosyl, methylalanyl, methyl- β -alanyl, etc.), amino acid residue substituted with optionally substituted amidino (e.g. amidinoglycyl, N-ethyl-N'-cyanoamidinoglycyl, etc.), amino acid residue substituted with acyl {e.g. amino acid

2122236

residue substituted with alkanoyl (e.g.
formylglycyl, acetylglycyl, acetylsarcosyl,
acetylalanyl, acetyl- β -alanyl, propionylglycyl,
butyrylglycyl, isobutyrylglycyl, valerylglycyl,
5 isovalerylglycyl, pivaloylglycyl,
hexanoylglycyl, heptanoylglycyl, etc.),
amino acid residue substituted with
halo(lower)alkanoyl (e.g. trifluoroacetylglycyl,
trifluoroacetylsarcosyl, trifluoroacetylalanyl,
10 bromoacetylglycyl, heptafluorobutyrylglycyl,
etc.), amino acid residue substituted with
hydroxy(lower)alkanoyl (e.g. glycoloylglycyl,
glycoloylsarcosyl, lactoylglycyl, lactoylalanyl,
etc.), amino acid residue substituted with lower
15 alkylsulfonyloxy(lower)alkanoyl (e.g.
mesyloxyacetylglycyl,
ethylsulfonyloxyacetylglycyl,
mesyloxyacetylsarcosyl, etc.),
amino acid residue substituted with lower
20 alkoxy(lower)alkanoyl (e.g. methoxyacetylglycyl,
ethoxyacetylglycyl, methoxyacetylsarcosyl,
methoxypropionylalanyl, etc.),
amino acid residue substituted with
aryloxy(lower)alkanoyl (e.g.
25 phenyloxyacetylglycyl, phenyloxypropionylglycyl,
phenyloxyacetylsarcosyl, etc.),
amino acid residue substituted with lower
alkylthio(lower)alkanoyl (e.g.
methylthioacetylglycyl,
30 methylthiopropionylglycyl, etc.),
amino acid residue substituted with lower
alkylcarbamoyl(lower)alkanoyl (e.g.
methylcarbamoylpropionylglycyl,
methylcarbamoylpropionylalanyl, etc.),
35 amino acid residue substituted with lower

2122236

alkanoyloxy(lower)alkanoyl (e.g.
acetyloxyacetylglucyl, acetyloxyacetylsarcosyl,
propionyloxyacetylglucyl,
acetyloxypropionylalanyl, etc.),
5 amino acid residue substituted with
carboxy(lower)alkanoyl (e.g.
carboxyacetylglucyl, carboxypropionylglucyl,
carboxypropionylsarcosyl, carboxyacetylalanyl,
etc.), amino acid residue substituted with lower
10 alkoxycarbonyl(lower)alkanoyl (e.g.
methoxycarbonylacetylglucyl,
ethoxycarbonylpropionylglucyl,
methoxycarbonylacetylsarcosyl, etc.),
amino acid residue substituted with
15 ar(lower)alkanoyl (e.g. phenylacetylglucyl,
phenylpropionylglucyl, phenylbutyrylglucyl,
phenylacetylsarcosyl, phenylpropionylalanyl,
naphthylacetylglucyl, etc.),
amino acid residue substituted with optionally
20 substituted heterocyclic(lower)alkanoyl (e.g.
morpholinoacetylglucyl, pyridylacetylglucyl,
morpholinopropionylalanyl,
imidazolylacetylglucyl, piperidinoacetylglucyl,
pyrrolidinylacetylglucyl,
25 hexamethyleneiminoacetylglucyl,
methylpiperazinylacetylglucyl,
pyridylpiperazinylacetylglucyl,
thiomorpholinoacetylglucyl, its oxide or
dioxide, etc.), amino acid residue substituted
30 with lower alkenoyl (e.g. acryloylglucyl,
crotonoylglucyl, 3-pentenoylglucyl,
3-butenoylglucyl, 4-pentenoylglucyl,
3-butenoylsarcosyl, etc.),
amino acid residue substituted with
35 ar(lower)alkenoyl (e.g. cinnamoylglucyl,

α -methylnammoylglycyl,
4-methylnammoylglycyl, etc.),
amino acid residue substituted with lower
alkoxy-ar(lower)alkenoyl (e.g.
5 methoxynammoylglycyl,
ethoxynammoylglycyl, dimethoxynammoylglycyl,
etc.), amino acid residue substituted with lower
alkylenedioxy-ar(lower)alkenoyl (e.g.
10 methylenedioxyammoylglycyl, ethylene-
dioxyammoylglycyl, etc.),
amino acid residue substituted with
nitro-ar(lower)alkenoyl (e.g.
nitroammoylglycyl, etc.),
amino acid residue substituted with
15 cyano-ar(lower)alkenoyl (e.g.
cyanammoylglycyl, etc.),
amino acid residue substituted with
halo-ar(lower)alkenoyl (e.g.
chloroammoylglycyl, fluoroammoylglycyl,
20 etc.), amino acid residue substituted with
hydroxy-ar(lower)alkenoyl (e.g.
hydroxyammoylglycyl, etc.),
amino acid residue substituted with
hydroxy(lower)alkoxy-ar(lower)alkenoyl (e.g.
25 hydroxymethoxynammoylglycyl,
hydroxyethoxynammoylglycyl, etc.),
amino acid residue substituted with
amino(lower)alkoxy-ar(lower)alkenoyl (e.g.
aminoethoxynammoylglycyl, etc.),
30 amino acid residue substituted with lower
alkylamino(lower)alkoxy-ar(lower)alkenoyl (e.g.
methylaminomethoxynammoylglycyl,
dimethylaminoethoxynammoylglycyl, etc.),
amino acid residue substituted with
35 heterocyclic(lower)alkoxy-ar(lower)alkenoyl

2122236

(e.g. pyridylmethoxycinnamoylglycyl, etc.),
amino acid residue substituted with optionally
substituted heterocyclic-ar(lower)alkenoyl (e.g.
morpholinocinnamoylglycyl, methylpiperazinylcin-
namoylglycyl, pyrrolidinylcinnamoylglycyl,
5 oxopyrrolidinylcinnamoylglycyl,
oxopiperidinocinnamoylglycyl,
dioxopyrrolidinylcinnamoylglycyl,
oxooxazolidinylcinnamoylglycyl,
10 pyrrolylcinnamoylglycyl,
tetrazolylcinnamoylglycyl, etc.),
amino acid residue substituted with
amino-ar(lower)alkenoyl (e.g.
aminocinnamoylglycyl, etc.),
15 amino acid residue substituted with lower
alkylamino-ar(lower)alkenoyl (e.g.
methylaminocinnamoylglycyl,
dimethylaminocinnamoylglycyl, etc.),
amino acid residue substituted with lower
20 alkanoylamino-ar(lower)alkenoyl (e.g.
acetylaminocinnamoylglycyl,
propionylaminocinnamoylglycyl,
isobutyrylamino-cinnamoylglycyl, etc.),
amino acid residue substituted with
25 cycloalkyl(lower)alkanoylamino-ar(lower)alkenoyl
(e.g. cyclopentylacetylaminocinnamoylglycyl,
cyclohexylacetylaminocinnamoylglycyl,
adamantylacetylaminocinnamoylglycyl, etc.),
amino acid residue substituted with
30 cycloalkylcarbonylamino-ar(lower)alkenoyl (e.g.
cyclopropylcarbonylamino-cinnamoylglycyl,
cyclopentylcarbonylamino-cinnamoylglycyl,
cyclohexylcarbonylamino-cinnamoylglycyl,
adamantylcarbonylamino-cinnamoylglycyl, etc.),
35 amino acid residue substituted with lower

2122236

alkenoylamino-ar(lower)alkenoyl (e.g.
acryloylamino-cinnamoylglycyl,
crotonoylamino-cinnamoylglycyl, etc.)
amino acid residue substituted with lower
5 alkoxy-carbonylamino-ar(lower)alkenoyl (e.g.
methoxy-carbonylamino-cinnamoylglycyl,
ethoxy-carbonylamino-cinnamoylglycyl, etc.),
amino acid residue substituted with
hydroxy(lower)alkanoylamino-ar(lower)alkenoyl
10 (e.g. hydroxyacetylaminocinnamoylglycyl,
hydroxypropionylaminocinnamoylglycyl, etc.),
amino acid residue substituted with lower
alkoxy(lower)alkanoylamino-ar(lower)alkenoyl
(e.g. methoxyacetylaminocinnamoylglycyl,
15 methoxypropionylaminocinnamoylglycyl, etc.),
amino acid residue substituted with
halo(lower)alkanoylamino-ar(lower)alkenoyl (e.g.
chloroacetylaminocinnamoylglycyl,
trifluoroacetylaminocinnamoylglycyl,
20 bromobutyrylamino-cinnamoylglycyl, etc.),
amino acid residue substituted with
amino(lower)alkanoylamino-ar(lower)alkenoyl
(e.g. aminoacetylaminocinnamoylglycyl,
aminopropionylaminocinnamoylglycyl, etc.),
25 amino acid residue substituted with lower
alkylamino(lower)alkanoylamino-ar(lower)alkenoyl
(e.g. methylaminoacetylaminocinnamoylglycyl,
dimethylaminoacetylaminocinnamoylglycyl, etc.),
amino acid residue substituted with lower
30 alkanoylamino(lower)alkanoylamino-
ar(lower)alkenoyl (e.g.
acetylaminopropionylaminocinnamoylglycyl,
acetylaminopropionylaminocinnamoylglycyl, etc.),
amino acid residue substituted with
35 carboxy(lower)alkanoylamino-ar(lower)alkenoyl

(e.g. carboxyacetylaminocinnamoylglycyl, carboxypropionylaminocinnamoylglycyl, etc.), amino acid residue substituted with lower alkoxy carbonyl(lower)alkanoylamino-

5 ar(lower)alkenoyl (e.g. ethoxycarbonyl-acetylaminocinnamoylglycyl, ethoxycarbonyl-propionylaminocinnamoylglycyl, etc.), amino acid residue substituted with lower alkoxy carbonyl(lower)alkenoylamino-

10 ar(lower)alkenoyl (e.g. ethoxycarbonyl-acryloylaminocinnamoylglycyl, etc.), amino acid residue substituted with halo(lower)alkoxy carbonylamino-ar(lower)alkenoyl (e.g. chloroethoxycarbonylaminocinnamoylglycyl,

15 etc.), amino acid residue substituted with optionally substituted heterocyclic-(lower)alkanoylamino-ar(lower)alkenoyl (e.g. pyridylacetylaminocinnamoylglycyl, thienylacetylaminocinnamoylglycyl,

20 methylpyrrolylacetylaminocinnamoylglycyl, etc.), amino acid residue substituted with aroylamino-ar(lower)alkenoyl (e.g. benzoylaminocinnamoylglycyl, etc.), amino acid residue substituted with optionally

25 substituted heterocyclic carbonylamino-ar(lower)alkenoyl (e.g. pyridyl carbonylamino cinnamoylglycyl, morpholinocarbonylamino cinnamoylglycyl, furyl carbonylamino cinnamoylglycyl,

30 thienyl carbonylamino cinnamoylglycyl, oxazolyl carbonylamino cinnamoylglycyl, methyloxazolyl carbonylamino cinnamoylglycyl, dimethylisoxazolyl carbonylamino cinnamoylglycyl, imidazolyl carbonylamino cinnamoylglycyl,

35 methylimidazolyl carbonylamino cinnamoylglycyl,

2122236

5 piperidylcarbonylamino-cinnamoylglycyl,
ethylpiperidylcarbonylamino-cinnamoylglycyl,
acetyl-piperidylcarbonylamino-cinnamoylglycyl,
pyrrolidinylcarbonylamino-cinnamoylglycyl,
acetylpyrrolidinylcarbonylamino-cinnamoylglycyl,
tert-butoxycarbonylpyrrolidinylcarbonylamino-
cinnamoylglycyl, etc.),
amino acid residue substituted with lower
alkylsulfonylamino-ar(lower)alkenoyl (e.g.
10 mesylaminocinnamoylglycyl,
ethylsulfonylamino-cinnamoylglycyl, etc.),
amino acid residue substituted with N-(lower
alkanoyl)-N-(lower alkyl)amino-ar(lower)alkenoyl
(e.g. N-acetyl-N-methylaminocinnamoylglycyl,
15 N-acetyl-N-ethylaminocinnamoylglycyl,
N-propionyl-N-methylaminocinnamoylglycyl, etc.),
amino acid residue substituted with N-[lower
alkoxy(lower)alkanoyl]-N-(lower alkyl)amino-
ar(lower)alkenoyl (e.g. N-methoxyacetyl-N-
20 methylaminocinnamoylglycyl, N-methoxypropionyl-
N-methylaminocinnamoylglycyl, etc.),
amino acid residue substituted with
N-(lower alkanoyl)-N-[heterocyclic(lower)alkyl]-
amino-ar(lower)alkenoyl (e.g. N-acetyl-N-
25 pyridylmethylaminocinnamoylglycyl, etc.),
amino acid residue substituted with N-(lower
alkanoyl)-N-[lower alkoxy(lower)alkyl]amino-
ar(lower)alkenoyl (e.g.
N-acetyl-N-methoxyethylaminocinnamoylglycyl,
30 N-acetyl-N-methoxymethylaminocinnamoylglycyl,
N-propionyl-N-methoxyethylaminocinnamoylglycyl,
etc.), amino acid residue substituted with
N-(lower alkanoyl)-N-[lower alkoxycarbonyl-
(lower)alkyl]amino-ar(lower)alkenoyl (e.g.
35 N-acetyl-N-tert-butoxycarbonylmethylamino-

2122236

cinnamoylglycyl, N-acetyl-N-tert-butoxycarbonyl-
ethylaminocinnamoylglycyl, N-propionyl-N-tert-
butoxycarbonylmethylaminocinnamoylglycyl, etc.),
amino acid residue substituted with N-(lower
5 alkanoyl)-N-[carboxy(lower)alkyl]amino-
ar(lower)alkenoyl (e.g.
N-acetyl-N-carboxymethylaminocinnamoylglycyl,
N-acetyl-N-carboxyethylaminocinnamoylglycyl,
N-propionyl-N-carboxymethylaminocinnamoylglycyl,
10 etc.), amino acid residue substituted with
N-[lower alkoxy(lower)alkanoyl]-N-[heterocyclic-
(lower)alkyl]amino-ar(lower)alkenoyl (e.g.
N-methoxyacetyl-N-pyridylmethylaminocinnamoyl-
glycyl, N-methoxypropionyl-N-pyridylmethyldamino-
15 cinnamoylglycyl, etc.), amino acid residue
substituted with N-[heterocycliccarbonyl]-N-[
lower alkoxy(lower)alkyl]amino-ar(lower)alkenoyl
(e.g. N-pyridylcarbonyl-N-methoxymethylamino-
cinnamoylglycyl, N-pyridylcarbonyl-N-methoxy-
20 ethylaminocinnamoylglycyl, N-thienylcarbonyl-
N-methoxyethylaminocinnamoylglycyl, etc.),
amino acid residue substituted with
ureido-ar(lower)alkenoyl (e.g.
ureidocinnamoylglycyl, etc.),
25 amino acid residue substituted with lower
alkylureido-ar(lower)alkenoyl (e.g.
methylureidocinnamoylglycyl,
ethylureidocinnamoylglycyl,
dimethylureidocinnamoylglycyl, etc.),
30 amino acid residue substituted with
heterocyclicureido-ar(lower)alkenoyl (e.g.
pyridylureidocinnamoylglycyl,
pyrimidinylureidocinnamoylglycyl,
thienylureidocinnamoylglycyl, etc.),
35 amino acid residue substituted with

2122236

lower alkanoyl-ar(lower)alkenoyl (e.g.
formylcinnamoylglycyl, acetylcinnamoylglycyl,
propionylcinnamoylglycyl, etc.),
amino acid residue substituted with
5 carboxy-ar(lower)alkenoyl (e.g.
carboxycinnamoylglycyl, etc.), amino acid
residue substituted with lower
alkoxycarbonyl-ar(lower)alkenoyl (e.g.
methoxycarbonylcinnamoylglycyl,
10 ethoxycarbonylcinnamoylglycyl, etc.),
amino acid residue substituted with
carbamoyl-ar(lower)alkenoyl (e.g.
carbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with lower
15 alkylcarbamoyl-ar(lower)alkenoyl (e.g.
methylcarbamoylcinnamoylglycyl,
ethylcarbamoylcinnamoylglycyl,
dimethylcarbamoylcinnamoylglycyl,
propylcarbamoylcinnamoylglycyl,
20 isopropylcarbamoylcinnamoylglycyl,
diethylcarbamoylcinnamoylglycyl, N-methyl-N-
ethylcarbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with hydroxy-
(lower)alkylcarbamoyl-ar(lower)alkenoyl (e.g.
25 hydroxyethylcarbamoylcinnamoylglycyl, bis-
(hydroxyethyl)carbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with N-[hydroxy-
(lower)alkyl]-N-(lower alkyl)carbamoyl-
ar(lower)alkenoyl (e.g. N-hydroxyethyl-
30 N-methylcarbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with lower
alkoxy(lower)alkylcarbamoyl-ar(lower)alkenoyl
(e.g. methoxymethylcarbamoylcinnamoylglycyl,
methoxyethylcarbamoylcinnamoylglycyl,
35 bis(methoxyethyl)carbamoylcinnamoylglycyl,

2122236

ethoxyethylcarbamoylcinnamoylglycyl,
methoxypropylcarbamoylcinnamoylglycyl,
bis(ethoxyethyl)carbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with N-[lower
5 alkoxy(lower)alkyl]-N-(lower alkyl)carbamoyl-
ar(lower)alkenoyl (e.g. N-methoxyethyl-N-
methylcarbamoylcinnamoylglycyl, N-ethoxyethyl-
N-methylcarbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with
10 heterocyclic(lower)alkylcarbamoyl-
ar(lower)alkenoyl (e.g.
pyridylmethylcarbamoylcinnamoylglycyl,
furylmethylcarbamoylcinnamoylglycyl,
thienylmethylcarbamoylcinnamoylglycyl, etc.),
15 amino acid residue substituted with
N-[heterocyclic(lower)alkyl]-N-(lower
alkyl)carbamoyl-ar(lower)alkenoyl (e.g.
N-pyridylmethyl-N-methylcarbamoylcinnamoyl-
glycyl, etc.), amino acid residue substituted
20 with heterocycliccarbamoyl-ar(lower)alkenoyl
(e.g. morpholinylcarbamoylcinnamoylglycyl,
thienylcarbamoylcinnamoylglycyl,
pyridylcarbamoylcinnamoylglycyl,
pyrimidinylcarbamoylcinnamoylglycyl,
25 tetrazolylcarbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with optionally
substituted heterocycliccarbonyl-
ar(lower)alkenoyl (e.g.
morpholinocarbonylcinnamoylglycyl,
30 pyrrolidinylcarbonylcinnamoylglycyl,
piperidinocarbonylcinnamoylglycyl,
tetrahydropyridylcarbonylcinnamoylglycyl,
methylpiperazinylcarbonylcinnamoylglycyl, etc.),
amino acid residue substituted with lower
35 alkenylcarbamoyl-ar(lower)alkenoyl (e.g.

2122236

vinylcarbamoylecinnamoylglycyl,
allylcarbamoylecinnamoylglycyl,
methylpropenylcarbamoylecinnamoylglycyl, etc.),
amino acid residue substituted with lower
5 alkynylcarbamoyl-ar(lower)alkenoyl (e.g.
ethynylcarbamoylecinnamoylglycyl,
propynylcarbamoylecinnamoylglycyl, etc.),
amino acid residue substituted with
amino(lower)alkylcarbamoyl-ar(lower)alkenoyl
10 (e.g. aminomethylcarbamoylecinnamoylglycyl,
aminoethylcarbamoylecinnamoylglycyl, etc.),
amino acid residue substituted with lower
alkylamino(lower)alkylcarbamoyl-
ar(lower)alkenoyl (e.g.
15 methylaminomethylcarbamoylecinnamoylglycyl,
methylaminoethylcarbamoylecinnamoylglycyl,
ethylaminoethylcarbamoylecinnamoylglycyl,
dimethylaminoethylcarbamoylecinnamoylglycyl,
etc.), amino acid residue substituted with lower
20 alkylcarbamoxy(lower)alkylcarbamoyl-
ar(lower)alkenoyl (e.g. methylcarbamoxy-
methylcarbamoylecinnamoylglycyl,
methylcarbamoxyethylcarbamoylecinnamoylglycyl,
ethylcarbamoxyethylcarbamoylecinnamoylglycyl,
25 dimethylcarbamoxyethylcarbamoylecinnamoyl-
glycyl, etc.), amino acid residue substituted
with lower alkylcarbamoyl(lower)alkylcarbamoyl-
ar(lower)alkenoyl (e.g.
methylcarbamoylethylcarbamoylecinnamoylglycyl,
30 methylcarbamoylethylcarbamoylecinnamoylglycyl,
ethylcarbamoylethylcarbamoylecinnamoylglycyl,
dimethylcarbamoylethylcarbamoylecinnamoylglycyl,
etc.), amino acid residue substituted with lower
alkoxycarbonyl(lower)alkylcarbamoyl-
35 ar(lower)alkenoyl (e.g.

2122236

methoxycarbonylmethylcarbamoylecinnamoylglycyl,
methoxycarbonylethylcarbamoylecinnamoylglycyl,
ethoxycarbonylmethylcarbamoylecinnamoylglycyl,
ethoxycarbonylethylcarbamoylecinnamoylglycyl,
5 etc.), amino acid residue substituted with
carboxy(lower)alkylcarbamoylecinnamoylglycyl
(e.g. carboxymethylcarbamoylecinnamoylglycyl,
carboxyethylcarbamoylecinnamoylglycyl, etc.),
amino acid residue substituted with [lower
10 alkylcarbamoylecinnamoylglycyl-
ar(lower)alkenoyl (e.g. (methylcarbamoylecinnamoylglycyl-
phenethyl)carbamoylecinnamoylglycyl,
(ethylcarbamoylecinnamoylglycyl)-
carbamoylecinnamoylglycyl, etc.),
15 amino acid residue substituted with [lower
alkoxycarbonyl-ar(lower)alkyl]carbamoylecinnamoylglycyl-
ar(lower)alkenoyl (e.g. (methoxycarbonyl-
phenethyl)carbamoylecinnamoylglycyl,
(ethoxycarbonyl-phenethyl)carbamoylecinnamoylglycyl,
20 glycyl, etc.), amino acid residue substituted
with [carboxy-ar(lower)alkyl]carbamoylecinnamoylglycyl-
ar(lower)alkenoyl (e.g. (carboxy-phenethyl)-
carbamoylecinnamoylglycyl, etc.),
amino acid residue substituted with N-[lower
25 alkylcarbamoylecinnamoylglycyl]-N-(lower
alkyl)carbamoylecinnamoylglycyl-
ar(lower)alkenoyl (e.g.
N-(methylcarbamoylecinnamoylglycyl)-N-methylcarbamoylecinnamoylglycyl,
N-(methylcarbamoylethyl)-N-methylcarbamoylecinnamoylglycyl,
30 N-(ethylcarbamoylethyl)-N-methylcarbamoylecinnamoylglycyl,
N-(dimethylcarbamoylethyl)-N-methylcarbamoylecinnamoylglycyl, etc.),
amino acid residue substituted with N-[lower
alkoxycarbonyl(lower)alkyl]-N-(lower
35 alkyl)carbamoylecinnamoylglycyl-
ar(lower)alkenoyl (e.g.

N-methoxycarbonylmethyl-N-methylcarbamoyl-
cinnamoylglycyl, N-methoxycarbonylethyl-N-
methylcarbamoylcinnamoylglycyl,
5 N-ethoxycarbonylmethyl-N-methylcarbamoyl-
cinnamoylglycyl, N-ethoxycarbonylethyl-N-
methylcarbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with
N-[carboxy(lower)alkyl]-N-(lower alkyl)-
carbamoyl-ar(lower)alkenoyl (e.g. N-carboxy-
10 methyl-N-methylcarbamoylcinnamoylglycyl,
N-carboxyethyl-N-methylcarbamoylcinnamoylglycyl,
etc.) amino acid residue substituted with
arylcarbamoyl-ar(lower)alkenoyl (e.g.
phenylcarbamoylcinnamoylglycyl,
15 naphthylcarbamoylcinnamoylglycyl, etc.),
amino acid residue substituted with ar(lower)-
alkynoyl (e.g. phenylpropioloylglycyl, etc.),
amino acid residue substituted with
heterocyclic(lower)alkenoyl (e.g.
20 morpholinylacryloylglycyl,
pyridylacryloylglycyl, thienylacryloylglycyl,
etc.), amino acid residue substituted with
amino-heterocyclic(lower)alkenoyl (e.g.
aminopyridylacryloylglycyl, etc.),
25 amino acid residue substituted with lower
alkylamino-heterocyclic(lower)alkenoyl (e.g.
methylaminopyridylacryloylglycyl,
dimethylaminopyridylacryloylglycyl, etc.),
amino acid residue substituted with lower
30 alkanoylamino-heterocyclic(lower)alkenoyl (e.g.
acetylaminopyridylacryloylglycyl,
propionylaminopyridylacryloylglycyl, etc.),
amino acid residue substituted with lower
alkenoylamino-heterocyclic(lower)alkenoyl (e.g.
35 acryloylamino-pyridylacryloylglycyl,

2122236

- crotonoylaminopyridylacryloylglycyl, etc.),
amino acid residue substituted with
heterocyclic(lower)alkanoylamino-heterocyclic-
(lower)alkenoyl (e.g.
- 5 pyridylacetylaminopyridylacryloylglycyl,
thienylacetylaminopyridylacryloylglycyl, etc.),
amino acid residue substituted with
heterocycliccarbonylamino-heterocyclic(lower)-
alkenoyl (e.g.
- 10 pyridylcarbonylaminopyridylacryloylglycyl,
furylcarbonylaminopyridylacryloylglycyl, etc.),
amino acid residue substituted with lower
alkanoylamino(lower)alkanoylamino-heterocyclic-
(lower)alkenoyl (e.g.
- 15 acetylaminopropionylaminopyridylacryloylglycyl,
acetylaminopropionylaminopyridylacryloylglycyl,
etc.), amino acid residue substituted with lower
alkoxycarbonyl(lower)alkanoylamino-heterocyclic-
(lower)alkenoyl (e.g.
- 20 ethoxycarbonylacetylaminopyridylacryloylglycyl,
ethoxycarbonylpropionylaminopyridylacryloyl-
glycyl, etc.), amino acid residue substituted
with lower alkoxy(lower)alkanoylamino-
heterocyclic(lower)alkenoyl (e.g.
- 25 methoxyacetylaminopyridylacryloylglycyl,
methoxypropionylaminopyridylacryloylglycyl,
ethoxypropionylaminopyridylacryloylglycyl,
etc.), amino acid residue substituted with lower
alkylureido-heterocyclic(lower)alkenoyl (e.g.
- 30 methylureidopyridylacryloylglycyl, etc.),
amino acid residue substituted with
carboxy-heterocyclic(lower)alkenoyl (e.g.
carboxypyridylacryloylglycyl, etc.),
amino acid residue substituted with lower
- 35 alkoxycarbonyl-heterocyclic(lower)alkenoyl (e.g.

2122236

ethoxycarbonylpyridylacryloylglycyl, etc.),
amino acid residue substituted with lower
alkylcarbamoyl-heterocyclic(lower)alkenoyl (e.g.
methylesterpyridylacryloylglycyl,
5 ethylesterpyridylacryloylglycyl,
dimethylesterpyridylacryloylglycyl,
diethylesterpyridylacryloylglycyl,
isopropylesterpyridylacryloylglycyl,
N-ethyl-N-methylesterpyridylacryloylglycyl,
10 etc.), amino acid residue substituted with lower
alkoxy(lower)alkylcarbamoyl-
heterocyclic(lower)alkenoyl (e.g.
methoxymethylesterpyridylacryloylglycyl,
methoxyethylesterpyridylacryloylglycyl,
15 methoxypropylesterpyridylacryloylglycyl,
ethoxyethylesterpyridylacryloylglycyl,
bis(methoxyethyl)carbamoylpyridylacryloylglycyl,
etc.), amino acid residue substituted with
hydroxy(lower)alkylcarbamoyl-
20 heterocyclic(lower)alkenoyl (e.g.
hydroxymethylesterpyridylacryloylglycyl,
hydroxyethylesterpyridylacryloylglycyl,
bis(hydroxyethyl)carbamoylpyridylacryloylglycyl,
etc.), amino acid residue substituted with
25 heterocycliccarbamoyl-heterocyclic(lower)-
alkenoyl (e.g.
pyridylcarbamoylpyridylacryloylglycyl,
morpholinylesterpyridylacryloylglycyl,
thienylesterpyridylacryloylglycyl,
30 pyrimidinylesterpyridylacryloylglycyl,
etc.), amino acid residue substituted with
heterocyclic(lower)alkylcarbamoyl-
heterocyclic(lower)alkenoyl (e.g.
pyridylmethylesterpyridylacryloylglycyl,
35 furylmethylesterpyridylacryloylglycyl,

2122236

thienylmethylcarbamoylpyridylacryloylglycyl,
etc.), amino acid residue substituted with
heterocycliccarbonyl-
heterocyclic(lower)alkenoyl (e.g.
5 morpholinocarbonylpyridylacryloylglycyl,
pyrrolidinylcarbonylpyridylacryloylglycyl,
piperidinocarbonylpyridylacryloylglycyl, etc.),
amino acid residue substituted with lower
alkenylcarbamoyl-heterocyclic(lower)alkenoyl
10 (e.g. vinylcarbamoylpyridylacryloylglycyl,
allylcarbamoylpyridylacryloylglycyl, etc.),
amino acid residue substituted with lower
alkynylcarbamoyl-heterocyclic(lower)alkenoyl
15 (e.g. ethylcarbamoylpyridylacryloylglycyl,
propynylcarbamoylpyridylacryloylglycyl, etc.),
amino acid residue substituted with
heterocyclicthio(lower)alkanoyl (e.g.
pyridylthioacetylglycyl,
pyrimidinylthioacetylglycyl,
20 imidazolylthiopropionylglycyl, etc.),
amino acid residue substituted with optionally
substituted heterocycliccarbonyl (e.g.
morpholinocarbonylglycyl, indolylcarbonylglycyl,
4-methyl-1-piperazinylcarbonylglycyl, etc.),
25 amino acid residue substituted with
cyclo(lower)alkylcarbonyl (e.g.
cyclopropylcarbonylglycyl,
cyclopentylcarbonylglycyl,
cyclohexylcarbonylglycyl,
30 cyclohexylcarbonylsarcosyl, etc.), amino acid
residue substituted with lower alkoxycarbonyl
(e.g. methoxycarbonylglycyl,
tert-butoxycarbonylglycyl,
tert-butoxycarbonylsarcosyl,
35 tert-butoxycarbonylalanyl, etc.), amino acid

2122236

residue substituted with aryloxy carbonyl
(e.g. phenoxy carbonyl glycy l, etc.), amino
acid residue substituted with
5 aroyl(lower)alkanoyl (e.g. phenyloxalyl glycy l,
benzoylpropionyl glycy l, etc.), amino acid
residue substituted with aroyl (e.g.
benzoyl glycy l, benzoylsarcosyl, naphthoyl glycy l,
benzoylalanyl, etc.), amino acid residue
substituted with nitro-aryloxy carbonyl (e.g.
10 nitrophenyloxycarbonyl glycy l, etc.), amino acid
residue substituted with carbamoyl (e.g.
carbamoyl glycy l, carbamoylalanyl,
carbamoylsarcosyl, carbamoyl- β -alanyl, etc.),
amino acid residue substituted with lower
15 alkylcarbamoyl (e.g. methylcarbamoyl glycy l,
ethylcarbamoyl glycy l, propylcarbamoyl glycy l,
isopropylcarbamoyl glycy l, pentylcarbamoyl glycy l,
methylcarbamoylsarcosyl, ethylcarbamoylalanyl,
isopropylcarbamoyl- β -alanyl, etc.), amino acid
20 residue substituted with lower
alkoxy carbonyl(lower)alkylcarbamoyl (e.g.
methoxy carbonylmethylcarbamoyl glycy l,
ethoxy carbonylmethylcarbamoyl glycy l, etc.),
amino acid residue substituted with lower
25 alkenylcarbamoyl (e.g. vinylcarbamoyl glycy l,
allylcarbamoyl glycy l, allylcarbamoylsarcosyl,
etc.), amino acid residue substituted with
cyclo(lower)alkylcarbamoyl (e.g.
cyclopropylcarbamoyl glycy l,
30 cyclohexylcarbamoyl glycy l,
cyclohexylcarbamoylsarcosyl, etc.),
amino acid residue substituted with
arylcarbamoyl (e.g. phenylcarbamoyl glycy l,
naphthylcarbamoyl glycy l, tolylcarbamoyl glycy l,
35 ethylphenylcarbamoyl glycy l,

2122236

phenylcarbamoylalanyl, phenylcarbamoylsarcosyl,
etc.), amino acid residue substituted with lower
alkoxy-arylcarbamoyl (e.g.
methoxyphenylcarbamoylglycyl,
5 ethoxyphenylcarbamoylglycyl,
methoxyphenylcarbamoylalanyl, etc.),
amino acid residue substituted with
halo(lower)alkyl-arylcarbamoyl (e.g.
trifluoromethylphenylcarbamoylglycyl,
10 trifluoromethylphenylcarbamoylalanyl,
trifluoromethylphenylcarbamoylsarcosyl, etc.),
amino acid residue substituted with
halo-arylcarbamoyl (e.g.
chlorophenylcarbamoylglycyl,
15 fluorophenylcarbamoylglycyl,
fluorophenylcarbamoylalanyl, etc.),
amino acid residue substituted with lower
alkanoyl-arylcarbamoyl (e.g.
acetylphenylcarbamoylglycyl,
20 propionylphenylcarbamoylalanyl, etc.),
amino acid residue substituted with
hydroxy(lower)alkyl-arylcarbamoyl (e.g.
hydroxymethylphenylcarbamoylglycyl,
hydroxyethylphenylcarbamoylglycyl,
25 hydroxyethylphenylcarbamoylalanyl, etc.),
amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyl (e.g.
morpholinocarbonylphenylcarbamoylglycyl,
piperidinocarbonylphenylcarbamoylglycyl,
30 thiomorpholinocarbonylphenylcarbamoylalanyl,
piperazinylcarbonylphenylcarbamoylglycyl,
pyrrolidinylcarbonylphenylcarbamoylglycyl,
1,2,3,6-tetrahydropyridylcarbonylphenyl-
carbamoylglycyl, etc.),
35 amino acid residue substituted with

2122236

carboxy-arylcarbamoyl (e.g.
carboxyphenylcarbamoylglycyl, etc.),
amino acid residue substituted with lower
alkoxycarbonyl-arylcarbamoyl (e.g.
5 methoxycarbonylphenylcarbamoylglycyl,
ethoxycarbonylphenylcarbamoylglycyl, etc.),
amino acid residue substituted with
carbamoyl-arylcarbamoyl (e.g.
carbamoylphenylcarbamoylglycyl, etc.),
10 amino acid residue substituted with lower
alkylcarbamoyl-arylcarbamoyl (e.g.
methylcarbamoylphenylcarbamoylglycyl,
ethylcarbamoylphenylcarbamoylglycyl,
propylcarbamoylphenylcarbamoylglycyl,
15 dimethylcarbamoylphenylcarbamoylglycyl,
diethylcarbamoylphenylcarbamoylglycyl,
N-ethyl-N-methylcarbamoylphenylcarbamoylglycyl,
N-isopropyl-N-methylcarbamoylphenyl-
carbamoylglycyl, etc.),
20 amino acid residue substituted with
nitro-arylcarbamoyl (e.g.
nitrophenylcarbamoylglycyl, etc.),
amino acid residue substituted with
cyano-arylcarbamoyl (e.g.
25 cyanophenylcarbamoylglycyl, etc.),
amino acid residue substituted with
amino-arylcarbamoyl (e.g.
aminophenylcarbamoylglycyl, etc.),
amino acid residue substituted with lower
30 alkylamino-arylcarbamoyl (e.g.
methylaminophenylcarbamoylglycyl,
ethylaminophenylcarbamoylglycyl,
dimethylaminophenylcarbamoylglycyl, etc.),
amino acid residue substituted with lower
35 alkanoylamino-arylcarbamoyl (e.g.

2122236

acetylamino-phenylcarbamoylglycyl,
propionylamino-phenylcarbamoylglycyl, etc.),
amino acid residue substituted with N-(lower
alkanoyl)-N-(lower alkyl)amino-arylcarbamoyl
5 (e.g. N-acetyl-N-methylamino-phenylcarbamoyl-
glycyl, N-propionyl-N-methylamino-phenyl-
carbamoylglycyl, etc.), amino acid residue
substituted with lower
alkoxy(lower)alkanoylamino-arylcarbamoyl (e.g.
10 methoxyacetylamino-phenylcarbamoylglycyl,
methoxypropionylamino-phenylcarbamoylglycyl,
etc.), amino acid residue substituted with lower
alkoxycarbonyl(lower)alkanoylamino-arylcarbamoyl
15 (e.g. ethoxycarbonylacetylamino-phenyl-
carbamoylglycyl, methoxycarbonylpropionylamino-
phenylcarbamoylglycyl, etc.),
amino acid residue substituted with
carboxyamino-arylcarbamoyl (e.g.
carboxyamino-phenylcarbamoylglycyl, etc.),
20 amino acid residue substituted with lower
alkoxycarbonylamino-arylcarbamoyl (e.g.
ethoxycarbonylamino-phenylcarbamoylglycyl, etc.),
amino acid residue substituted with
aroylamino-arylcarbamoyl (e.g.
25 benzoylamino-phenylcarbamoylglycyl, etc.),
amino acid residue substituted with
heterocycliccarbonylamino-arylcarbamoyl (e.g.
pyridylcarbonylamino-phenylcarbamoylglycyl,
furylcarbonylamino-phenylcarbamoylglycyl,
30 morpholinocarbonylamino-phenylcarbamoylglycyl,
etc.), amino acid residue substituted with
heterocyclic(lower)alkanoylamino-arylcarbamoyl
(e.g. pyridylacetylamino-phenylcarbamoylglycyl,
thienylacetylamino-phenylcarbamoylglycyl, etc.),
35 amino acid residue substituted with
ureido-arylcarbamoyl (e.g.

2122236

ureidophenylcarbamoyleglycyl, etc.),
amino acid residue substituted with lower
alkylureido-arylcarbamoyle (e.g.
methylureidophenylcarbamoyleglycyl,
5 ethylureidophenylcarbamoyleglycyl, etc.),
amino acid residue substituted with
hydroxyimino(lower)alkyl-arylcarbamoyle (e.g.
hydroxyiminoethylphenylcarbamoyleglycyl, etc.),
amino acid residue substituted with lower
10 alkoxyimino(lower)alkyl-arylcarbamoyle (e.g.
methoxyiminoethylphenylcarbamoyleglycyl, etc.),
amino acid residue substituted with lower
alkylhydrazono(lower)alkyl-arylcarbamoyle (e.g.
methylhydrazonoethylphenylcarbamoyleglycyl,
15 dimethylhydrazonoethylphenylcarbamoyleglycyl,
etc.), amino acid residue substituted with
optionally substituted
heterocyclic-arylcarbamoyle
(e.g. oxopyrrolidinylphenylcarbamoyleglycyl,
20 oxopiperidinophenylcarbamoyleglycyl,
dioxopyrrolidinylphenylcarbamoyleglycyl,
oxooxazolidinylphenylcarbamoyleglycyl,
pyrrolylphenylcarbamoyleglycyl, etc.),
amino acid residue substituted with
25 heterocycliccarbonyl-arylcarbamoyle having lower
alkyl (e.g. methylpiperazinylcarbonylphenyl-
carbamoyleglycyl, ethylpiperazinyl-
carbonylphenylcarbamoyleglycyl, etc.),
amino acid residue substituted with hetero-
30 cycliccarbonyl-arylcarbamoyle having aryl (e.g.
phenylpiperazinylcarbonylphenylcarbamoyleglycyl,
etc.), amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyle having a
heterocyclic group (e.g.
35 pyridylpiperazinylcarbonylphenylcarbamoyleglycyl,

2122236

etc.), amino acid residue substituted with
heterocycliccarbonyl-arylcarbamoyl having lower
alkanoyl (e.g. acetylpiperazinylcarbonylphenyl-
carbamoylglycyl, etc.), amino acid residue
5 substituted with heterocycliccarbonyl-aryl-
carbamoyl having lower alkoxycarbonyl (e.g.
ethoxycarbonylpiperazinylcarbonylphenyl-
carbamoylglycyl, etc.),
amino acid residue substituted with
10 heterocycliccarbonyl-arylcarbamoyl having lower
alkylamino (e.g. methylaminopiperazinylcarbonyl-
phenylcarbamoylglycyl, dimethylaminopiperidino-
carbonylphenylcarbamoylglycyl, etc.),
amino acid residue substituted with
15 heterocycliccarbonyl-arylcarbamoyl having lower
alkylcarbamoyl (e.g. methylcarbamoypiperazinyl-
carbonylphenylcarbamoylglycyl, etc.),
amino acid residue substituted with
hydroxy(lower)alkylcarbamoyl-arylcarbamoyl (e.g.
20 hydroxymethylcarbamoylphenylcarbamoylglycyl,
hydroxyethylcarbamoylphenylcarbamoylglycyl,
bis(hydroxyethyl)carbamoylphenylcarbamoylglycyl,
etc.), amino acid residue substituted with
N-[hydroxy(lower)alkyl]-N-(lower
25 alkyl)carbamoyl-arylcarbamoyl (e.g.
N-(hydroxyethyl)-N-methylcarbamoylphenyl-
carbamoylglycyl, etc.),
amino acid residue substituted with lower
alkoxy(lower)alkylcarbamoyl-arylcarbamoyl (e.g.
30 methoxymethylcarbamoylphenylcarbamoylglycyl,
methoxyethylcarbamoylphenylcarbamoylglycyl,
ethoxyethylcarbamoylphenylcarbamoylglycyl,
bis(methoxyethyl)carbamoylphenylcarbamoylglycyl,
bis(ethoxyethyl)carbamoylphenylcarbamoylglycyl
etc.), amino acid residue substituted with
35

2122236

5 N-[lower alkoxy(lower)alkyl]-N-(lower alkyl)-
carbamoylarylcarbamoyl (e.g. N-(methoxyethyl)-N-
methylcarbamoylphenylcarbamoylglycyl,
N-(methoxypropyl)-N-methylcarbamoylphenyl-
carbamoylglycyl, etc.),
amino acid residue substituted with lower
alkylamino(lower)alkylcarbamoyl-arylcarbamoyl
(e.g. methylaminoethylcarbamoylphenyl-
carbamoylglycyl, dimethylaminoethylcarbamoyl-
10 phenylcarbamoylglycyl, etc.), amino acid residue
substituted with N-[lower alkylamino(lower)-
alkyl]-N-(lower alkyl)carbamoyl-arylcarbamoyl
(e.g. N-(dimethylaminoethyl)-N-methyl-
carbamoylphenylcarbamoylglycyl,
15 N-(dimethylaminopropyl)-N-methylcarbamoylphenyl-
carbamoylglycyl, etc.),
amino acid residue substituted with
heterocycliccarbamoyl-arylcarbamoyl (e.g.
morpholinylcarbamoylphenylcarbamoylglycyl,
20 thienylcarbamoylphenylcarbamoylglycyl,
pyridylcarbamoylphenylcarbamoylglycyl,
pyrimidinylcarbamoylphenylcarbamoylglycyl,
etc.), amino acid residue substituted with
N-(heterocyclic)-N-(lower alkyl)carbamoyl-
25 arylcarbamoyl (e.g. N-pyridyl-N-methylcarbamoyl-
phenylcarbamoylglycyl, etc.), amino acid residue
substituted with heterocyclic(lower)-
alkylcarbamoyl-arylcarbamoyl (e.g.
pyridylmethylcarbamoylphenylcarbamoylglycyl,
30 pyridylethylcarbamoylphenylcarbamoylglycyl,
thienylmethylcarbamoylphenylcarbamoylglycyl,
etc.), amino acid residue substituted with
N-[heterocyclic(lower)alkyl]-N-(lower alkyl)-
carbamoyl-arylcarbamoyl (e.g. N-pyridylmethyl-N-
35 methylcarbamoylphenylcarbamoylglycyl, etc.),

2122236

- 5 amino acid residue substituted with
N-[heterocyclic(lower)alkyl]-N-[lower
alkoxy(lower)alkyl]carbamoyl-arylcarbamoyl (e.g.
N-pyridylmethyl-N-methoxyethylcarbamoylphenyl-
carbamoylglycyl, etc.),
- 10 amino acid residue substituted with
arylcarbamoyl-arylcarbamoyl (e.g.
phenylcarbamoylphenylcarbamoylglycyl, etc.),
amino acid residue substituted with lower
alkylaminoarylcarbamoyl-arylcarbamoyl (e.g.
dimethylaminophenylcarbamoylphenyl-
carbamoylglycyl, etc.),
- 15 amino acid residue substituted with
arylthiocarbamoyl (e.g.
phenylthiocarbamoylglycyl,
naphthylthiocarbamoylglycyl,
phenylthiocarbamoylalanyl,
phenylthiocarbamoylsarcosyl, etc.), amino acid
residue substituted with ar(lower)alkylcarbamoyl
20 (e.g. benzylcarbamoylglycyl,
benzylcarbamoylsarcosyl,
benzylcarbamoylalanyl, etc.),
- 25 amino acid residue substituted with aroyl-
carbamoyl (e.g. benzoylcarbamoylglycyl, etc.),
amino acid residue substituted with
heterocycliccarbamoyl (e.g.
pyridylcarbamoylglycyl, pyridylcarbamoylalanyl,
pyridylcarbamoylsarcosyl,
thienylcarbamoylglycyl,
30 pyrazolylcarbamoylglycyl,
pyrimidinylcarbamoylglycyl,
quinolylcarbamoylglycyl,
isoquinolylcarbamoylglycyl, etc.),
- 35 amino acid residue substituted with
heterocyclic(lower)alkylcarbamoyl (e.g.

2122236

pyridylmethylcarbamoylglycyl,
pyridylethylcarbamoylglycyl,
thienylmethylcarbamoylglycyl, etc.),
amino acid residue substituted with
5 arylaminocarbamoyl (e.g.
phenylaminocarbamoylglycyl, etc.),
amino acid residue substituted with
ar(lower)alkenylsulfonyl (e.g. styrylsulfonyl-
glycyl, cinnamoylsulfonylglycyl, etc.),
10 amino acid residue substituted with lower
alkylsulfonyl (e.g. mesylglycyl, ethylsulfonyl-
glycyl, mesylsarcosyl, mesylalanyl, etc.),
amino acid residue substituted with phthaloyl
(e.g. phthaloylglycyl, phthaloylalanyl,
15 phthaloyl- β -alanyl, etc.),
amino acid residue having unsubstituted amino
acid residue (e.g. glycylglycyl, alanylglycyl,
sarcosylglycyl, prolylglycyl, glycylsarcosyl,
prolylsarcosyl, etc.),
20 amino acid residue having substituted
amino acid residue such as amino acid residue
having amino acid residue substituted with lower
alkyl (e.g. dimethylglycylglycyl,
diethylglycylglycyl, dimethylglycylsarcosyl,
25 ethylsarcosylglycyl, isopropylsarcosylglycyl,
ethylglycylglycyl, propylglycylglycyl,
isopropylglycylglycyl, ethylglycylalanyl,
dimethylglycylalanyl, dimethylalanylglycyl,
dimethyl- β -alanylglycyl, etc.), amino acid
30 residue having amino acid residue substituted
with a heterocyclic group (e.g.
morpholinoglycylglycyl, piperidinoglycylglycyl,
pyridylglycylglycyl, piperidinosarcosylglycyl,
etc.), amino acid residue having amino acid
35 residue substituted with

2122236

heterocyclic(lower)alkyl
(e.g. pyridylmethylglycylglycyl,
imidazolymethylglycylglycyl,
furylmethylglycylglycyl,
5 thienylmethylsarcosylglycyl, etc.),
amino acid residue having amino acid residue
substituted with cycloalkyl (e.g.
cyclopropylglycylglycyl, cyclobutylglycylglycyl,
cyclopentylglycylglycyl, cyclohexylglycylglycyl,
10 cycloheptylglycylglycyl, cyclooctylglycylglycyl,
adamantylglycylglycyl, cyclohexylsarcosylglycyl,
cycloheptylsarcosylglycyl, cyclohexylglycyl-
sarcosyl, cyclohexylglycylalanyl, etc.),
amino acid residue having amino acid residue
15 substituted with aryl (e.g. phenylglycylglycyl,
phenylsarcosylglycyl, etc.),
amino acid residue having amino acid residue
substituted with lower alkanoyl (e.g.
acetylglycylglycyl, acetylprolylglycyl,
20 propionylglycylglycyl, acetylalanylglycyl,
etc.), amino acid residue having amino acid
residue substituted with lower alkoxycarbonyl
(e.g. tert-butoxycarbonylglycylglycyl,
tert-butoxycarbonylprolylglycyl, etc.),
25 amino acid residue having amino acid residue
substituted with ar(lower)alkyl (e.g.
benzylglycylglycyl, etc.) and
amino acid residue having amino acid residue
substituted with phthaloyl (e.g.
30 phthaloylglycylglycyl, etc.), etc.}, etc.];
or a heterocyclic group such as piperazinyl, which
may be substituted with substituent(s) such as
ar(lower)alkyl [e.g. benzyl, phenethyl, etc.], lower
alkoxycarbonyl(lower)alkyl [e.g.
35 methoxycarbonylmethyl, methoxycarbonylethyl

2122236

ethoxycarbonylmethyl, etc.] and/or oxo;
R⁴ and R⁵ are each hydrogen; or halogen such as fluorine,
chlorine, bromine and iodine;
Q is O or N-R⁹, in which R⁹ is hydrogen; or acyl such
5 as lower alkanoyl [e.g. formyl, acetyl, propionyl,
butyryl, etc.] and lower alkoxycarbonyl [e.g.
tert-butoxycarbonyl, etc.];
A is lower alkylene such as methylene, ethylene,
methylenemethylene and propylene.

10

Suitable "a leaving group" may be a conventional acid
residue such as halogen [e.g. fluoro, chloro, bromo and
iodo], arenesulfonyloxy [e.g. benzenesulfonyloxy,
tosyloxy, etc.], alkanesulfonyloxy [e.g. mesyloxy,
15 ethanesulfonyloxy, etc.], and the like.

Suitable pharmaceutically acceptable salts of the
object compound [I] are conventional non-toxic salts and
include a metal salt such as an alkali metal salt [e.g.
sodium salt, potassium salt, etc.] and an alkaline earth
20 metal salt [e.g. calcium salt, magnesium salt, etc.], an
ammonium salt, an organic base salt [e.g. trimethylamine
salt, triethylamine salt, pyridine salt, picoline salt,
dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt,
etc.], an organic acid addition salt [e.g. formate,
25 acetate, trifluoroacetate, maleate, tartrate, oxalate,
methanesulfonate, benzenesulfonate, toluenesulfonate,
etc.], an inorganic acid addition salt [e.g.
hydrochloride, hydrobromide, sulfate, phosphate, etc.], a
salt with an amino acid [e.g. arginine salt, aspartic acid
30 salt, glutamic acid salt, etc.], an intramolecular salt
and the like.

With respect to the salts of the compounds [Ia] to
[If] in the Processes 2 to 4, it is to be noted that these
compounds are included within the scope of the compound
35 [I], and accordingly the suitable examples of the salts of

2122236

these compounds are to be referred to those as exemplified for the object compound [I].

5 The processes for preparing the object compound [I] are explained in detail in the following.

Process 1

10 The object compound [I] or its salt can be prepared by reacting a compound [II] or its salt with a compound [III] or its salt.

Suitable salts of the compounds [II] and [III] may be the same as those exemplified for the compound [I].

15 The reaction is preferably carried out in the presence of a base such as alkali metal [e.g. lithium, sodium, potassium, etc.], the hydroxide or carbonate or bicarbonate thereof [e.g. sodium hydroxide, potassium carbonate, potassium bicarbonate, etc.], alkali metal alkoxide [e.g. sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.], or the like.

20 This reaction is usually carried out in a conventional solvent such as tetrahydrofuran, dioxane, N,N-dimethylformamide, acetone, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

25

Process 2

The object compound [Ib] or its salt can be prepared by acylating a compound [Ia] or its salt.

30 The acylation is carried out in the presence of an acylating agent.

Suitable acylating agents are the corresponding carboxylic acid or sulfonic acid compounds, which are represented by the formula : R-OH wherein R is acyl, and reactive derivatives thereof, and the corresponding isocyanate or isothiocyanate compounds.

35

2122236

As suitable said reactive derivatives, there may be mentioned acid halides, acid anhydrides, active amides and active esters. Suitable examples are acid halides such as acid chloride and acid bromide, mixed acid anhydrides with various acids [e.g. substituted phosphoric acid such as dialkyl phosphoric acid, sulfuric acid, aliphatic carboxylic acid, aromatic carboxylic acid, etc.], symmetric acid anhydrides, active amides with various imidazoles, and active esters such as p-nitrophenyl ester and N-hydroxysuccinimide ester. The kind of such reactive derivatives can be selected depending on the kind of acyl group to be introduced.

The reaction is usually carried out in a conventional solvent, such as methylene chloride, chloroform, pyridine, dioxane, tetrahydrofuran, N,N-dimethylformamide, or the like. In case that the acylating agent is liquid, it can also be used as a solvent. In case that the carboxylic acid or sulfonic acid compounds are used as acylating agent in the free acid form or salt form, it is preferable to carry out the reaction in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide or the like.

The reaction temperature is not critical and the reaction can be carried out under cooling, at ambient temperature, or under heating.

This reaction is preferably carried out in the presence of a conventional inorganic base or in the presence of a conventional organic base.

30 Process 3

The object compound [Id] or its salt can be prepared by acylating a compound [Ic] or its salt.

This reaction can be carried out in substantially the same manner as Process 2, and therefore the reaction mode and reaction condition of this reaction are to be referred

to those explained in Process 2.

Process 4

5 The object compound [If] or its salt can be prepared by reacting a compound [Ie] or its reactive derivative at the carboxy group or a salt thereof with a compound [IV] or its reactive derivative at the amino group or a salt thereof.

10 Suitable reactive derivative at the carboxy group of the compound [Ie] may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as dialkylphosphoric acid, sulfuric acid
15 aliphatic carboxylic acid or aromatic carboxylic acid; a symmetrical acid anhydride; an activated amide with imidazole; or an activated ester [e.g. p-nitrophenyl ester, etc.]. These reactive derivatives can optionally be selected from them according to the kind of the
20 compound [Ie] to be used.

Suitable reactive derivative at the amino group of the compound [IV] may be a silyl derivative formed by the reaction of the compound [IV] with a silyl compound such as bis(trimethylsilyl)acetamide or
25 mono(trimethylsilyl)acetamide, or the like.

Suitable salts of the compound [IV] and its reactive derivative can be referred to the organic or inorganic acid addition salts as exemplified for the compound [I].

30 This reaction can be carried out in substantially the same manner as Process 2, and therefore the reaction mode and reaction condition of this reaction are to be referred to those explained in Process 2.

The object compound [I] and the starting compounds can also be prepared by the methods of Examples and
35 Preparations mentioned below or similar manners thereto or

2122236

conventional manners.

5 The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, chromatography, reprecipitation or the like.

10 It is to be noted that the compound [I] and the other compounds may include one or more stereoisomers and geometrical isomers due to asymmetric carbon atoms and double bonds, and all of such isomers and mixture thereof are included within the scope of this invention.

15 The object compound [I] and pharmaceutically acceptable salts thereof possess strong activities as bradykinin antagonists, and are useful for the treatment and/or the prevention of bradykinin or its analogues mediated diseases such as allergy, inflammation,
20 autoimmune disease, shock, pain, or the like, and more particularly for the prevention and/or the treatment of asthma, cough, bronchitis, rhinitis, rhinorrhea, obstructive pulmonary disease [e.g. pulmonary emphysema, etc.], expectorant, pneumonitis, systemic inflammatory response syndrome (SIRS), septic shock, endotoxin shock, anaphylactic shock, adult respiratory distress syndrome, disseminated intravascular coagulopathy, arthritis,
25 rheumatism, osteoarthritis, lumbago, inflammation-induced bone resorption, conjunctivitis, vernal conjunctivitis, uveitis, iritis, iridocyclitis, headache, migraine, toothache, backache, superficial pain, cancerous pain, postoperative pain, tenalgia, trauma [e.g. wound, burn, etc.], rash, erythema, eczema or dermatitis [e.g. contact
30 dermatitis, atopic dermatitis, etc.], urticaria, herpes, itching, psoriasis, lichen, inflammatory bowel disease [e.g. ulcerative colitis, Crohn's disease, etc.], diarrhea, hepatitis, pancreatitis, gastritis, esophagitis, food allergy, ulcer, irritable bowel syndrome, nephritis,
35 angina, periodontitis, edema, hereditary angioneurotic

- 85 -

edema, cerebral edema, low blood pressure, thrombosis, myocardial infarction, cerebral vasospasm, congestion, coagulation, gout, central nervous system injury, premature labor, arteriosclerosis, postgastrectomy dumping syndrome, carcinoid syndrome, altered sperm mobility, diabetic neuropathy, neuralgia, graft rejection in transplantation, or the like, in human being or animals.

And further, it is known that bradykinin relates to the release of mediators such as prostaglandins, leukotrienes, tachykinins, histamine, thromboxanes, or the like, so the compound [I] is expected to be useful for the prevention and/or the treatment of such mediators mediated diseases.

In order to illustrate the usefulness of the object compound [I], the pharmacological test data of some representative compounds of the compound [I] are shown in the following.

³H-Bradykinin receptor binding

(i) Test Method :

(a) Crude ileum membrane preparation

Male Hartly strain guinea pigs were sacrificed by decapitation. The ileum was removed and homogenized in buffer (50 mM trimethylaminoethanesulfonic acid (TES), 1 mM 1,10-phenanthroline pH 6.8). The homogenate was centrifuged (1000 xg, 20 minutes) to remove tissue clumps and the supernatant was centrifuged (100,000 xg, 60 minutes) to yield a pellet. The pellet was resuspended in buffer (50 mM TES, 1 mM 1,10-phenanthroline, 140 mg/l bacitracin, 1 mM dithiothreitol, 0.1 % bovine serum albumin pH 6.8) and homogenized with a glass-teflon™ homogenizer to yield suspension which was referred to as crude membrane suspension. The obtained membrane suspension was stored

2122236

at -80°C until use.

(b) ³H-Bradykinin binding to the membrane

The frozen crude membrane suspension was thawed. In binding assays, ³H-Bradykinin (0.06 nM) and drug (1 x 10⁻⁶M) were incubated with 50 µl of the membrane suspension at room temperature for 60 minutes in a final volume of 250 µl. Separation of receptor-bound from free ³H-Bradykinin is achieved by immediate filtration under vacuum and washed three times with 5 ml of ice-cold buffer (50 mM Tris-HCl pH 7.5). Non-specific binding was defined as binding in the presence of 0.1 µM Bradykinin. The radioactivity retained on rinsed filters was determined by a liquid-scintillation counter.

(ii) Test Results

Test Compound (Example No.)	Inhibition % of ³ H-Bradykinin binding (concentration: 1 x 10 ⁻⁶ M)
29-(36)	98
34-(7)	100
35-(3)	99
41-(12)	95
41-(53)	99
41-(64)	95
57 (hydrochloride)	99
58-(11) (dihydrochloride)	99

The effects of the compound [I] on bradykinin-induced

2122236

bronchoconstriction and carrageenin-induced paw edema were measured according to similar manners described in British Journal of Pharmacology, 102, 774-777 (1991).

5 For therapeutic purpose, the compound [I] and a
pharmaceutically acceptable salt thereof of the present
invention can be used in a form of pharmaceutical
preparation containing one of said compounds, as an active
ingredient, in admixture with a pharmaceutically
10 acceptable carrier such as an organic or inorganic solid,
semi-solid or liquid excipient suitable for oral,
parenteral such as intravenous, intramuscular,
subcutaneous or intraarticular, external such as topical,
enteral, intrarectal, transvaginal, inhalant, ophthalmic,
15 nasal or hypoglossal administration. The pharmaceutical
preparations may be capsules, tablets, dragees, granules,
suppositories, solution, lotion, suspension, emulsion,
ointment, gel, cream, or the like. If desired, there may
be included in these preparations, auxiliary substances,
20 stabilizing agents, wetting or emulsifying agents, buffers
and other commonly used additives.

While the dosage of the compound [I] will vary
depending upon the age and condition of the patient, an
average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg,
25 100 mg, 250 mg, 500 mg and 1000 mg of the compound [I] may
be effective for preventing and/or treating the above-
mentioned diseases. In general, amounts between 0.1
mg/body and about 1,000 mg/body may be administered per
day.

30

35

2122236

The following Preparations and Examples are given for the purpose of illustrating this invention.

Preparation 1

5 2,6-Dichloro-3-(phthalimidoacetyl)aminotoluene was obtained according to a similar manner to that of Example 5 mentioned below.

mp : 245-246°C

10 NMR (CDCl₃, δ) : 2.48 (3H, s), 4.59 (2H, s), 7.27 (1H, d, J=9Hz), 7.70-7.96 (4H), 8.00 (1H, br s), 8.12 (1H, d, J=9Hz)

Preparation 2

15 2,6-Dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]-toluene was obtained according to a similar manner to that of Example 7 mentioned below.

mp : 193-194°C

20 NMR (CDCl₃, δ) : 2.58 (3H, s), 3.21 (3H, s), 4.10 (2H, s), 7.30 (1H, d, J=9Hz), 7.42 (1H, d, J=9Hz), 7.65-7.91 (4H)

Preparation 3

25 A mixture of 2,6-dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]toluene (303 mg), N-bromosuccinimide (150 mg), 2,2'-azobis-(2,4-dimethyl-4-methoxyvaleronitrile) (30 mg) and dichloromethane (6 ml) was heated under reflux for 5 hours. N-Bromosuccinimide (75 mg) was added therein and the mixture was heated under reflux for additional 3 hours. The reaction mixture was washed with saturated sodium bicarbonate solution twice and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized from diethyl ether to give 3-bromomethyl-2,4-dichloro-N-methyl-N-(phthalimido-

30 acetyl)aniline (102 mg) as crystals.

35 mp : 211°C (dec.)

NMR (CDCl_3 , δ) : 3.24 (3H, s), 4.09 (2H, s), 4.81 (2H, s), 7.44 (1H, d, $J=9\text{Hz}$), 7.51 (1H, d, $J=9\text{Hz}$), 7.68-7.91 (4H)

5 Preparation 4

A mixture of o-anisidine (15.11 g), ethyl propionyl-acetate (17.69 g) and acetic acid (0.5 ml) in benzene (30 ml) was refluxed removing water for 24 hours. The solvent was removed in vacuo, and the residue was dissolved in toluene (30 ml). The reaction mixture was refluxed for an additional 8 hours. The solvent was removed in vacuo. The residue was purified by column chromatography (hexane - ethyl acetate) to give ethyl 3-(2-methoxyanilino)-2-pentenoate (15.11 g) as an oil.

15 NMR (CDCl_3 , δ) : 1.06 (3H, t, $J=7\text{Hz}$), 1.30 (3H, t, $J=7\text{Hz}$), 2.32 (2H, q, $J=7\text{Hz}$), 3.85 (3H, s), 4.18 (2H, q, $J=7\text{Hz}$), 4.74 (1H, s), 6.83-6.98 (2H), 7.06-7.20 (2H), 10.18 (1H, br s)

20 Preparation 5

To a mixture of diphenyl ether (30 ml) and biphenyl (30 g) was added ethyl 3-(2-methoxyanilino)-2-pentenoate (15.1 g) during which time the internal temperature was maintained 230-235°C. The mixture was stirred at 235°C for 1 hour. To the reaction mixture was added hexane (150 ml). The precipitate was collected by vacuum filtration and washed with hexane to give 2-ethyl-4-hydroxy-8-methoxyquinoline (10.37 g) as crystals.

mp : 190-192°C

30 NMR (CDCl_3 , δ) : 1.38 (3H, t, $J=7\text{Hz}$), 2.70 (2H, q, $J=7\text{Hz}$), 4.00 (3H, s), 6.20 (1H, d, $J=1\text{Hz}$), 7.02 (1H, dd, $J=9, 1\text{Hz}$), 7.23 (1H, t, $J=9\text{Hz}$), 7.90 (1H, d, $J=9\text{Hz}$), 8.52 (1H, br s)

Preparation 6

To a solution of 2-ethyl-4-hydroxy-8-methoxyquinoline (9.96 g) in phosphoryl chloride (30 ml) was added N,N-dimethylaniline (12.44 ml) below 8°C in an ice bath. After 10 minutes the mixture was stirred at ambient temperature for 1.5 hours. The solvent was removed in vacuo. The residue was partitioned into dichloromethane and saturated sodium bicarbonate solution. The organic layer was washed with brine and dried over magnesium sulfate. The organic layer was evaporated in vacuo. The residue was purified by column chromatography (hexane - ethyl acetate) and recrystallized from hexane to give 4-chloro-2-ethyl-8-methoxyquinoline (8.90 g) as crystals.

mp : 80-81°C

NMR (CDCl₃, δ) : 1.40 (3H, t, J=7Hz), 3.08 (2H, q, J=7Hz), 4.09 (3H, s), 7.10 (1H, d, J=9Hz), 7.43-7.54 (2H), 7.78 (1H, d, J=9Hz)

Preparation 7

A solution of 4-chloro-2-ethyl-8-methoxyquinoline (4.0 g) in 48% hydrobromic acid (80 ml) was refluxed for 2 days. The mixture was adjusted to pH 12 with 28% ammonia solution. The precipitate was collected by vacuum filtration, and was washed with water and hexane to give 4-chloro-2-ethyl-8-hydroxyquinoline (3.13 g) as crystals.

mp : 45-47°C

NMR (CDCl₃, δ) : 1.40 (3H, t, J=7Hz), 2.98 (2H, q, J=7Hz), 7.19 (1H, d, J=9Hz), 7.39-7.66 (3H)

Preparation 8

To the solution of piperazine (3 g) in dichloromethane (30 ml) was added methyl isocyanate (2.16 ml) in an ice water bath with stirring. After 10 minutes the mixture was stirred at ambient temperature for 1 hour.

The reaction mixture was evaporated in vacuo. The residue was diluted with acetonitrile (15 ml) and crystals were filtered off. The filtrate was evaporated in vacuo. To the residue was added xylene and the solvent was
5 azeotropically removed in vacuo to give
N-methyl-1-piperazinecarboxamide (2.43 g) as an oil.

NMR (CDCl_3 - CD_3OD , δ) : 2.80 (3H, s), 2.83-2.93 (4H),
3.32-3.44 (4H)

10 Preparation 9

Dimethylamine (50% aqueous solution, 3.6 ml) was stirred in an ice bath and a solution of 3-nitrobenzoyl chloride (1.8 g) in 1,4-dioxan (4 ml) was dropwise added thereto. The resulting mixture was stirred vigorously at
15 ambient temperature for 2.5 hours. Ethyl acetate was added and organic layer was washed with water, 1N hydrochloric acid, 1N sodium hydroxide, water and saturated sodium chloride solution successively and dried over anhydrous magnesium sulfate. After filtration and
20 concentration, the residue was recrystallized from benzene-n-hexane to afford N,N-dimethyl-3-nitrobenzamide (1.5 g) as a pale yellow prism.

mp : 84.7-87.7°C

NMR (CDCl_3 , δ) : 3.00 (3H, s), 3.15 (3H, s), 7.61
25 (1H, t, $J=7.5\text{Hz}$), 7.78 (1H, d, $J=7.5\text{Hz}$),
8.22-8.35 (2H, m)

Preparation 10

To a stirred solution of 2-methoxyethylamine (0.9 ml)
30 in dichloromethane (20 ml) was added triethylamine (2.1 ml), and the mixture was cooled in an ice-cooling bath. A solution of 3-nitrobenzoyl chloride (1.8 g) in dichloromethane (10 ml) was dropwise added thereto and the resulting mixture was stirred for 1.5 hours at the same
35 temperature. The mixture was washed with water and

2122236

saturated sodium chloride solution, dried over anhydrous magnesium sulfate. After filtration, the solvent was removed in vacuo to afford N-(2-methoxyethyl)-3-nitrobenzamide (2.7 g) as a yellow oil.

5 NMR (CDCl_3 , δ) : 3.41 (3H, s), 3.53-3.63 (2H, m),
3.63-3.76 (2H, m), 6.62 (1H, br s), 7.65 (1H, dt, J=8 and 0.5Hz), 8.16 (1H, dt, J=8, 0.5Hz),
8.38 (1H, dt, J=8, 0.5Hz), 8.61 (1H, m)

10 Preparation 11

To a stirred two-phase solution of 3-nitrobenzoyl chloride (9.3 g) in a mixture of diethyl ether (50 ml) and saturated sodium bicarbonate solution (50 ml) was added 3-aminomethylpyridine (5.4 g) in an ice-cooled bath. The mixture was stirred vigorously at ambient temperature for 30 minutes. The reaction mixture was filtered, and the resulting solid was washed with water. The solid was further solidified with diisopropyl alcohol-water to afford 3-nitro-N-(3-pyridylmethyl)benzamide (5.91 g) as a pale yellow amorphous solid.

15 NMR (CDCl_3 , δ) : 4.70 (2H, d, J=5Hz), 7.05 (1H, br s), 7.30 (1H, dd, J=7, 5Hz), 7.68 (1H, t, J=9Hz), 7.76 (1H, dt, J=8, 0.5Hz), 8.22 (1H, d, J=8Hz), 8.39 (1H, m), 8.54 (1H, dd, J=5, 0.5Hz),
20 8.60 (1H, d, J=0.5Hz), 8.65 (1H, t, J=0.5Hz)
25

Preparation 12

The following compounds were obtained according to similar manners to those of Preparation 9 to 11.

30

(1) N-Methyl-3-nitro-N-(2-pyridyl)benzamide

mp : 79-82°C

35 NMR (CDCl_3 , δ) : 3.61 (3H, s), 6.92 (1H, d, J=9Hz),
7.10 (1H, dd, J=7, 5Hz), 7.41 (1H, dt, J=1, 7Hz), 7.56 (1H, dt, J=1, 7Hz), 7.67 (1H, dt,

2122236

J=7,1Hz), 8.11-8.21 (2H), 8.41 (1H, dt, J=5, 1Hz)

(2) 3-Nitro-N-(4-pyridyl)benzamide

5 mp : >250°C

NMR (DMSO-d₆, δ) : 7.80 (2H, d, J=6Hz), 7.89 (1H, t, J=7Hz), 8.38-8.58 (4H), 8.80 (1H, t, J=1Hz)

(3) 4-Methyl-1-(3-nitrobenzoyl)piperazine

10 mp : 97-98°C

NMR (CDCl₃, δ) : 2.31-2.66 (7H), 3.38-3.97 (4H), 7.62 (1H, dt, J=8, 1Hz), 7.78 (1H, dt, J=1, 8Hz), 8.25-8.34 (2H)

15 Preparation 13

To a stirred solution of 3-nitro-N-(3-pyridylmethyl)-benzamide (2.00 g) in tetrahydrofuran (40 ml) was added potassium tert-butoxide (917 mg) in one portion in an ice-cooled bath. The stirring was continued for 40 minutes and then iodomethane (0.53 ml) was added thereto. The reaction mixture was stirred at 0°C for one hour, then at ambient temperature for five hours. Saturated sodium bicarbonate solution was added thereto and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution. After dried over anhydrous magnesium sulfate and filtered, the solvent was removed in vacuo and the residue was purified by flash chromatography (methanol-chloroform 3%, V/V) to afford 3-nitro-N-methyl-N-(3-pyridylmethyl)-benzamide (1.8 g) as a yellow oil.

30 NMR (CDCl₃, δ) : 2.80-3.22 (3H, m), 4.40-4.93 (2H, m), 7.30-7.42 (1H, m), 7.44-7.90 (3H, m), 8.24-8.37 (2H, m), 8.40-8.75 (2H, m)

2122236

Preparation 14

N-(2-Methoxyethyl)-N-methyl-3-nitrobenzamide was obtained according to a similar manner to that of Preparation 13.

5 NMR (CDCl_3 , δ) : 2.96-3.21 (3H, m), 3.25-3.90 (7H, m), 7.60 (1H, br t, $J=8\text{Hz}$), 7.79 (1H, br d, $J=8\text{Hz}$), 8.20-8.46 (2H, m)

Preparation 15

10 3-Amino-N,N-dimethylbenzamide was obtained from 3-nitro-N,N-dimethylbenzamide according to a similar manner to that of Example 3.

15 NMR (CDCl_3 , δ) : 2.96 (3H, br s), 3.09 (3H, br s), 3.74 (2H, br s), 6.62-6.82 (3H, m), 7.08-7.22 (1H, m)

Preparation 16

20 To a stirred solution of N-(2-methoxyethyl)-N-methyl-3-nitrobenzamide (840 mg) in ethyl acetate (8 ml) was added platinum dioxide (160 mg) and the resulting heterogeneous mixture was stirred under hydrogen atmosphere for 8 hours. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography eluting with ethyl acetate to give 3-amino-N-(2-methoxyethyl)-N-methylbenzamide (761 mg) as a brown viscous oil.

25 NMR (CDCl_3 , δ) : 2.90-3.17 (3H, m), 3.18-3.96 (9H, m), 6.56-6.83 (3H, m), 7.15 (1H, t, $J=9\text{Hz}$)

30 Preparation 17

The following compounds were obtained according to similar manners to those of Preparations 15 or 16.

(1) 3-Amino-N-methyl-N-(3-pyridylmethyl)benzamide

35 NMR (CDCl_3 , δ) : 2.87 (3H, br s), 3.75 (1 or 2H, br

2122236

s), 4.41-4.88 (2H, m), 6.55-6.84 (3H, m),
7.03-7.40 (2H, m), 7.42-7.84 (1H, m), 8.35-8.70
(2H, m)

5 (2) 3-Amino-N-methyl-N-(2-pyridyl)benzamide

NMR (CDCl₃, δ) : 3.58 (3H, s), 3.66 (2H, br s),
6.55-6.68 (2H), 6.79 (1H, t, J=1Hz), 6.81-7.09
(3H), 7.48 (1H, dt, J=7, 1Hz), 8.45 (1H, d,
J=5Hz)

10

(3) 3-Amino-N-(4-pyridyl)benzamide .

mp : 232-234°C

15 NMR (DMSO-d₆, δ) : 5.39 (2H, br s), 6.79 (1H, br d,
J=8Hz), 7.02-7.11 (2H), 7.19 (1H, t, J=8Hz),
7.78 (2H, d, J=7Hz), 8.46 (2H, d, J=7Hz)

(4) 1-(3-Aminobenzoyl)-4-methylpiperazine

mp : 114-116°C

20 NMR (CDCl₃, δ) : 2.28-2.60 (7H), 3.38-3.90 (6H),
6.68-6.79 (3H), 7.68 (1H, t, J=8Hz)

Preparation 18

To a stirred solution of 3-amino-N,N-
25 dimethylbenzamide (1.3 g) in 1,4-dioxane(20 ml) was added
1N sodium hydroxide (23.4 ml) and phenyl chloroformate
(1.5 ml) successively in an ice-cooled bath. The bath was
removed and the reaction mixture was stirred vigorously
for 3 hours during which time, phenyl chloroformate (0.7
30 ml) was further added. The mixture was extracted with
ethyl acetate and the organic layer was washed with water
and saturated sodium chloride solution. After dried over
anhydrous magnesium sulfate and filtered, the solvent was
removed in vacuo and the residual oil was purified by
35 flash chromatography eluting with ethyl acetate - n-hexane

2122236

(2:1, V/V) to give a solid, which was recrystallized from benzene - n-hexane (5:1, V/V) to afford phenyl 3-(dimethylcarbamoyl)phenylcarbamate (1.4 g) as a colorless powder.

5 mp : 151.2-153.0°C
 NMR (CDCl₃, δ) : 3.00 (3H, s), 3.10 (3H, s),
 7.09-7.46 (6H, m), 7.49-7.65 (3H, m)

Preparation 19

10 To a stirred mixture of ethyl 3-aminobenzoate (1 g)
 and triethylamine (1.1 ml) in dichloromethane (10 ml) was
 dropwise added phenyl chloroformate (0.8 ml) in an
 ice-cooled bath. The ice-bath was removed and the
 resulting mixture was stirred at ambient temperature for 5
15 hours. The mixture was extracted with dichloromethane and
 washed with water and saturated sodium chloride. The
 organic layer was dried over anhydrous magnesium sulfate,
 filtered and concentrated in vacuo to give a pale yellow
 solid. The solid was purified by flash chromatography
20 eluting with ethyl acetate - dichloromethane (1:9, V/V) to
 give a desired compound. Diisopropyl ether was added
 thereto and the resulting suspension was heated on a
 water-bath (90°C) and then cooled to ambient temperature
 with stirring and filtered to afford phenyl
25 3-(ethoxycarbonyl)phenylcarbamate (0.7 g) as a colorless
 needle.

 mp : 138°C
 NMR (CDCl₃, δ) : 1.39 (3H, t, J=7.5Hz), 4.38 (2H,
 q, J=7.5Hz), 7.04-7.33 (4H, m), 7.34-7.51 (3H,
30 m), 7.73-7.88 (2H, m), 8.05 (1H, t, J=0.5Hz)

Preparation 20

 The following compounds were obtained according to
 similar manners to those of Preparations 18 or 19.

35

2122236

(1) Phenyl 3-[N-(4-pyridyl)carbamoyl]phenylcarbamate
mp : 204-206°C
NMR (DMSO-d₆, δ) : 5.39 (1H, br s), 6.71-6.82 (2H),
7.02-7.33 (4H), 7.40-7.81 (4H), 8.09 (1H, br s),
8.41-8.51 (2H), 9.32 (1H, br s)

(2) Phenyl 3-(4-methyl-1-piperazinylcarbonyl)phenyl-
carbamate
mp : 152-154°C
NMR (CDCl₃, δ) : 2.27-2.56 (7H), 3.38-3.91 (4H),
7.10-7.60 (9H)

Preparation 21

Benzyl 3-pyridylmethylcarbamate was obtained reacting
3-aminomethylpyridine with benzyl chloroformate according
to a similar manner to that of Preparation 19.

mp : 73.6-77.1°C
NMR (CDCl₃, δ) : 4.40 (2H, d, J=6Hz), 5.64 (2H, s),
5.60-5.77 (1H, m), 7.19-7.45 (6H, m), 7.65 (1H,
d, J=7Hz), 8.46-8.60 (2H, m)

Preparation 22

Benzyl N-(2-methoxyethyl)-N-(3-pyridylmethyl)-
carbamate was obtained by reacting benzyl
3-pyridylmethylcarbamate with 2-methoxyethyl chloride
according to a similar manner to that of Preparation 13.

NMR (CDCl₃, δ) : 3.25-3.30 (3H, m), 3.33-3.63 (4H,
m), 4.59 (2H, br s), 5.16 (2H, br s), 7.11-7.71
(7H, m), 8.49 (2H, br d, J=3Hz)

Preparation 23

A mixture of benzyl N-(2-methoxyethyl)-N-(3-
pyridylmethyl)carbamate (5.4 g) and 10% palladium on
carbon (1.0 g) in ethanol (50 ml) was stirred under

2122236

hydrogen atmosphere for 9 hours. The catalyst was removed by filtration, and the filtrate was concentrated under azeotropic condition with toluene and ethanol. The residue was dissolved in ethanol and diethyl ether was added thereto to give precipitates, which were collected by filtration to give N-(2-methoxyethyl)-N-(3-pyridylmethyl)amine (1.3 g).

mp : 134-135°C

NMR (CDCl₃, δ) : 3.06 (2H, t, J=5Hz), 3.39 (3H, s), 3.80 (2H, t, J=5Hz), 4.26 (2H, s), 7.36 (1H, dd, J=8 and 5Hz), 8.21 (1H, br d, J=8Hz), 8.60 (1H, d, J=5Hz), 8.74 (1H, br s).

Preparation 24

To a mixture of ethyl 4-aminocinnamate (300 mg), triethylamine (167 mg) and dichloromethane (3 ml) was added a solution of propionyl chloride (182 mg) in dichloromethane (1 ml) in an ice-water bath, and the mixture was stirred for 1 hour at the same temperature. To the reaction mixture was added 4 drops of N,N-dimethylpropanediamine, and the mixture was further stirred for 5 minutes. The reaction mixture was washed with water, dried over magnesium sulfate, and evaporated in vacuo. The residue was crystallized from diisopropyl ether to give ethyl 4-propionamidocinnamate (341 mg) as a colorless powder.

mp : 138°C

NMR (CDCl₃, δ) : 1.26 (3H, t, J=8Hz), 1.34 (3H, t, J=8Hz), 2.42 (2H, q, J=8Hz), 4.26 (2H, q, J=8Hz), 6.37 (1H, d, J=16Hz), 7.21 (1H, br s), 7.49 (2H, d, J=8Hz), 7.58 (2H, d, J=8Hz), 7.68 (1H, d, J=16Hz)

Preparation 25

To a suspension of sodium hydride (60% active, 31 mg)

2122236

in dimethylformamide (1 ml) was added a solution of ethyl 4-propionamidocinnamate (160 mg) in dimethylformamide (2 ml) at ambient temperature under nitrogen atmosphere. The mixture was stirred for 1 hour at same temperature, and a solution of iodomethane (111 mg) in dimethylformamide (2 ml) was added thereto. The reaction mixture was stirred at same temperature for 2 hours, poured into water, and extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate and evaporated in vacuo to give ethyl 4-(N-methylpropionamido)cinnamate (168 mg) as an oil.

NMR (CDCl_3 , δ) : 1.07 (3H, t, $J=8\text{Hz}$), 1.35 (3H, t, $J=8\text{Hz}$), 2.13 (2H, q, $J=8\text{Hz}$), 3.27 (3H, s), 4.29 (2H, q, $J=8\text{Hz}$), 6.44 (1H, d, $J=16\text{Hz}$), 7.21 (2H, d, $J=8\text{Hz}$), 7.57 (2H, d, $J=8\text{Hz}$), 7.68 (1H, d, $J=16\text{Hz}$)

Preparation 26

Ethyl 4-(N-ethylacetamido)cinnamate was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl_3 , δ) : 1.13 (3H, t, $J=7.5\text{Hz}$), 1.35 (3H, t, $J=7.5\text{Hz}$), 1.86 (3H, br s), 3.77 (2H, q, $J=7.5\text{Hz}$), 4.29 (2H, q, $J=7.5\text{Hz}$), 6.45 (1H, d, $J=16\text{Hz}$), 7.19 (2H, d, $J=8\text{Hz}$), 7.58 (2H, d, $J=8\text{Hz}$), 7.68 (1H, d, $J=16\text{Hz}$)

Preparation 27

To a suspension of sodium hydride (60% active, 125 mg) in dimethylformamide (2 ml) at ambient temperature was added ethyl 4-hydroxycinnamate (250 mg) under nitrogen atmosphere, and the mixture was stirred for 1 hour. 2-Picolyl chloride hydrochloride (256 mg) was added to the mixture at the same temperature, and allowed to stand for 16 hours. The reaction mixture was poured into water, extracted with ethyl acetate. The organic layer was

2122236

washed with water, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized from diisopropyl ether to give ethyl 4-(2-pyridylmethoxy)cinnamate (188 mg) as colorless powder.

mp : 95°C

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 4.26 (2H, q, J=7.5Hz), 5.22 (2H, s), 6.30 (1H, d, J=16Hz), 7.00 (2H, d, J=8Hz), 7.20-7.30 (1H, m), 7.42-7.56 (3H, m), 7.64 (1H, d, J=16Hz), 7.73 (1H, td, J=8, 1Hz), 8.61 (1H, dif-dd, J=5Hz)

Preparation 28

The following compounds were obtained according to a similar manner to that of Preparation 27.

(1) Ethyl 4-[2-(N,N-dimethylamino)ethoxy]cinnamate

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 2.34 (6H, s), 2.74 (2H, t, J=6Hz), 4.10 (2H, t, J=6Hz), 4.26 (2H, q, J=7.5Hz), 6.30 (1H, d, J=16Hz), 6.92 (2H, d, J=8Hz), 7.48 (2H, d, J=8Hz), 7.64 (1H, d, J=16Hz)

(2) Ethyl 4-(2-acetoxyethoxy)cinnamate

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 2.11 (3H, s), 4.19 (2H, t, J=6Hz), 4.25 (2H, q, J=7.5Hz), 4.44 (2H, t, J=6Hz), 6.31 (1H, d, J=16Hz), 6.94 (2H, d, J=8Hz), 7.49 (2H, d, J=8Hz), 7.64 (1H, d, J=16Hz)

Preparation 29

To a suspension of 4-formylbenzoic acid (1.00 g) in dry tetrahydrofuran (15 ml) was added methyl(triphenylphosphoranylidene)acetate (2.50 g) at ambient temperature under nitrogen atmosphere. The

2122236

reaction mixture was stirred for 1 hour at the same temperature, poured into aqueous sodium bicarbonate solution, and washed with ethyl acetate. 1N-Hydrochloric acid was added to the aqueous layer until the layer was adjusted to pH 2. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized from diisopropyl ether to give methyl 4-carboxycinnamate (1.21 g) as colorless powder.

mp : 243°C

NMR (DMSO-d₆, δ) : 3.74 (3H, s), 6.76 (1H, d, J=16Hz), 7.73 (1H, d, J=16Hz), 7.85 (2H, d, J=8Hz), 7.96 (2H, d, J=8Hz)

Preparation 30

To a solution of methyl 4-carboxycinnamate (160 mg) in methylene chloride was added methylamine hydrochloride (58 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (140 mg) at ambient temperature, and the mixture was stirred for 2 hours. To this suspension was added 1-hydroxybenzotriazole (137 mg) and dimethylformamide (2 ml), and the mixture was stirred for 14 hours at same temperature. The reaction mixture was poured into water, and extracted with dichloromethane. The organic layer was washed with aqueous sodium bicarbonate solution and water, dried over magnesium sulfate, and evaporated in vacuo. The residue was crystallized from diisopropyl ether to give methyl 4-(methylcarbamoyl)cinnamate (82 mg) as a colorless powder.

mp : 210.5°C

NMR (DMSO-d₆, δ) : 2.79 (3H, d, J=5Hz), 3.74 (3H, s), 6.74 (1H, d, J=16Hz), 7.69 (1H, d, J=16Hz), 7.80 (2H, d, J=8Hz), 7.87 (2H, d, J=8Hz), 8.51 (1H, q-like)

Preparation 31

The following compounds were obtained according to a similar manner to that of Preparation 30.

5 (1) Methyl 4-(N,N-dimethylcarbamoyl)cinnamate

mp : 130°C

NMR (CDCl₃, δ) : 3.00 (3H, s), 3.12 (3H, s), 3.83
10 (3H, s), 6.49 (1H, d, J=16Hz), 7.45 (2H, d,
J=8Hz), 7.58 (2H, d, J=8Hz), 7.70 (1H, d,
J=16Hz)

(2) Methyl 4-[N-(2-methoxyethyl)carbamoyl]cinnamate

mp : 122-124°C

15 NMR (CDCl₃, δ) : 3.40 (3H, s), 3.53-3.72 (4H), 3.83
(3H, s), 6.45-6.60 (3H), 7.58 (2H, d, J=8Hz),
7.71 (1H, d, J=15Hz), 7.80 (2H, d, J=8Hz)

(3) Methyl 4-[N,N-bis(2-methoxyethyl)carbamoyl]cinnamate

20 NMR (CDCl₃, δ) : 3.21-3.86 (17H), 6.48 (1H, d,
J=15Hz), 7.44 (1H, d, J=9Hz), 7.57 (1H, d,
J=9Hz), 7.70 (1H, d, J=15Hz)

Preparation 32

25 Ethyl 4-(3-methylureido)cinnamate was obtained by
reacting ethyl 4-aminocinnamate with methyl isocyanate
according to a similar manner to that of Preparation 8.

mp : 166°C

30 NMR (DMSO-d₆, δ) : 1.25 (3H, t, J=7.5Hz), 2.64 (3H,
d, J=5Hz), 4.17 (2H, q, J=7.5Hz), 6.12 (1H, q,
J=5Hz), 6.43 (1H, d, J=16Hz), 7.45 (2H, d,
J=8Hz), 7.56 (1H, d, J=16Hz), 7.59 (2H, d,
J=8Hz), 8.81 (1H, s)

Preparation 33

35 To a solution of ethyl 4-propionamidocinnamate (160

2122236

mg) in ethanol (5 ml) was added 1N aqueous sodium hydroxide solution (1.5 ml) at ambient temperature. The mixture was stirred at same temperature for 14 hours, and then at 40°C for 2 hours. 1N-hydrochloric acid (1.5 ml) was added to the reaction mixture and evaporated in vacuo. The residue was diluted with 10% methanol-dichloromethane, washed with water, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized from diisopropyl ether to give 4-propionamidocinnamic acid (115 mg) as a colorless powder.

mp : 243°C

NMR (DMSO-d₆, δ) : 1.08 (3H, t, J=8Hz), 2.34 (2H, q, J=8Hz), 6.39 (1H, d, J=16Hz), 7.51 (1H, d, J=16Hz), 7.62 (4H, s-like), 10.07 (1H, s)

Preparation 34

The following compounds were obtained according to a similar manner to that of Preparation 33.

(1) 4-(N-Methylpropionamido)cinnamic acid

mp : 168°C

NMR (DMSO-d₆, δ) : 0.93 (3H, t, J=8Hz), 2.11 (2H, dif-q), 3.16 (3H, s), 6.55 (1H, d, J=16Hz), 7.37 (2H, d, J=8Hz), 7.61 (1H, d, J=16Hz), 7.76 (2H, d, J=8Hz)

(2) 4-(N-Ethylacetamido)cinnamic acid

mp : 203.5°C

NMR (DMSO-d₆, δ) : 1.01 (3H, t, J=7.5Hz), 1.78 (3H, br s), 3.67 (2H, q, J=7.5Hz), 6.57 (1H, d, J=16Hz), 7.33 (2H, d, J=8Hz), 7.62 (1H, d, J=16Hz), 7.78 (2H, d, J=8Hz)

(3) 4-(2-Pyridylmethoxy)cinnamic acid

mp : 208°C

NMR (DMSO- d_6 , δ) : 5.23 (2H, s), 6.38 (1H, d, J=16Hz), 7.06 (2H, d, J=8Hz), 7.35 (1H, dd, J=8, 5Hz), 7.51 (1H, d, J=8Hz), 7.53 (1H, d, J=16Hz), 7.64 (2H, d, J=8Hz), 7.83 (1H, td, J=8, 1Hz), 8.58 (1H, dif-dd, J=5Hz)

5

(4) 4-[2-(N,N-Dimethylamino)ethoxy]cinnamic acid

mp : 187°C

NMR (DMSO- d_6 , δ) : 2.23 (6H, s), 2.66 (2H, t, J=6Hz), 4.12 (2H, t, J=6Hz), 6.38 (1H, d, J=16Hz), 6.97 (2H, d, J=8Hz), 7.51 (1H, d, J=16Hz), 7.62 (1H, d, J=8Hz)

10

(5) 4-(2-Hydroxyethoxy)cinnamic acid

mp 194°C

NMR (DMSO- d_6 , δ) : 3.64-3.79 (2H, br peak), 4.02 (2H, t, J=6Hz), 4.90 (1H, br peak), 6.37 (1H, d, J=16Hz), 6.98 (2H, d, J=8Hz), 7.54 (1H, d, J=16Hz), 7.63 (2H, d, J=8Hz)

15

20

(6) 4-(Methylcarbamoyl)cinnamic acid

mp : >250°C

NMR (DMSO- d_6 , δ) : 2.78 (3H, d, J=5Hz), 6.62 (1H, d, J=16Hz), 7.61 (1H, d, J=16Hz), 7.77 (2H, d, J=8Hz), 7.85 (2H, d, J=8Hz), 8.51 (1H, q-like)

25

(7) 4-(N,N-Dimethylcarbamoyl)cinnamic acid

mp : 82°C

NMR (DMSO- d_6 , δ) : 2.93 (3H, s), 2.97 (3H, s), 6.59 (1H, d, J=16Hz), 7.43 (2H, d, J=8Hz), 7.61 (1H, d, J=16Hz), 7.75 (2H, d, J=8Hz)

30

(8) 4-(3-Methylureido)cinnamic acid

mp : 234°C

35

2122236

NMR (DMSO- d_6 , δ) : 2.64 (3H, d, J=5Hz), 6.12 (1H, q, J=5Hz), 6.33 (1H, d, J=16Hz), 7.44 (2H, d, J=8Hz), 7.51 (1H, d, J=16Hz), 7.55 (2H, d, J=8Hz), 8.78 (1H, s)

5

(9) 4-[N-(2-Methoxyethyl)carbamoyl]cinnamic acid

mp : 207-209°C

NMR (DMSO- d_6 , δ) : 3.20-3.50 (7H), 6.63 (1H, d, J=15Hz), 7.62 (1H, d, J=15Hz), 7.79 (2H, d, J=8Hz), 7.89 (2H, d, J=8Hz), 8.61 (1H, br s)

10

(10) 4-[N,N-Bis(2-methoxyethyl)carbamoyl]cinnamic acid

NMR (CDCl₃, δ) : 3.21-3.86 (17H), 6.48 (1H, d, J=15Hz), 7.44 (2H, d, J=9Hz), 7.57 (2H, d, J=9Hz), 7.70 (1H, d, J=15Hz)

15

Preparation 35

To a solution of ethyl 4-aminocinnamate (150 mg) and triethylamine (94 mg) in methylene chloride (3 ml) was added mesyl chloride (0.08 ml) under ice-cooling under nitrogen atmosphere, and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was poured into water, and extracted with methylene chloride twice. The combined organic layer was washed with water, dried over magnesium sulfate and concentrated to give a residue including ethyl 4-mesylaminocinnamate and ethyl 4-(N,N-dimesylamino)cinnamate. The residue was dissolved in ethanol, and 1N aqueous sodium hydroxide solution (1.5 ml) was added thereto at 40°C. The mixture was stirred at ambient temperature for 2 days, and 1N hydrochloric acid (1.5 ml) was added thereto. The mixture was concentrated in vacuo, and the residue was partitioned between 10% methanol-methylene chloride and water. The organic layer was washed with water, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by

20

25

30

35

2122236

preparative thin-layer chromatography (methylene chloride - methanol, 10:1, V/V) to give 4-mesylaminocinnamic acid (49.3 mg).

mp : 218°C

NMR (DMSO- d_6 , δ) : 3.05 (3H, s), 6.44 (1H, d, J=16Hz), 7.21 (2H, d, J=8Hz), 7.53 (1H, d, J=16Hz), 7.66 (2H, d, J=8Hz)

Preparation 36

To a solution of N-methylethanolamine (600 mg), in N,N-dimethylformamide were added imidazole (1.13 g) and tert-butyldiphenylsilyl chloride (2.20 g) at ambient temperature with stirring. After 8 hours, the mixture was diluted with water (60 ml) and was extracted with ethyl acetate (20 ml) twice. The organic layer was washed with water three times and brine, dried over magnesium sulfate. The solvent was removed in vacuo. The residue was purified by column chromatography eluting with dichloromethane-methanol to give N-(2-tert-butyldiphenylsilyloxyethyl)-N-methylamine (780 mg) as an oil.

NMR (CDCl₃, δ) : 1.06 (9H, s), 2.45 (3H, s), 2.72 (2H, t, J=5Hz), 3.78 (2H, t, J=5Hz), 7.32-7.49 (6H), 7.61-7.71 (4H)

Preparation 37

A mixture of 4-chloro-8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylquinoline (200 mg) and N,N-dimethylformamide (3 ml) was heated under reflux for 18 hours. The reaction mixture was partitioned into ethyl acetate and saturated aqueous solution of sodium bicarbonate. The organic layer was washed with water, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by preparative thin-layer chromatography (dichloromethane-methanol) to give

2122236

8-hydroxy-2-methyl-4-dimethylaminoquinoline (26 mg) as a brownish powder.

5 NMR (CDCl_3 , δ) : 2.62 (3H, s), 3.03 (6H, s), 5.29 (1H, br s), 6.63 (1H, s), 7.07 (1H, d, $J=8\text{Hz}$), 7.28 (1H, t, $J=8\text{Hz}$), 7.46 (1H, d, $J=8\text{Hz}$)

Preparation 38

10 To a stirred solution of 3,4-dimethoxybenzyl alcohol (1.68 g) in 1,3-dimethyl-2-imidazolidinone (10 ml) was added sodium hydride (60% in oil, 400 mg) portionwise in an ice-water bath under a nitrogen atmosphere. The mixture was stirred for 30 minutes and then 4-chloro-8-hydroxy-2-methylquinoline (770 mg) was added thereto. The reaction mixture was stirred at 150°C for 3 15 hours and cooled to ambient temperature followed by partition into ethyl acetate and water. The organic layer was washed with water twice, dried over magnesium sulfate and evaporated in vacuo. The residue was washed with diethyl ether to give a pale yellow powder (812 mg) of 20 8-hydroxy-4-(3,4-dimethoxybenzyloxy)-2-methylquinoline.

mp : $129-131^\circ\text{C}$

25 NMR (CDCl_3 , δ) : 2.67 (3H, s), 3.91 (6H, s), 5.20 (2H, s), 6.71 (1H, s), 6.91 (1H, d, $J=8\text{Hz}$), 7.02 (1H, s), 7.06 (1H, d, $J=8\text{Hz}$), 7.12 (1H, d, $J=8\text{Hz}$), 7.32 (1H, t, $J=8\text{Hz}$), 7.60 (1H, d, $J=8\text{Hz}$)

Preparation 39

30 A mixture of 4-chloro-8-hydroxy-2-methylquinoline (9 g), 1,3-dimethyl-2-imidazolidinone (100 ml) and 28% solution of sodium methoxide in methanol (135 ml) was stirred at 150°C for 4 hours. The reaction mixture was cooled to ambient temperature followed by partition into ethyl acetate and water. The organic layer was washed with water and brine, dried over magnesium sulfate and 35 concentrated in vacuo. The crystalline residue was washed

2122236

with n-hexane to give 8-hydroxy-4-methoxy-2-methylquinoline (5.57 g).

mp : 110.5-112°C

5 NMR (CDCl₃, δ) : 2.67 (3H, s), 4.01 (3H, s), 6.63 (1H, s), 7.11 (1H, d, J=8Hz), 7.31 (1H, t, J=8Hz), 7.56 (1H, d, J=8Hz)

Preparation 40

10 The following compounds were obtained according to similar manners to those of Preparations 38 or 39.

(1) 4-Ethoxy-8-hydroxy-2-methylquinoline

mp : 85-86°C

15 NMR (CDCl₃, δ) : 1.56 (3H, t, J=6Hz), 2.66 (3H, s), 4.23 (2H, q, J=6Hz), 6.60 (1H, s), 7.10 (1H, d, J=8Hz), 7.31 (1H, t, J=8Hz), 7.60 (1H, d, J=8Hz)

(2) 8-Hydroxy-2-methyl-4-methylthioquinoline

mp : 98-99°C

20 NMR (CDCl₃, δ) : 2.60 (3H, s), 2.70 (3H, s), 7.00 (1H, s), 7.13 (1H, d, J=8Hz), 7.38 (1H, t, J=8Hz), 7.50 (1H, d, J=8Hz)

(3) 8-Hydroxy-4-(2-methoxyethoxy)-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.40 (3H, s), 3.52 (3H, s), 3.91 (2H, t, J=6Hz), 4.32 (2H, t, J=6Hz), 6.64 (1H, s), 7.12 (1H, d, J=8Hz), 7.32 (1H, t, J=8Hz), 7.62 (1H, d, J=8Hz)

30 (4) 8-Hydroxy-2-methyl-4-(2-dimethylaminoethoxy)quinoline

mp : 94-96°C

35 NMR (CDCl₃, δ) : 2.40 (6H, s), 2.67 (3H, s), 2.91 (2H, t, J=6Hz), 4.29 (2H, t, J=6Hz), 6.63 (1H, s), 7.12 (1H, d, J=8Hz), 7.31 (1H, t, J=8Hz), 7.59 (1H, d, J=8Hz)

2122236

Preparation 41

8-Hydroxy-2-methoxyquinoline was obtained reacting 2-chloro-8-hydroxyquinoline with sodium methoxide according to a similar manner to that of Preparation 39.

5 mp : 40-41°C

NMR (CDCl₃, δ) : 4.09 (3H, s), 6.94 (1H, d, J=8Hz),
7.17 (1H, dd, J=8, 3Hz), 7.20-7.36 (2H), 7.60
(1H, s), 8.00 (1H, d, J=8Hz)

10 Example 1

To a mixture of sodium hydride (40% in oil, 24 mg) and N,N-dimethylformamide (1 ml) was added 8-hydroxy-2-methylquinoline (80 mg) in an ice-water bath. The mixture was stirred for 30 minutes at the same
15 temperature and then 2,6-dichlorobenzyl bromide (120 mg) was added therein. The reaction mixture was stirred at ambient temperature for 1 hour. To this mixture was added water (0.5 ml) in an ice-water bath. The precipitates
20 were corrected by vacuum filtration and washed with water (3 ml) to give 8-(2,6-dichlorobenzyloxy)-2-methylquinoline (117 mg) as a white powder.

NMR (CDCl₃, δ) : 2.76 (3H, s), 5.62 (2H, s),
7.18-7.47 (7H), 8.01 (1H, d, J=8Hz)

25 Example 2

The following compounds were obtained according to a similar manner to that of Example 1.

(1) 8-(2,6-Dichloro-3-nitrobenzyloxy)-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.76 (3H, s), 5.70 (2H, s),
7.21-7.57 (5H), 7.76 (1H, d, J=8Hz), 8.02 (1H,
d, J=8Hz)

(2) 4-Chloro-8-(2,6-dichloro-3-nitrobenzyloxy)-2-
35 methylquinoline

2122236

NMR (CDCl₃, δ) : 2.70 (3H, s), 5.67 (2H, s),
7.23-7.92 (6H)

(3) 2-Ethyl-4-chloro-8-[2,6-dichloro-3-[N-methyl-N-
(phthalimidoacetyl)amino]benzyloxy]quinoline

mp : 109-110°C

NMR (CDCl₃, δ) : 1.40 (3H, t, J=7Hz), 3.00 (2H, q,
J=7Hz), 3.24 (3H, s), 4.04 (2H, s), 5.72 (2H,
s), 7.31-7.58 (5H), 7.69-7.91 (5H)

(4) 2-Ethyl-8-[2,6-dichloro-3-[N-methyl-N-(phthalimido-
acetyl)amino]benzyloxy]quinoline

mp : 115-116°C

NMR (CDCl₃, δ) : 1.40 (3H, t, J=7Hz), 3.01 (2H, q,
J=7Hz), 3.22 (3H, s), 4.04 (2H, s), 5.78 (2H,
s), 7.25-7.59 (6H), 7.70-7.91 (4H), 8.06 (1H, d,
J=9Hz)

Example 3

To a mixture of 8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylquinoline (1.0 g), concentrated hydrochloric acid (5.2 ml) and methanol (5.2 ml) was added iron powder (666 mg). The mixture was heated under reflux for 2 hours and stirred in an ice-water bath for 1 hour. The precipitate was collected by vacuum filtration and washed with 1N hydrochloric acid and water to give 8-(3-amino-2,6-dichlorobenzyloxy)-2-methylquinoline dihydrochloride (635 mg) as a brownish powder.

NMR (DMSO-d₆, δ) : 2.93 (3H, s), 5.50 (2H, s), 6.98
(1H, d, J=8Hz), 7.23 (1H, d, J=8Hz), 7.80-8.02
(4H), 9.03 (1H, d, J=8Hz)

Example 4

8-(3-Amino-2,6-dichlorobenzyloxy)-4-chloro-2-methylquinoline dihydrochloride was obtained according to

2122236

a similar manner to that of Example 3.

NMR (DMSO- d_6 , δ) : 2.61 (3H, s), 5.30-5.45 (2H),
6.80-7.26 (2H), 7.50-7.95 (4H)

5 Example 5

To a mixture of 8-(3-amino-2,6-dichlorobenzyloxy)-2-methylquinoline dihydrochloride (4.06 g),
4-dimethylaminopyridine (120 mg), N-methylpyrrolidone (30 ml) and pyridine (10 ml) was added phthalimidoacetyl
10 chloride (3.35 g) at ambient temperature. The mixture was stirred at 50°C for 1.5 hours and cooled in an ice-water bath. Water (40 ml) was added therein and the mixture was stirred for 30 minutes in an ice water bath. The
precipitate was collected by vacuum filtration and washed
15 with water and ethyl acetate to give 8-[2,6-dichloro-3-(phthalimidoacetylamino)benzyloxy]-2-methylquinoline (4.45 g) as a yellowish powder.

NMR (CDCl₃, δ) : 2.86 (3H, s), 4.74 (2H, s), 5.51
(2H, s), 7.20-7.50 (5H), 7.63-7.93 (4H), 8.03
20 (1H, d, J=8Hz), 8.29 (1H, d, J=8Hz)

Example 6

4-Chloro-8-[2,6-dichloro-3-(phthalimidoacetylamino)benzyloxy]-2-methylquinoline was obtained according to a
25 similar manner to that of Example 5.

NMR (DMSO- d_6 , δ) : 2.60 (3H, s), 4.56 (2H, s), 5.48
(2H, s), 7.48-8.02 (10H)

Example 7

30 To a mixture of 8-[2,6-dichloro-3-(phthalimidoacetylamino)benzyloxy]-2-methylquinoline (4.44 g) and N,N-dimethylformamide (44 ml) was added sodium hydride (60% in oil, 375 mg) in an ice-water bath. After stirring for 30 minutes in an ice-water bath, methyl iodide (0.6
35 ml) was added thereto and the mixture was stirred at

2122236

ambient temperature for 1 hour. To this mixture was added water (88 ml) in an ice-water bath and the mixture was stirred at the same temperature for 1.5 hours. The precipitate was collected by vacuum filtration and washed with water and methanol to give 8-[2,6-dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline (3.99 g) as a yellow powder.

NMR (CDCl_3 , δ) : 2.76 (3H, s), 3.23 (3H, s), 4.08 (2H, s), 5.68 (1H, d, $J=12\text{Hz}$), 5.75 (1H, d, $J=12\text{Hz}$), 7.24-7.59 (6H), 7.66-7.91 (4H), 8.03 (1H, d, $J=8\text{Hz}$)

Example 8

4-Chloro-8-[2,6-dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline was obtained according to a similar manner to that of Example 7.

NMR (CDCl_3 , δ) : 2.72 (3H, s), 3.23 (3H, s), 4.06 (2H, s), 5.66 (1H, d, $J=12\text{Hz}$), 5.73 (1H, d, $J=12\text{Hz}$), 7.30-7.92 (10H)

Example 9

A mixture of 8-[2,6-dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline (3.98 g), hydrazine monohydrate (0.72 ml) and ethanol (40 ml) was heated under reflux for 1 hour. The precipitate was removed by vacuum filtration and the filtrate was evaporated in vacuo. The residue was dissolved with dichloromethane and the precipitate was removed by vacuum filtration. The filtrate was evaporated in vacuo to give 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline (2.99 g) as a yellow amorphous powder.

NMR (CDCl_3 , δ) : 2.76 (3H, s), 2.96 (1H, d, $J=16\text{Hz}$), 3.10 (1H, d, $J=16\text{Hz}$), 3.21 (3H, s), 5.66 (2H, s), 7.20-7.50 (6H), 8.02 (1H, d, $J=8\text{Hz}$)

2122236

Example 10

The following compounds were obtained according to a similar manner to that of Example 9.

5 (1) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
4-chloro-2-methylquinoline
NMR (CDCl₃, δ) : 2.72 (3H, s), 2.96 (1H, d, J=16Hz),
3.15 (1H, d, J=16Hz), 3.21 (3H, s), 5.63 (2H,
s), 7.22-7.55 (5H), 7.88 (1H, d, J=8Hz)

10

(2) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
4-chloro-2-ethylquinoline
mp : 161-164°C
NMR (CDCl₃, δ) : 1.40 (3H, t, J=7Hz), 2.89-3.09
15 (4H), 3.20 (3H, s), 5.70 (2H, s), 7.19-7.52
(5H), 7.88 (1H, t, J=9Hz)

15

(3) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
2-ethylquinoline
20 mp : 125-128°C
NMR (CDCl₃, δ) : 1.40 (3H, t, J=7Hz), 2.89-3.14
(4H), 3.20 (3H, s), 5.71 (2H, s), 7.20-7.51
(6H), 8.06 (1H, d, J=9Hz)

20

25 Example 11

To a solution of 8-[3-(N-glycyl-N-methylamino)-2,6-
dichlorobenzyloxy]-2-methylquinoline (100 mg) in
dichloromethane (2 ml) was added ethyl isocyanate (0.04
ml) in an ice-water bath. The mixture was stirred at the
30 same temperature for 30 minutes and then evaporated in
vacuo. The residue was purified by preparative thin layer
chromatography (ethyl acetate-methanol) to give 8-[2,6-
dichloro-3-[N-(N'-ethylureidoacetyl)-N-methylamino]-
benzyloxy]-2-methylquinoline (115 mg) as a white amorphous
35 powder.

30

35

2122336

NMR (CDCl_3 , δ) : 1.02 (3H, t, $J=7\text{Hz}$), 2.69 (3H, s),
3.10 (2H, m), 3.23 (3H, s), 3.82 (2H, t, $J=4\text{Hz}$),
5.18 (1H, m), 5.52 (1H, d, $J=12\text{Hz}$), 5.68 (1H, d,
 $J=12\text{Hz}$), 7.20-7.50 (6H), 8.04 (1H, d, $J=8\text{Hz}$)

5

Example 12

To a stirred solution of N,N'-carbonyldiimidazole
(78.2 mg) in 1,4-dioxane (1 ml) was added a solution of
3-acetamidoaniline (72 mg) in 1,4-dioxane (2 ml) at
10 ambient temperature and the solution was stirred at the
same temperature for 21 hours. 8-[2,6-Dichloro-3-
(N-glycyl-N-methylamino)benzyloxy]-2-methylquinoline (150
mg) was added thereto at ambient temperature and the
resulting mixture was heated at 110°C for 6.5 hours.
15 Dimethylsulfoxide (0.5 ml) was added thereto and the
resulting solution was stirred at 110°C for 5 hours.
After cooling, the mixture was concentrated in vacuo and
the residue was purified by preparative thin-layer
chromatography (methanol-chloroform, 10%, V/V) to afford
20 8-[2,6-dichloro-3-[N-[N'-(3-acetamidophenyl)ureidoacetyl]-
N-methylamino]benzyloxy]-2-methylquinoline (75 mg) as a
pale yellow amorphous solid.

NMR (CDCl_3 , δ) : 1.99 (3H, s), 2.62 (3H, s), 3.16
(3H, s), 3.79 (1H, dd, $J=20, 4\text{Hz}$), 3.91 (1H, dd,
25 $J=20, 5\text{Hz}$), 5.22 (2H, s), 6.07 (1H, br t),
6.93-7.13 (2H, m), 7.16-7.37 (5H, m), 7.39-7.56
(3H, m), 8.06 (1H, d, $J=9\text{Hz}$), 8.40 (1H, br s),
9.00 (1H, br s)

30 Example 13

To a stirred mixture of 8-[3-(N-glycyl-N-
methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline (100
mg) and triethylamine (68 μl) in dichloromethane (2 ml)
was added 4-nitrophenyl chloroformate (55 mg) at ambient
35 temperature and the mixture was stirred at the same

temperature for 2.5 hours. The mixture was diluted with chloroform and washed with saturated sodium bicarbonate solution. After dried with magnesium sulfate, the solvent was removed in vacuo to afford a yellow amorphous solid including 8-[2,6-dichloro-3-[N-methyl-N-(4-nitrophenoxy-carbonylglycyl)amino]benzyloxy]-2-methylquinoline. This solid was dissolved in anhydrous dioxane (2 ml) and to the solution was added ethyl 3-aminobenzoate (45 mg) at ambient temperature. The mixture was stirred at 100°C for 18 hours. After cooled and concentrated in vacuo, the residue was purified by flash chromatography eluting with ethyl acetate-hexane (2:1 then 4:1, V/V) to give 8-[2,6-dichloro-3-[N-[N'-(3-ethoxycarbonylphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline (107 mg) as an amorphous solid.

NMR (CDCl₃, δ) : 1.24 (3H, t, J=7.5Hz), 2.60 (3H, s), 3.23 (3H, s), 3.81 (1H, dd, J=17.5, 5Hz), 4.24 (2H, q, J=7.5Hz), 4.34 (1H, dd, J=17.5, and 7Hz), 5.43 (1H, d, J=10Hz), 5.56 (1H, dd, J=7, 5Hz), 5.62 (1H, d, J=10Hz), 7.12-7.37 (5H, m), 7.41-7.54 (3H, m), 7.60 (1H, dt, J=7.5, 0.5Hz), 7.82 (1H, t, J=0.5Hz), 8.09 (1H, d, J=7.5Hz), 8.55 (1H, br s)

Example 14

The following compounds were obtained according to similar manners to those of Examples 11 to 13.

(1) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.40 (3H, s), 2.62 (3H, s), 3.23 (3H, s), 3.83 (1H, dd, J=17, 4Hz), 4.37 (1H, dd, J=17, 6Hz), 5.47 (1H, d, J=12Hz), 5.60 (1H, m), 5.65 (1H, d, J=12Hz), 7.17-7.58 (9H), 7.82 (1H, t, J=1Hz), 8.10 (1H, d, J=8Hz), 8.71 (1H, s)

- (2) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methyl-amino]-2,6-dichlorobenzyloxy]-4-chloro-2-methylquinoline

5 NMR (CDCl₃, δ) : 2.46 (3H, s), 2.62 (3H, s), 3.23 (3H, s), 3.82 (1H, dd, J=17, 4Hz), 4.26 (1H, dd, J=17, 6Hz), 5.49 (1H, d, J=12Hz), 5.56 (1H, m), 5.65 (1H, d, J=12Hz), 7.17-7.64 (9H), 7.84 (1H, t, J=1Hz), 7.90 (1H, d, J=8Hz), 8.32 (1H, s)

- 10 (3) 8-[3-[N-(N'-Benzoylureidoacetyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

mp : 220-221°C

15 NMR (CDCl₃, δ) : 2.70 (3H, s), 3.26 (3H, s), 3.70 (1H, dd, J=16, 4Hz), 4.00 (1H, dd, J=16, 4Hz), 5.63 (2H, s), 7.20-7.60 (9H), 7.83 (2H, d, J=8Hz), 8.01 (1H, d, J=8Hz), 8.87 (1H, s), 9.20 (1H, t like)

- 20 (4) 8-[2,6-Dichloro-3-[N-(N'-pentylureidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 0.80 (3H, t, J=7.5Hz), 1.05-1.60 (6H, m), 2.70 (3H, s), 3.07 (2H, m), 3.25 (3H, s), 3.80 (2H, d, J=5Hz), 5.03-5.28 (2H, m), 5.53 (1H, d, J=9Hz), 5.67 (1H, d, J=9Hz), 7.16-7.56 (6H, m), 8.03 (1H, d, J=8Hz)

- (5) 8-[2,6-Dichloro-3-[N-[N'-[3-(N-methyl-N-acetylamino)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 1.81 (3H, s), 2.59 (3H, s), 3.13 (3H, s), 3.23 (3H, s), 3.27 (1H, dd, J=18, 4Hz), 4.49 (1H, dd, J=18, 7Hz), 5.42 (1H, d, J=10Hz), 5.45 (1H, m), 5.63 (1H, dd, J=10Hz), 6.69 (1H, dt, J=6, 1Hz), 7.00-7.16 (2H, m), 7.17-7.42 (5H, m), 7.43-7.56 (2H, m), 8.11 (1H, d, J=8Hz), 8.90 (1H, br s)

35

2122236

- (6) 8-[2,6-Dichloro-3-[N-[N'-(3-dimethylaminophenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.66 (3H, s), 2.82 (6H, s), 3.22 (3H, s), 3.81 (1H, dd, J=17, 5Hz), 4.05 (1H, dd, J=17, 5Hz), 5.51 (1H, d, J=10Hz), 5.61-5.70 (2H), 6.89 (1H, dd, J=9, 1Hz), 6.51 (1H, d, J=9Hz), 6.74 (1H, t, J=1Hz), 7.05 (1H, t, J=9Hz), 7.20-7.49 (6H), 7.56 (1H, s), 8.06 (1H, d, J=9Hz)

- (7) 8-[2,6-Dichloro-3-[N-[N'-[3-(N'-methylureido)phenyl]-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.63 (3H, s), 2.71 (3H, s), 3.19 (3H, s), 3.68 (1H, d, J=17Hz), 3.89 (1H, d, J=17Hz), 5.51 (2H, s), 6.82 (1H, d, J=7Hz), 6.96-7.50 (9H), 8.07 (1H, d, J=9Hz)

- (8) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(3-nitrophenyl)-ureidoacetyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.60 (3H, s), 3.22 (3H, s), 3.81 (1H, dd, J=17, 5Hz), 4.43 (1H, dd, J=17, 8Hz), 5.42 (1H, d, J=10Hz), 5.56-5.69 (2H), 7.13-7.57 (8H), 7.71 (1H, dd, J=8, 1Hz), 8.12 (1H, d, J=8Hz), 8.20 (1H, t, J=1Hz), 9.33 (1H, br s)

- (9) 8-[3-[N-[N'-(4-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.50 (3H, s), 2.59 (3H, s), 3.22 (3H, s), 3.80 (1H, dd, J=17, 4Hz), 4.42 (1H, dd, J=17, 8Hz), 5.45 (1H, d, J=10Hz), 5.56-5.69 (2H), 7.20-7.40 (6H), 7.46-7.59 (2H), 7.73 (2H, d, J=9Hz), 8.12 (1H, d, J=9Hz), 9.09 (1H, s)

2122236

(10) 8-[2,6-Dichloro-3-[N-methyl-N-(N'-phenylureido-
acetyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.62 (3H, s), 3.21 (3H, s), 3.80
(1H, dd, J=17, 5Hz), 4.20 (1H, dd, J=17, 6Hz),
5.48 (1H, d, J=10Hz), 5.56-5.69 (2H), 6.91 (1H,
t, J=7Hz), 7.10-7.37 (8H), 7.48 (2H, d, J=5Hz),
8.09 (1H, d, J=9Hz), 8.12 (1H, s)

(11) 8-[3-[N-(N'-Benzylureidoacetyl)-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.61 (3H, s), 3.17 (3H, s), 3.81
(2H, d, J=5Hz), 4.19 (1H, dd, J=17, 5Hz), 4.84
(1H, dd, J=17, 5Hz), 5.31 (1H, br t, J=5Hz),
5.52 (1H, d, J=9Hz), 5.60-5.73 (2H), 7.10-7.52
(11H), 8.01 (1H, d, J=9Hz)

(12) 8-[2,6-Dichloro-3-[N-[N'-(3-ethoxycarbonylamino-
phenyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-
methylquinoline

mp : 233-235°C

NMR (CDCl₃-CD₃OD, δ) : 1.30 (3H, t, J=7Hz), 2.69
(3H, s), 3.25 (3H, s), 3.64 (1H, d, J=17Hz),
3.90 (1H, d, J=17Hz), 4.19 (2H, q, J=7Hz), 5.56
(2H, s), 6.01 (1/3H, t, J=5Hz), 6.89 (1H, d,
J=8Hz), 7.06-7.56 (9H), 7.97 (1/3H, br s), 8.09
(1H, d, J=9Hz)

(13) 8-[2,6-Dichloro-3-[N-[N'-(1-naphthyl)ureidoacetyl]-N-
methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.70 (3H, s), 3.17 (3H, s), 3.68
(1H, dd, J=17, 5Hz), 3.89 (1H, dd, J=17, 5Hz),
5.54 (1H, d, J=10Hz), 5.62 (1H, d, J=10Hz), 5.93
(1H, br t, J=5Hz), 7.12-7.52 (10H), 7.70 (2H, d,
J=9Hz), 7.83 (1H, d, J=9Hz), 7.91-8.08 (2H)

2122236

(14) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-4-chloro-2-ethylquinoline

NMR (CDCl₃, δ) : 1.27 (3H, t, J=7Hz), 2.47 (3H, s),
2.89 (2H, q, J=7Hz), 3.24 (3H, s), 3.82 (1H, dd,
J=17, 5Hz), 4.12 (1H, dd, J=17, 6Hz), 5.52 (1H,
d, J=10Hz), 5.61-5.72 (2H), 7.18-7.69 (8H),
7.81-7.93 (2H), 8.19 (1H, br s)

(15) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-ethylquinoline

NMR (CDCl₃, δ) : 1.21 (3H, t, J=7Hz), 2.40 (3H, s),
2.90 (2H, q, J=7Hz), 3.22 (3H, s), 3.82 (1H, dd,
J=17, 5Hz), 4.31 (1H, dd, J=17, 6Hz), 5.50 (1H,
d, J=10Hz), 5.58 (1H, m), 5.69 (1H, d, J=10Hz),
7.15-7.54 (9H), 7.82 (1H, t, J=1Hz), 8.12 (1H,
d, J=9Hz), 8.51 (1H, s)

Example 15

To a mixture of 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline (100 mg), triethylamine (50 mg) and dichloromethane (2.0 ml) was added heptanoyl chloride (0.05 ml) in an ice-water bath. The mixture was stirred at the same temperature for 30 minutes and washed with water. The organic layer was collected and dried over magnesium sulfate and evaporated in vacuo. The residue was purified by preparative thin layer chromatography (dichloromethane - methanol) to give 8-[2,6-dichloro-3-[N-(heptanoylglycyl)-N-methylamino]-benzyloxy]-2-methylquinoline (130 mg) as a pale yellow oil.

NMR (CDCl₃, δ) : 0.88 (3H, t, J=7Hz), 1.20-1.40 (4H),
1.53-1.80 (4H), 2.22 (2H, t, J=7Hz), 2.76 (3H,
s), 3.26 (3H, s), 3.50 (1H, dd, J=17, 4Hz), 3.83
(1H, dd, J=17, 6Hz), 5.64 (2H, s), 6.41 (1H,

t-like), 7.22-7.52 (6H), 8.03 (1H, d, J=8Hz)

Example 16

To a mixture of 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline (81 mg), 4-phenylbutyric acid (40 mg) and dimethylformamide (2 ml) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (50 mg) and 1-hydroxybenzotriazole (41 mg). After being stirred for an hour at ambient temperature, the mixture was poured into water and extracted with ethyl acetate. The organic layer was separated, washed with water, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by preparative thin-layer chromatography (dichloromethane - methanol) to give 8-[2,6-dichloro-3-[N-methyl-N-(4-phenylbutyryl)glycyl]-amino]benzyloxy]-2-methylquinoline (105 mg) as a colorless glass.

NMR (CDCl₃, δ) : 1.95 (2H, m), 2.23 (2H, t, J=7Hz), 2.64 (2H, t, J=7Hz), 2.74 (3H, s), 3.23 (3H, s), 3.48 (1H, dd, J=18, 4Hz), 3.82 (1H, dd, J=18, 4Hz), 5.63 (2H, s), 6.39 (1H, t-like), 7.11-7.51 (11H), 8.03 (1H, d, J=8Hz)

Example 17

The following compounds were obtained according to similar manners to those of Examples 15 or 16.

- (1) 8-[2,6-Dichloro-3-[N-methyl-N-(phenylacetyl)glycyl]-amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.20 (3H, s), 3.43 (1H, dd, J=17, 4Hz), 3.59 (2H, s), 3.80 (1H, dd, J=17, 5Hz), 5.63 (2H, s), 6.38 (1H, t-like), 7.18-7.50 (11H), 8.01 (1H, d, J=8Hz)

- (2) 8-[2,6-Dichloro-3-[N-methyl-N-(3-phenylpropionyl)-

2122236

glycyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.53 (2H, t, J=7Hz), 2.73 (3H, s),
2.94 (2H, t, J=7Hz), 3.23 (3H, s), 3.46 (1H, dd,
J=17, 4Hz), 3.80 (1H, dd, J=17, 5Hz), 5.66 (2H,
s), 6.38 (1H, t-like), 7.12-7.52 (11H), 8.03
(1H, d, J=8Hz)

(3) 8-[2,6-Dichloro-3-[N-methyl-N-(phenoxyacetyl)glycyl)-
amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.26 (3H, s), 3.58
(1H, dd, J=17, 4Hz), 3.90 (1H, dd, J=17, 5Hz),
4.50 (2H, s), 5.66 (2H, s), 6.89-7.08 (3H),
7.20-7.58 (9H), 8.03 (1H, d, J=8Hz)

(4) 8-[2,6-Dichloro-3-[N-methyl-N-(2-naphthoyl)glycyl)-
amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.75 (3H, s), 3.30 (3H, s), 3.77
(1H, dd, J=16, 4Hz), 4.08 (1H, dd, J=16, 5Hz),
5.68 (2H, s), 7.23-7.63 (9H), 7.82-7.98 (4H),
8.03 (1H, d, J=8Hz), 8.33 (1H, s)

(5) 8-[3-[N-(Cinnamoyl)glycyl)-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.26 (3H, s), 3.65
(1H, dd, J=17.5, 4Hz), 3.85 (1H, dd, J=17.5,
5Hz), 5.65 (2H, s), 6.48 (1H, d, J=20Hz), 6.65
(1H, br t), 7.19-7.53 (11H, m), 7.57 (1H, d,
J=20Hz), 8.02 (1H, d, J=8Hz)

(6) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(2-thienyl)-
acryloyl)glycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.27 (3H, s), 3.63
(1H, dd, J=16, 4Hz), 3.94 (1H, dd, J=16, 5Hz),
5.64 (2H, s), 6.29 (1H, d, J=15Hz), 6.59 (1H,
t-like), 7.02 (1H, dd, J=5, 4Hz), 7.16-7.54
(8H),

2122236

7.70 (1H, d, J=15Hz), 8.03 (1H, d, J=8Hz)

- (7) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(3-thienyl)-acryloylglycyl]amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.72 (3H, s), 3.24 (3H, s), 3.63 (1H, dd, J=18, 4Hz), 3.95 (1H, dd, J=18, 5Hz), 5.63 (2H, s), 6.30 (1H, d, J=15Hz), 6.60 (1H, t-like), 7.18-7.63 (10H), 8.02 (1H, d, J=8Hz)
- (8) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(3-pyridyl)-acryloylglycyl]amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.72 (3H, s), 3.27 (3H, s), 3.67 (1H, dd, J=17, 4Hz), 3.95 (1H, dd, J=17, 5Hz), 5.65 (2H, s), 6.57 (1H, d, J=15Hz), 6.77 (1H, t-like), 7.21-7.64 (8H), 7.80 (1H, dt, J=8, 1Hz), 8.03 (1H, d, J=8Hz), 8.57 (1H, dd, J=5, 1Hz), 8.72 (1H, d, J=1Hz)
- (9) 8-[2,6-Dichloro-3-[N-methyl-N-(phenyloxalylglycyl)-amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.77 (3H, s), 3.29 (3H, s), 3.63 (1H, dd, J=17, 4Hz), 3.94 (1H, dd, J=17, 5Hz), 5.68 (2H, s), 7.21-7.68 (9H), 7.78 (1H, t-like), 8.04 (1H, d, J=8Hz), 8.23-8.35 (2H)
- (10) 8-[2,6-Dichloro-3-[N-methyl-N-(N-phenylglycylglycyl)-amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.66 (3H, s), 3.20 (3H, s), 3.61 (1H, dd, J=17, 5Hz), 3.73-3.86 (2H), 3.89 (1H, dd, J=17, 5Hz), 4.58 (1H, t-like), 5.62 (2H, s), 6.58 (2H, d, J=8Hz), 6.78 (1H, t, J=8Hz), 7.11-7.53 (9H), 8.02 (1H, d, J=8Hz)
- (11) 8-[2,6-Dichloro-3-[N-methyl-N-(1-naphthylacetyl-glycyl)amino]benzyloxy]-2-methylquinoline

2122236

NMR (CDCl₃, δ) : 2.70 (3H, s), 3.13 (3H, s), 3.35 (1H, dd, J=16, 4Hz), 3.74 (1H, dd, J=16, 5Hz), 4.03 (2H, s), 5.61 (2H, s), 6.29 (1H, t-like), 7.16-7.59 (10H), 7.77-8.03 (4H)

(12) 8-[2,6-Dichloro-3-[N-methyl-N-(2-naphthylacetyl-glycyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.71 (3H, s), 3.17 (3H, s), 3.43 (1H, dd, J=16, 4Hz), 3.73 (2H, s), 3.81 (1H, dd, J=16, 5Hz), 5.62 (2H, s), 6.41 (1H, t-like), 7.14-7.55 (9H), 7.70-7.90 (4H), 8.00 (1H, d, J=8Hz)

(13) 8-[2,6-Dichloro-3-[N-methyl-N-(phenoxycarbonyl-glycyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.26 (3H, s), 3.52 (1H, dd, J=17, 4Hz), 3.83 (1H, dd, J=17, 5Hz), 5.66 (2H, s), 5.90 (1H, t-like), 7.05-7.54 (11H), 8.03 (1H, d, J=8Hz)

(14) 8-[2,6-Dichloro-3-[N-methyl-N-(2-nitrocinnamoyl-glycyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.28 (3H, s), 3.67 (1H, dd, J=16, 4Hz), 3.95 (1H, dd, J=16, 5Hz), 5.65 (2H, s), 6.42 (1H, d, J=15Hz), 6.79 (1H, t-like), 7.20-7.67 (9H), 7.92-8.08 (3H)

(15) 8-[2,6-Dichloro-3-[N-methyl-N-(3-nitrocinnamoyl-glycylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.28 (3H, s), 3.69 (1H, dd, J=16, 4Hz), 3.97 (1H, dd, J=16, 5Hz), 5.66 (2H, s), 6.63 (1H, d, J=15Hz), 6.80 (1H, t-like), 7.22-7.57 (7H), 7.62 (1H, d, J=15Hz), 7.79 (1H, d, J=8Hz), 8.04 (1H, d, J=8Hz), 8.20 (1H, d, J=8Hz), 8.36 (1H, t, J=1Hz)

2122236

- (16) 8-[2,6-Dichloro-3-[N-methyl-N-(4-nitrocinnamoyl-glycyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.28 (3H, s), 3.70 (1H, dd, J=16, 4Hz), 3.97 (1H, dd, J=16, 5Hz), 5.66 (2H, s), 6.62 (1H, d, J=15Hz), 6.82 (1H, t-like), 7.21-7.70 (9H), 8.03 (1H, d, J=8Hz), 8.21 (2H, d, J=8Hz)

- (17) 8-[2,6-Dichloro-3-[N-(2-methoxycinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.27 (3H, s), 3.63 (1H, dd, J=16, 4Hz), 3.87 (3H, s), 3.96 (1H, dd, J=16, 4Hz), 5.65 (2H, s), 6.61 (1H, d, J=15Hz), 6.62 (1H, t-like), 6.87-7.01 (2H), 7.21-7.55 (8H), 7.81 (1H, d, J=15Hz), 8.03 (1H, d, J=8Hz)

- (18) 8-[2,6-Dichloro-3-[N-(3-methoxycinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.26 (3H, s), 3.66 (1H, dd, J=16, 4Hz), 3.81 (3H, s), 3.96 (1H, dd, J=16, 4Hz), 5.66 (2H, s), 6.48 (1H, d, J=15Hz), 6.67 (1H, t-like), 6.90 (1H, dd, J=8, 2Hz), 7.10 (1H, s), 7.10 (1H, d, J=8Hz), 7.20-7.61 (8H), 8.03 (1H, d, J=8Hz)

- (19) 8-[2,6-Dichloro-3-[N-(4-methoxycinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.27 (3H, s), 3.64 (1H, dd, J=16, 4Hz), 3.82 (3H, s), 3.96 (1H, dd, J=16, 5Hz), 5.66 (2H, s), 6.36 (1H, d, J=15Hz), 6.60 (1H, t-like), 6.83-6.94 (2H), 7.18-7.60 (9H), 8.04 (1H, d, J=8Hz)

Example 18

A mixture of phenylhydrazine (54 mg),

2122236

N,N'-carbonyldiimidazole (81 mg) and 1,4-dioxane (3 ml) was stirred at ambient temperature for 3 days under nitrogen atmosphere. To this mixture was added 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline (121 mg). The mixture was heated under reflux for 1 hour. After being cooled to ambient temperature, the mixture was poured into water and extracted with dichloromethane. The organic layer was dried over magnesium sulfate and evaporated in vacuo. The residue was purified by preparative thin-layer chromatography (dichloromethane - methanol) to give 8-[2,6-dichloro-3-[N-methyl-N-(N'-anilinoureidoacetyl)amino]benzyloxy]-2-methylquinoline (143 mg) as an amorphous powder.

NMR (CDCl₃, δ) : 2.60 (3H, s), 3.20 (3H, s), 3.72 (1H, dd, J=16, 5Hz), 3.88 (1H, dd, J=16, 5Hz), 5.62 (2H, s), 5.98 (1H, s), 6.34 (1H, t-like), 6.46 (1H, s), 6.68-7.52 (11H), 8.00 (1H, d, J=8Hz)

Example 19

To a solution of 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline (81 mg) and triethylamine (0.04 ml) in dichloromethane (2 ml) was added a solution of (E)-styrenesulfonyl chloride (48 mg) in dichloromethane (1 ml) in an ice-water bath. After being stirred for 30 minutes under ice-cooling, the reaction mixture was partitioned into dichloromethane and water. The organic layer was dried over magnesium sulfate and evaporated in vacuo. The residue was purified by preparative thin-layer chromatography (dichloromethane - methanol) to give 8-[2,6-dichloro-3-[N-methyl-N-((E)-styrylsulfonylglycyl)amino]benzyloxy]-2-methylquinoline (78 mg) as an amorphous powder.

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.18 (3H, s), 3.38 (1H, dd, J=16, 5Hz), 3.54 (1H, dd, J=16, 5Hz),

2122236

5.35 (1H, t like), 5.60 (2H, s), 6.70 (1H, d, J=15Hz), 7.11-7.52 (12H), 8.03 (1H, d, J=8Hz)

Example 20

5 To a solution of 8-[2,6-dichloro-3-[N-[N'-(3-ethoxycarbonylphenyl)ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline (97 mg) in ethanol (1 ml) was added 1N sodium hydroxide solution (0.179 ml) at ambient temperature. The mixture was stirred for 3 hours at the
10 same temperature and for 3 hours at 50°C. The reaction mixture was adjusted to pH 5 with 1N hydrochloric acid and water (1 ml) was added therein. The precipitate was collected by vacuum filtration and washed with water and acetonitrile to give 8-[3-[N-[N'-(3-carboxyphenyl)-ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-
15 methylquinoline (62 mg) as crystals.

mp : 240-241°C

NMR (DMSO-d₆, δ) : 2.63 (3H, s), 3.18 (3H, s), 3.43 (1H, dd, J=17, 5Hz), 3.69 (1H, dd, J=17, 5Hz),
20 5.49 (1H, d, J=10Hz), 5.58 (1H, d, J=10Hz), 7.27-7.72 (8H), 7.30 (2H, s), 8.02 (1H, s), 8.29 (1H, br s), 9.09 (1H, s)

Example 21

25 To a mixture of 8-[3-[N-[N'-(3-carboxyphenyl)-ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (130 mg), morpholine (22 µl) and N,N-dimethylformamide (1.5 ml) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (58
30 mg) and 1-hydroxybenzotriazole (41 mg), and the mixture was stirred for 1 hour at ambient temperature. The reaction mixture was diluted with a mixture of methanol and chloroform (1:10, V/V), washed with saturated sodium bicarbonate solution and brine, dried over magnesium
35 sulfate, and concentrated in vacuo. The residue was

2122236

purified by flash chromatography (chloroform - methanol) to give 8-[2,6-dichloro-3-[N-methyl-N-[N'-[3-(morpholino-carbonyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline (137 mg) as colorless amorphous solid.

5 NMR (CDCl₃, δ) : 2.60 (3H, s), 3.20 (3H, s),
3.25-3.88 (8H, m), 3.78 (1H, dd, J=17.5, 5Hz),
4.27 (1H, dd, J=17.5, 7Hz), 5.44 (1H, d,
J=10Hz), 5.51-5.66 (1H, m), 5.60 (1H, d,
J=10Hz), 6.95 (1H, dt, J=7.5, 0.5Hz), 7.16 (1H,
10 t, J=7.5Hz), 7.18-7.37 (6H, m), 7.44-7.54 (2H,
m), 8.09 (1H, d, J=8Hz), 8.69 (1H, br s)

Example 22

15 The following compounds were obtained according to a similar manner to that of Example 21.

(1) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-methyl-1-piperazinylcarbonyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline

20 NMR (CDCl₃, δ) : 2.06-2.50 (4H, m), 2.23 (3H, s),
2.61 (3H, s), 3.21 (3H, s), 3.23-3.81 (4H, m),
3.76 (1H, dd, J=17.5, 5Hz), 4.80 (1H, dd,
J=17.5, 7Hz), 5.45 (1H, d, J=10Hz), 5.56 (1H,
dd, J=7, 5Hz), 5.62 (1H, d, J=10Hz), 6.95 (1H,
25 br d, J=7.5Hz), 7.16 (1H, t, J=7.5Hz), 7.18-7.39
(6H, m), 7.44-7.55 (2H, m), 8.09 (1H, d, J=8Hz),
8.68 (1H, br s)

(2) 8-[2,6-Dichloro-3-[N-[N'-[3-(2-methoxyethyl-carbamoyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.62 (3H, s), 3.20 (3H, s), 3.33
(3H, s), 3.45-3.66 (4H, m), 3.83 (1H, dd,
J=17.5, 4Hz), 4.11 (1H, dd, J=17.5, 6Hz), 5.50
35 (1H, d, J=10Hz), 5.65 (1H, d, J=10Hz), 5.82 (1H,

br t, J=4Hz), 6.70 (1H, m), 7.05-7.53 (9H, m),
7.61 (1H, br s), 8.07 (1H, d, J=9Hz), 8.55 (1H,
br s)

- 5 (3) 8-[2,6-Dichloro-3-[N-[N'-(3-[N-[2-(N,N-dimethyl-
amino)ethyl]-N-methylcarbamoyl]phenyl]ureidoacetyl]-
N-methylamino]benzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 1.73-2.58 (10H, m), 2.60 (3H, s),
2.79-3.10 (3H, m), 3.22 (3H, s), 3.58 (1H, m),
3.78 (1H, dd, J=17, 5Hz), 4.20 (1H, m), 5.47
(1H, d, J=10Hz), 5.63 (1H, d, J=10Hz), 5.64 (1H,
m), 6.95 (1H, d, J=6Hz), 7.07-7.54 (6H, m), 7.99
(1H, d, J=8Hz), 8.60 (1H, m)

- 15 (4) 8-[2,6-Dichloro-3-[N-[N'-(3-methylcarbamoylphenyl)-
ureidoacetyl]-N-methylamino]benzyloxy]-2-
methylquinoline

mp : 157-161°C (dec.)

20 NMR (CDCl₃, δ) : 2.62 (3H, s), 2.90 (3H, d, J=5Hz),
3.20 (3H, s), 3.82 (1H, dd, J=18, 5Hz), 4.00
(1H, dd, J=18, 5Hz), 5.52 (1H, d, J=10Hz), 5.64
(1H, d, J=10Hz), 5.99 (1H, br s), 6.68 (1H, br
s), 7.07-7.51 (9H), 7.59 (1H, br s), 8.09 (1H,
d, J=9Hz), 8.56 (1H, br s)

- 25 (5) 8-[3-[N-[N'-(3-Dimethylcarbamoylphenyl)ureidoacetyl]-
N-methylamino]-2,6-dichlorobenzyloxy]-2-
methylquinoline

30 NMR (CDCl₃, δ) : 2.61 (3H, s), 2.90 (3H, br s), 3.04
(3H, br s), 3.22 (3H, s), 3.79 (1H, dd, J=18,
5Hz), 4.20 (1H, dd, J=18, 6Hz), 5.48 (1H, d,
J=10Hz), 5.59-5.70 (2H), 6.95 (1H, d, J=7Hz),
7.09-7.51 (9H), 8.09 (1H, d, J=9Hz), 8.59 (1H,
s)

2122236

(6) 8-[2,6-Dichloro-3-[N-[N'-[3-(3-pyridylmethyl-carbamoyl)phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline

mp : 204-206°C

NMR (CDCl₃-CD₃OD, δ) : 2.66 (3H, s), 3.26 (3H, s), 3.68 (1H, d, J=17Hz), 3.90 (1H, d, J=17Hz), 4.60 (2H, s), 5.56 (2H, s), 7.20-7.56 (10H), 7.72-7.82 (2H), 8.09 (1H, d, J=9Hz), 8.45 (1H, dd, J=5, 1Hz), 8.53 (1H, d, J=1Hz)

(7) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[4-(4-pyridyl)-1-piperazinylcarbonyl]phenyl]ureidoacetyl]amino]-benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.61 (3H, s), 3.08-3.91 (12H), 4.28 (1H, dd, J=17.6Hz), 5.46 (1H, d, J=10Hz), 5.58-5.70 (2H), 6.61 (2H, br d, J=6Hz), 6.99 (1H, d, J=7Hz), 7.12-7.50 (9H), 8.08 (1H, d, J=9Hz), 8.30 (2H, br d, J=6Hz), 8.81 (1H, s)

(8) 8-[3-[N-[N'-[3-(4-Acetyl-1-piperazinylcarbonyl)-phenyl]ureidoacetyl]-N-methylamino]-2,6-dichloro-benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.10 (3H, s), 2.60 (3H, s), 3.21 (3H, s), 3.23-3.87 (9H), 4.30 (1H, dd, J=17, 6Hz), 5.45 (1H, d, J=10Hz), 5.51-5.69 (2H), 6.94 (1H, d, J=8Hz), 7.10-7.54 (9H), 8.10 (1H, d, J=9Hz), 8.79 (1H, br s)

(9) 8-[2,6-Dichloro-3-[N-[N'-[3-(3-pyridylcarbamoyl)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

mp : 156-160°C (broad)

NMR (CDCl₃, δ) : 2.68 (3H, s), 3.21 (3H, s), 3.77-4.05 (2H), 5.41 (1H, d, J=10Hz), 5.57 (1H, d, J=10Hz), 6.39 (1H, br t, J=5Hz), 6.96-7.52

2122236

(11H), 8.03 (1H, d, J=9Hz), 8.32 (1H, d, J=5Hz),
8.39-8.50 (2H), 9.01 (1H, d, J=1Hz), 9.56 (1H,
br s)

- 5 (10) 8-[2,6-Dichloro-3-[N-[N'-[3-(2-pyridylmethyl-
carbamoyl)phenyl]ureidoacetyl]-N-methylamino]-
benzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 2.62 (3H, s), 3.21 (3H, s), 3.81
(1H, dd, J=17, 5Hz), 4.11 (1H, dd, J=17, 6Hz),
4.70 (2H, d, J=5Hz), 5.50 (1H, d, J=10Hz), 5.65
(1H, d, J=10Hz), 5.81 (1H, br t, J=5Hz),
7.10-7.73 (13H), 8.06 (1H, d, J=9Hz), 8.50 (1H,
d, J=5Hz), 8.60 (1H, s)

- 15 (11) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-pyridylmethyl-
carbamoyl)phenyl]ureidoacetyl]-N-methylamino]-
benzyloxy]-2-methylquinoline

20 NMR (CDCl₃, δ) : 2.61 (3H, s), 3.19 (3H, s), 3.81
(1H, dd, J=17, 5Hz), 4.03 (1H, dd, J=17, 6Hz),
4.52 (2H, d, J=6Hz), 5.51 (1H, d, J=10Hz), 5.61
(1H, d, J=10Hz), 5.90 (1H, br t, J=5Hz),
7.07-7.50 (12H), 7.58 (1H, s), 8.08 (1H, d,
J=9Hz), 8.50 (2H, d, J=6Hz), 8.60 (1H, s)

- 25 (12) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(1-
piperazinylcarbonyl)phenyl]ureidoacetyl]amino]-
benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.53-2.98 (4H, m), 2.62 (3H, s),
3.14-3.86 (5H, m), 3.78 (1H, dd, J=16, 5Hz),
4.18 (1H, dd, J=16, 7Hz), 5.25 (1H, d, J=10Hz),
5.61 (1H, d, J=10Hz), 5.71 (1H, br t, J=5Hz),
6.94 (1H, br d, J=7.5Hz), 7.08-7.40 (6H, m),
7.15 (1H, t, J=7.5Hz), 7.48 (2H, d, J=5Hz), 8.08
(1H, d, J=9Hz), 8.70 (1H, br s)

2122226

(13) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-phenyl-1-piperazinylcarbonyl)phenyl]ureidoacetyl]amino]-benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.60 (3H, s), 2.64-4.11 (8H, m),
3.21 (3H, s), 3.79 (1H, dd, J=17, 4Hz), 4.30
(1H, dd, J=17, 7Hz), 5.44 (1H, d, J=9Hz), 5.57
(1H, m), 5.61 (1H, d, J=9Hz), 6.81-7.05 (4H, m),
7.11-7.53 (10H, m), 8.03 (1H, d, J=9Hz), 8.71
(1H, br s)

(14) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-ethoxycarbonyl-1-piperazinylcarbonyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.28 (3H, t, J=7.5Hz), 2.60 (3H,
s), 3.10-4.16 (8H, m), 3.79 (1H, dd, J=17.5,
7.5Hz), 4.17 (2H, q, J=7.5Hz), 4.31 (1H, dd,
J=17.5, 7.5Hz), 5.45 (1H, d, J=9Hz), 5.55 (1H,
dd, J=7.5, 5Hz), 5.63 (1H, d, J=9Hz), 6.93 (1H,
d, J=7Hz), 7.10-7.39 (6H, m), 7.40-7.56 (2H, m),
8.10 (2H, m), 8.73 (1H, br s)

(15) 8-[2,6-Dichloro-3-[N-[N'-[3-[2-(N,N-dimethylamino)-ethylcarbonyl]phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.40 (6H, s), 2.64 (3H, s), 2.70
(2H, t, J=7Hz), 3.20 (3H, s), 3.37-3.69 (3H, m),
3.80 (1H, dd, J=16, 4Hz), 4.04 (1H, dd, J=16,
and 6Hz), 5.50 (1H, d, J=10Hz), 5.64 (1H, d,
J=10Hz), 5.87 (1H, br t, J=5Hz), 7.15 (1H, t,
J=7.5Hz), 7.20-7.50 (8H, m), 7.66 (1H, br s),
8.06 (1H, d, J=9Hz), 8.64 (1H, br s)

Example 23

To a mixture of 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline (150 ml),

2122236

triethylamine (0.077 ml) and dichloromethane (1.5 ml) was added bromoacetyl chloride (0.034 ml) in a dry ice-acetone bath. After 30 minutes, to the mixture was added N-methyl-N-cycloheptylamine (236 mg). The mixture was stirred for 3 hours at ambient temperature. The reaction mixture was washed with aqueous sodium bicarbonate solution, water and brine. The organic layer was dried over magnesium sulfate and evaporated in vacuo. The residue was purified by a silica gel column chromatography (dichloromethane - methanol) to yield 8-[3-[N-[(N-cycloheptyl-N-methylglycyl)glycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (151 mg) as amorphous.

NMR (CDCl₃, δ) : 1.29-1.96 (12H), 2.30 (3H, s), 2.58 (1H, m), 2.75 (3H, s), 3.01 (2H, s), 3.26 (3H, s), 3.50 (1H, dd, J=18, 4Hz), 3.89 (1H, dd, J=18, 5Hz), 5.63 (2H, s), 7.19-7.52 (6H), 8.02 (1H, d, J=8Hz), 8.13 (1H, br t, J=5Hz)

Example 24

8-[2,6-Dichloro-3-[N-methyl-N-[[[4-(4-pyridyl)-1-piperazinyl]acetyl]glycyl]amino]benzyloxy]-2-methylquinoline was obtained according to a similar manner to that of Example 23.

NMR (CDCl₃, δ) : 2.60-2.80 (7H), 3.10 (2H, s), 3.24 (3H, s), 3.38-3.61 (5H), 3.91 (1H, dd, J=18, 5Hz), 5.65 (2H, s), 6.70 (2H, d, J=6Hz), 7.22-7.55 (6H), 7.89 (1H, br t, J=5Hz), 8.03 (1H, d, J=8Hz), 8.28 (2H, d, J=6Hz)

Example 25

A mixture of 8-[3-[N-[N'-(3-acetylphenyl)-ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (200 mg), methoxyamine hydrochloride (58.5 mg) and pyridine (71 μl) in ethanol (3 ml) was stirred at

ambient temperature for one hour and then at 70°C for two hours. After being cooled, the mixture was diluted with chloroform and washed with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was crystallized from ethyl acetate and filtered to give 8-[2,6-dichloro-3-[N-[N'-[3-(1-methoxyiminoethyl)phenyl]-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline (161 mg) as a colorless powder.

mp : 218-224°C

NMR (DMSO-d₆, δ) : 2.12 (3H, s), 2.60 (3H, s), 3.15 (3H, s), 3.43 (1H, dd, J=17.5, 5Hz), 3.66 (1H, dd, J=17.5, 4Hz), 3.89 (3H, s), 5.46 (1H, d, J=9Hz), 5.53 (1H, d, J=9Hz), 6.37 (1H, br t), 7.11-7.30 (2H, m), 7.32-7.60 (5H, m), 7.70 (1H, m), 7.80 (2H, s), 8.20 (1H, d, J=9Hz), 8.92-9.08 (1H, m)

Example 26

8-[2,6-Dichloro-3-[N-[N'-[3-(1-hydroxyiminoethyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline was obtained according to a similar manner to that of Example 25.

NMR (CDCl₃, δ) : 2.10 (3H, s), 2.64 (3H, s), 3.17 (3H, s), 3.81 (2H, br d, J=5Hz), 5.45 (1H, d, J=10Hz), 5.59 (1H, d, J=10Hz), 6.03 (1H, br t, J=5Hz), 7.09-7.52 (10H), 8.03 (1H, d, J=9Hz), 8.51 (1H, s), 9.23 (1H, br s)

Example 27

A mixture of 8-[3-[N-[N'-(3-acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (200 mg) and N,N-dimethylhydrazine (35 μl) in ethanol (2 ml) was heated at 50°C for one hour and then at 90°C for 6 hours. Then the mixture was heated at 100°C

2122236

for 15 hours during which time an additional
N,N-dimethylhydrazine (108 μ l) and acetic acid (0.5 ml)
was added therein. The mixture was concentrated in vacuo
and the residue was diluted with ethyl acetate. The
5 organic phase was washed with saturated sodium bicarbonate
solution and brine and then dried over anhydrous magnesium
sulfate. The organic layer was concentrated in vacuo and
the residue was purified by flash chromatography eluting
with ethyl acetate. The desired fraction was concentrated
10 and the residue was powderized with diethyl ether and
filtered to afford 8-[2,6-dichloro-3-[N-[N'-(3-(1-
dimethylhydrazonoethyl)phenyl]ureidoacetyl]-N-methyl-
amino]benzyloxy]-2-methylquinoline (50 mg) as a colorless
powder.

15 mp : 174.4-187.4°C
NMR (CDCl_3 , δ) : 2.16 (3H, s), 2.50 (6H, s), 2.63
(3H, s), 3.22 (3H, s), 3.82 (1H, dd, J=16, 4Hz),
4.20 (1H, dd, J=16, 6Hz), 5.48 (1H, d, J=18Hz),
5.62 (1H, m), 5.66 (1H, d, J=18Hz), 7.08-7.37
20 (6H, m), 7.40-7.53 (3H, m), 7.57 (1H, m), 8.06
(1H, d, J=8Hz), 8.18 (1H, br s)

Example 28

To a solution of 8-[2,6-dichloro-3-[N-(N'-
25 ethylureidoacetyl)-N-methylamino]benzyloxy]-2-
methylquinoline (111 mg) in ethanol (3 ml) was added 10%
solution of hydrogen chloride in methanol (0.5 ml). The
mixture was evaporated in vacuo to give a pale yellow
glass which was washed with ether to give
30 8-[2,6-dichloro-3-[N-(N'-ethylureidoacetyl)-N-
methylamino]benzyloxy]-2-methylquinoline hydrochloride
(112 mg) as a pale yellow amorphous powder.

NMR ($\text{DMSO}-d_6$, δ) : 0.94 (3H, t, J=7Hz), 2.94 (3H,
s), 2.95 (2H, q, J=7Hz), 3.13 (3H, s), 3.39 (1H,
35 d, J=16Hz), 3.70 (1H, d, J=16Hz), 5.65 (2H, s),

2122236

7.55-8.06 (6H), 9.05 (1H, d, J=8Hz)

Example 29

The following compounds were obtained according to a similar manner to that of Example 28.

(1) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

mp : 168-170°C

NMR (DMSO-d₆, δ) : 2.51 (3H, s), 2.90 (3H, s), 3.17 (3H, s), 3.52 (1H, d, J=16Hz), 3.76 (1H, d, J=16Hz), 5.62 (2H, s), 6.56 (1H, br s), 7.31-8.06 (10H), 8.90 (1H, d like), 9.32 (1H, s)

(2) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-4-chloro-2-methylquinoline hydrochloride

NMR (DMSO-d₆, δ) : 2.53 (3H, s), 2.68 (3H, s), 3.16 (3H, s), 3.46 (1H, d, J=16Hz), 3.70 (1H, d, J=16Hz), 5.52 (1H, d, J=12Hz), 5.61 (1H, d, J=12Hz), 6.50 (1H, br s), 7.31-7.93 (9H), 8.00 (1H, t, J=1Hz), 9.20 (1H, s)

(3) 8-[2,6-Dichloro-3-[N-(heptanoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (DMSO-d₆, δ) : 0.86 (3H, t, J=7Hz), 1.11-1.54 (8H), 2.09 (2H, t, J=7Hz), 2.90 (3H, s), 3.11 (3H, s), 3.40 (1H, dd, J=16, 4Hz), 3.72 (1H, dd, J=16, 6Hz), 5.58 (1H, d, J=12Hz), 5.67 (1H, d, J=12Hz), 7.50-8.10 (6H), 8.94 (1H, d, J=8Hz)

(4) 8-[3-[N-(Cinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

2122236

NMR (CDCl₃-CD₃OD 4:1 V/V, δ) : 3.09 (3H, s), 3.21 (3H, s), 3.91 (2H, s), 5.59 (1H, d, J=10Hz), 5.79 (1H, d, J=10Hz), 6.59 (1H, d, J=20Hz), 7.28-7.66 (6H, m), 7.58 (1H, d, J=20Hz), 7.61 (1H, d, J=14Hz), 7.72 (1H, br d, J=6Hz), 7.81-8.03 (3H, m), 8.98 (1H, d, J=6Hz)

(5) 8-[2,6-Dichloro-3-[N-[N'-(3-ethoxycarbonylphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.37 (3H, t, J=7Hz), 3.01 (3H, s), 3.31 (3H, s), 3.89 (2H, br s), 4.30 (2H, q, J=7Hz), 5.61 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 7.26-7.47 (2H), 7.58-8.00 (7H), 8.09 (1H, t, J=1Hz), 8.96 (1H, d, J=9Hz)

(6) 8-[2,6-Dichloro-3-[N-(N'-pentylureidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (DMSO-d₆, δ) : 0.85 (3H, t, J=7.5Hz), 1.10-1.44 (6H, m), 2.50 (3H, s), 3.11 (3H, s), 2.85-2.95 (2H, m), 3.38 (1H, d, J=17.5Hz), 3.68 (1H, d, J=17.5Hz), 5.61 (2H, s), 7.79 (2H, br s), 7.90 (3H, br s), 7.98 (1H, d, J=7.5Hz), 9.01 (1H, d, J=8Hz)

(7) 8-[2,6-Dichloro-3-[N-[N'-(3-acetamidophenyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 2.07 (3H, s), 2.86 (3H, br s), 3.29 (3H, s), 3.89 (2H, s), 5.58 (1H, br d, J=8Hz), 5.79 (1H, br d, J=8Hz), 6.91-7.23 (3H, m), 7.26-8.03 (7H, m), 8.90 (1H, br d, J=6Hz)

(8) 8-[2,6-Dichloro-3-[N-[N'-[3-(N-methyl-N-acetylamino)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

5 NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 1.81 (3H, s), 3.04 (3H, br s), 3.11 (3H, s), 3.27 (3H, s), 3.84 (1H, d, J=17Hz), 3.96 (1H, d, J=17Hz), 5.59 (1H, d, J=8Hz), 5.75 (1H, d, J=8Hz), 6.75 (1H, m), 7.17-8.02 (9H, m), 8.91 (1H, m)

10 (9) 8-[2,6-Dichloro-3-[N-[N'-[3-(N,N-dimethylamino)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride-

15 NMR (CDCl₃-CD₃OD, δ) : 3.08 (3H, s), 3.22 (6H, s), 3.30 (3H, s), 3.81 (2H, s), 5.61 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 7.25 (1H, d, J=7Hz), 7.33-7.52 (2H), 7.60 (1H, d, J=9Hz), 7.68 (1H, d, J=9Hz), 7.76-7.98 (5H), 8.96 (1H, d, J=9Hz)

20 (10) 8-[2,6-Dichloro-3-[N-[N'-[3-(N'-methylureido)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 2.75 (3H, s), 2.90 (3H, s), 3.30 (3H, s), 3.80 (1H, d, J=17Hz), 3.92 (1H, d, J=17Hz), 5.61 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.80-7.00 (3H), 7.32 (1H, s), 7.56 (1H, d, J=9Hz), 7.64 (1H, d, J=9Hz), 7.70-8.00 (4H), 8.90 (1H, d, J=9Hz)

30 (11) 8-[3-[N-[N'-(3-Carboxyphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 3.00 (3H, s), 3.31 (3H, s), 3.81 (1H, d, J=18Hz), 3.95 (1H, d, J=18Hz), 5.60 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 7.23-7.40

2122236

(2H), 7.56-8.02 (7H), 8.11 (1H, s), 8.94 (1H, d, J=9Hz)

5 (12) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(morpholino-carbonyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline hydrochloride

10 NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 2.93 (3H, s), 3.20-3.44 (8H, m), 3.29 (3H, s), 3.80 (1H, d, J=17Hz), 3.97 (1H, d, J=17Hz), 5.58 (1H, d, J=10Hz), 5.79 (1H, d, J=10Hz), 6.91 (1H, br d J=7.5Hz), 7.16-8.01 (9H, m), 8.89 (1H, d, J=9Hz)

15 (13) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-methyl-1-piperazinylcarbonyl)phenyl]ureidoacetyl]amino]-benzyloxy]-2-methylquinoline dihydrochloride

20 NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 2.84-3.96 (8H, m), 2.90 (3H, s), 2.98 (3H, s), 3.30 (3H, s), 3.84 (2H, br s), 5.60 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 7.01 (1H, br d, J=6Hz), 7.28 (1H, t, J=7.5Hz), 7.36 (1H, br t, J=7Hz), 7.43-8.03 (7H, m), 8.94 (1H, d, J=9Hz)

25 (14) 8-[2,6-Dichloro-3-[N-[N'-[3-(2-methoxyethyl-carbamoyl)phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline hydrochloride

30 NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 2.92 (3H, s), 3.27 (3H, s), 3.36 (3H, s), 3.44-3.60 (4H, m), 3.85 (1H, d, J=17Hz), 3.96 (1H, d, J=17Hz), 5.58 (1H, d, J=9Hz), 5.80 (1H, d, J=9Hz), 7.20 (1H, t, J=7Hz), 7.30-7.50 (2H, m), 7.53-7.99 (7H, m), 8.90 (1H, d, J=9Hz)

35 (15) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(2-dimethylamino-ethyl)-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

2122236

dihydrochloride

NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 2.99 (9H, br s), 3.08 (3H, s), 3.25 (3H, s), 3.30-3.54 (4H, m), 3.91 (2H, m), 5.61 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 7.08 (1H, d, J=7Hz), 7.28 (1H, t, J=8Hz), 7.40-7.55 (1H, m), 7.59 (1H, d, J=9Hz), 7.66 (1H, d, J=9Hz), 7.78 (1H, d, J=7Hz), 7.82-8.02 (4H, m), 8.96 (1H, d, J=9Hz)

10 (16) 8-[2,6-Dichloro-3-[N-[N'-(3-methylcarbamoylphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 2.91 (3H, s), 3.00 (3H, s), 3.31 (3H, s), 3.79 (1H, d, J=18Hz), 3.91 (1H, d, J=18Hz), 5.60 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 7.20-7.46 (3H), 7.60 (1H, d, J=9Hz), 7.69 (1H, d, J=9Hz), 7.74-8.00 (5H), 8.95 (1H, d, J=9Hz)

20 (17) 8-[3-[N-[N'-(3-Dimethylcarbamoylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 2.99 (6H, s), 3.06 (3H, s), 3.30 (3H, s), 3.85 (2H, s), 5.60 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 6.98 (1H, d, J=6Hz), 7.20-7.38 (2H), 7.43-8.02 (7H), 8.94 (1H, d, J=8Hz)

30 (18) 8-[2,6-Dichloro-3-[N-[N'-[3-(3-pyridylmethylcarbamoyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 2.98 (3H, s), 3.30 (3H, s), 3.86 (2H, s), 4.74 (2H, s), 5.60 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 7.28 (1H, d, J=8Hz), 7.48-8.09 (10H), 8.61-8.74 (2H),

2122236

8.88-9.01 (2H)

- (19) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[4-(4-pyridyl)-
1-piperazinylcarbonyl]phenyl]ureidoacetyl]amino]-
benzyloxy]-2-methylquinoline trihydrochloride
NMR (CDCl₃-CD₃OD, δ) : 2.99 (3H, s), 3.30 (3H, s),
3.64-4.00 (10H), 5.62 (1H, d, J=10Hz), 5.82 (1H,
d, J=10Hz), 7.04 (1H, d, J=7Hz), 7.13 (2H, br d,
J=7Hz), 7.30 (1H, t, J=8Hz), 7.40-7.55 (2H),
7.60 (1H, d, J=9Hz), 7.68 (1H, d, J=9Hz), 7.78
(1H, d, J=7Hz), 7.83-8.00 (3H), 8.16 (2H, br d,
J=7Hz), 8.95 (1H, d, J=9Hz)
- (20) 8-[3-[N-[N'-[3-(4-Acetyl-1-piperazinylcarbonyl)-
phenyl]ureidoacetyl]-N-methylamino]-2,6-dichloro-
benzyloxy]-2-methylquinoline hydrochloride
NMR (CDCl₃-CD₃OD, δ) : 2.14 (3H, s), 2.98 (3H, s),
3.30 (3H, s), 3.35-3.90 (10H), 5.60 (1H, d,
J=10Hz), 5.81 (1H, d, J=10Hz), 6.99 (1H, d,
J=7Hz), 7.22-7.53 (3H), 7.60 (1H, d, J=9Hz),
7.68 (1H, d, J=9Hz), 7.71-8.00 (4H), 8.93 (1H,
d, J=9Hz)
- (21) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(3-nitrophenyl)-
ureidoacetyl]amino]benzyloxy]-2-methylquinoline
hydrochloride
NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.31 (3H, s),
3.82 (1H, d, J=17Hz), 3.96 (1H, d, J=17Hz), 5.61
(1H, d, J=10Hz), 5.83 (1H, d, J=10Hz), 7.33-7.48
(2H), 7.61 (1H, d, J=9Hz), 7.19 (1H, d, J=9Hz),
7.27-8.01 (5H), 8.61 (1H, br s), 8.99 (1H, d,
J=9Hz)
- (22) 8-[3-[N-[N'-(4-Acetylphenyl)ureidoacetyl]-N-
methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

2122236

hydrochloride

mp : 173-176°C

NMR (CDCl₃-CD₃OD, δ) : 2.58 (3H, s), 3.03 (3H, s),
3.30 (3H, s), 3.79 (1H, d, J=18Hz), 3.90 (1H, d,
J=18Hz), 5.62 (1H, d, J=10Hz), 5.83 (1H, d,
J=10Hz), 7.45 (1H, d, J=9Hz), 7.60 (1H, d,
J=9Hz), 7.68 (1H, d, J=9Hz), 7.76-8.01 (7H),
8.99 (1H, d, J=9Hz)

10 (23) 8-[2,6-Dichloro-3-[N-methyl-N-(N'-phenylureido
acetyl)amino]benzyloxy]-2-methylquinoline
hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 2.91 (3H, s), 3.30 (3H, s),
3.88 (2H, s), 5.61 (1H, d, J=10Hz), 5.84 (1H, d,
J=10Hz), 6.98 (1H, t, J=6Hz), 7.12-7.31 (4H),
7.59 (1H, d, J=9Hz), 7.68 (1H, d, J=9Hz),
7.74-8.00 (4H), 8.93 (1H, d, J=9Hz)

20 (24) 8-[3-[N-(N'-Benzylureidoacetyl)-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 2.78 (3H, s), 3.29 (3H, s),
3.84 (2H, s), 4.19 (1H, d, J=16Hz), 4.29 (1H, d,
J=16Hz), 5.59 (1H, d, J=10Hz), 5.82 (1H, d,
J=10Hz), 7.11-7.31 (5H), 7.58 (1H, d, J=9Hz),
7.68 (1H, d, J=9Hz), 7.71-8.00 (4H), 8.92 (1H,
d, J=9Hz)

30 (25) 8-[3-[N-[(N-Cycloheptyl-N-methylglycyl)glycyl]-N-
methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline
dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.40-2.68 (12H), 2.86 (3H,
s), 3.23 (6H, s), 3.59 (1H, m), 3.70-4.13 (4H),
5.59 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz),
7.50-7.90 (6H), 8.75 (1H, d, J=9Hz)

35

2122236

- (26) 8-[2,6-Dichloro-3-[N-methyl-N-[[4-(4-pyridyl)-1-piperazinyl]acetylglycyl]amino]benzyloxy]-2-methylquinoline tetrahydrochloride

5 NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.28 (3H, s),
3.60-3.75 (4H), 3.81 (2H, d, J=5Hz), 4.00-4.30
(6H), 5.68 (1H, d, J=10Hz), 5.79 (1H, d,
J=10Hz), 7.28 (2H, d, J=7Hz), 7.58-8.00 (6H),
8.20 (2H, d, J=7Hz), 8.95 (1H, d, J=9Hz)

- 10 (27) 8-[2,6-Dichloro-3-[N-[N'-[3-(3-pyridylcarbamoyl)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 3.03 (3H, s), 3.30 (3H, s),
3.89 (2H, s), 5.61 (1H, d, J=10Hz), 5.82 (1H, d,
J=10Hz), 7.38 (1H, t, J=9Hz), 7.46-8.11 (10H),
8.51 (1H, d, J=6Hz), 8.94 (1H, dd, J=9, 1Hz),
9.00 (1H, d, J=9Hz), 9.61 (1H, d, J=1Hz)

- 20 (28) 8-[2,6-Dichloro-3-[N-[N'-[3-(2-pyridylmethylcarbamoyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 3.00 (3H, s), 3.30 (3H, s),
3.78 (1H, d, J=17Hz), 3.90 (1H, d, J=17Hz), 4.93
(2H, s), 5.60 (1H, d, J=10Hz), 5.82 (1H, d,
J=10Hz), 7.31 (1H, t, J=9Hz), 7.50-8.01 (10H),
8.10 (1H, d, J=9Hz), 8.52 (1H, t, J=9Hz), 8.72
(1H, d, J=6Hz), 8.97 (1H, d, J=9Hz)

- 30 (29) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-pyridylmethylcarbamoyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 2.97 (3H, s), 3.30 (3H, s),
3.86 (2H, s), 4.82 (2H, s), 5.60 (1H, d,
J=10Hz), 5.81 (1H, d, J=10Hz), 7.29 (1H, t,
J=9Hz), 7.50-8.00 (9H), 8.04 (2H, d, J=6Hz),

2122236

8.71 (2H, d, J=6Hz), 8.94 (1H, d, J=9Hz)

- (30) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(1-piperazinyl-carbonyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 2.96 (3H, s),
3.11-3.45 (8H, m), 3.29 (3H, s), 3.86 (2H, s),
5.58 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 6.99
(1H, d, J=7Hz), 7.18-8.01 (9H, m), 8.91 (1H, d,
J=9Hz)

- (31) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-phenyl-1-piperazinylcarbonyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 2.91 (3H, s), 3.23
(3H, s), 3.26-3.40 (4H, m), 3.60 (4H, br s),
3.72 (2H, br s), 5.52 (1H, d, J=10Hz), 5.76 (1H,
d, J=10Hz), 7.00 (1H, br d, J=7Hz), 7.15-7.37
(3H, m), 7.39-7.95 (11H, m), 8.86 (1H, d, J=9Hz)

- (32) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-ethoxycarbonyl-1-piperazinylcarbonyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 1.28 (3H, t,
J=7.5Hz), 2.92 (3H, s), 3.20-3.83 (8H, m), 3.95
(2H, s), 4.16 (2H, q, J=7.5Hz), 5.59 (1H, d,
J=9Hz), 5.79 (1H, d, J=9Hz), 6.90 (1H, d,
J=5Hz), 7.22 (1H, t, J=7.5Hz), 7.40-7.74 (6H,
m), 7.75-7.98 (3H, m), 8.88 (1H, d, J=9Hz)

- (33) 8-[2,6-Dichloro-3-[N-[N'-[3-[2-(N,N-dimethylamino)-ethylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD 3:1 V/V, δ) : 3.06 (6H, s), 3.08

2122236

5 (3H, s), 3.30 (3H, s), 3.33-3.46 (2H, m), 3.79 (2H, br t, J=6Hz), 3.81 (1H, d, J=20Hz), 3.89 (1H, d, J=20Hz), 5.59 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 7.28 (1H, t, J=8Hz), 7.45-8.00 (9H, m), 8.94 (1H, d, J=9Hz)

(34) 8-[2,6-Dichloro-3-[N-[N'-(3-ethoxycarbonylamino-phenyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

10 NMR (CDCl₃-CD₃OD, δ) : 1.28 (3H, t, J=7Hz), 2.91 (3H, s), 3.30 (3H, s) 3.89 (2H, s), 4.09 (2H, q, J=7Hz), 5.60 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.90-7.19 (3H), 7.39 (1H, br s), 7.58 (1H, d, J=9Hz), 7.64 (1H, d, J=9Hz), 7.70-8.00
15 (4H), 8.91 (1H, d, J=9Hz)

(35) 8-[2,6-Dichloro-3-[N-[N'-(1-naphthyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

20 NMR (CDCl₃-CD₃OD, δ) : 2.50 (3H, s), 3.32 (3H, s), 3.99 (2H, s) 5.62 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 7.13 (1H, t, J=9Hz), 7.35-8.07 (12H), 8.81 (1H, d, J=9Hz)

25 (36) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-4-chloro-2-ethylquinoline hydrochloride

30 NMR (CDCl₃-CD₃OD, δ) : 1.35 (3H, t, J=7Hz), 2.52 (3H, s), 3.19-3.46 (5H), 3.85 (1H, d, J=17Hz), 3.99 (1H, d, J=17Hz), 5.60 (1H, d, J=10Hz), 5.84 (1H, d, J=10Hz), 7.29-7.63 (5H), 7.85 (1H, d, J=8Hz), 7.98-8.19 (4H)

35 (37) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-ethylquinoline

2122236

hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.39 (3H, t, J=8Hz), 2.54
(3H, s), 3.22-3.44 (5H), 3.89 (2H s) 5.60 (1H,
d, J=10Hz), 5.85 (1H, d, J=10Hz), 7.30-7.70
(5H), 7.77-8.02 (5H), 9.00 (1H, d, J=9Hz)

5

(38) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(3-pyridyl)-
acryloylglycyl]amino]benzyloxy]-2-methylquinoline
dihydrochloride

10

NMR (DMSO-d₆, δ) : 2.90 (3H, s), 3.15 (3H, s), 3.60
(1H, dd, J=16, 5Hz), 3.92 (1H, dd, J=16, 5Hz),
5.64 (2H, s) 7.08 (1H, d, J=15Hz), 7.53 (1H, d,
J=15Hz), 7.77-8.00 (7H), 8.43-8.59 (2H), 8.77
(1H, d, J=8Hz), 8.90-9.08 (2H)

15

(39) 8-[2,6-Dichloro-3-[N-methyl-N-(4-nitrocinnamoyl-
glycyl)amino]benzyloxy]-2-methylquinoline
hydrochloride

20

NMR (DMSO-d₆, δ) : 2.89 (3H, s), 3.17 (3H, s),
3.60 (1H, dd, J=16, 5Hz), 3.90 (1H, dd, J=16,
4Hz), 5.62 (2H, s), 7.02 (1H, d, J=15Hz),
7.50 (1H, d, J=15Hz), 7.65-7.97 (9H),
8.26 (1H, d, J=8Hz), 8.52 (1H, t like),
8.88 (1H, br s)

25

Example 30

The following compounds were obtained according to a
similar manner to that of Example 1.

30

(1) 8-(2,6-Dichloro-3-nitrobenzyloxy)-2-methyl-4-
dimethylaminoquinoline

NMR (CDCl₃, δ) : 2.59 (3H, s), 3.18 (6H, s), 5.52
(2H, s), 6.61 (1H, s), 7.19-7.49 (3H), 7.67-7.78
(2H)

35

2122236

(2) 8-(2,6-Dichloro-3-nitrobenzyloxy)-2,4-dimethylquinoline

mp : 218-219°C

5 NMR (CDCl₃, δ) : 2.66 (3H, s), 2.70 (3H, s), 5.70 (2H, s), 7.15 (1H, s), 7.26 (1H, d, J=8Hz), 7.41 (1H, t, J=8Hz), 7.52 (1H, d, J=8Hz), 7.65 (1H, d, J=8Hz), 7.77 (1H, d, J=8Hz)

10 (3) 8-(2,6-Dichloro-3-nitrobenzyloxy)-4-(3,4-dimethoxybenzyloxy)-2-methylquinoline

mp : 218-220°C

15 NMR (CDCl₃, δ) : 2.70 (3H, s), 3.91 (6H, s), 5.18 (2H, s), 5.68 (2H, s), 6.74 (1H, s), 6.92 (1H, d, J=8Hz), 7.02 (1H, s), 7.06 (1H, d, J=8Hz), 7.19-7.39 (2H), 7.50 (1H, d, J=8Hz), 7.76 (1H, d, J=8Hz), 7.88 (1H, d, J=8Hz)

(4) 8-(2,6-Dichloro-3-nitrobenzyloxy)-4-methoxy-2-methylquinoline

20 NMR (CDCl₃, δ) : 2.70 (3H, s), 4.02 (3H, s), 5.68 (2H, s), 6.67 (1H, s), 7.25 (1H, dd, J=8, 1Hz), 7.34 (1H, t, J=8Hz), 7.50 (1H, d, J=8Hz), 7.75 (1H, d, J=8Hz), 7.84 (1H, dd, J=8, 1Hz)

25 (5) 8-(2,6-Dichloro-3-nitrobenzyloxy)-4-ethoxy-2-methylquinoline

mp : 212-213°C

30 NMR (CDCl₃, δ) : 1.57 (3H, t, J=6Hz), 2.69 (3H, s), 4.24 (2H, q, J=6Hz), 5.68 (2H, s), 6.62 (1H, s), 7.23 (1H, d, J=8Hz), 7.34 (1H, t, J=8Hz), 7.50 (1H, d, J=8Hz), 7.76 (1H, d, J=8Hz), 7.87 (1H, d, J=8Hz)

35 (6) 8-(2,6-Dichloro-3-nitrobenzyloxy)-2-methyl-4-methylthioquinoline

2122236

mp : 225-226°C

NMR (CDCl₃, δ) : 2.61 (3H, s), 2.72 (3H, s), 5.69
(2H, s), 7.02 (1H, s), 7.26 (1H, d, J=8Hz), 7.40
(1H, t, J=8Hz), 7.50 (1H, d, J=8Hz), 7.75 (1H,
5 d, J=8Hz), 7.76 (1H, d, J=8Hz)

(7) 8-(2,6-Dichloro-3-nitrobenzyloxy)-4-(2-methoxyethoxy)-2-methylquinoline

mp : 185-188°C

10 NMR (CDCl₃, δ) : 2.69 (3H, s), 3.51 (3H, s), 3.90
(2H, t, J=6Hz), 4.32 (2H, t, J=6Hz), 5.68 (2H,
s), 6.66 (1H, s), 7.24 (1H, d, J=8Hz), 7.34 (1H,
t, J=8Hz), 7.50 (1H, d, J=8Hz), 7.76 (1H, d,
J=8Hz), 7.89 (1H, d, J=8Hz)

15

(8) 8-(2,6-Dichloro-3-nitrobenzyloxy)-2-methyl-4-(2-dimethylaminoethoxy)quinoline

mp : 144-146°C

20 NMR (CDCl₃, δ) : 2.41 (6H, s), 2.70 (3H, s), 2.90
(2H, t, J=6Hz), 4.28 (2H, t, J=6Hz), 5.68 (2H,
s), 6.64 (1H, s), 7.23 (1H, d, J=8Hz), 7.33 (1H,
t, J=8Hz), 7.50 (1H, d, J=8Hz), 7.75 (1H, d,
J=8Hz), 7.85 (1H, d, J=8Hz)

25 (9) 2-Chloro-8-(2,6-dichloro-3-nitrobenzyloxy)quinoline

mp : 198-199°C

NMR (CDCl₃, δ) : 5.66 (2H, s), 7.27-7.58 (5H),
7.80 (1H, d, J=8Hz), 8.10 (1H, d, J=8Hz)

30 (10) 8-(2,6-Dichloro-3-nitrobenzyloxy)-2-methoxyquinoline

mp : 137-138°C

35 NMR (CDCl₃, δ) : 4.10 (3H, s), 5.70 (2H, s), 6.95
(1H, d, J=8Hz), 7.30 (1H, d, J=5Hz), 7.47 (1H,
dd, J=8, 5Hz), 7.52 (1H, d, J=8Hz), 7.77 (1H, d,
J=8Hz), 8.00 (1H, d, J=8Hz)

2122236

Example 31

A mixture of 8-(2,6-dichloro-3-nitrobenzyloxy)-4-(3,4-dimethoxybenzyloxy)-2-methylquinoline (106 mg), 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (50 mg) and dichloromethane-water (18:1, V/V, 2.85 ml) was heated under reflux for 19 hours. The reaction mixture was partitioned into dichloromethane and saturated aqueous sodium hydrogen carbonate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by a preparative thin-layer chromatography (dichloromethane-methanol) followed by washing with ethanol to give a brownish powder (26 mg) of 8-(2,6-dichloro-3-nitrobenzyloxy)-4-hydroxy-2-methylquinoline.

mp : 255-258°C

NMR (DMSO-d₆, δ) : 2.32 (3H, s), 5.47 (2H, s), 5.91 (1H, s), 7.27 (1H, t, J=8Hz), 7.46 (1H, d, J=8Hz), 7.69 (1H, d, J=8Hz), 7.90 (1H, d, J=8Hz), 8.20 (1H, d, J=8Hz)

Example 32

To a suspension of 8-[2,6-dichloro-3-[N-methyl-N-[N'-(3-nitrophenyl)ureidoacetyl]amino]benzyloxy]-2-methylquinoline (4.7 g) in ethanol (47 ml) was added tin(II) chloride (6.45 g) at ambient temperature. The mixture was refluxed for 2 hours. After cooling, the mixture was adjusted to pH 10 with 1N sodium hydroxide solution. To this mixture was added dichloromethane (50 ml) and the precipitate was removed by filtration. The filtrate was extracted with dichloromethane twice. The organic layer was washed with saturated sodium bicarbonate solution, water and brine. After dried over magnesium sulfate, the solvent was removed in vacuo. The residue was purified by column chromatography eluting with dichloromethane-methanol to give 8-[3-[N-[N'-(3-

2122236

aminophenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (3.22 g) as amorphous.

5 NMR (CDCl₃, δ) : 2.63 (3H, s), 3.20 (3H, s), 3.59 (2H, br s), 3.79 (1H, dd, J=17, 5Hz), 4.03 (1H, dd, J=17, 6Hz), 5.50 (1H, d, J=10Hz), 5.59-5.75 (2H), 6.79 (1H, dd, J=8, 1Hz), 6.48 (1H, d, J=8Hz), 6.80 (1H, t, J=1Hz), 6.91 (1H, t, J=8Hz), 7.19-7.50 (6H), 7.82 (1H, br s), 8.06
10 (1H, d, J=9Hz)

Example 33

The following compounds were obtained according to similar manners to those of Example 11 to 13.

15

(1) 8-[2,6-Dichloro-3-[N-[N'-(3-methoxyphenyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

20 NMR (CDCl₃, δ) : 2.63 (3H, s), 3.21 (3H, s), 3.68 (3H, s), 3.80 (1H, dd, J=17, 5Hz), 4.20 (1H, dd, J=17, 6Hz), 5.49 (1H, d, J=10Hz), 5.57-5.70 (2H), 6.50 (1H, dd, J=8, 1Hz), 6.71 (1H, d, J=8Hz), 6.94-7.09 (2H), 7.21-7.50 (6H), 8.08 (1H, d, J=9Hz), 8.15 (1H, br s)

25

(2) 8-[2,6-Dichloro-3-[N-[N'-(4-methoxyphenyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.64 (3H, s), 3.20 (3H, s), 3.70-3.88 (4H), 4.07 (1H, dd, J=17.5Hz), 5.42-5.57 (2H), 5.67 (2H, d, J=10Hz), 6.76 (2H, d, J=9Hz), 7.10-7.50 (8H), 7.61 (1H, br s), 8.05 (1H, d, J=9Hz)

35

(3) 8-[2,6-Dichloro-3-[N-[N'-(2-ethoxycarbonylphenyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

2122233

NMR (CDCl₃, δ) : 1.40 (3H, t, J=7Hz), 2.75 (3H, s),
3.25 (3H, s), 3.52 (1H, dd, J=17, 4Hz), 3.89
(1H, dd, J=17, 5Hz), 4.35 (2H, q, J=7Hz),
5.57-5.69 (3H), 6.95 (1H, t, J=7Hz), 7.20-7.52
(8H), 7.93-8.06 (2H), 8.43 (1H, d, J=9Hz)

5

(4) 8-[3-[N-[N'-(3-Cyanophenyl)ureidoacetyl]-N-methyl-
amino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.48 (3H, s), 3.21 (3H, s), 3.78
(1H, dd, J=17, 5Hz), 4.40 (1H, dd, J=17, 7Hz),
5.44 (1H, d, J=10Hz), 5.56 (1H, dd, J=7, 5Hz),
5.63 (1H, d, J=10Hz), 7.15- (2H, d, J=5Hz),
7.20-7.44 (5H, m), 7.45-7.58 (2H, m), 7.64 (1H,
br s), 8.11 (1H, d, J=9Hz), 9.23 (1H, br s)

10

15

(5) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(2-pyridylmethyl)-
ureidoacetyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.70 (3H, s), 3.21 (3H, s), 3.68
(1H, dd, J=17, 5Hz), 3.85 (1H, dd, J=17, 5Hz),
4.42 (2H, t, J=5Hz), 5.48-5.61 (2H), 5.68 (1H,
d, J=10Hz), 6.02 (1H, br t, J=5Hz), 7.11 (1H, t,
J=6Hz), 7.20-7.50 (7H), 7.60 (1H, dt, J=6, 1Hz),
8.02 (1H, d, J=9Hz), 8.48 (1H, d, J=5Hz)

20

25

(6) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(2-pyridyl)-
ureidoacetyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.62 (3H, s), 3.26 (3H, s), 3.80
(1H, dd, J=17, 5Hz), 4.10 (1H, dd, J=17, 5Hz),
5.58 (1H, d, J=10Hz), 5.63 (1H, d, J=10Hz), 6.68
(1H, d, J=8Hz), 6.86 (1H, dd, J=7, 6Hz),
7.20-7.56 (7H), 7.96-8.08 (2H), 8.26 (1H, dd,
J=5, 1Hz), 9.80 (1H, br t, J=5Hz)

30

(7) 8-[2,6-Dichloro-3-[N-[N'-(3-pyridylmethyl)ureido-
acetyl]-N-methylamino]benzyloxy]-2-methylquinoline

35

2122236

NMR (CDCl₃, δ) : 2.56 (3H, s), 3.20 (3H, s), 3.79 (1H, dd, J=17, 4Hz), 4.02 (1H, dd, J=17, 6Hz), 4.12 (1H, dd, J=15, 5Hz), 4.33 (1H, dd, J=15, 6Hz), 5.28 (1H, br t, J=5Hz), 5.49 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.24 (1H, br t, J=6Hz), 7.08 (1H, dd, J=8, 5Hz), 7.17-7.30 (3H, m), 7.31 (1H, d, J=9Hz), 7.38-7.58 (4H, m), 8.01 (1H, d, J=8Hz), 8.29-8.50 (2H, m)

10 (8) 8-[3-[N-[N'-(3-Aminophenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

15 NMR (CDCl₃, δ) : 2.64 (3H, s), 3.20 (3H, s), 3.60 (2H, br s), 3.80 (1H, dd, J=17, 5Hz), 4.06 (1H, dd, J=17, 6Hz), 5.50 (1H, d, J=10Hz), 5.63 (1H, d, J=10Hz), 5.64 (1H, br s), 6.29 (1H, dd, J=8, 1Hz), 6.46 (1H, br s, J=8Hz), 6.80 (1H, t, J=1Hz), 6.91 (1H, t, J=8Hz), 7.17-7.55 (7H, m), 7.84 (1H, br s), 8.05 (1H, d, J=9Hz)

20 (9) 8-[2,6-Dichloro-3-[N-[N'-(4-pyridyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.58 (3H, s), 3.20 (3H, s), 3.76 (1H, dd, J=17, 5Hz), 4.41 (1H, dd, J=17, 7Hz), 5.43 (1H, d, J=10Hz), 5.61 (1H, d, J=10Hz), 5.63 (1H, m), 7.11 (2H, dd, J=6, 1Hz), 7.19-7.40 (4H, m), 7.43-7.60 (2H, m), 8.12 (1H, d, J=9Hz), 8.23 (2H, dd, J=6, 0.5Hz), 9.43 (1H, br s)

30 (10) 8-[2,6-Dichloro-3-[N-[N'-(4-pyridylmethyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

35 NMR (CDCl₃, δ) : 2.59 (3H, s), 3.20 (3H, s), 3.80 (1H, dd, J=17, 4Hz), 4.01 (1H, dd, J=17, 6Hz), 4.10 (1H, dd, J=16, 6Hz), 4.31 (1H, dd, J=16, 6Hz), 5.38 (1H, br t, J=5Hz), 5.50 (1H, d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.24 (1H, br t,

J=6Hz), 7.08 (2H, d, J=6Hz), 7.16-7.36 (2H, m),
7.31 (1H, d, J=8Hz), 7.45 (2H, d, J=4Hz), 7.49
(1H, d, J=8Hz), 8.01 (1H, d, J=8Hz), 8.40 (2H,
d, J=5Hz)

5

(11) 8-[2,6-Dichloro-3-[N-[N'-(3-pyridyl)ureidoacetyl]-
N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.58 (3H, s), 3.22 (3H, s), 3.80
10 (1H, dd, J=18, 5Hz), 4.51 (1H, dd, J=18, 8Hz),
5.41 (1H, d, J=10Hz), 5.50 (1H, br t, J=4Hz),
5.63 (1H, d, J=10Hz), 7.09 (1H, dd, J=8, 5Hz),
7.18-7.39 (4H, m), 7.42-7.55 (2H, m), 7.90 (1H,
dt, J=8, 0.5Hz), 8.04-8.16 (2H, m), 8.20 (1H, d,
J=2Hz), 9.15 (1H, br s)

15

(12) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(2-methoxyethyl)-
N-methylcarbamoyl]phenyl]ureidoacetyl]-N-methyl-
amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.61 (3H, s), 2.84-3.29 (7H, m),
20 3.20 (3H, s), 3.28 (1H, dd, J=17, 5Hz), 4.20
(1H, dd, J=7, 17Hz), 5.47 (1H, d, J=10Hz), 5.63
(1H, d, J=10Hz), 5.64 (1H, m), 6.94 (1H, d,
J=7Hz), 7.13 (1H, t, J=8Hz), 7.15-7.56 (8H, m),
8.09 (1H, d, J=9Hz), 8.60 (1H, m)

25

(13) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-
(3-pyridylmethyl)carbamoyl]phenyl]ureidoacetyl]-
amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.59 (3H, s), 2.70-3.04 (3H, m),
30 3.21 (3H, s), 3.79 (1H, dd, J=16, 4Hz), 4.25
(1H, dd, J=16, 6Hz), 4.39-4.88 (2H, m), 5.46
(1H, d, J=10Hz), 5.60 (1H, d, J=10Hz), 5.62 (1H,
m), 6.98 (1H, br d, J=6Hz), 7.08-7.76 (10H, m),
8.10 (1H, d, J=10Hz), 8.30-8.79 (3H, m)

35

(14) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(2-pyridyl)carbamoyl]phenyl]ureidoacetyl]amino]-benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.59 (3H, s), 3.21 (3H, s), 3.50 (3H, s), 3.78 (1H, dd, J=17, 5Hz), 4.19 (1H, dd, J=17, 6Hz), 5.48 (1H, d, J=10Hz), 5.56-5.69 (2H), 6.77-7.02 (4H), 7.20-7.51 (9H), 8.09 (1H, d, J=8Hz), 8.30 (1H, dd, J=5, 1Hz), 8.39 (1H, br s)

(15) 8-[2,6-Dichloro-3-[N-(N'-ethylureidoacetyl)-N-methylamino]benzyloxy]-4-methoxy-2-methylquinoline

NMR (CDCl₃, δ) : 1.00 (3H, t, J=7Hz), 2.62 (3H, s), 3.00-3.17 (2H), 3.21 (3H, s), 3.77 (1H, dd, J=17, 5Hz), 3.91 (1H, dd, J=17, 6Hz), 4.02 (3H, s), 5.69 (1H, br s), 5.85-5.02 (2H), 5.66 (1H, d, J=10Hz), 6.67 (1H, s), 7.19-7.50 (4H), 7.80 (1H, dd, J=8, 1Hz)

(16) 8-[2,6-Dichloro-3-[N-[N'-(3-dimethylcarbamoylphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-4-methoxy-2-methylquinoline

NMR (CDCl₃, δ) : 2.54 (3H, s), 2.88 (3H, br s), 3.00 (3H, br s), 3.21 (3H, s), 3.79 (1H, dd, J=17, 5Hz), 4.05 (3H, s), 4.31 (1H, dd, J=17, 6Hz), 5.41 (1H, d, J=10Hz), 5.60 (1H, d, J=10Hz), 5.69 (1H, br s), 6.68 (1H, s), 6.94 (1H, d, J=8Hz), 7.07-7.39 (6H), 7.45 (1H, t, J=8Hz), 7.83 (1H, d, J=9Hz), 8.89 (1H, br s)

(17) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-pyridyl-carbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-4-methoxy-2-methylquinoline

NMR (CDCl₃, δ) : 2.61 (3H, s), 3.21 (3H, s), 3.87-4.09 (5H), 5.41 (1H, d, J=10Hz), 5.51 (1H,

d, J=10Hz), 6.32 (1H, br s), 6.63 (1H, s),
6.98-7.13 (2H), 7.20-7.50 (5H), 7.79-7.90 (3H),
8.50 (2H, d, J=6Hz), 8.60 (1H, br s), 9.55 (1H,
br s)

5

(18) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(3-(4-methyl-1-
piperazinylcarbonyl)phenyl]ureidoacetyl]amino]-
benzyloxy]-4-methoxy-2-methylquinoline

10 NMR (CDCl₃, δ) : 2.03-2.48 (7H), 2.52 (3H, s),
3.15-3.87 (8H), 4.03 (3H, s), 4.45 (1H, dd,
J=17, 8Hz), 5.40 (1H, d, J=10Hz), 5.49-5.62
(2H), 6.67 (1H, s), 6.91 (1H, d, J=7Hz),
7.10-7.50 (9H), 7.82 (1H, d, J=8Hz), 9.01 (1H,
br s)

15

(19) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-
methylamino]-2,6-dichlorobenzyloxy]-4-methoxy-2-
methylquinoline

20 NMR (CDCl₃, δ) : 2.38 (3H, s), 2.55 (3H, s), 3.22
(3H, s), 3.81 (1H, dd, J=17, 4Hz), 4.05 (3H, s),
4.49 (1H, dd, J=17, 7Hz), 5.40 (1H, d, J=10Hz),
5.51-5.68 (2H), 6.69 (1H, s), 7.12-7.52 (8H),
7.79-7.89 (2H), 9.06 (1H, br s)

25

(20) 8-[2,6-Dichloro-3-[N-[N'-(2-methoxyphenyl)ureido-
acetyl]-N-methylamino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.71 (3H, s), 3.24 (3H, s), 3.67
(3H, s), 3.69 (1H, dd, J=17, 5Hz), 3.86 (1H, dd,
J=17, 5Hz), 5.58 (1H, d, J=10Hz), 5.65 (1H, d,
J=10Hz), 5.89 (1H, br t, J=5Hz), 6.72-6.84 (1H,
m), 6.85-7.00 (2H, m), 7.16 (1H, br s),
7.20-7.51 (6H, m), 7.93-8.02 (1H, m), 8.02 (1H,
d, J=10Hz)

35

2122236

Example 34

The following compounds were obtained according to a similar manner to that of Example 21.

- 5 (1) 8-[2,6-Dichloro-3-[N-[N'-[3-(N-ethyl-N-methyl-carbamoyl)phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 0.96-1.20 (3H), 2.62 (3H, s),
2.79-3.06 (3H), 3.13-3.30 (4H), 3.50 (1H, m),
3.79 (1H, dd, J=18, 5Hz), 4.19 (1H, dd, J=18,
6Hz), 5.48 (1H, d, J=10Hz), 5.59-5.72 (2H), 6.91
(1H, d, J=8Hz), 7.09-7.53 (9H), 8.09 (1H, d,
J=9Hz), 8.59 (1H, br s)

- 15 (2) 8-[2,6-Dichloro-3-[N-[N'-[3-(N-isopropyl-N-methylcarbamoyl)phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline

20 NMR (CDCl₃, δ) : 0.99-1.19 (6H), 2.59-2.92 (6H), 3.21
(3H, s), 3.79 (1H, dd, J=18, 5Hz), 3.96 (1H, m),
4.20 (1H, dd, J=18, 6Hz), 5.48 (1H, d, J=10Hz),
5.59-5.70 (2H), 6.90 (1H, br d, J=7Hz),
7.10-7.51 (9H), 8.09 (1H, d, J=9Hz), 8.59 (1H,
br s)

- 25 (3) 8-[2,6-Dichloro-3-[N-[N'-(3-diethylcarbamoylphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 0.86-1.31 (6H, m), 2.61 (3H, s),
3.04-3.63 (4H, m), 3.22 (3H, s), 3.80 (1H, dd,
J=17, 5Hz), 4.20 (1H, dd, J=17, 7Hz), 5.47 (1H,
d, J=10Hz), 5.63 (1H, d, J=10Hz), 5.65 (1H, m),
6.90 (1H, dt, J=7, 0.5Hz), 7.09-7.38 (6H, m),
7.14 (1H, t, J=8Hz), 7.43-7.51 (2H, m), 8.09
(1H, d, J=9Hz), 8.58 (1H, br s)

35

2122236

- (4) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(2-pyridyl-carbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline

5 NMR (CDCl₃, δ) : 2.62 (3H, s), 3.22 (3H, s), 3.86
(1H, dd, J=17, 5Hz), 4.22 (1H, dd, J=17, 6Hz),
5.50 (1H, d, J=10Hz), 5.66 (1H, d, J=10Hz), 5.80
(1H, br t, J=6Hz), 7.03 (1H, dd, J=7, 5Hz),
7.16-7.50 (9H), 7.71 (1H, dt, J=8, 1Hz), 7.80
(1H, br s), 8.09 (1H, d, J=9Hz), 8.25-8.33 (2H),
10 8.68 (1H, br s), 8.71 (1H, br s)

- (5) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-pyridyl-carbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline

15 NMR (CDCl₃, δ) : 2.69 (3H, s), 3.23 (3H, s), 3.89
(1H, dd, J=17, 5Hz), 4.03 (1H, dd, J=17, 5Hz),
5.42 (1H, d, J=10Hz), 5.54 (1H, d, J=10Hz), 6.45
(1H, br t, J=5Hz), 6.96 (1H, br s), 7.02 (1H, t,
J=9Hz), 7.20-7.56 (9H), 7.89 (2H, d, J=6Hz),
20 8.06 (1H, d, J=9Hz), 8.44 (1H, s), 8.51 (2H, d,
J=6Hz), 9.61 (1H, br s)

- (6) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(4-pyridyl)carbamoyl]phenyl]ureidoacetyl]amino]-benzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.50 (3H, s), 3.21 (3H, s), 3.40
(3H, s), 3.73 (1H, dd, J=18, 5Hz), 4.33 (1H, dd,
J=18, 7Hz), 5.39-5.50 (2H), 5.61 (1H, d,
J=10Hz), 6.80 (2H, d, J=5Hz), 6.90 (1H, d,
30 J=7Hz), 7.02 (1H, t, J=8Hz), 7.18-7.38 (6H),
7.45-7.58 (2H), 8.10 (1H, d, J=9Hz), 8.31 (2H,
br d, J=5Hz), 8.61 (1H, br s)

- (7) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(3-pyridyl)carbamoyl]phenyl]ureidoacetyl]amino]-

35

2122236

benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.56 (3H, s), 3.21 (3H, s), 3.40
(3H, s), 3.79 (1H, dd, J=17, 5Hz), 4.25 (1H, dd,
J=17, 6Hz), 5.41-5.69 (3H), 6.80 (1H, d, J=7Hz),
6.99 (1H, t, J=8Hz), 7.04-7.54 (10H), 8.11 (1H,
d, J=8Hz), 8.22 (1H, d, J=2Hz), 8.31 (1H, d,
J=5Hz), 8.50 (1H, br s)

(8) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(5-pyrimidinyl-
carbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 2.63 (3H, s), 3.21 (3H, s),
3.72-4.03 (2H), 5.49 (1H, d, J=10Hz), 5.59 (1H,
d, J=10Hz), 6.36 (1H, br s), 6.98-7.51 (10H),
8.07 (1H, d, J=9Hz), 8.50 (1H, br s), 8.95 (1H,
s), 9.37 (2H, s), 9.85 (1H, br s)

(9) 8-[2,6-Dichloro-3-[N-[N'-[3-[3-(N,N-dimethylamino)-
phenylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.70 (3H, s), 2.95 (6H, s), 3.22
(3H, s), 3.83 (1H, dd, J=17, 5Hz), 4.02 (1H, dd,
J=17, 6Hz), 5.51 (2H, s), 6.79 (1H, br t,
J=5Hz), 6.55 (1H, dt, J=7.1Hz), 6.99-7.10 (2H),
7.16-7.55 (11H), 8.06 (1H, d, J=9Hz), 8.32 (1H,
s), 9.04 (1H, br s)

(10) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-ethyl-1-piperazinyl-
carbonyl)phenyl]ureidoacetyl]-N-methylamino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.08 (3H, t, J=7Hz), 2.13-2.48
(6H), 2.60 (3H, s), 3.28-3.43 (2H), 3.61-3.85
(3H), 4.39 (1H, dd, J=18, 8Hz), 5.41-5.54 (2H),
5.62 (1H, d, J=10Hz), 6.95 (1H, d, J=8Hz),
7.11-7.39 (7H), 7.45-7.53 (2H), 8.10 (1H, d,

2122236

J=9Hz), 8.67 (1H, br s)

(11) 8-[2,6-Dichloro-3-[N-[N'-[3-[4-(methylcarbamoyl)-1-pyperazinylcarbonyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

5

10

NMR (CDCl₃, δ) : 2.61 (3H, s), 2.80 (3H, d, J=5Hz), 3.16-3.77 (11H), 3.80 (1H, dd, J=17, 5Hz), 4.15 (1H, dd, J=17, 6Hz), 4.73 (1H, br d, J=5Hz), 5.48 (1H, d, J=10Hz), 5.62 (1H, d, J=10Hz), 5.77 (1H, br t, J=5Hz), 6.93 (1H, d, J=7Hz), 7.10-7.52 (9H), 8.10 (1H, d, J=9Hz), 8.77 (1H, br s)

(12) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-dimethylaminopiperidinocarbonyl)phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

15

20

NMR (CDCl₃-CD₃OD, δ) : 1.10-2.10 (5H), 2.29 (6H, s), 2.39 (1H, m), 2.66 (3H, s), 2.92 (1H, m), 3.23 (3H, s), 3.75 (1H, d, J=17Hz), 3.91 (1H, d, J=17Hz), 4.70 (1H, m), 5.52 (1H, d, J=10Hz), 5.60 (1H, d, J=10Hz), 6.94 (1H, d, J=7Hz), 7.18-7.52 (9H), 8.07 (1H, d, J=9Hz)

(13) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(1-pyrrolidinylcarbonyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline

25

30

NMR (CDCl₃, δ) : 1.61-1.97 (4H), 2.62 (3H, s), 3.21 (3H, s), 3.30 (2H, t, J=6Hz), 3.57 (2H, t, J=6Hz), 3.80 (1H, dd, J=18, 5Hz), 4.19 (1H, dd, J=18, 6Hz), 5.48 (1H, d, J=10Hz), 5.59-5.73 (2H), 7.02-7.52 (10H), 8.09 (1H, d, J=9Hz), 8.62 (1H, br s)

(14) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(1,2,3,6-tetrahydropyridin-1-ylcarbonyl)phenyl]ureidoacetyl]-

35

2122236

amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.95-2.31 (2H, m), 2.60 (3H, s),
3.21 (3H, s), 3.32-3.52 (1H, m), 3.66-3.88 (2H,
m), 3.77 (1H, dd, J=18, 5Hz), 4.02-4.23 (1H, m),
4.17 (1H, dd, J=18, 6Hz), 5.45 (1H, d, J=10Hz),
5.56-5.88 (3H, m), 5.62 (1H, d, J=10Hz), 6.96
(1H, br d, J=6Hz), 7.11-7.40 (6H, m), 7.16 (1H,
t, J=8Hz), 7.42-7.52 (2H, m), 8.08 (1H, d,
J=10Hz), 8.59 (1H, br s)

(15) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-[3-(dimethylamino)-
propyl]-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-
methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.60-1.92 (2H), 2.09-2.68 (12H),
2.80-3.08 (2H), 3.13-3.31 (4H), 3.49 (1H, m),
3.78 (1H, dd, J=17, 5Hz), 4.09 (1H, m), 5.49
(1H, d, J=10Hz), 5.62 (1H, d, J=10Hz), 5.73 (1H,
br s), 6.90 (1H, d, J=7Hz), 7.08-7.52 (9H), 8.08
(1H, d, J=9Hz), 8.69 (1H, br s)

(16) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(3-methoxypropyl)-N-
methylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.53-2.04 (4H, m), 2.60 (3H, s),
2.79-3.12 (3H, m), 3.14-3.64 (8H, m), 3.80 (1H,
dd, J=17, 5Hz), 4.09-4.32 (1H, m), 5.48 (1H, d,
J=10Hz), 5.58-5.74 (1H, m), 5.54 (1H, d,
J=10Hz), 6.94 (1H, br d, J=7Hz), 7.14 (1H, d,
J=8Hz), 7.19-7.60 (8H, m), 8.09 (1H, d, J=9Hz),
8.50-8.68 (1H, m)

(17) 8-[3-[N-[N'-[3-[N,N-Bis(2-methoxyethyl)carbamoyl]-
phenyl]ureidoacetyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.61 (3H, s), 3.12-3.87 (18H), 4.22

(1H, dd, J=18, 6Hz), 5.48 (1H, d, J=10Hz),
5.53-5.70 (2H), 6.93 (1H, d, J=7Hz), 7.09-7.51
(9H), 8.09 (1H, d, J=9Hz), 8.53 (1H, br s)

- 5 (18) 8-[3-[N-[N'-[3-[N,N-Bis(2-ethoxyethyl)carbamoyl]-
phenyl]ureidoacetyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 1.00-1.28 (6H, m), 2.62 (3H, s),
3.21 (3H, s), 3.23-3.80 (12H, m), 3.77 (1H, dd,
J=17.5, 5Hz), 4.20 (1H, dd, J=17.5, 6Hz), 5.46
(1H, d, J=10Hz), 5.60 (1H, br t, J=5Hz), 5.64
(1H, d, J=10Hz), 6.94 (1H, br d, J=8Hz), 7.14
(1H, t, J=7.5Hz), 7.17-7.55 (8H, m), 8.08 (1H,
d, J=8Hz), 8.47 (1H, br s)

15

- (19) 8-[3-[N-[N'-[3-[N-[2-(tert-Butyldiphenylsilyloxy)-
ethyl]-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-
methylamino]-2,6-dichlorobenzyloxy]-2-
methylquinoline

20 NMR (CDCl₃, δ) : 1.03 (9H, br s), 2.60 (3H, s), 2.98
(3H, br d, J=6Hz), 3.21 (3H, s), 3.27-3.92 (5H),
4.22 (1H, m), 5.45 (1H, d, J=10Hz), 5.56 (1H, br
s), 5.62 (1H, d, J=10Hz), 6.91 (1H, br d,
J=7Hz), 7.02-7.72 (19H), 8.07 (1H, d, J=9Hz),
25 8.29 (0.5H, br s), 8.48 (0.5H, br s)

- (20) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(2-
pyridylmethyl)carbamoyl]phenyl]ureidoacetyl]amino]-
benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.59 (3H, s), 2.80-3.09 (3H, m),
3.20 (3H, s), 3.78 (1H, br d, J=17Hz), 4.19 (1H,
dd, J=17 and 6Hz), 4.49-4.89 (2H, m), 5.45 (1H,
d, J=10Hz), 5.53-5.71 (2H, m), 6.92-7.70 (13H,
m), 8.09 (1H, d, J=9Hz), 8.51 (1H, d, J=4Hz),
35 8.60 (1H, m)

(21) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(2-methoxyethyl)-N-(3-pyridylmethyl)carbamoyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.59 (3H, s), 3.04-3.70 (7H, m),
3.20 (3H, s), 3.28 (1H, dd, J=16, 5Hz),
4.30 (1H, dd, J=16, 6Hz), 4.51-4.88 (2H, m),
5.44 (1H, d, J=10Hz), 5.49-5.69 (3H, m),
6.95 (1H, br d, J=6Hz), 7.05-7.77 (11H, m),
8.08 (1H, d, J=8Hz), 8.30-8.74 (3H, m)

Example 35

The following compounds were obtained according to similar manners to those of Examples 15 or 16.

(1) 8-[2,6-Dichloro-3-[N-methyl-N-(3-phenylpropioloylglycyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.75 (3H, s), 3.26 (3H, s),
3.60 (1H, dd, J=18, 4Hz), 3.90 (1H, dd, J=18, 4Hz), 5.65 (2H, s), 6.95 (1H, br s), 7.20-7.61 (11H, m), 8.04 (1H, d, J=8Hz)

(2) 8-[2,6-Dichloro-3-[N-(4-formylcinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.28 (3H, s),
3.69 (1H, dd, J=18, 4Hz), 3.96 (1H, dd, J=18, 4Hz), 5.65 (2H, s), 6.61 (1H, d, J=16Hz),
6.75 (1H, br s), 7.20-7.71 (9H, m),
7.88 (2H, d, J=8Hz), 8.06 (1H, d, J=8Hz),
10.01 (1H, s)

(3) 8-[3-[N-(4-Aminocinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.25 (3H, s), 3.62 (1H, dd, J=18, 4Hz), 3.94 (1H, dd, J=18, 5Hz),

5.65 (2H, s), 6.28 (1H, d, J=15Hz), 6.52 (1H, t-like), 6.63 (2H, d, J=8Hz), 7.18-7.54 (9H), 8.03 (1H, d, J=8Hz)

- 5 (4) 8-[2,6-Dichloro-3-[N-methyl-N-((E)-2-methyl-3-phenyl-acryloylglycyl)amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.11 (3H, s), 2.74 (3H, s), 3.26 (3H, s), 3.61 (1H, dd, J=16Hz, 5Hz), 3.93 (1H, dd, J=16, 5Hz), 5.63 (2H, s), 6.87 (1H, t-like), 7.20-7.54 (12H, m), 8.02 (1H, d, J=8Hz)

- (5) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(4-pyridyl)-acryloylglycyl]amino]benzyloxy]-2-methylquinoline

mp : 111-114.5°C

15 NMR (CDCl₃, δ) : 2.73 (3H, s), 3.28 (3H, s), 3.72 (1H, dd, J=16, 5Hz), 3.95 (1H, dd, J=16, 5Hz), 5.63 (2H, s), 6.65 (1H, d, J=16Hz), 6.87 (1H, t-like), 7.21-7.40 (5H, m), 7.40-7.57 (4H, m), 8.03 (1H, d, J=8Hz), 8.60 (2H, d, J=6Hz)

- 20 (6) 8-[2,6-Dichloro-3-[N-[4-(N,N-dimethylamino)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.00 (6H, s), 3.25 (3H, s), 3.60 (1H, dd, J=16, 5Hz), 3.93 (1H, dd, J=16, 5Hz), 5.62 (2H, s), 6.25 (1H, d, J=16Hz), 6.47 (1H, t-like), 6.56-6.77 (2H, m), 7.14-7.60 (9H, m), 8.03 (1H, d, J=8Hz)

- 25 (7) 8-[3-[N-(4-Chlorocinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.74 (3H, s), 3.26 (3H, s), 3.64 (1H, dd, J=17, 3Hz), 3.94 (1H, dd, J=17, 3Hz), 5.64 (1H, s), 6.45 (1H, d, J=16Hz), 6.65 (1H, t-like), 7.20-7.60 (11H, m), 8.03 (1H, d, J=8Hz)

2122236

- (8) 8-[2,6-Dichloro-3-[N-methyl-N-(4-methylcinnamoyl-glycyl)amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.36 (3H, s), 2.75 (3H, s), 3.26 (3H, s), 3.63 (1H, dd, J=4, 17Hz), 3.94 (1H, dd, J=4, 17Hz), 5.64 (2H, s), 6.42 (1H, d, J=16Hz), 6.58 (1H, t-like), 7.16 (2H, d, J=8Hz), 7.20-7.50 (8H, m), 7.53 (1H, d, J=16Hz), 8.02 (1H, d, J=8Hz)
- 5
- 10 (9) 8-[3-[N-[4-(Acetamido)cinnamoylglycyl]-N-methyl-amino]-2,6-dichlorobenzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.10 (3H, s), 2.68 (3H, s), 3.23 (3H, s), 3.61 (1H, dd, J=16, 5Hz), 3.87 (1H, dd, J=16, 5Hz), 5.60 (2H, s), 6.38 (1H, d, J=16Hz), 6.62 (1H, t-like), 7.15-7.65 (11H, m), 8.05 (1H, d, J=8Hz), 8.44 (1H, s)
- 15
- (10) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(N-methylacetamido)-cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 1.90 (3H, s), 2.75 (3H, s), 3.28 (6H, s), 3.66 (1H, dd, J=17, 3Hz), 3.95 (1H, dd, J=17, 3Hz), 5.66 (2H, s), 6.49 (1H, d, J=16Hz), 6.67 (1H, t-like), 7.13-7.65 (11H, m), 8.03 (1H, d, J=8Hz)
- 20
- 25
- (11) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(propionamido)-cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 1.21 (3H, t, J=8Hz), 2.35 (2H, q, J=8Hz), 2.70 (3H, s), 3.25 (3H, s), 3.62 (1H, dd, J=4, 17Hz), 3.90 (1H, dd, J=4, 17Hz), 5.60 (2H, s), 6.40 (1H, d, J=16Hz), 6.61 (1H, t-like), 7.13-7.61 (11H, m), 7.86 (1H, s), 8.04 (1H, d, J=8Hz)
- 30
- 35 (12) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(N-

2122236

methylpropionamido)cinnamoylglycyl]amino]benzyloxy]-
2-methylquinoline

NMR (CDCl₃, δ) : 1.06 (3H, t, J=8Hz), 2.13 (2H,
dif-q), 2.74 (3H, s), 3.18-3.29 (6H, m), 3.65
(1H, dd, J=17, 4Hz), 3.95 (1H, dd, J=17, 4Hz),
5.66 (2H, s), 6.48 (1H, d, J=16Hz), 6.67 (1H,
t-like), 7.07-7.64 (11H, m), 8.03 (1H, d, J=8Hz)

(13) 8-[2,6-Dichloro-3-[N-[4-(N-ethylacetamido)cinnamoyl-
glycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.10 (3H, t, J=7.5Hz), 1.84 (3H,
s), 2.74 (3H, s), 3.28 (3H, s), 3.65 (1H, dd,
J=17, 4Hz), 3.74 (2H, q, J=7.5Hz), 3.95 (1H, dd,
J=17, 4Hz), 5.65 (2H, s), 6.48 (1H, d, J=16Hz),
6.67 (1H, t-like), 7.15 (2H, d, J=8Hz),
7.20-7.65 (9H, m), 8.03 (1H, d, J=8Hz)

(14) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-pyridylmethoxy)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.27 (3H, s), 3.63
(1H, dd, J=17, 3Hz), 3.94 (1H, dd, J=17, 3Hz),
5.23 (2H, s), 5.65 (2H, s), 6.35 (1H, d,
J=16Hz), 6.56 (1H, t-like), 6.98 (2H, d, J=8Hz),
7.18-7.59 (11H, m), 7.73 (1H, td, J=8, 1Hz),
8.02 (1H, d, J=8Hz), 8.62 (1H, dif-dd, J=5Hz)

(15) 8-[2,6-Dichloro-3-[N-[4-[2-(N,N-dimethylamino)-
ethoxy]cinnamoylglycyl]-N-methylamino]benzyloxy]-
2-methylquinoline

NMR (CDCl₃, δ) : 2.35 (6H, s), 2.67-2.81 (5H, m),
3.27 (3H, s), 3.62 (1H, dd, J=16, 4Hz), 3.95
(1H, dd, J=16, 4Hz), 4.10 (2H, t, J=6Hz), 5.68
(2H, s), 6.35 (1H, d, J=16Hz), 6.55 (1H,
t-like), 6.92 (2H, d, J=8Hz), 7.20-7.45 (3H, m),
7.45-7.58 (6H, m), 8.02 (1H, d, J=8Hz)

- (16) 8-[2,6-Dichloro-3-[N-[4-(2-hydroxyethoxy)cinnamoyl-glycyl]-N-methylamino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.01 (1H, t-like), 2.73 (3H, s),
3.27 (3H, s), 3.63 (1H, dd, J=18, 4Hz),
5 3.86-4.04 (3H, m), 4.11 (2H, t, J=5Hz), 5.65
(2H, s), 6.35 (1H, d, J=16Hz), 6.58 (1H,
t-like), 6.90 (2H, d, J=8Hz), 7.21-7.48 (3H, m),
7.48-7.60 (6H, m), 8.03 (1H, d, J=8Hz)
- 10 (17) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.73 (3H, s), 3.00 (3H, d, J=5Hz),
3.26 (3H, s), 3.64 (1H, dd, J=4, 17Hz), 3.93
(1H, dd, J=4, 17Hz), 5.66 (2H, s), 6.28 (1H,
15 q-like), 6.53 (1H, d, J=16Hz), 6.69 (1H,
t-like), 7.18-7.64 (9H, m), 7.75 (2H, d, J=8Hz),
8.03 (1H, d, J=8Hz)
- (18) 8-[2,6-Dichloro-3-[N-[4-(dimethylcarbamoyl)-
20 cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline
NMR (CDCl₃, δ) : 2.74 (3H, s), 2.99 (3H, s), 3.12
(3H, s), 3.28 (3H, s), 3.65 (1H, dd, J=17, 4Hz),
3.95 (1H, dd, J=17, 4Hz), 5.64 (2H, s), 6.52
25 (1H, d, J=16Hz), 6.68 (1H, t-like), 7.20-7.66
(11H, m), 8.05 (1H, d, J=8Hz)
- (19) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(3-methylureido)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
30 NMR (CDCl₃, δ) : 2.63 (3H, s), 2.71 (3H, d, J=5Hz),
3.14 (3H, s), 3.62 (1H, dd, J=17, 4Hz), 3.80
(1H, dd, J=17, 4Hz), 5.32 (1H, q-like), 5.55
(2H, s), 6.32 (1H, d, J=16Hz), 6.70 (1H,
t-like), 7.18-7.38 (8H, m), 7.38-7.55 (3H, m),
35 8.02-8.14 (2H, m)

2122236

(20) 8-[2,6-Dichloro-3-[N-[4-(methanesulfonamido)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline

5 NMR (CDCl₃, δ) : 2.74 (3H, s), 3.04 (3H, s), 3.28
(3H, s), 3.66 (1H, dd, J=18, 4Hz), 3.95 (1H, dd,
J=18, 4Hz), 5.65 (2H, s), 6.41 (1H, d, J=16Hz),
6.64 (1H, t-like), 6.78 (1H, br s), 7.13-7.59
(11H, m), 8.02 (1H, d, J=8Hz)

10 (21) 8-[2,6-Dichloro-3-[N-methyl-N-(butyrylglycyl)-
amino]benzyloxy]-4-methoxy-2-methylquinoline

15 NMR (CDCl₃, δ) : 0.93 (3H, t, J=7Hz), 1.54-1.80
(2H), 2.20 (2H, t, J=7Hz), 2.71 (3H, s), 3.22
(3H, s), 3.49 (1H, dd, J=17, 4Hz), 3.82 (1H, dd,
J=17, 5Hz), 4.01 (3H, s), 5.60 (2H, s), 6.41
(1H, br s), 6.65 (1H, s), 7.19-7.51 (4H), 7.81
(1H, dd, J=8, 1Hz)

20 (22) 8-[2,6-Dichloro-3-[N-(heptanoylglycyl)-N-methyl-
amino]benzyloxy]-4-methoxy-2-methylquinoline

25 NMR (CDCl₃, δ) : 0.81-0.99 (3H), 1.20-1.40 (6H),
1.52-1.80 (2H), 2.21 (2H, t, J=7Hz), 2.70 (3H,
s), 3.25 (3H, s), 3.48 (1H, dd, J=17, 4Hz), 3.83
(1H, dd, J=17, 5Hz), 4.01 (3H, s), 5.61 (2H, s),
6.40 (1H, br s), 6.67 (1H, s), 7.20-7.41 (3H),
7.49 (1H, d, J=9Hz), 7.81 (1H, dd, J=8, 1Hz)

30 (23) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(3-pyridyl)-
acryloylglycyl]amino]benzyloxy]-4-methoxy-2-
methylquinoline

35 NMR (CDCl₃, δ) : 2.69 (3H, s), 3.28 (3H, s), 3.66
(1H, dd, J=17, 4Hz), 3.89-4.04 (4H), 5.61 (2H,
s), 6.57 (1H, d, J=15Hz), 6.65 (1H, s), 6.75
(1H, m), 7.20-7.62 (4H), 7.74-7.88 (2H), 8.57
(1H, dd, J=5, 1Hz), 8.71 (1H, d, J=1Hz)

2122236

(24) 8-[2,6-Dichloro-3-[N-[4-(dimethylcarbamoyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-4-methoxy-
2-methylquinoline

5 NMR (CDCl₃, δ) : 2.69 (3H, s), 2.99 (3H, br s), 3.11
(3H, br s), 3.29 (3H, s), 3.67 (1H, dd, J=17,
4Hz), 3.78-4.08 (4H), 5.61 (2H, s), 6.51 (1H, d,
J=15Hz), 6.67 (1H, s), 6.72 (1H, br s),
7.20-7.63 (8H), 7.82 (1H, dd, J=8, 1Hz)

10 (25) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(N-methylacetamido)-
cinnamoylglycyl]amino]benzyloxy]-4-methoxy-2-
methylquinoline

15 NMR (CDCl₃, δ) : 1.91 (3H, br s), 2.70 (3H, s), 3.28
(6H, s), 3.68 (1H, dd, J=17, 4Hz), 3.89-4.06
(4H), 5.62 (2H, s), 6.49 (1H, d, J=15Hz), 6.67
(1H, s), 6.73 (1H, br s), 7.12-7.62 (9H), 7.82
(1H, d, J=8Hz)

20 (26) 8-[2,6-Dichloro-3-[N-[4-[N-(2-methoxyethyl)-
carbamoyl]cinnamoylglycyl]-N-methylamino]benzyloxy]-
2-methylquinoline

25 NMR (CDCl₃, δ) : 2.72 (3H, s), 3.28 (3H, s), 3.39
(3H, s), 3.51-3.76 (5H), 3.96 (1H, dd, J=18,
5Hz), 5.64 (2H, s), 6.49-6.62 (2H), 6.75 (1H, br
t, J=4Hz), 7.21-7.66 (9H), 7.78 (2H, d, J=8Hz),
8.03 (1H, d, J=8Hz)

30 (27) 8-[3-[N-[4-[N,N-Bis(2-methoxyethyl)carbamoyl]-
cinnamoylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.20-3.84 (18H), 3.96
(1H, dd, J=18, 5Hz), 5.63 (2H, s), 6.50 (1H, d,
J=15Hz), 6.69 (1H, br t, J=4Hz), 7.20-7.63
(11H), 8.02 (1H, d, J=8Hz)

Example 36

8-[2,6-Dichloro-3-[N-[4-(methoxyacetamido)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methyl-
quinoline was obtained by reacting 8-[2,6-dichloro-3-
5 [N-(4-aminocinnamoylglycyl)-N-methylamino]benzyloxy]-2-
methylquinoline with methoxyacetic acid according to a
similar manner to that of Example 16.

10 NMR (CDCl₃, δ) : 2.74 (3H, s), 3.26 (3H, s), 3.51
(3H, s), 3.65 (1H, dd, J=18, 4Hz), 3.86-4.07
(3H, m), 5.65 (2H, s), 6.43 (1H, d, J=16Hz),
6.61 (1H, br peak), 7.22-7.40 (3H, m), 7.40-7.66
(8H, m), 8.03 (1H, d, J=8Hz), 8.35 (1H, s)

Example 37

15 The following compounds were obtained according to a
similar manner to that of Example 36.

(1) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(3-pyridyl-
acetamido)cinnamoylglycyl]amino]benzyloxy]-2-
20 methylquinoline

NMR (CDCl₃, δ) : 2.64 (3H, s), 3.21 (3H, s),
3.51-3.70 (3H, m), 3.88 (1H, dd, J=18, 4Hz),
5.60 (2H, s), 6.38 (1H, d, J=16Hz), 6.62 (1H,
t-like), 7.16-7.74 (13H, m), 8.07 (1H, d,
25 J=8Hz), 8.36 (1H, s), 8.47-8.60 (2H, m)

(2) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(isonicotinoyl-
amino)cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

30 NMR (CDCl₃, δ) : 2.62 (3H, s), 3.19 (3H, s), 3.60
(1H, dd, J=18, 4Hz), 3.88 (1H, dd, J=18, 4Hz),
5.60 (2H, s), 6.41 (1H, d, J=16Hz), 6.65 (1H,
t-like), 7.18-7.60 (9H, m), 7.64-7.80 (4H, m),
8.05 (1H, d, J=8Hz), 8.68 (2H, d, J=5Hz), 8.93
35 (1H, s)

2122236

(3) 8-[3-[N-[4-(Benzamido)cinnamoylglycyl]-N-methyl-amino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.70 (3H, s), 3.25 (3H, s), 3.63 (1H, dd, J=4, 18Hz), 3.93 (1H, dd, J=4, 18Hz), 5.64 (2H, s), 6.43 (1H, d, J=16Hz), 6.63 (1H, t-like), 7.14-7.36 (4H, m), 7.36-7.62 (9H, m), 7.69 (2H, d, J=8Hz), 7.89 (2H, d, J=8Hz), 7.98-8.14 (2H, m)

(4) 8-[3-[N-[4-(4-Bromobutyramido)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.18 (3H, t, J=6Hz), 2.55 (3H, t, J=6Hz), 2.75 (3H, s), 3.26 (3H, s), 3.46-3.72 (4H, m), 3.94 (1H, dd, J=18, 4Hz), 5.63 (2H, s), 6.40 (1H, d, J=16Hz), 6.63 (1H, br peak), 7.18-7.37 (4H, m), 7.37-7.62 (7H, m), 7.68 (1H, s), 8.06 (1H, d, J=8Hz)

Example 38

To a solution of 8-[3-[N-[N'-[3-[N-[2-(tert-butyl-diphenylsilyloxy)ethyl]-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (256 mg) in tetrahydrofuran (2.5 ml) was added 1M tetrabutylammonium fluoride in tetrahydrofuran (0.6 ml) at ambient temperature. The reaction mixture was stirred for 2 hours. The mixture was partitioned between dichloromethane and water. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography eluting with dichloromethane-methanol to give 8-[2,6-dichloro-3-[N-[N'-[3-[N-(2-hydroxyethyl)-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline (148 mg) as amorphous.

NMR (CDCl₃, δ) : 2.65 (3H, s), 2.91-3.14 (3H), 3.21 (3H, s), 3.32-4.09 (7H), 5.50 (1H, d, J=10Hz),

5.63 (1H, d, J=10Hz), 5.90 (1H, br t, J=5Hz),
6.92-7.51 (10H), 8.09 (1H, d, J=9Hz), 8.72 (1H,
br s)

5 Example 39

To a stirred solution of 8-[3-[N-[4-(bromobutyramido)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (50 mg) in N,N-dimethylformamide was added potassium carbonate (30 mg) at ambient temperature and the resulting mixture was stirred at the same temperature for 16 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtration, the solvent was removed in vacuo and the residue was purified by preparative thin layer chromatography (methanol - ethyl acetate = 1:12, V/V) to afford 8-[2,6-dichloro-3-[N-methyl-N-[4-(2-oxo-1-pyrrolidinyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline (33.4 mg) as an amorphous solid.

NMR (CDCl₃, δ) : 2.18 (2H, quint., J=7.5Hz), 2.64 (2H, t, J=7.5Hz), 2.74 (3H, s), 3.27 (3H, s), 3.63 (1H, dd, J=18, 4Hz), 3.80-4.04 (3H, m), 5.65 (2H, s), 6.44 (1H, d, J=16Hz), 6.60 (1H, t-like), 7.15-7.56 (9H, m), 7.56-7.70 (2H, m), 8.02 (1H, d, J=8Hz)

Example 40

(1) 8-(3-Amino-2,6-dichlorobenzyloxy)-4-methoxy-2-methylquinoline was obtained from 8-(2,6-dichloro-3-nitrobenzyloxy)-4-methoxy-2-methylquinoline according to a similar manner to that of Example 32.

mp : >250°C

NMR (DMSO-d₆, δ) : 2.58 (3H, s), 4.00 (3H, s), 5.31 (2H, s), 5.68 (2H, br s), 6.90 (1H, d, J=8Hz),

7.23 (1H, d, J=8Hz), 7.31-7.46 (2H), 7.68 (1H, dd, J=8, 2Hz)

(2) 8-[2,6-Dichloro-3-(phthalimidoacetylamino)benzyloxy]-4-methoxy-2-methylquinoline was obtained according to a similar manner to that of Example 5.

mp : 184-185°C

NMR (CDCl₃, δ) : 2.62 (3H, s), 4.27 (3H, s), 4.78-5.02 (2H), 5.10-5.79 (2H), 6.60 (1H, br d, J=9Hz), 7.19-7.38 (2H), 7.58 (1H, t, J=9Hz), 7.70-7.99 (7H)

(3) 8-[2,6-Dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-4-methoxy-2-methylquinoline was obtained according to a similar manner to that of Example 7.

mp : 209-210°C

NMR (CDCl₃, δ) : 2.70 (3H, s), 3.22 (3H, s), 3.99 (3H, s), 4.02 (2H, s), 5.65 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 6.63 (1H, s), 7.21-7.40 (2H), 7.46 (1H, d, J=9Hz), 7.53 (1H, d, J=9Hz), 7.68-7.91 (5H)

(4) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-4-methoxy-2-methylquinoline was obtained according to a similar manner to that of Example 9.

NMR (CDCl₃, δ) : 2.70 (3H, s), 2.95 (1H, d, J=17Hz), 3.10 (1H, d, J=17Hz), 3.21 (3H, s), 4.01 (3H, s), 5.62 (2H, s), 7.18-7.29 (2H), 7.33 (1H, t, J=8Hz), 7.46 (1H, d, J=9Hz), 7.32 (1H, d, J=8Hz)

Example 41

The following compounds were obtained according to a similar manner to that of Example 28.

2122236

- (1) 8-[2,6-Dichloro-3-[N-(2-methoxycinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

5 NMR (DMSO-d₆, δ) : 2.88 (3H, s), 3.15 (3H, s), 3.60 (1H, dd, J=16, 5Hz), 3.85 (3H, s), 3.86 (1H, dd, J=16, 4Hz), 5.62 (2H, s), 6.80 (1H, d, J=15Hz), 6.91-7.11 (2H), 7.38 (1H, t, J=8Hz), 7.46-7.98 (8H), 8.34 (1H, t-like), 8.92 (1H, d-like)

- 10 (2) 8-[2,6-Dichloro-3-[N-(3-methoxycinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

15 NMR (DMSO-d₆, δ) : 2.86 (3H, s), 3.13 (3H, s), 3.58 (1H, dd, J=16, 6Hz), 3.78 (3H, s), 3.90 (1H, dd, J=16, 5Hz), 5.63 (2H, s), 6.83 (1H, d, J=15Hz), 6.98 (1H, dd, J=8, 3Hz), 7.09-7.20 (2H), 7.28-7.42 (2H), 7.70-7.97 (6H), 8.32 (1H, t-like), 8.90 (1H, d-like)

- 20 (3) 8-[2,6-Dichloro-3-[N-(4-methoxycinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

25 NMR (DMSO-d₆, δ) : 2.91 (3H, s), 3.16 (3H, s), 3.59 (1H, dd, J=16, 5Hz), 3.79 (3H, s), 3.89 (1H, dd, J=16, 6Hz), 5.63 (2H, s), 6.66 (1H, d, J=15Hz), 6.99 (2H, d, J=8Hz), 7.34 (1H, d, J=15Hz), 7.52 (2H, d, J=8Hz), 7.74-7.99 (6H), 8.24 (1H, t-like), 8.96 (1H, d-like)

- 30 (4) 8-[2,6-Dichloro-3-[N-[N'-(2-methoxyphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

35 NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.93 (3H, s), 3.30 (3H, s), 3.86 (5H, s), 5.60 (1H, d, J=10Hz), 5.83 (1H, d, J=10Hz), 6.74 (1H, dt, J=7, 0.5Hz),

2122236

6.82-7.02 (2H, m), 7.57 (1H, d, J=9Hz), 7.65
(1H, d, J=9Hz), 7.70-7.80 (2H, m), 7.81-8.01
(3H, m), 8.95 (1H, d, J=10Hz)

- 5 (5) 8-[2,6-Dichloro-3-[N-[N'-(3-methoxyphenyl)-
ureidoacetyl]-N-methylamino]benzyloxy]-2-
methylquinoline hydrochloride

10 NMR (CDCl₃-CD₃OD, δ) : 2.94 (3H, s), 3.30 (3H, s),
3.70 (3H, s), 3.88 (2H, s), 5.60 (1H, d,
J=10Hz), 5.82 (1H, d, J=10Hz), 6.50 (1H, dd,
J=8, 1Hz), 6.80 (1H, dd, J=8, 1Hz), 6.98 (1H, t,
J=1Hz), 7.09 (1H, t, J=7Hz), 7.58 (1H, d,
J=9Hz), 7.66 (1H, d, J=9Hz), 7.76 (1H, d,
J=7Hz), 7.81-8.00 (3H), 8.93 (1H, d, J=9Hz)

15

- (6) 8-[2,6-Dichloro-3-[N-[N'-(4-methoxyphenyl)-
ureidoacetyl]-N-methylamino]benzyloxy]-2-
methylquinoline hydrochloride

20 NMR (CDCl₃-CD₃OD, δ) : 2.86 (3H, s), 3.29 (3H, s),
3.71 (3H, s), 3.82 (1H, d, J=16Hz), 3.96 (1H, d,
J=16Hz), 5.60 (1H, d, J=10Hz), 5.82 (1H, d,
J=10Hz), 6.68 (2H, d, J=10Hz), 7.14 (2H, d,
J=10Hz), 7.58 (1H, d, J=9Hz), 7.63 (1H, d,
J=9Hz), 7.70-8.00 (4H), 8.90 (1H, d, J=9Hz)

25

- (7) 8-[2,6-Dichloro-3-[N-[N'-(2-ethoxycarbonylphenyl)-
ureidoacetyl]-N-methylamino]benzyloxy]-2-
methylquinoline hydrochloride

30 NMR (CDCl₃-CD₃OD, δ) : 1.41 (3H, t, J=7Hz),
2.99 (3H, s), 3.31 (3H, s), 3.79 (1H, d,
J=17Hz), 3.89 (1H, d, J=17Hz), 4.39 (2H, q,
J=7Hz), 5.61 (1H, d, J=10Hz), 5.81 (1H, d,
J=10Hz), 7.01 (1H, t, J=8Hz), 7.40 (1H, dt,
J=9, 1Hz), 7.57 (1H, d, J=9Hz), 7.66 (1H, d,
J=9Hz), 7.77 (1H, dd, J=8, 1Hz), 7.84-8.05 (4H),

35

2122236

8.13 (1H, d, J=9Hz), 8.98 (1H, J=9Hz)

- 5 (8) 8-[3-[N-[N'-(3-Cyanophenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

10 NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 3.06 (3H, s), 3.30 (3H, s), 3.83 (1H, d, J=17Hz), 3.92 (1H, d, J=17Hz), 5.60 (1H, d, J=10Hz), 5.83 (1H, d, J=10Hz), 7.18-7.30 (1H, m), 7.31-7.41 (2H, m), 7.59 (1H, d, J=8Hz), 7.65 (1H, d, J=8Hz), 7.77 (1H, br d, J=7Hz), 7.82-8.04 (4H, m), 8.95 (1H, d, J=9Hz)

- 15 (9) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(2-pyridylmethyl)-ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

20 NMR (CDCl₃, δ) : 3.01 (3H, s), 3.28 (3H, s), 3.73 (2H, s), 4.76 (2H, br s), 5.62 (1H, d, J=10Hz), 5.79 (1H, d, J=10Hz), 7.58 (1H, d, J=9Hz), 7.67 (1H, d, J=9Hz), 7.75 (1H, dd, J=6, 1Hz), 7.81-8.10 (5H), 8.54 (1H, dt, J=7, 1Hz), 8.71 (1H, br d, J=6Hz), 8.95 (1H, d, J=9Hz)

- 25 (10) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(2-pyridyl)-ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

30 NMR (CDCl₃-CD₃OD, δ) : 3.10 (1H, s), 3.12 (2H, s), 3.29 (3H, s), 3.76 (0.8H, d, J=17Hz), 3.92 (0.8H, d, J=17Hz), 4.31 (0.2H, d, J=17Hz), 4.51 (0.2H, d, J=17Hz), 5.50 (0.3H, d, J=10Hz), 5.68 (0.7H, d, J=10Hz), 5.76 (0.7H, d, J=10Hz), 5.89 (0.3H, d, J=10Hz), 7.30-7.49 (8H), 8.20 (1H, br d, J=7Hz), 8.30 (1H, br t, J=7Hz), 8.92 (1H, d, J=9Hz)

35

- (11) 8-[2,6-Dichloro-3-[N-[N'-(3-pyridylmethyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

5 NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 3.01 (3H, s), 3.27 (3H, s), 3.75 (2H, s), 4.50 (2H, s), 5.60 (1H, d, J=10Hz), 5.77 (1H, d, J=10Hz), 7.55 (1H, d, J=9Hz), 7.64 (1H, d, J=9Hz), 7.73 (1H, d, J=7Hz), 7.80-8.11 (4H, m), 8.58 (1H, br d, J=7Hz), 8.70 (1H, d, J=6Hz), 8.76 (1H, br s), 10 8.93 (1H, d, J=8Hz)

- (12) 8-[3-[N-[N'-(3-Aminophenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline dihydrochloride

15 NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 3.05 (3H, s), 3.29 (3H, s), 3.83 (2H, s), 5.60 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.98 (1H, br d, J=9Hz), 7.27 (1H, t, J=8Hz), 7.31-7.54 (2H, m), 7.59 (1H, d, J=9Hz), 7.65 (1H, d, J=9Hz), 7.75 (1H, d, J=8Hz), 20 7.80-8.04 (2H, m), 8.93 (1H, d, J=8Hz)

- (13) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(4-pyridyl)-ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

25 NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 3.08 (1H, s), 3.12 (2H, s), 3.28 (2H, s), 3.42 (1H, s), 3.80 (0.67H, d, J=15Hz), 3.90 (0.67H, d, J=15Hz), 4.29 (0.33H, d, J=17Hz), 4.46 (0.33H, d, J=17Hz), 5.49 (0.33H, d, J=9Hz), 5.65 (0.67H, d, J=10Hz), 5.75 (0.67H, d, J=10Hz), 5.89 (0.33H, d, J=9Hz), 7.41-8.04 (8H, m), 8.35 (0.67H, d, J=7Hz), 8.48 (1.33H, d, J=7Hz), 8.89 (0.33H, d, J=9Hz), 30 9.05 (0.67H, d, J=9Hz)

2122236

- (14) 8-[2,6-Dichloro-3-[N-[N'-(4-pyridylmethyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.93 (3H, s), 3.27 (3H, s), 3.74 (2H, s), 4.58 (2H, s), 5.60 (1H, d, J=10Hz), 5.78 (1H, d, J=10Hz), 7.57 (1H, d, J=9Hz), 7.66 (1H, d, J=9Hz), 7.76 (1H, d, J=7Hz), 7.80-8.10 (5H, m), 8.65-8.81 (2H, m), 8.95 (1H, d, J=9Hz)

- (15) 8-[2,6-Dichloro-3-[N-[N'-(3-pyridyl)ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 3.08 (0.6H, s), 3.18 (2.4H, s), 3.29 (2.4H, s), 3.41 (0.6H, s), 3.36 (1.6H, s), 4.28 (0.2H, d, J=17Hz), 4.41 (0.2H, d, J=17Hz), 5.46 (0.2H, d, J=10Hz), 5.60 (0.8H, d, J=10Hz), 5.78 (0.8H, d, J=10Hz), 5.90 (0.2H, d, J=10Hz), 7.44-8.07 (7H, m), 8.23-8.44 (1.8H, m), 8.53 (0.2H, br d), 8.91 (0.2H, d, J=10Hz), 8.93 (0.8H, d, J=10Hz), 9.25 (0.8H, br s), 9.35 (0.2H, d, J=0.5Hz)

- (16) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(2-methoxyethyl)-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.88-3.18 (6H, m), 3.21-3.55 (8H, m), 3.64 (2H, br s), 3.86 (2H, br s), 5.59 (1H, d, J=10Hz), 5.83 (1H, d, J=10Hz), 6.96 (1H, br d, J=6Hz), 7.19-7.38 (2H, m), 7.46-8.04 (7H, m), 8.94 (1H, d, J=9Hz)

- (17) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(3-pyridylmethyl)carbamoyl]phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

2122236

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.94 (3H, s), 3.09 (3H, s), 3.29 (3H, s), 3.82 (1H, d, J=14Hz), 3.91 (1H, d, J=14Hz), 4.88 (2H, br s), 5.62 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 7.02 (1H, br d, J=6Hz), 7.27 (1H, t, J=7Hz), 7.35-8.22 (10H, m), 8.54-8.70 (1H, m), 8.81 (1H, d, J=10Hz), 8.88-9.10 (2H, m)

(18) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(2-pyridyl)carbamoyl]phenyl]ureidoacetyl]amino]-benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.02 (3H, s), 3.29 (3H, s), 3.59 (3H, s), 3.83 (2H, s), 5.60 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.91 (1H, d, J=7Hz), 7.14 (1H, t, J=8Hz), 7.28-7.70 (6H), 7.75 (1H, d, J=7Hz), 7.81-8.07 (4H), 8.53 (1H, d, J=6Hz), 8.93 (1H, d, J=9Hz)

(19) 8-[2,6-Dichloro-3-[N-[N'-[3-(N-ethyl-N-methyl-carbamoyl)phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.05-1.22 (3H), 2.82-3.09 (6H), 3.19-3.50 (5H), 3.78-4.12 (2H), 5.09 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 6.91 (1H, d, J=7Hz), 7.17-8.00 (9H), 8.90 (1H, d, J=9Hz)

(20) 8-[2,6-Dichloro-3-[N-[N'-[3-(N-isopropyl-N-methylcarbamoyl)phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.00 (6H, br d, J=6Hz), 2.59-2.91 (6H), 3.18 (3H, s), 3.64-4.00 (3H), 5.47 (1H, d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.77 (1H, d, J=7Hz), 7.03-7.30 (3H), 7.43-7.86 (6H), 8.78 (1H, d, J=9Hz)

2122236

- (21) 8-[2,6-Dichloro-3-[N-[N'-(3-diethylcarbamoylphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 1.14 (6H, br q, J=9Hz), 2.90 (3H, s), 3.11-3.61 (4H, m), 3.30 (3H, s), 3.83 (1H, d, J=14Hz), 3.96 (1H, d, J=14Hz), 5.58 (1H, d, J=10Hz), 5.79 (1H, d, J=10Hz), 6.90 (1H, m), 7.16-7.35 (2H, m), 7.38-7.77 (4H, m), 7.79-8.01 (3H, m), 8.90 (1H, d, J=9Hz)

- (22) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(2-pyridylcarbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.04 (3H, s), 3.30 (3H, s), 3.81 (1H, d, J=16Hz), 3.93 (1H, d, J=16Hz), 5.60 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 7.32-8.12 (11H), 8.41 (2H, br d, J=5Hz), 8.53 (1H, br d, J=6Hz), 8.96 (1H, d, J=9Hz)

- (23) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-pyridylcarbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.01 (3H, s), 3.30 (3H, s), 3.90 (2H, s), 5.61 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 7.38 (1H, t, J=9Hz), 7.57-8.08 (9H), 8.48 (2H, d, J=7Hz), 8.57 (2H, d, J=7Hz), 8.96 (1H, d, J=9Hz)

- (24) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(4-pyridyl)carbamoyl]phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.02 (3H, s), 3.30 (3H, s), 3.60 (3H, s), 3.86 (2H, s), 5.62 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 7.10 (1H, d,

J=8Hz), 7.31 (1H, t, J=8Hz), 7.49 (1H, m), 7.60 (1H, d, J=8Hz), 7.67 (1H, d, J=8Hz), 7.71-8.00 (7H), 8.58 (2H, d, J=6Hz), 8.99 (1H, d, J=9Hz)

- 5 (25) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(5-pyrimidinyl-carbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

10 NMR (CDCl₃-CD₃OD, δ) : 2.98 (3H, s), 3.29 (3H, s), 3.32-4.13 (2H), 5.59 (1H, d, J=10Hz), 5.78 (1H, d, J=10Hz), 7.30 (1H, t, J=8Hz), 7.49 (1H, d, J=9Hz), 7.58-8.04 (9H), 8.92 (1H, d, J=9Hz), 9.10 (1H, br s), 9.52 (1H, br s)

- 15 (26) 8-[2,6-Dichloro-3-[N-[N'-[3-[3-(N,N-dimethylamino)-phenylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline dihydrochloride

20 NMR (CDCl₃-CD₃OD, δ) : 3.00 (3H, s), 3.29 (6H, s), 3.31 (3H, s), 3.90 (2H, s), 5.60 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 7.31 (1H, t, J=8Hz), 7.40-7.98 (12H), 8.24 (1H, br s), 8.91 (1H, d, J=9Hz)

- 25 (27) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-ethyl-1-piperazinyl-carbonyl)phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoline dihydrochloride

30 NMR (CDCl₃-CD₃OD, δ) : 1.46 (3H, t, J=7Hz), 2.89-4.09 (18H), 5.59 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.99 (1H, d, J=7Hz), 7.23 (1H, t, J=7Hz), 7.31-7.62 (4H), 7.72 (1H, d, J=7Hz), 7.79-8.00 (3H), 8.90 (1H, d, J=9Hz)

- 35 (28) 8-[2,6-Dichloro-3-[N-[N'-[3-[4-(methylcarbamoyl)-1-piperazinylcarbonyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

2122236

NMR (CDCl₃-CD₃OD, δ) : 2.78 (3H, s), 2.99 (3H, s),
3.26-3.79 (11H), 3.85 (2H, s), 5.61 (1H, d,
J=10Hz), 5.82 (1H, d, J=10Hz), 6.98 (1H, d,
J=7Hz), 7.22-7.53 (3H), 7.60 (1H, d, J=9Hz),
7.69 (1H, d, J=9Hz), 7.79 (1H, d, J=7Hz),
7.81-8.01 (3H), 8.96 (1H, d, J=9Hz)

(29) 8-[2,6-Dichloro-3-[N-[N'-[3-(4-dimethylamino-
piperidinocarbonyl)phenyl]ureidoacetyl]-N-
methylamino]benzyloxy]-2-methylquinoline
dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.67-1.91 (2H), 2.02-2.48
(2H), 2.74-3.14 (10H), 3.29 (3H, s), 3.49 (1H,
m), 3.80-4.02 (3H), 4.78 (1H, m), 5.59 (1H, d,
J=10Hz), 5.82 (1H, d, J=10Hz), 6.99 (1H, d,
J=7Hz), 7.25 (1H, t, J=7Hz), 7.33-7.49 (2H),
7.58 (1H, d, J=9Hz), 7.66 (1H, d, J=9Hz), 7.77
(1H, d, J=7Hz), 7.81-8.00 (3H), 8.92 (1H, d,
J=9Hz)

(30) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(1-
pyrrolidinylcarbonyl)phenyl]ureidoacetyl]amino]-
benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.81-2.08 (4H), 2.98 (3H, s),
3.30 (3H, s), 3.33-3.60 (4H), 3.87 (2H, s), 5.60
(1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 7.06 (1H,
d, J=7Hz), 7.20-7.39 (2H), 7.51-7.61 (2H), 7.66
(1H, d, J=9Hz), 7.74 (1H, d, J=7Hz), 7.81-8.00
(3H), 8.92 (1H, d, J=9Hz)

(31) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(1,2,3,6-
tetrahydropyridin-1-yl-carbonyl)phenyl]ureidoacetyl]-
amino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.18-2.32 (2H, m),
2.85-3.05 (3H, m), 3.29 (3H, m), 3.38-4.30 (6H,

m), 5.56 (1H, d, J=10Hz), 5.68-5.98 (2H, m),
5.81 (1H, d, J=10Hz), 6.88-7.02 (1H, m),
7.19-7.38 (2H, m), 7.43-8.00 (7H, m), 8.90 (1H,
d, J=9Hz)

5

(32) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-[3-(dimethylamino)-
propyl]-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-
methylamino]benzyloxy]-2-methylquinoline
dihydrochloride

10

NMR (CDCl₃-CD₃OD, δ) : 2.07-2.30 (2H), 2.80-3.42
(17H), 3.50-4.01 (4H), 5.60 (1H, br d, J=10Hz),
5.79 (1H, br d, J=10Hz), 6.96 (1H, d, J=8Hz),
7.10-7.49 (3H), 7.56 (1H, d, J=9Hz), 7.62 (1H,
d, J=9Hz), 7.71 (1H, d, J=7Hz), 7.80-8.00 (3H),
8.90 (1H, m)

15

(33) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(3-methoxypropyl)-N-
methylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]-
benzyloxy]-2-methylquinoline hydrochloride

20

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 1.66-2.02 (2H, m),
2.94 (3H, s), 3.00 (3H, s), 3.13-3.66 (10H, m),
3.85 (2H, s), 5.59 (1H, d, J=8Hz), 5.82 (1H, d,
J=8Hz), 6.92 (1H, d, J=5Hz), 7.15-8.06 (9H, m),
8.92 (1H, br s)

25

(34) 8-[3-[N-[N'-[3-[N,N-Bis(2-methoxyethyl)carbamoyl]-
phenyl]ureidoacetyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline hydrochloride

30

NMR (CDCl₃-CD₃OD, δ) : 2.98 (3H, s), 3.21-3.97
(19H), 5.61 (1H, d, J=10Hz), 5.85 (1H, d,
J=10Hz), 6.99 (1H, m), 7.21-7.34 (2H), 7.47 (1H,
br s), 7.60 (1H, d, J=9Hz), 7.69 (1H, d, J=9Hz),
7.74-8.00 (4H), 8.95 (1H, d, J=9Hz)

35

(35) 8-[3-[N-[N'-[3-[N,N-Bis(2-ethoxyethyl)carbamoyl]-

2122236

phenyl]ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 1.05-1.34 (6H, m), 2.93 (3H, s), 3.23-3.78 (12H, m), 3.29 (3H, s), 3.83 (2H, s), 5.59 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 6.98 (1H, d, J=7Hz), 7.18-7.35 (2H, m), 7.39-7.52 (1H, m), 7.60 (1H, d, J=8Hz), 7.68 (1H, d, J=8Hz), 7.76 (1H, d, J=7Hz), 7.80-8.00 (3H, m), 8.91 (1H, d, J=9Hz)

(36) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(2-hydroxyethyl)-N-methylcarbamoyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.95-3.13 (6H), 3.31 (3H, s), 3.58-3.90 (6H), 5.61 (1H, d, J=10Hz), 5.85 (1H, d, J=10Hz), 7.00 (1H, m), 7.21-7.35 (2H), 7.49 (1H, m), 7.60 (1H, d, J=9Hz), 7.69 (1H, d, J=9Hz), 7.76-7.99 (4H), 8.95 (1H, d, J=9Hz)

(37) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-[N-methyl-N-(2-pyridylmethyl)carbamoyl]phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.98 (3H, s), 3.20 (3H, br s), 3.30 (3H, s), 3.86 (2H, s), 5.10 (2H, s), 5.60 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 7.01-7.17 (1H, m), 7.20-7.36 (1H, m), 7.37-7.50 (1H, m), 7.52-7.69 (2H, m), 7.76 (1H, d, J=7Hz), 7.80-8.15 (6H, m), 8.50-8.68 (1H, m), 8.81 (1H, br d, J=5Hz), 8.95 (1H, br d, J=9Hz)

(38) 8-[2,6-Dichloro-3-[N-[N'-[3-[N-(2-methoxyethyl)-N-(3-pyridylmethyl)carbamoyl]phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.93 (3H, s), 3.23 (3H, s), 3.29 (3H, s), 3.36-3.71 (4H, m), 3.80 (1H, d, J=16Hz), 3.91 (1H, d, J=16Hz), 4.30-5.02 (2H, m), 5.60 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 6.95-7.10 (1H, m), 7.25 (1H, br t, J=8Hz), 7.34-8.14 (9H, m), 8.44-9.06 (4H, m)

(39) 8-[2,6-Dichloro-3-[N-methyl-N-(3-phenylpropioloyl-glycyl)amino]benzyloxy]-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.14 (3H, s), 3.31 (3H, s), 3.89 (2H, s), 5.65 (1H, d, J=10Hz), 5.74 (1H, d, J=10Hz), 7.29-7.76 (8H, m), 7.76-7.98 (3H, m), 8.90 (1H, dif-d)

(40) 8-[2,6-Dichloro-3-[N-(4-formylcinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride and its hydrate

NMR (CDCl₃-CD₃OD, δ) : 3.16 (15/8H, s), 3.18 (9/8H), 3.32 (3H, s), 3.80-4.10 (2H, m), 5.40 (5/8H, s), 5.61 (1H, d, J=10Hz), 5.72 (3/8H, d, J=10Hz), 5.75 (5/8H, d, J=10Hz), 6.57 (5/8H, d, J=16Hz), 6.75 (3/8H, d, J=16Hz), 7.38-7.73 (7H, m), 7.73-7.96 (4H, m), 8.88 (3/8H, d, J=8Hz), 8.91 (5/8H, d, J=8Hz), 10.00 (3/5H, s)

(41) 8-[3-[N-(4-Aminocinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.04 (3H, s), 3.23 (3H, s), 3.80 (1H, d, J=17Hz), 3.98 (1H, d, J=17Hz), 5.51 (1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 6.51 (1H, d, J=16Hz), 7.19-7.28 (1H, m), 7.28-7.56 (6H, m), 7.60 (1H, d, J=7.5Hz), 7.68-7.92 (3H, m), 8.86 (1H, d, J=8Hz)

2122236

- (42) 8-[2,6-Dichloro-3-[N-methyl-N-((E)-2-methyl-3-phenylacryloylglycyl)amino]benzyloxy]-2-methylquinoline hydrochloride

5 NMR (CDCl₃-CD₃OD, δ) : 2.11 (3H, s), 3.16 (3H, s), 3.36 (3H, s), 3.88 (2H, s), 5.61 (1H, d, J=10Hz), 5.74 (1H, d, J=10Hz), 7.25-7.44 (5H, m), 7.44-7.72 (3H, m), 7.76-7.98 (3H, m), 8.93 (1H, d, J=8Hz)

- 10 (43) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(4-pyridyl)-acryloylglycyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

15 NMR (CDCl₃-CD₃OD, 3:1, δ) : 3.90 (1H, d, J=15Hz), 4.20 (1H, d, J=15Hz), 5.58 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 7.30 (1H, d, J=16Hz), 7.44-7.71 (4H, m), 7.71-7.97 (3H, m), 8.19 (2H, d, J=6Hz), 8.77 (2H, d, J=6Hz), 8.88 (1H, d, J=8Hz)

- 20 (44) 8-[2,6-Dichloro-3-[N-[4-(N,N-dimethylamino)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 3.01 (3H, s), 3.83 (1H, d, J=17.5Hz), 3.97 (1H, d, J=17.5Hz), 5.67 (1H, d, J=11Hz), 5.80 (1H, d, J=11Hz), 6.68 (1H, d, J=16Hz), 7.33-8.00 (11H, m), 9.00 (1H, d, J=8Hz)

- (45) 8-[3-[N-(4-Chlorocinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

30 NMR (CDCl₃-CD₃OD, 3:1, δ) : 3.26 (3H, s), 3.81 (1H, d, J=17Hz), 3.93 (1H, d, J=17Hz), 5.57 (1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 6.51 (1H, d, J=16Hz), 7.25 (2H, d, J=8Hz), 7.33-7.67 (6H, m), 7.71-7.91 (3H, m), 8.85 (1H, d, J=8Hz)

- 35 (46) 8-[2,6-Dichloro-3-[N-methyl-N-(4-methylcinnamoyl-

2122236

glycyl)amino]benzyloxy]-2-methylquinoline
hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.37 (3H, s), 3.14 (3H, s),
3.31 (3H, s), 3.86 (1H, d, J=17Hz), 3.96 (1H, d,
J=17Hz), 5.60 (1H, d, J=10Hz), 5.73 (1H, d,
J=10Hz), 6.51 (1H, d, J=16Hz), 7.16 (2H, d,
J=8Hz), 7.35-7.71 (6H, m), 7.78-7.98 (3H, m),
8.93 (1H, d, J=8Hz)

10 (47) 8-[3-[N-[4-(Acetamido)cinnamoylglycyl]-N-
methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline
hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 2.15 (3H, s), 3.07 (3H, s),
3.28 (3H, s), 3.87 (1H, d, J=16Hz), 4.03 (1H, d,
J=16Hz), 5.58 (1H, d, J=10Hz), 5.74 (1H, d,
J=10Hz), 6.44 (1H, d, J=16Hz), 7.27-7.42 (2H,
m), 7.42-7.71 (6H, m), 7.79-7.97 (3H, m), 8.92
(1H, d, J=8Hz)

20 (48) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(N-methylacetamido)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 1.89 (3H, s), 3.12 (3H, s),
3.27 (3H, s), 3.30 (3H, s), 5.61 (1H, d,
J=10Hz), 5.77 (1H, d, J=10Hz), 6.62 (1H, d,
J=16Hz), 7.23 (1H, d, J=8Hz), 7.41-7.77 (6H, m),
7.77-8.05 (3H, m), 8.95 (1H, d, J=8Hz)

30 (49) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(propionamido)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
hydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 1.17 (3H, t, J=8Hz), 2.37
(3H, t, J=8Hz), 3.03 (3H, s), 3.81 (1H, d,
J=17Hz), 3.97 (1H, d, J=17Hz), 5.52 (1H, d,
J=9Hz), 5.69 (1H, d, J=9Hz), 6.40 (1H, d,

2122236

J=16Hz), 7.20-7.39 (3H, m), 7.39-7.69 (5H, m), 7.69-7.95 (3H, m), 8.75-8.97 (1H, dif-d)

- (50) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(N-methylpropionamido)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline hydrochloride
5
NMR (CDCl₃-CD₃OD, δ) : 0.98 (3H, t, J=8Hz),
1.93-2.14 (2H, dif-q), 3.03 (3H, s), 3.17 (3H, s), 3.23 (3H, s), 3.72-3.95 (2H, m), 5.52 (1H, d, J=10Hz), 5.66 (1H, d, J=10Hz), 6.52 (1H, d, J=16Hz), 7.12 (2H, d, J=8Hz), 7.33-7.65 (6H, m), 7.70-7.90 (3H, m), 8.86 (1H, d, J=8Hz)
10
- (51) 8-[2,6-Dichloro-3-[N-[4-(N-ethylacetamido)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride
15
NMR (CDCl₃-CD₃OD, δ) : 1.16 (3H, t, J=7.5Hz), 1.89 (3H, s), 3.17 (3H, s), 3.36 (3H, s), 3.91 (1H, d, J=17Hz), 4.03 (1H, d, J=17Hz), 5.67 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 6.68 (1H, d, J=16Hz), 7.23 (2H, d, J=8Hz), 7.49-7.80 (6H, m), 7.83-8.06 (3H, m), 9.00 (1H, d, J=8Hz)
20
- (52) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-pyridylmethoxy)-cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline dihydrochloride
25
NMR (CDCl₃-CD₃OD, δ) : 3.04 (3H, s), 3.83 (1H, d, J=16Hz), 3.98 (1H, d, J=16Hz), 5.45-5.76 (4H, m), 6.42 (1H, d, J=16Hz), 7.01 (2H, d, J=8Hz), 7.21-7.67 (6H, m), 7.70-7.99 (4H, m), 8.16 (1H, d, J=8Hz), 8.50 (1H, d, J=8Hz), 8.77-8.99 (2H, m)
30
- (53) 8-[2,6-Dichloro-3-[N-[4-[2-(N,N-dimethylamino)-ethoxy]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-

2122236

methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.94 (6H, s), 3.13 (3H, s),
3.30 (3H, s), 3.55 (2H, br peak), 3.87 (1H, d,
J=16Hz), 4.02 (1H, d, J=16Hz), 4.47 (2H, br
peak), 5.58 (1H, d, J=10Hz), 5.73 (1H, d,
J=10Hz), 6.46 (1H, d, J=16Hz), 6.91 (2H, d,
J=8Hz), 7.32-7.74 (6H, m), 7.74-8.00 (3H, m),
8.95 (1H, d, J=8Hz)

10 (54) 8-[2,6-Dichloro-3-[N-[4-(2-hydroxyethoxy)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.33 (3H, s),
3.85-4.00 (4H, m), 4.11 (2H, t, J=5Hz), 5.61
(1H, d, J=10Hz), 5.78 (1H, d, J=10Hz), 6.44 (1H,
d, J=16Hz), 6.93 (2H, d, J=8Hz), 7.38-7.77 (6H,
m), 7.77-8.03 (3H, m), 8.97 (1H, d, J=8Hz)

20 (55) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 2.98 (3H, s), 3.10 (3H, s),
3.31 (3H, s), 3.89 (1H, d, J=17Hz), 4.05 (1H, d,
J=17Hz), 5.59 (1H, d, J=10Hz), 5.75 (1H, d,
J=10Hz), 6.65 (1H, d, J=16Hz), 7.37-7.73 (6H,
m), 7.73-8.00 (5H, m), 8.92 (1H, d, J=8Hz)

30 (56) 8-[2,6-Dichloro-3-[N-[4-(dimethylcarbamoyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline hydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 3.01 (3H, s), 3.10 (6H, s),
3.31 (3H, s), 3.84-4.05 (2H, m), 5.60 (1H, d,
J=10Hz), 5.77 (1H, d, J=10Hz), 6.64 (1H, d,
J=16Hz), 7.34-7.59 (3H, m), 7.59-7.75 (5H, m),
7.81-8.02 (3H, m), 8.95 (1H, d, J=8Hz)

2122236

(57) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(3-methylureido)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.72 (3H, s), 2.96 (3H, s),
3.24 (3H, s), 3.91 (2H, s), 5.55 (1H, d,
J=10Hz), 5.68 (1H, d, J=10Hz), 6.26 (1H, d,
J=16Hz), 7.11-7.22 (3H, m), 7.34 (2H, d, J=8Hz),
7.41-7.55 (2H, m), 7.60 (1H, d, J=7.5Hz),
7.71-7.90 (3H, m), 8.87 (1H, d, J=8Hz)

(58) 8-[2,6-Dichloro-3-[N-[4-(methanesulfonamido)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.94 (3H, s), 3.08 (3H, s),
3.25 (3H, s), 3.84 (1H, d, J=17.5Hz), 4.00 (1H,
d, J=17.5Hz), 5.54 (1H, d, J=10Hz), 5.68 (1H, d,
J=10Hz), 6.45 (1H, d, J=16Hz), 7.16 (2H, d,
J=8Hz), 7.21-7.42 (3H, m), 7.42-7.65 (3H, m),
7.70-7.91 (3H, m), 8.85 (1H, d, J=8Hz)

(59) 8-[2,6-Dichloro-3-[N-[4-(methoxyacetamido)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.09 (3H, s), 3.52 (3H, s),
3.92 (2H, d, J=12.5Hz), 4.03 (2H, s), 5.60 (1H,
d, J=10Hz), 5.76 (1H, d, J=10Hz), 7.38-7.74 (8H,
m), 7.80-7.98 (3H, m), 8.94 (1H, d, J=8Hz)

(60) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(3-
pyridylacetamido)cinnamoylglycyl]amino]benzyloxy]-
2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.08 (3H, s), 3.30 (3H, s),
3.95 (2H, s), 4.10 (2H, s), 5.58 (1H, d,
J=10Hz), 5.77 (1H, d, J=10Hz), 6.48 (1H, d,
J=16Hz), 7.28-7.44 (3H, m), 7.44-7.75 (5H, m),

2122236

7.80-8.03 (4H, m), 8.66-8.79 (2H, m), 8.96 (1H, d, J=8Hz), 9.03 (1H, dif-d)

(61) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(isonicotinoylamino)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline dihydrochloride

5 NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.30 (3H, s),
3.96 (2H, d, J=2.5Hz), 5.60 (1H, d, J=10Hz),
5.78 (1H, d, J=10Hz), 6.54 (1H, d, J=16Hz),
10 7.28-7.41 (1H, m), 7.41-7.78 (5H, m), 7.78-8.02
(5H, m), 8.62 (2H, d, J=5Hz), 8.86-9.04 (3H, m)

(62) 8-[3-[N-[4-(Benzamido)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 3.11 (3H, s), 3.98 (1H, d, J=17.5Hz),
4.05 (1H, d, J=17.5Hz), 5.60 (1H, d, J=10Hz), 5.75 (1H, d, J=10Hz),
7.36-7.63 (8H, m), 7.63-7.80 (3H, m), 7.80-8.01 (5H, m), 8.94
20 (1H, d, J=8Hz)

(63) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-oxo-1-pyrrolidinyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline hydrochloride

25 NMR (CDCl₃-CD₃OD, 3:1 V/V, δ) : 2.14 (3H, quint, J=7.5Hz),
2.59 (2H, t, J=7.5Hz), 3.10 (3H, s), 3.25 (3H, s),
3.76-4.03 (4H, m), 5.56 (1H, d, J=10Hz), 5.69 (1H, d, J=10Hz),
6.48 (1H, d, J=16Hz), 7.34-7.69 (8H, m), 7.70-7.91 (3H, m),
30 8.88 (1H, d, J=8Hz)

(64) 8-[2,6-Dichloro-3-[N-(N'-ethylureidoacetyl)-N-methylamino]benzyloxy]-4-methoxy-2-methylquinoline hydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 0.93 (3H, t, J=7Hz), 2.80

2122236

(3H, s), 2.96 (2H, q, J=7Hz), 3.11 (3H, s), 3.64
(2H, s), 4.20 (3H, s), 5.36 (1H, d, J=10Hz),
5.59 (1H, d, J=10Hz), 7.11 (1H, s), 7.38 (1H, d,
J=9Hz), 7.42-7.52 (2H), 7.64 (1H, t, J=8Hz),
7.83 (1H, d, J=8Hz)

5

(65) 8-[2,6-Dichloro-3-[N-methyl-N-(butyrylglycyl)amino]-
benzyloxy]-4-methoxy-2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 0.94 (3H, t, J=7Hz),
1.51-1.72 (2H), 2.21 (2H, t, J=7Hz), 2.93 (3H,
s), 3.30 (3H, s), 3.78 (2H, s), 4.38 (3H, s),
5.58 (1H, d, J=10Hz), 5.77 (1H, d, J=10Hz), 7.31
(1H, s), 7.56 (1H, d, J=9Hz), 7.61-7.72 (2H),
7.81 (1H, t, J=8Hz), 8.01 (1H, d, J=8Hz)

10

15

(66) 8-[2,6-Dichloro-3-[N-(heptanoylglycyl)-N-
methylamino]benzyloxy]-4-methoxy-2-methylquinoline
hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 0.80-0.95 (3H), 1.20-1.40
(6H), 1.49-1.68 (2H), 2.22 (2H, t, J=7Hz), 2.94
(3H, s), 3.30 (3H, s), 3.69 (1H, d, J=17Hz),
3.80 (1H, d, J=17Hz), 4.37 (3H, s), 5.56 (1H, d,
J=10Hz), 5.74 (1H, d, J=10Hz), 7.31 (1H, s),
7.52 (1H, d, J=8Hz), 7.66 (2H, d, J=8Hz), 7.80
(1H, t, J=8Hz), 8.00 (1H, d, J=8Hz)

20

25

(67) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-(3-pyridyl)-
acryloylglycyl]amino]benzyloxy]-4-methoxy-2-
methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.99 (3H, s), 3.31 (3H, s),
3.89 (1H, d, J=17Hz), 4.03 (1H, d, J=17Hz), 5.60
(1H, d, J=10Hz), 5.78 (1H, d, J=10Hz), 7.10 (1H,
d, J=15Hz), 7.40 (1H, s), 7.59-7.89 (5H),
7.98-8.14 (2H), 8.71-8.83 (2H), 9.16 (1H, br s)

30

35

(68) 8-[2,6-Dichloro-3-[N-[4-(dimethylcarbamoyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-4-methoxy-
2-methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.98 (3H, s), 3.02 (3H, br
s), 3.13 (3H, br s), 3.31 (3H, s), 3.93 (2H, s),
4.34 (2H, s), 5.59 (1H, d, J=10Hz), 5.77 (1H, d,
J=10Hz), 6.68 (1H, d, J=15Hz), 7.32 (1H, s),
7.40-7.73 (8H), 7.82 (1H, t, J=8Hz), 8.01 (1H,
d, J=8Hz)

(69) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(N-methylacetamido)-
cinnamoylglycyl]amino]benzyloxy]-4-methoxy-2-
methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.91 (3H, s), 2.98 (3H, s),
3.23-3.33 (6H), 3.89 (1H, d, J=17Hz), 4.00 (1H,
d, J=17Hz), 4.36 (3H, s), 5.60 (1H, d, J=10Hz),
5.79 (1H, d, J=10Hz), 6.65 (1H, d, J=15Hz),
7.21-7.37 (3H), 7.44-7.77 (6H), 7.82 (1H, t,
J=8Hz), 8.02 (1H, d, J=8Hz)

(70) 8-[2,6-Dichloro-3-[N-[N'-(3-dimethylcarbamoylphenyl)-
ureidoacetyl]-N-methylamino]benzyloxy]-4-methoxy-2-
methylquinoline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.83 (3H, s), 2.98 (3H, br
s), 3.02 (3H, br s), 3.29 (3H, s), 3.87 (2H, s),
4.33 (3H, s), 5.52 (1H, d, J=10Hz), 5.78 (1H, d,
J=10Hz), 6.95 (1H, d, J=7Hz), 7.20-7.32 (3H),
7.49 (1H, s), 7.52-7.70 (3H), 7.80 (1H, t,
J=8Hz), 8.00 (1H, d, J=8Hz)

(71) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-pyridyl)-
carbamoylphenyl]ureidoacetyl]amino]benzyloxy]-4-
methoxy-2-methylquinoline dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.88 (3H, s), 3.30 (3H, s),
3.81 (1H, d, J=17Hz), 3.93 (1H, d, J=17Hz), 4.30

2122236

(3H, s), 5.57 (1H, d, J=10Hz), 5.79 (1H, d, J=10Hz), 7.25-7.48 (2H), 7.54-7.71 (6H), 7.80 (1H, t, J=8Hz), 7.93-8.04 (2H), 8.45-8.61 (4H)

- 5 (72) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(3-(4-methyl-1-piperazinylcarbonyl)phenyl]ureidoacetyl]amino]-benzyloxy]-4-methoxy-2-methylquinoline dihydrochloride
- 10 NMR (CDCl₃-CD₃OD, δ) : 2.90 (3H, s), 2.92 (3H, s), 3.03-3.95 (13H), 4.36 (3H, s), 5.56 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 7.06 (1H, m), 7.27-7.77 (7H), 7.82 (1H, t, J=8Hz), 8.00 (1H, d, J=8Hz)
- 15 (73) 8-[3-[N-[N'-(3-Acetylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-4-methoxy-2-methylquinoline hydrochloride
- 20 NMR (CDCl₃-CD₃OD, δ) : 2.59 (3H, s), 2.95 (3H, s), 3.31 (3H, s), 3.80 (1H, d, J=17Hz), 3.92 (1H, d, J=17Hz), 4.34 (3H, s), 5.56 (1H, d, J=10Hz), 5.79 (1H, d, J=10Hz), 7.29 (1H, s), 7.32-7.48 (2H), 7.53-7.73 (4H), 7.81 (1H, t, J=8Hz), 8.01 (1H, d, J=8Hz), 8.09 (1H, br s)
- 25 (74) 8-[2,6-Dichloro-3-[N-[4-[N-(2-methoxyethyl)-carbamoyl]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline hydrochloride
- 30 NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.31 (3H, s), 3.41 (3H, s), 3.61 (4H, s), 3.95 (2H, s), 5.61 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 6.69 (1H, d, J=15Hz), 7.40-8.01 (11H), 8.99 (1H, d, J=9Hz)
- 35 (75) 8-[3-[N-[4-[N,N-Bis(2-methoxyethyl)carbamoyl]-cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline hydrochloride

2122236

NMR (CDCl_3 - CD_3OD , δ) : 3.09 (3H, s), 3.22-3.85
(17H), 3.95 (2H, s), 5.63 (1H, d, $J=10\text{Hz}$), 5.82
(1H, d, $J=10\text{Hz}$), 6.68 (1H, d, $J=15\text{Hz}$), 7.40-7.71
(8H), 7.80 (1H, d, $J=7\text{Hz}$), 7.87-8.02 (3H), 9.00
(1H, d, $J=8\text{Hz}$)

5

10

15

20

25

30

35

2122236

Preparation 42

(1) Benzyl 2-ethoxyethylcarbamate was obtained by reacting 2-ethoxyethylamine with benzyl chloroformate according to a similar manner to that of Preparation 18.

NMR (CDCl₃, δ) : 1.15 (3H, t, J=7.5Hz), 3.38 (2H, q, J=6Hz), 3.42-3.53 (4H, m), 5.10 (3H, s-like), 7.27-7.43 (5H, m)

(2) Benzyl N-(2-ethoxyethyl)-N-methylcarbamate was obtained by reacting benzyl 2-ethoxyethylcarbamate with iodomethane according to a similar manner to that of Preparation 13.

NMR (CDCl₃, δ) : 1.10-1.24 (3H, m), 3.00 (3H, s), 3.35-3.62 (6H, m), 5.13 (2H, s), 7.24-7.44 (5H, m)

(3) N-(2-Ethoxyethyl)-N-methylamine hydrochloride was obtained according to a similar manner to that of Preparation 23.

NMR (CD₃OD, δ) : 1.14-1.30 (3H, m), 2.70 (3H, s), 3.12-3.23 (2H, m), 3.50-3.63 (2H, m), 3.63-3.73 (2H, m)

Preparation 43

(1) To a solution of ethyl 4-aminocinnamate (3.00 g) in dichloromethane (21 ml) were added di-tert-butyl dicarbonate (3.77 g) and triethylamine (318 mg) in ice water bath and the mixture was stirred for 1 hour at 0°C and at ambient temperature for 3 hours and heated to reflux for 12 hours. The reaction mixture was poured into water and extracted with dichloromethane. The precipitate was filtered off. The organic layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on

2122236

silica gel eluting with chloroform and recrystallized from a mixture of ethyl acetate and n-hexane to give ethyl 4-(tert-butoxycarbonylamino)cinnamate (2.38 g) as crystals.

mp : 104.6-108.6 °C

5 NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 4.52 (9H, s), 4.25 (2H, q, J=7.5Hz), 6.33 (1H, d, J=16Hz), 6.57 (1H, br s), 7.38 (2H, d, J=8Hz), 7.46 (2H, d, J=8Hz), 7.62 (1H, d, J=16Hz)

10 (2) To a suspension of sodium hydride (60% dispersion in mineral oil, 165 mg) in N,N-dimethylformamide (1 ml) was added dropwise a solution of ethyl 4-(tert-butoxycarbonylamino)cinnamate (1.00 g) in N,N-dimethylformamide (5 ml) in ice water bath under nitrogen and stirred for 1 hour
15 under same condition. To the mixture was added 2-bromoethyl methyl ether (602 mg) and stirred for 1 hour at same condition and at ambient temperature for 20 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was separated,
20 washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting to a mixture of n-hexane and ethyl acetate (4:1) to give ethyl 4-[N-tert-butoxycarbonyl-N-(2-methoxyethyl)amino]cinnamate (935 mg) as an oil.

25 NMR (CDCl₃, δ) : 1.34 (1H, t, J=7.5Hz), 1.45 (9H, s), 3.33 (3H, s), 3.54 (2H, t, J=6Hz), 3.80 (2H, t, J=6Hz), 4.26 (2H, q, J=7.5Hz), 6.39 (1H, d, J=16Hz), 7.29 (2H, d, J=8Hz), 7.48 (2H, d, J=8Hz), 7.65 (1H, d, J=16Hz)

30 (3) Trifluoroacetic acid (3 ml) was added to ethyl 4-[N-tert-butoxycarbonyl-N-(2-methoxyethyl)amino]cinnamate (932 mg) in ice water bath and stirred for 15 minutes at same temperature. The solvent was evaporated under reduced
35 pressure. The residue was partitioned between ethyl

2122236

acetate and aqueous sodium bicarbonate solution. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel eluting to a mixture of n-hexane and ethyl acetate (3:1) and recrystallized from a mixture of n-hexane and ethyl acetate to give ethyl 4-(2-methoxyethylamino)cinnamate (470 mg) as crystals.

mp : 49.9-53.4°C

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 3.32 (2H, q-like, J=6Hz), 3.40 (3H, s), 3.60 (2H, t, J=6Hz), 4.24 (2H, q, J=7.5Hz), 4.35 (1H, t-like), 6.21 (1H, d, J=16Hz), 6.60 (2H, d, J=8Hz), 7.38 (2H, d, J=8Hz), 7.60 (1H, d, J=16Hz)

(4) Ethyl 4-[N-(2-methoxyethyl)-N-(isonicotinoyl)amino]-cinnamate was obtained by reacting ethyl 4-(2-methoxyethylamino)cinnamate with isonicotinoyl chloride hydrochloride according to a similar manner to that of Preparation 24.

mp : 98.4-102.3°C

NMR (CDCl₃, δ) : 1.31 (3H, t, J=7.5Hz), 3.35 (3H, s), 3.65 (2H, t, J=6Hz), 4.08 (2H, t, J=6Hz), 4.25 (2H, q, J=7.5Hz), 6.36 (1H, d, J=16Hz), 7.06-7.20 (4H, m), 7.40 (2H, d, J=8Hz), 7.57 (1H, d, J=16Hz), 8.47 (2H, d, J=6Hz)

Preparation 44

To a suspension of (E)-3-(6-acetylaminopyridin-3-yl)-acrylic acid (460 mg) in ethanol (5.4 ml) was added 1N sodium hydroxide (5.4 ml) at ambient temperature, and the mixture was stirred for 3 hours at 50°C. The reaction mixture was adjusted to pH 7, and the resulting precipitate was collected by filtration and dried to give (E)-(6-aminopyridin-3-yl)acrylic acid (295 mg).

mp : 243.6-246.4°C

NMR (DMSO- d_6 , δ) : 6.21 (1H, d, J=15Hz), 6.45 (1H, d, J=8Hz), 6.52 (2H, s), 7.42 (1H, d, J=15Hz), 7.75 (1H, d, J=8Hz), 8.11 (1H, s)

5 Preparation 45

(1) 1-(tert-Butyldiphenylsilyloxymethyl)-2,6-dichloro-3-nitrobenzene was obtained by reacting 2,6-dichloro-3-nitrobenzyl alcohol with tert-butyldiphenylsilyl chloride according to a similar manner to that of Preparation 36.

NMR (CDCl₃, δ) : 1.05 (9H, s), 4.96 (2H, s), 7.27-7.51 (7H, m), 7.58-7.81 (5H, m)

(2) To a stirred mixture of 1-(tert-butyldiphenylsilyloxymethyl)-2,6-dichloro-3-nitrobenzene (433 mg), ferric chloride hexahydrate (17.5 mg) and activated carbon (17.5 mg) in a mixture of methanol (2.78 ml) and water (0.69 ml) was added hydrazine monohydrate (0.135 ml) dropwise at 60-70°C. After the addition was finished, the mixture was refluxed for half an hour. The mixture was allowed to cool and filtered. The filtrate was concentrated in vacuo. The residue was extracted with dichloromethane and the organic phase was dried over anhydrous magnesium sulfate. After being filtered, the filtrate was concentrated in vacuo and the resulting residue was washed with n-hexane to give 3-amino-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dichlorobenzene (348 mg) as a white mass.

NMR (CDCl₃, δ) : 1.05 (9H, s), 4.07 (2H, br s), 4.87 (2H, s), 6.66 (1H, d, J=9Hz), 7.08 (1H, d, J=9Hz), 7.30-7.50 (6H, m), 7.70-7.84 (4H, m)

(3) 1-(tert-Butyldiphenylsilyloxymethyl)-2,6-dichloro-3-(phthalimidoacetyl-amino)benzene was obtained according to a similar manner to that of Example 5.

mp : 198.1°C

NMR (CDCl₃, δ) : 1.04 (9H, s), 4.57 (2H, s), 4.90
(2H, s), 7.25-7.50 (7H, m), 7.55-7.83 (6H, m),
7.85-8.07 (2H, m), 8.00 (1H, br s), 8.25 (1H, d,
J=8Hz)

(4) 1-(tert-Butyldiphenylsilyloxymethyl)-2,6-dichloro-3-
[N-methyl-N-(phthalimidoacetyl)amino]benzene was
obtained according to a similar manner to that of
Example 7.

mp : 167-172°C

NMR (CDCl₃, δ) : 1.06 (9H, s), 3.20 (3H, s), 4.04
(2H, s), 4.98 (2H, s), 7.31-7.51 (9H, m), 7.65-
7.79 (6H, m), 7.80-7.92 (2H, m)

(5) 2,6-Dichloro-1-hydroxymethyl-3-[N-methyl-N-
(phthalimidoacetyl)amino]benzene was obtained
according to a similar manner to that of Example 38.

mp : 236.2-240.8°C

NMR (CDCl₃, δ) : 2.24 (1H, t, J=7Hz), 3.21 (3H, s),
4.09 (2H, s), 5.04 (2H, d, J=7Hz), 7.43 (1H, d,
J=8Hz), 7.48 (1H, d, J=8Hz), 7.67-7.75 (2H, m),
7.80-7.88 (2H, m)

(6) To a mixture of 2,6-dichloro-1-hydroxymethyl-3-[N-
methyl-N-(phthalimidoacetyl)amino]benzene (399 mg) and
triethylamine (0.17 ml) in methylene chloride (8 ml) was
added methanesulfonyl chloride (0.086 ml) under -20°C, and
the mixture was stirred for 1 hour. The mixture was
washed with sodium bicarbonate solution and brine, dried
over magnesium sulfate and concentrated in vacuo to give
2,6-dichloro-1-methylsulfonyloxymethyl-3-[N-methyl-N-
(phthalimidoacetyl)amino]benzene (561 mg)

NMR (CDCl₃, δ) : 3.15 (3H, s), 3.24 (3H, s), 4.09
(2H, s), 5.48 (2H, s), 7.56 (2H, s), 7.67-7.78

2122236

(2H, m), 7.80-7.93 (2H, m)

Preparation 46

To a suspension of 2,3-diaminophenol (2.93 g) in 2M
aqueous acetic acid solution (47 ml) and 4M aqueous sodium
acetate solution (29 ml) was added 40% aqueous pyruvic
aldehyde solution (3.79 ml) at 60°C. The reaction mixture
was stirred at 60°C for 40 minutes. After cooling the
reaction mixture was adjusted to pH 8 with saturated
sodium hydrogen carbonate and extracted with
dichloromethane (50 ml) twice. The organic layer was
washed with saturated sodium hydrogen carbonate, water and
brine. After dried over anhydrous magnesium sulfate, the
solution was evaporated in vacuo. The residue was
purified by flash column chromatography (silica gel 450
ml) eluting with n-hexane/ethyl acetate (5/1, V/V) to give
8-hydroxy-2-methylquinoxaline (the less polar product) as
crystals and with n-hexane/ethyl acetate (3/1, V/V) to
give 8-hydroxy-3-methylquinoxaline (the more polar
product) as crystals. The former was washed with n-hexane
to afford pale yellow crystals (1.27 g). The latter was
washed with isopropyl ether to afford pale yellow crystals
(1.30 g).

8-Hydroxy-2-methylquinoxaline

mp : 83-84°C

NMR (CDCl₃, δ) : 2.78 (3H, s), 7.21 (1H, m), 7.60
(2H, d, J=5Hz), 7.84 (1H, s), 8.79 (1H, s)

8-Hydroxy-3-methylquinoxaline

mp : 104-105°C

NMR (CDCl₃, δ) : 2.80 (3H, s), 7.18 (1H, d,
J=7.5Hz), 7.55 (1H, d, J=7.5Hz), 7.67 (1H, t,
J=7.5Hz), 7.79 (1H, s), 8.60 (1H, s)

2122236

Preparation 47

(1) 3-Amino-N-(2-methoxyethyl)benzamide was obtained from 3-nitro-N-(2-methoxyethyl)benzamide according to a similar manner to that of Preparation 16.

NMR (CDCl₃, δ) : 3.39 (3H, s), 3.56 (2H, d, J=5Hz), 3.62 (2H, d, J=5Hz), 6.48 (1H, br s), 6.79 (1H, d, J=7.5Hz), 7.06 (1H, d, J=7.5Hz), 7.10-7.27 (3H)

(2) Phenyl 3-[(2-methoxyethyl)carbamoyl]phenylcarbamate was obtained according to a similar manner to that of Preparation 18.

mp : 142.1-150.3°C

NMR (CDCl₃, δ) : 3.38 (3H, s), 3.52 (2H, d, J=5Hz), 3.62-3.72 (2H), 6.59 (1H, br s), 7.16-7.29 (3H), 7.37-7.50 (4H), 7.65 (1H, br s), 7.80 (1H, br d, J=7.5Hz), 7.95 (1H, s)

Preparation 48

(1) To a solution of 2-amino-3-methoxybenzoic acid (10.3 g), 4-dimethylaminopyridine (0.65 g) and triethylamine (34.3 ml) in N,N-dimethylformamide (60 ml) was added acetyl chloride (10.5 ml) at 3-15°C for 20 minutes. Then the reaction mixture was heated at 90°C. After 3 hours, to the reaction mixture was added portionwise ammonium carbonate (17.7 g) for 10 minutes. The mixture was stirred at the same temperature for 1 hour. Cooling the mixture, water (300 ml) was added thereto. The precipitate was collected by filtration, washed with water and acetonitrile to give 8-methoxy-2-methyl-4-oxo-3,4-dihydroquinazoline (9.24 g) as colorless crystals.

mp : 261-262°C

NMR (CDCl₃, δ) : 2.32 (3H, s), 3.88 (3H, s), 7.30 (1H, d, J=7.5Hz), 7.38 (1H, t, J=7.5Hz), 7.61 (1H, d, J=7.5Hz)

2122236

(2) 4-Chloro-8-methoxy-2-methylquinazoline was obtained according to a similar manner to that of Preparation 6.

mp : 101-102°C

5 NMR (CDCl₃, δ) : 2.91 (3H, s), 4.09 (3H, s), 7.27
(1H, d, J=7.5Hz), 7.58 (1H, t, J=7.5Hz), 7.80
(1H, d, J=7.5Hz)

10 (3) A mixture of 4-chloro-8-methoxy-2-methylquinazoline
(5.12 g), 10% palladium on carbon (512 mg) and
triethylamine (3.72 g) in ethyl acetate (51 ml) was
stirred under hydrogen atmosphere for 3 hours. The
catalyst was removed by filtration, and the filtrate was
concentrated. The residue was dissolved in methylene
15 chloride, and the solution was washed with saturated
sodium bicarbonate solution, water and brine, dried over
magnesium sulfate, and concentrated. The residue was
purified by silica gel column chromatography (methylene
chloride-methanol) to give 8-methoxy-2-methylquinazoline
20 (3.07 g).

mp : 131-132°C

25 NMR (CDCl₃, δ) : 2.95 (3H, s), 4.09 (3H, s), 7.21
(1H, d, J=7.5Hz), 7.48 (1H, d, J=7.5Hz), 7.52
(1H, t, J=7.5Hz), 9.30 (1H, s)

30 (4) To a solution of 8-methoxy-2-methylquinazoline (1.50
g) in dichloromethane (10 ml) was added 1M solution of
boron tribromide in dichloromethane (12.9 ml) at 3-5°C.
After 10 minutes, the reaction mixture was stirred at
ambient temperature for 2 days. The mixture was adjusted
to pH 7 with saturated sodium hydrogen carbonate, and
extracted with dichloromethane twice. The organic layer
was dried over anhydrous magnesium sulfate, filtered and
evaporated in vacuo. The residue was crystallized from
35 n-hexane to give 8-hydroxy-2-methylquinazoline (1.22 g) as

2122236

colorless crystals.

mp : 135-137°C

NMR (CDCl₃, δ) : 2.89 (3H, s), 7.32 (1H, d,
J=7.5Hz), 7.41 (1H, d, J=7.5Hz), 7.49 (1H, t,
J=7.5Hz), 9.30 (1H, s)

Preparation 49

(1) 8-Hydroxy-2-methyl-4-oxo-3,4-dihydroquinazoline was
obtained from 2-amino-3-hydroxybenzoic acid, acetyl
chloride and ammonium carbonate according to a
similar manner to that of Preparation 48-(1).

mp : 258°C

NMR (DMSO-d₆, δ) : 2.36 (3H, s), 3.35 (1H, br, s),
7.13 (1H, dd, J=8, 2Hz), 7.25 (1H, t, J=8Hz),
7.49 (1H, dd, J=8, 2Hz)

(2) 8-(2,6-Dichloro-3-nitrobenzyloxy)-2-methyl-4-oxo-3,4-
dihydroquinazoline was obtained according to a
similar manner to that of Example 1.

mp : 270-290°C (dec.)

NMR (DMSO-d₆, δ) : 2.30 (3H, s), 5.44 (2H, s), 7.40
(1H, t, J=8Hz), 7.52 (1H, dd, J=8, 2Hz), 7.73
(1H, dd, J=8, 2Hz), 7.89 (1H, d, J=9Hz), 8.19
(1H, d, J=9Hz)

Preparation 50

A mixture of 2-acetylamino-5-formylpyridine (241 mg)
and malonic acid (168 mg) in pyridine (0.12 ml) and
ethanol (0.36 ml) was refluxed for 2 hours. After cooling
the mixture, the precipitate was collected by filtration,
and washed with ethyl acetate to give (E)-3-(6-acetylamino
-3-pyridyl)acrylic acid (248 mg) as a colorless powder.

mp : 291-292°C

NMR (DMSO-d₆, δ) : 2.10 (3H, s), 6.55 (1H, d,
J=16Hz), 7.58 (1H, d, J=16Hz), 8.07-8.21 (2H),

8.59 (1H, br s)

Preparation 51

(E)-3-(6-Ethoxycarbonyl-3-pyridyl)acrylic acid (from ethyl 5-formyl-2-pyridinecarboxylate) was obtained according to a similar manner to that of Preparation 50.

mp : 201-202°C

NMR (DMSO-d₆, δ) : 1.33 (3H, t, J=7Hz), 4.36 (2H, q, J=7Hz), 6.80 (1H, d, J=16Hz), 7.69 (1H, d, J=16Hz), 8.07 (1H, d, J=9Hz), 8.33 (1H, dd, J=9, 2Hz), 9.00 (1H, d, J=2Hz)

Preparation 52

(1) 4-(Methylcarbamoyl)benzaldehyde was obtained by reacting 4-formylbenzoic acid with methylamine hydrochloride according to a similar manner to that of Preparation 30.

mp : 160.3-161°C

NMR (DMSO-d₆, δ) : 2.81 (3H, d, J=5.5Hz), 7.97 (2H, d, J=9.0Hz), 8.02 (2H, d, J=9.0Hz), 8.67 (1H, m), 10.06 (1H, s)

(2) 4-(Methylcarbamoyl)cinnamic acid was obtained by reacting 4-(methylcarbamoyl)benzaldehyde with malonic acid according to a similar manner to that of Preparation 50.

mp : 272.7°C

NMR (DMSO-d₆, δ) : 2.78 (3H, d, J=5Hz), 3.34 (1H, br s), 6.62 (1H, d, J=16Hz), 7.61 (1H, d, J=16Hz), 7.77 (2H, d, J=8Hz), 7.85 (2H, d, J=8Hz), 8.51 (1H, q-like)

Preparation 53

(1) To a suspension of 2-(2-hydroxyethyl)phthalimide (10.0 g) and triethylamine (0.729 ml) in 1,4-dioxane (50

ml) was added methyl isocyanate (4.63 ml) under ice-bath cooling, and the mixture was stirred for 4 days at ambient temperature. The solvent was removed in vacuo, and the residue was recrystallized with methanol to give 2-phthalimidoethyl methylcarbamate (10.13 g).

mp : 142.3-145.0°C

NMR (CDCl₃, δ) : 2.73 (3H, d, J=4.5Hz), 3.95 (2H, t, J=7.5Hz), 4.30 (2H, t, J=7.5Hz), 4.60 (1H, br s), 7.67-7.77 (2H, m), 7.80-7.90 (2H, m)

(2) 2-Aminoethyl methylcarbamate was obtained according to a similar manner to that of Example 9.

NMR (CDCl₃, δ) : 3.30 (3H, d, J=6Hz), 3.40 (2H, t, J=7.5Hz), 4.06 (2H, t, J=7.5Hz), 4.74 (2H, br s)

Preparation 54

Phenyl 4-ethoxycarbonylphenylcarbamate was obtained by reacting ethyl 4-aminobenzoate with phenyl chloroformate according to a similar manner to that of Preparation 18.

mp : 155.6-161.7°C

NMR (CDCl₃, δ) : 1.38 (3H, t, J=7.5Hz), 4.37 (2H, q, J=7.5Hz), 7.00-7.27 (4H, m), 7.27-7.45 (2H, m), 7.51 (2H, d, J=8Hz), 8.02 (2H, d, J=8Hz)

Preparation 55

The following compounds were obtained according to a similar manner to that of Preparation 13.

(1) Ethyl 4-[N-(3-pyridylmethyl)acetamido]cinnamate (from ethyl 4-acetamidocinnamate and 3-pyridylmethyl chloride hydrochloride)

NMR (CDCl₃, δ) : 1.34 (3H, t, J=7Hz), 1.92 (3H, s), 4.29 (2H, q, J=7Hz), 4.90 (2H, s), 6.41 (1H, d, J=15Hz), 7.02 (2H, d, J=7Hz), 7.24 (1H, m), 7.51

2122236

(2H, d, J=7Hz), 7.60-7.70 (2H), 8.38 (1H, br s),
8.51 (1H, d, J=3Hz)

- 5 (2) Ethyl 4-[N-(tert-butoxycarbonylmethyl)acetamido]-
cinnamate (from ethyl 4-acetamidocinnamate and tert-
butyl bromoacetate)

10 NMR (CDCl₃, δ) : 1.36 (3H, t, J=7Hz), 1.47 (9H, s),
1.94 (3H, s), 4.21-4.32 (4H), 6.45 (1H, d,
J=16Hz), 7.35 (2H, d, J=8Hz), 7.58 (2H, d,
J=8Hz), 7.68 (1H, d, J=16Hz)

- (3) Ethyl 4-[N-(2-pyridylmethyl)acetamido]cinnamate (from
ethyl 4-acetamidocinnamate and 2-pyridylmethyl
chloride hydrochloride)

15 NMR (CDCl₃, δ) : 1.31 (3H, t, J=7.5Hz), 1.96 (3H,
s), 4.25 (2H, q, J=7.5Hz), 5.01 (2H, s), 6.39
(1H, d, J=16Hz), 7.06-7.23 (3H, m), 7.36 (1H, d,
J=7.5Hz), 7.49 (2H, d, J=7.5Hz), 7.55-7.70 (2H,
m), 8.49 (1H, d, J=5Hz)

- 20 (4) Ethyl 4-[N-(4-pyridylmethyl)acetamido]cinnamate (from
ethyl 4-acetamidocinnamate and 4-pyridylmethyl
chloride hydrochloride)

25 NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 1.95 (3H,
s), 4.28 (2H, q, J=7.5Hz), 4.90 (3H, s), 6.43
(1H, d, J=16Hz), 7.07 (2H, d, J=8Hz), 7.14 (2H,
d, J=7Hz), 7.51 (2H, d, J=8Hz), 7.65 (1H, d,
J=16Hz), 8.53 (2H, d, J=7Hz)

- 30 (5) Ethyl 4-[N-(2-methoxyethyl)acetamido]cinnamate (from
ethyl 4-acetamidocinnamate and 2-methoxyethyl
bromide)

35 NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 1.85 (3H,
s), 3.30 (3H, s), 3.52 (2H, t, J=6Hz), 3.88 (2H,
t, J=6Hz), 4.28 (2H, q, J=7.5Hz), 6.44 (1H, d,

J=16Hz), 7.25 (2H, d, J=8Hz), 7.56 (2H, d, J=8Hz), 7.68 (1H, d, J=16Hz)

(6) Ethyl 4-[N-methoxyacetyl-N-(3-pyridylmethyl)amino]-
cinnamate (from ethyl 4-(methoxyacetamido)cinnamate
and 3-pyridylmethyl chloride hydrochloride)

NMR (CDCl₃, δ) : 1.32 (3H, t, J=7.5Hz), 3.35 (3H, s), 3.81 (2H, s), 4.27 (2H, q, J=7.5Hz), 4.91 (2H, s), 6.42 (1H, d, J=16Hz), 7.01 (2H, d, J=8Hz), 7.18-7.28 (1H, m), 7.50 (2H, d, J=8Hz), 7.57-7.72 (2H, m), 8.35 (1H, d, J=2Hz), 8.52 (1H, dd, J=6, 2Hz)

Preparation 56

(1) Ethyl 4-(phenoxycarbonylamino)cinnamate was obtained by reacting ethyl 4-aminocinnamate with phenyl chloroformate according to a similar manner to that of Preparation 18.

mp : 136-138°C

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7Hz), 4.27 (2H, q, J=7Hz), 6.39 (1H, d, J=15Hz), 7.09 (1H, br s), 7.15-7.58 (9H), 7.65 (1H, d, J=15Hz)

(2) A solution of ethyl 4-(phenoxycarbonylamino)-cinnamate (500 mg), 3-aminopyridine (154 mg) and triethylamine (325 mg) in N,N-dimethylformamide (5 ml) was stirred for 2 hours at 80°C. Water was added thereto, and the resulting precipitate was collected by filtration to give ethyl 4-[3-(3-pyridyl)ureido]-cinnamate (307 mg) as a colorless powder.

mp : 188-189°C

NMR (DMSO-d₆, δ) : 1.26 (3H, t, J=7Hz), 4.19 (2H, q, J=7Hz), 6.50 (1H, d, J=15Hz), 7.34 (1H, dd, J=9, 5Hz), 7.46-7.72 (5H), 7.96 (1H, dt, J=9, 1Hz), 8.21 (1H, dd, J=9, 1Hz), 8.62 (1H, d, J=1Hz),

2122236

8.98 (1H, br s), 9.10 (1H, m)

Preparation 57

The following compounds were obtained according to a similar manner to that of Preparation 24.

(1) Ethyl 4-(morpholinocarbonylamino)cinnamate

mp : 170-173°C

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7Hz), 3.43-3.56 (4H), 3.70-3.81 (4H), 4.28 (2H, q, J=7Hz), 6.35 (1H, d, J=15Hz), 6.49 (1H, br s), 7.40 (2H, d, J=9Hz), 7.48 (2H, d, J=9Hz), 7.63 (1H, d, J=15Hz)

(2) Ethyl 4-(4-bromobutyramido)cinnamate

mp : 119-124°C

NMR (CDCl₃, δ) : 1.32 (3H, t, J=7.5Hz), 2.21 (2H, quint, J=6Hz), 2.59 (2H, t, J=6Hz), 3.66 (2H, t, J=6Hz), 4.25 (2H, q, J=7.5Hz), 6.34 (1H, d, J=16Hz), 7.47 (2H, d, J=8Hz), 7.55 (2H, d, J=8Hz), 7.61 (1H, d, J=16Hz)

(3) Ethyl 4-[(2-pyridyl)acetamido]cinnamate

mp : 127°C

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 3.88 (2H, s), 4.25 (2H, q, J=7.5Hz), 6.35 (1H, d, J=16Hz), 7.20-7.35 (2H, m), 7.49 (2H, d, J=8Hz), 7.54-7.80 (4H, m), 8.63 (1H, d, J=5Hz), 10.18 (1H, s)

(4) Ethyl 4-[(4-pyridyl)acetamido]cinnamate

mp : 188°C

NMR (CDCl₃, δ) : 1.34 (3H, t, J=7.5Hz), 3.73 (2H, s), 4.25 (2H, q, J=7.5Hz), 6.37 (1H, d, J=16Hz), 7.20-7.35 (2H, m), 7.40 (1H, s), 7.43-7.55 (4H, m), 7.52 (1H, d, J=16Hz), 8.62 (2H, d, J=6Hz)

2122236

Preparation 58

To a stirred suspension of methyl 4-carboxycinnamate (400 mg) in thionyl chloride (1.4 ml) was added one drop of N,N-dimethylformamide. The mixture was refluxed for 20 minutes. The solvent was removed in vacuo. To the residue was added toluene (2 ml) and the mixture was evaporated in vacuo twice. The residue was dissolved with dichloromethane (4 ml), and 4-aminopyridine (201 mg) and triethylamine (0.81 ml) were added thereto in an ice-water bath. After 10 minutes the mixture was stirred at ambient temperature. After 3 hours, to the reaction mixture was added water and the mixture was extracted with dichloromethane-methanol (5:1, V/V). The organic layer was washed with saturated sodium bicarbonate solution, water and brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo. The residue was crystallized from ethyl acetate to give methyl 4-[N-(4-pyridyl)carbamoyl]cinnamate (555 mg) as a colorless powder.

mp : 209-211°C

NMR (DMSO-d₆, δ) : 3.76 (3H, s), 6.82 (1H, d, J=15Hz), 7.69-7.83 (3H), 7.92 (2H, d, J=9Hz), 8.01 (2H, d, J=9Hz), 8.50 (2H, d, J=7Hz)

Preparation 59

The following compounds were obtained according to similar manners to those of Preparations 30 or 58.

(1) Methyl 4-(ethylcarbamoyl)cinnamate

mp : 132-134.5°C

(2) Methyl 4-(4-methyl-1-piperazinylcarbonyl)cinnamate

mp : 88-90°C

Preparation 60

The following compounds were obtained according to a

2122236

similar manner to that of Preparation 33.

(1) 4-[N-(4-Pyridyl)carbamoyl]cinnamic acid

mp : >250°C

5 NMR (DMSO-d₆, δ) : 6.69 (1H, d, J=16Hz), 7.52-8.08
(7H), 8.49 (2H, d, J=6Hz)

(2) 4-[N-(3-Pyridylmethyl)acetamido]cinnamic acid

mp : 184-186°C

10 NMR (DMSO-d₆, δ) : 1.90 (3H, s), 4.91 (2H, s), 6.52
(1H, d, J=15Hz), 7.21-7.39 (3H), 7.50-7.79 (4H),
8.39 (1H, d, J=2Hz), 8.43 (1H, dd, J=5, 2Hz)

(3) 4-[3-(3-Pyridyl)ureido]cinnamic acid

15 mp : 219-221°C

NMR (DMSO-d₆, δ) : 6.40 (1H, d, J=15Hz), 7.37 (1H,
dd, J=9, 5Hz), 7.47-7.70 (5H), 7.98 (1H, dt,
J=9, 1Hz), 8.21 (1H, br d, J=5Hz), 8.62 (1H, d,
J=1Hz), 9.03 (1H, s), 9.16 (1H, s)

20

(4) 4-(Morpholinocarbonylamino)cinnamic acid

mp : 219-221°C

(5) 4-(Ethylcarbamoyl)cinnamic acid

25 mp : 256-261°C

(6) 4-(4-Methyl-1-piperazinylcarbonyl)cinnamic acid

NMR (DMSO-d₆, δ) : 2.12-2.58 (7H), 2.92-3.87 (4H,
overlapped with H₂O), 6.60 (1H, d, J=16Hz), 7.41
(2H, d, J=8Hz), 7.62 (1H, d, J=16Hz), 7.78 (2H,
d, J=8Hz)

30

(7) 4-(N-Acetyl-N-tert-butoxycarbonylmethylamino)cinnamic
acid

mp : 177-178°C

NMR (CDCl₃, δ) : 1.48 (9H, s), 1.98 (3H, s), 4.28
(2H, s), 6.48 (1H, d, J=16Hz), 7.39 (2H, d,

35

2122236

J=8Hz), 7.60 (2H, d, J=8Hz), 7.79 (1H, d, J=16Hz)

(8) 4-[(2-Pyridyl)acetamido]cinnamic acid

5 mp : 215°C

NMR (DMSO-d₆, δ) : 3.90 (2H, s), 6.40 (1H, d, J=16Hz), 7.34 (1H, dd, J=5, 8Hz), 7.38-7.72 (6H, m), 7.84 (1H, td, J=8, 1Hz), 8.54 (1H, d, J=5Hz)

10 (9) 4-[(4-Pyridyl)acetamido]cinnamic acid

mp : >250°C

NMR (DMSO-d₆, δ) : 3.75 (2H, s), 6.42 (1H, d, J=16Hz), 7.35 (2H, d, J=5Hz), 7.52 (1H, d, J=16Hz), 7.65 (4H, s-like), 8.51 (2H, d, J=5Hz)

15

(10) 4-[N-(2-Pyridylmethyl)acetamido]cinnamic acid

NMR (DMSO-d₆, δ) : 1.90 (3H, s), 4.97 (2H, s), 6.51 (1H, d, J=16Hz), 7.24 (1H, dd, J=5, 7.5Hz), 7.29-7.45 (3H, m), 7.55 (1H, d, J=16Hz), 7.61-7.80 (3H, m), 8.41-8.50 (1H, m)

20

(11) 4-[N-(4-Pyridylmethyl)acetamido]cinnamic acid

NMR (CDCl₃, δ) : 2.00 (3H, s), 4.91 (2H, s), 6.45 (1H, d, J=16Hz), 7.09 (2H, d, J=8Hz), 7.20 (2H, d, J=6Hz), 8.54 (2H, d, J=8Hz), 7.70 (1H, d, J=16Hz), 8.55 (2H, d, J=6Hz)

25

(12) 4-[N-(2-Methoxyethyl)acetamido]cinnamic acid

mp : 102-106°C

NMR (CDCl₃, δ) : 1.88 (3H, s), 3.30 (3H, s), 3.53 (2H, t, J=6Hz), 5.89 (2H, t, J=6Hz), 6.45 (1H, d, J=16Hz), 7.28 (2H, d, J=8Hz), 7.60 (2H, d, J=8Hz), 7.77 (1H, d, J=16Hz)

30

(13) 4-[N-(2-Methoxyethyl)-N-(isonicotinoyl)amino]cinnamic

35

2122236

acid

NMR (CDCl₃, δ) : 3.33 (3H, s), 3.66 (2H, t, J=5Hz),
4.10 (2H, t, J=5Hz), 6.37 (1H, d, J=16Hz), 7.15
(2H, d, J=8Hz), 7.20 (2H, d, J=6Hz), 7.40 (2H,
d, J=8Hz), 7.62 (1H, d, J=16Hz), 8.50 (2H, d,
J=6Hz)

(14) 4-[N-Methoxyacetyl-N-(3-pyridylmethyl)amino]cinnamic
acid

mp : 160°C

NMR (DMSO-d₆, δ) : 3.20 (3H, s), 3.87 (2H, s), 4.91
(2H, s), 6.54 (1H, d, J=16Hz), 7.27 (8H, d),
7.27-7.38 (1H, m), 7.56 (1H, d, J=16Hz), 7.62
(1H, dd-like, J=8Hz), 7.70 (2H, d, J=8Hz), 8.37
(1H, d, J=2Hz), 8.43 (1H, d, J=6Hz)

(15) 4-(2-Oxo-1-pyrrolidinyl)cinnamic acid

mp : >250°C

NMR (DMSO-d₆, δ) : 2.06 (2H, quint, J=8Hz), 3.86
(2H, t, J=8Hz), 6.46 (1H, d, J=16Hz), 7.55 (1H,
d, J=16Hz), 7.65-7.76 (4H, m)

Preparation 61

To a solution of N,N-bis(2-methoxyethyl)amine (2.40
g) and triethylamine (2.27 g) in dichloromethane (30 ml)
was added 3-nitrobenzoyl chloride (2.78 g) in an ice-water
bath. The mixture was stirred at ambient temperature for
1 hour. The reaction mixture was washed with saturated
sodium bicarbonate solution, water and brine, dried over
anhydrous magnesium sulfate, and evaporated in vacuo. The
residue was purified with column chromatography eluting
with dichloromethane-methanol to give N,N-bis(2-
methoxyethyl)-3-nitrobenzamide (4.12 g) as an oil.

NMR (CDCl₃, δ) : 3.22-3.88 (14H), 7.59 (1H, t,
J=8Hz), 7.80 (1H, dt, J=8, 1Hz), 8.26 (1H, dt,

2122236

J=8, 1Hz), 8.39 (1H, t, J=1Hz)

Preparation 62

5 A mixture of N,N-bis(2-methoxyethyl)-3-nitrobenzamide
(4.11 g) and palladium on charcoal (411 mg) in ethyl
acetate (41 ml) was hydrogenated under 1 atmospheric
pressure to hydrogen for 1 hour at ambient temperature.
The catalyst was removed by filtration and washed with
ethyl acetate, and the volatiles were removed in vacuo.
10 The residue was purified with column chromatography
eluting with dichloromethane-methanol to give 3-amino-N,N-
bis(2-methoxyethyl)benzamide (3.62 g) as an oil.

NMR (CDCl₃, δ) : 3.19-3.86 (16H), 6.62-6.79 (3H),
7.16 (1H, dt, J=8, 1Hz)

Preparation 63

To a stirred solution of 3-amino-N,N-bis(2-
methoxyethyl)benzamide (1.01 g) in 1,4-dioxane (10 ml) was
added 1N sodium hydroxide solution (5.2 ml) and phenyl
20 chloroformate (0.55 ml) successively in an ice-cooled
bath. The bath was removed and the reaction mixture was
stirred vigorously for 1 hour, during which time phenyl
chloroformate (0.25 ml) was further added. The mixture
was extracted with dichloromethane and the organic layer
25 was washed with water twice and brine, dried over
anhydrous magnesium sulfate, and evaporated in vacuo. The
residue was crystallized from diisopropyl ether to give
phenyl 3-[N,N-bis(2-methoxyethyl)carbamoyl]phenylcarbamate
(1.30 g) as a colorless powder.

30 mp : 116-118°C

NMR (CDCl₃, δ) : 3.19-3.82 (14H), 7.10-7.57 (10H)

Preparation 64

35 To a stirred solution of ethyl 4-(4-
bromobutyramido)cinnamate (420 mg) in N,N-

2122236

dimethylformamide (5 ml) was added potassium carbonate (552 mg) at ambient temperature and the resulting mixture was warmed at 50°C for three hours. The reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography eluting with chloroform to afford ethyl 4-(2-oxo-1-pyrrolidinyl)cinnamate (281 mg) as a pale yellow solid.

mp : 134°C

NMR (CDCl₃, δ) : 1.34 (3H, t, J=7.7Hz), 2.19 (2H, quint, J=7.7Hz), 2.63 (2H, t, J=7.7Hz), 3.88 (2H, t, J=7.7Hz), 4.26 (2H, q, J=7.7Hz), 6.38 (1H, d, J=16Hz), 7.53 (2H, d, J=8Hz), 7.64 (1H, d, J=16Hz), 7.68 (2H, d, J=8Hz)

Example 42

8-(2,6-Dichloro-3-nitrobenzyloxy)-3-methylquinoline was obtained according to a similar manner to that of Example 1.

NMR (CDCl₃, δ) : 2.50 (3H, s), 5.58 (2H, s), 7.18 (1H, dd, J=8, 1Hz), 7.36-7.57 (3H), 7.78 (1H, d, J=8Hz), 7.90 (1H, d, J=1Hz), 8.79 (1H, d, J=1Hz)

Example 43

To a solution of 8-hydroxy-2-methylquinoline (17.8 g) in N,N-dimethylformamide (89 ml) was added sodium hydride (40% in oil, 4.48 g) under ice-bath cooling, and the mixture was stirred for 40 minutes at ambient temperature. A solution of 2,6-dichloro-1-methylsulfonyloxy-3-[N-methyl-N-(phthalimidoacetyl)amino]benzene (56.1 g) in N,N-dimethylformamide (200 ml) was added thereto under ice-bath cooling, and the mixture was stirred for 70 minutes at ambient temperature. Water (290 ml) was dropwise added thereto, and the resulting precipitate was collected by

filtration to give 8-[2,6-dichloro-3-[N-methyl-N-(phthalimidoacetyl)amino]benzyloxy]-2-methylquinoline (57.07 g).

mp : 204°C

5

Example 44

The following compounds were obtained according to a similar manner to that of Example 43.

10

(1) 8-[2,6-Dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-3-methylquinoxaline

mp : 238.8-240°C

15

NMR (CDCl₃, δ) : 2.78 (3H, s), 3.25 (3H, s), 4.12 (2H, s), 5.59 (1H, d, J=10Hz), 5.63 (1H, d, J=10Hz), 7.25-7.31 (1H, overlapped with CDCl₃), 7.51 (1H, d, J=9Hz), 7.56 (1H, d, J=9Hz), 7.67-7.77 (4H), 7.82-7.89 (2H), 8.74 (1H, s)

20

(2) 8-[2,6-Dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoxaline

mp : 218-220°C

25

NMR (CDCl₃, δ) : 2.78 (3H, s), 3.24 (3H, s), 4.10 (2H, s), 5.63 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 7.33 (1H, br d, J=7.5Hz), 7.50 (1H, d, J=8Hz), 7.54 (1H, d, J=8Hz), 7.63 (1H, t, J=7.5Hz), 7.69-7.78 (3H), 7.82-7.90 (2H), 8.73 (1H, s)

30

(3) 8-[2,6-Dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]cinnoline

mp : 221.4-222°C

35

NMR (CDCl₃, δ) : 3.27 (3H, s), 4.12 (2H, s), 5.71 (2H, s), 7.36 (1H, d, J=7.5Hz), 7.48 (1H, d, J=7.5Hz), 7.52 (1H, d, J=8Hz), 7.58 (1H, d, J=8Hz), 7.69-7.78 (3H), 7.81-7.90 (3H), 9.35

(1H, d, J=6Hz)

(4) 8-[2,6-Dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinazoline

mp : 237.5-238°C

NMR (CDCl₃, δ) : 2.90 (3H, s), 3.24 (3H, s), 4.10 (2H, s), 5.66 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 7.43-7.60 (5H), 7.70-7.75 (2H), 7.82-7.89 (2H), 9.30 (1H, s)

(5) 5,7-Dibromo-8-[2,6-dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline

mp : 204-207°C

NMR (CDCl₃, δ) : 2.79 (3H, s), 3.17 (3H, s), 3.87 (1H, d, J=16.5Hz), 3.98 (1H, d, J=16.5Hz), 5.92 (1H, d, J=11.5Hz), 6.00 (1H, d, J=11.5Hz), 7.38 (1H, d, J=8.5Hz), 7.44 (1H, d, J=8.5Hz), 7.51 (1H, d, J=8.5Hz), 7.67-7.77 (2H, m), 7.81-7.91 (3H, m), 8.30 (1H, d, J=8.5Hz)

Example 45

8-[3-[N-Benzyl-N-(phthalimidoacetyl)amino]-2,6-dichlorobenzyloxy]-2-methylquinoline was obtained by reacting 8-[2,6-dichloro-3-(phthalimidoacetyl)amino]benzyloxy]-2-methylquinoline with benzyl bromide according to a similar manner to that of Example 7.

NMR (CDCl₃, δ) : 2.75 (3H, s), 3.98-4.06 (2H), 4.09 (1H, d, J=17Hz), 5.62 (1H, d, J=14Hz), 5.68 (1H, d, J=10Hz), 5.73 (1H, d, J=10Hz), 6.92 (1H, d, J=8Hz), 7.16-7.35 (8H), 7.40 (1H, t, J=7.5Hz), 7.47 (1H, d, J=7.5Hz), 7.70-7.78 (2H), 7.85-7.91 (2H), 8.02 (1H, d, J=7.5Hz)

Example 46

The following compounds were obtained according to a

2122236

similar manner to that of Example 9.

- (1) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
3-methylquinoxaline

5 NMR (CDCl₃, δ) : 2.77 (3H, s), 2.98-3.32 (5H), 5.57
(2H, s), 7.21-7.30 (2H), 7.48 (1H, d, J=8Hz),
7.67-7.75 (2H), 8.74 (1H, s)

- (2) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
2-methylquinoxaline

10 NMR (CDCl₃, δ) : 2.79 (3H, s), 3.00 (1H, d, J=17Hz),
3.11 (1H, d, J=17Hz), 3.22 (3H, s), 5.62 (2H,
s), 7.23-7.33 (2H), 7.49 (1H, d, J=8Hz), 7.64
(1H, d, J=7.5Hz), 7.63 (1H, br d, J=7.5Hz), 8.75
15 (1H, s)

- (3) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
cinnoline

20 NMR (CDCl₃, δ) : 3.02 (1H, d, J=17Hz), 3.13 (1H, d,
J=17Hz), 3.24 (3H, s), 5.65 (1H, d, J=10Hz),
5.70 (1H, d, J=10Hz), 7.28-7.36 (2H), 7.42-7.51
(2H), 7.71 (1H, t, J=7.5Hz), 7.82 (1H, d,
J=7.5Hz), 9.36 (1H, d, J=6Hz)

- (4) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
2-methylquinazoline

25 NMR (CDCl₃, δ) : 2.90 (3H, s), 3.00 (1H, d, J=16Hz),
3.11 (1H, d, J=16Hz), 3.22 (3H, s), 5.62 (2H,
s), 7.28 (1H, d, J=8Hz), 7.40-7.59 (4H), 9.31
30 (1H, s)

- (5) 8-[3-(N-Glycyl-N-benzylamino)-2,6-dichlorobenzyloxy]-
2-methylquinoline

35 NMR (CDCl₃, δ) : 2.75 (3H, s), 2.99 (1H, d, J=17Hz),
3.08 (1H, d, J=17Hz), 3.94 (1, d, J=14Hz), 3.60-

2122236

3.72 (3H), 6.69 (1H, d, J=7.5Hz), 7.15-7.33
(8H), 7.39 (1H, t, J=7.5Hz), 7.48 (1H, d,
J=7.5Hz), 8.03 (1H, br d, J=7.5Hz)

5 (6) 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-
5,7-dibromo-2-methylquinoline
NMR (CDCl₃, δ) : 2.78 (3H, s), 2.84 (1H, d,
J=16.5Hz), 3.03 (1H, d, J=16.5Hz), 3.16 (3H, s),
5.90 (2H, s), 7.22 (1H, d, J=8.5Hz), 7.41 (1H,
10 d, J=8.5Hz), 7.43 (1H, d, J=8.5Hz), 7.85 (1H,
s), 8.34 (1H, d, J=8.5Hz)

Example 47

15 (1) 8-[2,6-Dichloro-3-[N-ethoxycarbonylmethyl-N-
(phthalimidoacetyl)amino]benzyloxy]-2-methylquinoline was
obtained by reacting 8-[2,6-dichloro-3-(phthalimidoacetyl-
amino)benzyloxy]-2-methylquinoline with ethyl bromoacetate
according to a similar manner to that of Example 7.

mp : 211-213°C

20 NMR (CDCl₃, δ) : 1.28 (3H, t, J=7.5Hz), 2.73 (3H,
s), 3.68 (1H, d, J=17Hz), 4.03 (1H, d, J=17Hz),
4.13-4.30 (3H), 5.00 (1H, d, J=17Hz), 5.65 (1H,
d, J=10Hz), 5.70 (1H, d, J=10Hz), 7.23-7.31
(2H), 7.36-7.49 (3H), 7.69-7.75 (2H), 7.81-7.91
25 (3H), 8.01 (1H, d, J=8Hz)

(2) To the solution of 8-[2,6-dichloro-3-[N-ethoxy-
carbonylmethyl-N-(phthalimidoacetyl)amino]benzyloxy]-2-
methylquinoline (527 mg) in dichloromethane (5.3 ml) was
30 added 30% solution of methylamine in methanol (2 ml) at
ambient temperature. After stirring for 24 hours, the
reaction mixture was evaporated in vacuo. The residue was
purified by flash column chromatography (silica gel 50 ml)
eluting with dichloromethane/methanol (20/1, V/V) and by
35 crystallizing from isopropyl ether to give 8-[2,6-

dichloro-3-(2,5-dioxopiperazin-1-yl)benzyloxy]-2-methylquinoline (187 mg) as colorless crystals.

mp : 211-213°C

NMR (CDCl₃, δ) : 2.74 (3H, s), 4.09-4.21 (3H), 4.40
(1H, d, J=17Hz), 5.62 (2H, s), 6.38 (1H, br s),
7.21-7.51 (6H), 8.01 (1H, d, J=8Hz)

(3) 8-[3-(4-Benzyl-2,5-dioxopiperazin-1-yl)-2,6-dichlorobenzyloxy]-2-methylquinoline was obtained by reacting 8-[2,6-dichloro-3-(2,5-dioxopiperazin-1-yl)benzyloxy]-2-methylquinoline with benzyl bromide according to a similar manner to that of Example 7.

NMR (CDCl₃, δ) : 2.75 (3H, s), 4.01 (1H, d, J=17Hz), 4.10 (1H, d, J=17Hz), 4.21 (1H, d, J=17Hz), 4.48 (1H, d, J=17Hz), 4.63 (1H, d, J=15Hz), 4.72 (1H, d, J=15Hz), 5.62 (2H, s), 7.20-7.52 (11H), 8.02 (1H, d, J=8Hz)

(4) 8-[2,6-Dichloro-3-(4-ethoxycarbonylmethyl-2,5-dioxopiperazin-1-yl)benzyloxy]-2-methylquinoline was obtained by reacting 8-[2,6-dichloro-3-(2,5-dioxopiperazin-1-yl)benzyloxy]-2-methylquinoline with ethyl bromoacetate according to a similar manner to that of Example 7.

NMR (CDCl₃, δ) : 1.31 (3H, t, J=7.5Hz), 2.74 (3H, s), 4.11-4.36 (7H), 4.48 (1H, d, J=17Hz), 5.61 (2H, s), 7.21-7.32 (3H), 7.36-7.51 (3H), 8.02 (1H, d, J=8Hz)

Example 48

4-Chloro-8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylquinazoline was obtained from 8-(2,6-dichloro-3-nitrobenzyloxy)-2-methyl-4-oxo-3,4-dihydroquinazoline according to a similar manner to that of Preparation 6.

mp : 192.8-194.3°C

2122236

NMR (CDCl₃, δ) : 2.86 (3H, s), 5.66 (2H, s), 7.44-7.65 (3H, m), 7.80 (1H, d, J=9Hz), 7.91 (1H, dd, J=8, 0.5Hz)

5 Example 49

A mixture of 8-[2,6-dichloro-3-(N-glycyl-N-methylamino)benzyloxy]-2-methylquinoline (100 mg), acetic anhydride (35 ml), pyridine (60 μl) and methylene chloride (2 ml) was stirred for 3 hours at ambient temperature.

10 The reaction mixture was concentrated and the residue was purified by preparative thin-layer chromatography (ethyl acetate-methanol) to give 8-[3-[N-(acetylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (138 mg).

15 NMR (CDCl₃, δ) : 2.00 (3H, s), 2.74 (3H, s), 3.24 (3H, s), 3.50 (1H, dd, J=17, 4Hz), 3.80 (1H, dd, J=17, 5Hz), 5.63 (2H, s), 6.33 (1H, br s), 7.21-7.34 (2H, m), 7.37-7.52 (4H, m), 8.01 (1H, d, J=7.5Hz)

20 its hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 1.98 (3H, s), 3.01 (3H, s), 3.28 (3H, s), 3.75 (1H, d, J=15Hz), 3.80 (1H, d, J=15Hz), 5.65 (1H, d, J=9Hz), 5.80 (1H, d, J=9Hz), 7.60 (1H, d, J=8Hz), 7.70 (1H, d, J=8Hz), 7.83 (1H, d, J=8Hz), 7.86-8.02 (3H, m), 9.00 (1H, d, J=8Hz)

Example 50

30 The following compounds were obtained according to a similar manner to that of Example 49.

(1) 8-[3-[N-(Acetylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-3-methylquinoxaline

35 NMR (CDCl₃, δ) : 2.01 (3H, s), 2.78 (3H, s), 3.25 (3H, s), 3.53 (1H, dd, J=17, 4Hz), 3.80 (1H, dd,

2122236

J=17, 5Hz), 5.54 (2H, s), 6.42 (1H, br s), 7.26 (1H, overlapped with CDCl₃), 7.31 (1H, d, J=8Hz), 7.49 (1H, d, J=8Hz), 7.66-7.78 (2H), 8.23 (1H, s)

5

- (2) 8-[3-[N-(Acetylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoxaline

NMR (CDCl₃, δ) : 2.01 (3H, s), 2.78 (3H, s), 3.24 (3H, s), 3.52 (1H, dd, J=17, 4Hz), 3.80 (1H, dd, J=17, 4Hz), 5.60 (2H, s), 6.42 (1H, br s), 7.30 (1H, d, J=9Hz), 7.50 (1H, d, J=7.5Hz), 7.65 (1H, t, J=7.5Hz), 7.77 (1H, br d, J=7.5Hz), 8.72 (1H, s)

10

15

- (3) 8-[3-[N-(Acetylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]cinnoline

NMR (CDCl₃, δ) : 2.01 (3H, s), 3.28 (3H, s), 3.54 (1H, dd, J=17, 4Hz), 3.80 (1H, dd, J=17, 5Hz), 5.63 (1H, d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.45 (1H, br s), 7.30-7.38 (2H), 7.42-7.52 (2H), 7.73 (1H, t, J=7.5Hz), 7.82 (1H, d, J=7.5Hz), 9.34 (1H, d, J=6Hz)

20

25

- (4) 8-[3-[N-(Acetylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinazoline

NMR (CDCl₃, δ) : 2.01 (3H, s), 2.90 (3H, s), 3.26 (3H, s), 3.51 (1H, dd, J=17, 4Hz), 3.80 (1H, dd, J=17, 4Hz), 5.62 (2H, s), 6.43 (1H, br s), 7.30 (1H, d, J=7.5Hz), 7.31-7.59 (4H), 9.30 (1H, s)

30

- (5) 8-[3-[N-(Acetylglycyl)-N-benzylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.02 (3H, s), 2.77 (3H, s), 3.51 (1H, dd, J=17, 4Hz), 3.79 (1H, dd, J=17, 5Hz), 3.98 (1H, d, J=14Hz), 5.60-5.72 (3H), 6.47 (1H,

35

2122236

br s), 6.71 (1H, d, J=8Hz), 7.15-7.33 (8H), 7.40
(1H, t, J=7.5Hz), 7.48 (1H, d, J=7.5Hz), 8.03
(1H, d, J=7.5Hz)

5 its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.01 (3H, s), 3.08 (3H, s),
3.68-3.80 (2H, overlapped with H₂O), 4.24 (1H,
d, J=14Hz), 5.53 (1H, d, J=14Hz), 5.59 (1H, d,
J=10Hz), 5.73 (1H, d, J=10Hz), 6.99 (1H, d,
J=7.5Hz), 7.21-7.34 (5H), 7.43 (1H, d, J=7.5Hz),
7.70 (1H, d, J=7.5Hz), 7.82-7.98 (3H), 8.96 (1H,
d, J=7.5Hz)

10

(6) 8-[3-[N-(Acetylglycyl)-N-methylamino]-2,6-
15 dichlorobenzyloxy]-5,7-dibromo-2-methylquinoline
mp : 179-183.5°C

NMR (CDCl₃, δ) : 2.01 (3H, s), 2.81 (3H, s), 3.20
(3H, s), 3.41 (1H, dd, J=16.5, 3.0Hz), 3.78 (1H,
dd, J=16.5, 3.0Hz), 5.87 (1H, d, J=10.5Hz), 5.93
(1H, d, J=10.5Hz), 6.38 (1H, br t), 7.25 (1H, d,
J=8.5Hz), 7.41 (1H, d, J=8.5Hz), 7.44 (1H, d,
J=8.5Hz), 7.86 (1H, s), 8.34 (1H, d, J=8.5Hz)

20

its hydrochloride

25

mp : 93-96.5°C

NMR (CDCl₃-CD₃OD, δ) : 2.01 (3H, s), 2.96 (3H, s),
3.20 (3H, s), 3.42 (1H, d, J=16.5Hz), 3.80 (1H,
d, J=16.5Hz), 5.88 (2H, s), 7.31 (1H, d,
J=8.5Hz), 7.46 (1H, d, J=8.5Hz), 7.54 (1H, d,
J=8.5Hz), 7.97 (1H, s), 8.52 (1H, d, J=8.5Hz)

30

Example 51

The following compounds were obtained according to
similar manners to those of Examples 11 to 13.

35

2122236

- (1) 8-[2,6-Dichloro-3-[N-[N'-(4-ethoxycarbonylphenyl)-ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

5 NMR (CDCl₃, δ) : 1.32 (3H, t, J=7.5Hz), 2.55 (3H, s), 3.21 (3H, s), 3.77 (1H, dd, J=4.5, 18Hz), 4.30 (2H, q, J=7.5Hz), 4.45 (1H, dd, J=7.5, 18Hz), 5.43 (1H, d, J=10Hz), 5.55 (1H, dd, J=4.5, 7.5Hz), 5.62 (1H, d, J=10Hz), 7.20-7.35 (6H, m), 7.44-7.55 (2H, m), 7.80 (2H, d, J=8Hz), 10 8.10 (1H, d, J=8Hz), 8.99 (1H, s)

- (2) 8-[3-[N-[N'-[3-[N,N-Bis(2-methoxyethyl)carbamoyl]-phenyl]ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-4-methoxy-2-methylquinoline

15 NMR (CDCl₃, δ) : 2.53 (3H, s), 3.12-3.85 (18H), 4.03 (3H, s), 4.39 (1H, dd, J=18, 7Hz), 5.40 (1H, d, J=10Hz), 5.50-5.67 (2H), 6.68 (1H, s), 6.91 (1H, d, J=8Hz), 7.08-7.50 (7H), 7.82 (1H, d, J=8Hz), 8.85 (1H, br s)

20 its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.87 (3H, s), 3.20-3.81 (18H), 3.89 (1H, d, J=17Hz), 4.32 (3H, s), 5.54 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 6.99 (1H, m), 7.20-7.38 (2H), 7.41-7.52 (2H), 7.58 (1H, d, J=9Hz), 7.62-7.72 (2H), 7.81 (1H, t, J=8Hz), 25 8.00 (1H, d, J=8Hz)

- (3) 8-[2,6-Dichloro-3-[N-[N'-[3-(dimethylcarbamoyl)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoxaline

30 NMR (CDCl₃, δ) : 2.71 (3H, s), 2.94 (3H, br s), 3.09 (3H, br s), 3.23 (3H, s), 3.78 (1H, dd, J=17, 5Hz), 3.84 (1H, dd, J=17, 5Hz), 5.56 (1H, d, J=10Hz), 5.62 (1H, d, J=10Hz), 5.82 (1H, br t, 35

2122236

J=5Hz), 6.99 (1H, d, J=7.5Hz), 7.10 (1H, t, J=7.5Hz), 7.29-7.38 (4H), 7.43 (1H, d, J=8Hz), 7.68 (1H, t, J=7.5Hz), 7.78 (1H, d, J=7.5Hz), 7.89 (1H, br s), 8.76 (1H, s)

5

(4) 8-[2,6-Dichloro-3-[N-[N'-(3-[(2-methoxyethyl)-carbamoyl]phenyl]ureidoacetyl]-N-methylamino]-benzyloxy]-2-methylquinoxaline

NMR (CDCl₃, δ) : 2.71 (3H, s), 3.23 (3H, br s), 3.37 (3H, s), 3.49-3.66 (4H), 3.79 (1H, dd, J=17, 5Hz), 3.89 (1H, dd, J=17, 5Hz), 5.56 (1H, d, J=10Hz), 5.64 (1H, d, J=10Hz), 5.92 (1H, br t, J=5Hz), 6.80 (1H, br t, J=5Hz), 7.18-7.58 (7H), 7.68 (1H, t, J=8Hz), 7.78 (1H, d, J=8Hz), 7.83 (1H, br s), 8.73 (1H, s)

10

15

Example 52

The following compounds were obtained according to similar manners to those of Examples 15 or 16.

20

(1) 8-[2,6-Dichloro-3-[N-[4-(methoxycarbonyl)cinnamoyl-glycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.27 (3H, s), 3.64 (1H, dd, J=18, 4Hz), 3.87-4.00 (4H, m), 5.60-5.70 (2H, m), 6.57 (1H, d, J=16Hz), 6.75 (1H, t-like), 7.24-7.63 (11H, m), 7.99-8.05 (1H, m)

25

(2) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(4-methyl-1-piperazinylcarbonyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.26-2.57 (7H), 2.74 (3H, s), 3.29 (3H, s), 3.36-3.89 (9H), 3.96 (1H, dd, J=18, 5Hz), 5.65 (2H, s), 6.51 (1H, d, J=16Hz), 6.70 (1H, br t, J=4Hz), 7.21-7.63 (11H), 8.03 (1H, d, J=8Hz)

30

35

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.90 (3H, s), 2.99-3.21 (5H),
3.28-3.88 (9H), 3.94 (2H, s), 5.62 (1H, d,
J=10Hz), 5.81 (1H, d, J=10Hz), 6.70 (1H, d,
J=16Hz), 7.40-7.70 (7H), 7.89 (1H, d, J=7Hz),
7.87-8.01 (3H), 9.00 (H, d, J=9Hz)

(3) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(4-pyridyl)-
carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.69 (3H, s), 3.28 (3H, s),
3.58-3.73 (1H, overlapped with H₂O), 4.02 (1H,
d, J=18Hz), 5.09 (2H, s), 6.62 (1H, d, J=16Hz),
7.21-7.62 (9H), 7.76 (2H, d, J=7Hz), 7.89 (2H,
d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.43 (1H, d,
J=7Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.32 (3H, s),
3.91 (1H, d, J=17Hz), 4.03 (1H, d, J=17Hz), 5.63
(1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 6.78 (1H,
d, J=15Hz), 7.51-8.02 (9H), 8.16 (2H, d, J=8Hz),
8.58 (4H, s), 9.00 (1H, d, J=8Hz)

(4) 8-[3-[N-[4-(N-Acetyl-N-tert-butoxycarbonylmethyl-
amino)cinnamoylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.48 (9H, s), 1.94 (3H, s), 2.73
(3H, s), 3.29 (3H, s), 3.69 (1H, dd, J=18, 4Hz),
3.98 (1H, dd, J=18, 5Hz), 4.26 (2H, s), 5.65
(2H, s), 6.49 (1H, d, J=15Hz), 6.70 (1H, br t,
J=4Hz), 7.22-7.63 (11H), 8.03 (1H, d, J=8Hz)

(5) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[N-(3-
pyridylmethyl)acetamido]cinnamoylglycyl]amino]-

2122236

benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.91 (3H, s), 2.73 (3H, s), 3.28 (3H, s), 3.68 (1H, dd, J=18, 4Hz), 3.98 (1H, dd, J=18, 5Hz), 4.89 (2H, s), 5.65 (2H, s), 6.48 (1H, d, J=16Hz), 6.70 (1H, br t, J=4Hz), 6.99 (2H, d, J=8Hz), 7.19-7.69 (11H), 8.03 (1H, d, J=8Hz), 8.38 (1H, d, J=2Hz), 8.51 (1H, dd, J=5, 2Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.99 (3H, s), 3.09 (3H, s), 3.31 (3H, s), 3.93 (2H, br s), 5.10 (2H, s), 5.62 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.68 (1H, d, J=16Hz), 7.21 (1H, d, J=9Hz), 7.49-7.70 (5H), 7.78 (1H, br d, J=8Hz), 7.85-8.11 (4H), 8.52 (1H, br d, J=8Hz), 8.72-8.82 (2H), 9.00 (1H, d, J=9Hz)

(6) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[N'-(3-pyridyl)ureido]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.70 (3H, s), 3.22 (3H, s), 3.63 (1H, br d, J=18Hz), 3.93 (1H, br d, J=18Hz), 5.59 (2H, s), 6.40 (1H, d, J=15Hz), 7.08 (0.7H, m), 7.20-7.58 (12H), 8.09 (1H, d, J=15Hz), 8.13-8.32 (3H)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.09 (3H, s), 3.31 (3H, s), 3.96 (2H, s), 5.60 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.49 (1H, d, J=15Hz), 7.36-7.68 (7H), 7.77 (1H, br d, J=8Hz), 7.84-8.00 (4H), 8.31 (1H, br d, J=5Hz), 8.62 (1H, br d, J=9Hz), 8.99 (1H, d, J=9Hz), 9.33 (1H, d, J=2Hz)

2122236

(7) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(morpholinocarbonyl-
amino)cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 2.71 (3H, s), 3.23 (3H, s), 3.41-
3.60 (5H), 3.64-3.77 (4H), 3.92 (1H, dd, J=17,
5Hz), 5.62 (2H s), 6.39 (1H, d, J=15Hz), 6.59
(1H, br t, J=4Hz), 6.73 (1H, br s), 7.22-7.58
(11H), 8.03 (1H, d, J=9Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.09 (3H, s), 3.30 (3H, s),
3.50-3.60 (4H), 3.70-3.80 (4H), 3.95 (2H, s),
5.61 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.48
(1H, d, J=15Hz), 7.37-7.53 (5H), 7.59 (1H, d,
J=9Hz), 7.67 (1H, d, J=9Hz), 7.79 (1H, d,
J=7Hz), 7.85-8.00 (3H), 8.99 (1H, d, J=9Hz)

(8) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(2-pyridyl)-
acetamido]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 2.71 (3H, s), 3.26 (3H, s), 3.64
(1H, dd, J=4, 18Hz), 3.81-4.02 (3H, m), 5.60
(2H, s), 6.39 (1H, d, J=16Hz), 6.63 (1H, t-
like), 7.16-7.34 (5H, m), 7.34-7.63 (8H, m),
7.70 (1H, td, J=8Hz, 1Hz), 8.03 (1H, d, J=8Hz),
8.63 (1H, dd, J=5Hz, 1Hz), 10.13 (1H, s)

its dihydrochloride

NMR (CDCl₃-CD₃OD) : 3.09 (3H, s), 3.29 (3H, s), 3.92
(2H, s), 4.36-4.47 (2H, m), 5.60 (1H, d,
J=10Hz), 5.76 (1H, d, J=10Hz), 6.48 (1H, d,
J=16Hz), 7.26-7.48 (3H, m), 7.48-7.74 (5H, m),
7.80-7.99 (4H, m), 8.18 (1H, d, J=8Hz), 8.50
(1H, td, J=8, 1Hz), 8.75 (1H, d, J=6Hz), 8.97
(1H, d, J=8Hz)

2122236

- (9) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(4-pyridyl)-acetamido]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.60 (3H, s), 3.22 (3H, s), 3.53-
3.70 (3H, m), 3.88 (1H, dd, J=18, 4Hz), 5.61
(2H, s), 6.38 (1H, d, J=16Hz), 6.63 (1H, t-
like), 7.10-7.62 (13H, m), 8.06 (1H, d, J=8Hz),
8.45 (1H, s), 8.53 (2H, d, J=6Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.09 (3H, s), 3.30 (3H, s),
3.90 (1H, d, J=16Hz), 4.01 (1H, d, J=16Hz), 5.56
(1H, d, J=10Hz), 5.75 (1H, d, J=10Hz), 6.43 (1H,
d, J=16Hz), 7.23-7.41 (3H, m), 7.49-7.61 (2H,
m), 7.61-7.75 (3H, m), 7.75-7.97 (3H, m), 8.20
(2H, d, J=6Hz), 8.70 (2H, d, J=6Hz), 8.94 (1H,
d, J=8Hz)

- (10) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[N-(2-pyridyl-methyl)acetamido]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.96 (3H, s), 2.73 (3H, s), 3.26
(3H, s), 3.64 (1H, dd, J=4, 16Hz), 3.94 (1H, dd,
J=4, 16Hz), 5.02 (2H, s), 5.64 (2H, s-like),
6.43 (1H, d, J=16Hz), 6.64 (1H, t-like), 7.10-
7.20 (3H, m), 7.20-7.59 (10H, m), 7.65 (1H, t,
J=7.5Hz), 8.03 (1H, d, J=8Hz), 8.50 (1H, d,
J=5Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.03 (3H, s), 3.14 (3H, s),
3.30 (3H, s), 3.88 (1H, d, J=16Hz), 4.12 (1H, d,
J=16Hz), 5.43 (2H, s), 5.58 (1H, d, J=10Hz),
5.71 (1H, d, J=10Hz), 6.63 (1H, d, J=16Hz),
7.24-7.33 (1H, m), 7.39 (1H, d, J=16Hz), 7.50-

2122236

7.59 (4H, m), 7.64 (1H, d, J=7.5Hz), 7.75-8.01
(6H, m), 8.43 (1H, t, J=7.5Hz), 8.73 (1H, d,
J=6Hz), 8.89 (1H, d, J=8Hz)

- 5 (11) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[N-(4-pyridyl-
methyl)acetamido]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

10 NMR (CDCl₃, δ) : 1.95 (3H, s), 2.74 (3H, s), 3.26
(3H, s), 3.64 (1H, dd, J=4, 16Hz), 3.94 (1H, dd,
J=4, 16Hz), 4.88 (2H, s), 5.65 (2H, s), 6.45
(1H, d, J=16Hz), 6.65 (1H, t-like), 7.03 (2H, d,
J=7.5Hz), 7.14 (2H, d, J=5Hz), 7.21-7.33 (3H,
m), 7.33-7.59 (6H, m), 8.03 (1H, d, J=8Hz), 8.52
(2H, d, J=5Hz)

15

its dihydrochloride

20 NMR (CDCl₃-CD₃OD, δ) : 2.01 (3H, s), 3.16 (3H, s),
3.29 (3H, s), 3.88 (1H, d, J=16Hz), 4.06 (1H, d,
J=16Hz), 5.10 (2H, s), 5.60 (1H, d, J=10Hz),
5.71 (1H, d, J=10Hz), 6.65 (1H, d, J=16Hz), 7.15
(2H, d, J=7.5Hz), 7.45 (1H, d, J=16Hz), 7.50-
7.70 (5H, m), 7.79 (1H, d, J=7.5Hz), 7.82-7.95
(4H, m), 8.79 (2H, d, J=6Hz), 8.86 (1H, d,
J=7.5Hz)

25

- (12) 8-[2,6-Dichloro-3-[N-[3-(methoxycarbonyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline

30 NMR (CDCl₃, δ) : 2.72 (3H, s), 3.27 (3H, s), 3.65
(1H, dd, J=4, 16Hz), 3.85-4.01 (4H, m), 5.65
(2H, s), 6.55 (1H, d, J=16Hz), 6.68 (1H, t-
like), 7.20-7.36 (3H, m), 7.36-7.54 (4H, m),
7.54-7.70 (2H, m), 7.95-8.06 (2H, m), 8.20 (1H,
s-like)

35

2122236

(13) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(N-methylpropionamido)cinnamoylglycyl]amino]benzyloxy]-4-methoxy-2-methylquinoline

NMR (CDCl₃, δ) : 1.08 (3H, t, J=7Hz), 2.02-2.21 (2H), 2.70 (3H, s), 3.28 (6H, s), 3.67 (1H, dd, J=17, 4Hz), 3.89-4.06 (4H), 5.62 (2H, s), 6.49 (1H, d, J=15Hz), 6.64 (1H, s), 6.71 (1H, br s), 7.11-7.63 (9H), 7.82 (1H, d, J=9Hz)

10 its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.08 (3H, t, J=7Hz), 2.03-2.26 (2H), 2.99 (3H, s), 3.28 (3H, s), 3.31 (3H, s), 3.82-4.06 (2H, overlapped with H₂O), 4.37 (3H, s), 5.55 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 6.60 (1H, d, J=15Hz), 7.21 (1H, d, J=9Hz), 7.30-7.70 (7H), 7.80 (1H, t, J=9Hz), 8.00 (1H, d, J=9Hz)

(14) 8-[2,6-Dichloro-3-[N-[4-(mesylamino)cinnamoylglycyl]-N-methylamino]benzyloxy]-4-methoxy-2-methylquinoline

NMR (CDCl₃, δ) : 2.69 (3H, s), 3.03 (3H, s), 3.28 (3H, s), 3.63 (1H, dd, J=17, 4Hz), 3.88-4.09 (4H), 5.62 (2H, s), 6.40 (1H, d, J=15Hz), 6.62-6.77 (2H), 7.14-7.60 (10H), 7.82 (1H, d, J=9Hz)

25 its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.95 (3H, s), 3.02 (3H, s), 3.30 (3H, s), 3.89 (1H, d, J=16Hz), 4.00 (1H, d, J=16Hz), 4.35 (3H, s), 5.59 (1H, d, J=10Hz), 5.79 (1H, d, J=10Hz), 6.54 (1H, d, J=15Hz), 7.21-7.34 (3H), 7.39-7.74 (6H), 7.81 (1H, t, J=9Hz), 8.01 (1H, d, J=9Hz)

(15) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(3-

methylureido)cinnamoylglycyl]amino]benzyloxy]-4-

2122236

methoxy-2-methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.63 (3H, s), 2.79 (3H, s),
3.22 (3H, s), 3.62 (1H, d, J=17Hz), 3.83-4.10
(4H), 5.53 (2H, s), 6.41 (1H, d, J=16Hz), 6.71
(1H, s), 7.18-7.60 (9H), 7.81 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.81 (3H, s), 2.93 (3H, s),
3.31 (3H, s), 3.94 (2H, s), 4.34 (3H, s), 5.56
(1H, d, J=10Hz), 5.78 (1H, d, J=10Hz), 6.41 (1H,
d, J=15Hz), 7.25-7.72 (9H), 7.81 (1H, t, J=9Hz),
8.01 (1H, d, J=9Hz)

(16) 8-[3-[N-(4-Cyanocinnamoylglycyl)-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.27 (3H, s), 3.68
(1H, dd, J=18, 4Hz), 3.95 (1H, dd, J=18, 5Hz),
5.65 (2H, s), 6.57 (1H, d, J=15Hz), 6.79 (1H, br
t, J=5Hz), 7.21-7.69 (11H, m), 8.03 (1H, d,
J=9Hz)

(17) 8-[2,6-Dichloro-3-[N-[4-[N-(2-methoxyethyl)-
acetamido]cinnamoylglycyl]-N-methylamino]benzyloxy]-
2-methylquinoline

NMR (CDCl₃, δ) : 1.85 (3H, s), 2.73 (3H, s), 3.26
(3H, s), 3.30 (3H, s), 3.51 (2H, t, J=6Hz), 3.65
(1H, dd, J=4, 16Hz), 3.86 (2H, t, J=6Hz), 3.95
(1H, dd, J=4, 16Hz), 5.65 (2H, s-like), 6.48
(1H, d, J=16Hz), 6.66 (1H, t-like), 7.17-7.35
(5H, m), 7.35-7.62 (6H, m), 8.03 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.85 (3H, s), 3.20-3.33 (9H,
m), 3.47 (2H, t, J=6Hz), 3.84 (2H, t, J=6Hz),
3.92 (1H, d, J=16Hz), 4.03 (1H, d, J=16Hz), 5.64

2122236

(2H, s), 6.61 (1H, d, J=16Hz), 7.16 (2H, d, J=8Hz), 7.43-7.92 (9H, m), 8.75 (1H, d, J=8Hz)

(18) 8-[2,6-Dichloro-3-[N-[4-[N-(2-methoxyethyl)-N-(isonicotinoyl)amino]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.25 (3H, s), 3.35 (3H, s), 3.58-3.70 (3H, m), 3.93 (1H, dd, J=4, 16Hz), 4.07 (2H, t, J=6Hz), 5.64 (2H, s-like), 6.40 (1H, d, J=16Hz), 6.64 (1H, br), 7.10 (2H, d, J=8Hz), 7.15 (2H, d, J=6Hz), 7.22-7.53 (9H, m), 8.03 (1H, d, J=8Hz), 8.47 (2H, d, J=6Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.14 (3H, s), 3.26 (3H, s), 3.36 (3H, s), 3.62 (2H, t-like), 3.86 (1H, d, J=16Hz), 4.03-4.17 (3H, m), 5.56 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.61 (1H, d, J=16Hz), 7.13 (2H, d, J=8Hz), 7.33 (1H, d, J=16Hz), 7.45 (2H, d, J=8Hz), 7.50-7.59 (2H, m), 7.63 (1H, d, J=8Hz), 7.71-7.93 (5H, m), 8.69 (2H, d, J=6Hz), 8.83 (1H, d, J=8Hz)

(19) 8-[2,6-Dichloro-3-[N-[(E)-3-(6-ethoxycarbonylpyridin-3-yl)acryloylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.45 (3H, t, J=7.5Hz), 2.72 (3H, s), 3.27 (3H, s), 3.70 (1H, dd, J=18, 4Hz), 3.94 (1H, dd, J=18, 4Hz), 4.49 (2H, q, J=7.5Hz), 5.59-5.70 (2H, m), 6.66 (1H, d, J=16Hz), 6.80 (1H, t-like), 7.22-7.35 (3H, m), 7.37-7.53 (3H, m), 7.60 (1H, d, J=16Hz), 7.88-7.94 (1H, m), 8.02 (1H, d, J=8Hz), 8.12 (1H, d, J=8Hz), 8.81-8.86 (1H, m)

2122236

(20) 8-[3-[N-[(E)-3-(6-Aminopyridin-3-yl)acryloyl]glycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

5 NMR (CDCl₃, δ) : 2.73 (3H, s), 3.27 (3H, s), 3.65
(1H, dd, J=17, 4Hz), 3.94 (1H, dd, J=17, 5Hz),
4.75 (2H, s), 5.64 (2H, s), 5.84 (1H, d,
J=10Hz), 6.30 (1H, d, J=15Hz), 6.48 (1H, d,
J=8.5Hz), 6.62 (1H, br t, J=4Hz), 7.23-7.35
10 (3H), 7.39-7.52 (4H), 7.60 (1H, dd, J=8.5,
1.5Hz), 8.02 (1H, d, J=8.5Hz), 8.16 (1H, d,
J=1.5Hz)

(21) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-cinnamoyl]glycyl]amino]benzyloxy]-3-methylquinoxaline

15 NMR (CDCl₃, δ) : 2.78 (3H, s), 3.02 (3H, d, J=5Hz),
3.28 (3H, s), 3.69 (1H, dd, J=17, 4Hz), 3.93
(1H, dd, J=17, 5Hz), 5.57 (2H, s), 6.18 (1H, br
d, J=5Hz), 6.52 (1H, d, J=15Hz), 6.68 (1H, br t,
J=4Hz), 7.27 (1H, overlapped with CDCl₃), 7.35
20 (1H, d, J=9Hz), 7.49-7.79 (8H), 8.73 (1H, s)

(22) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-cinnamoyl]glycyl]amino]benzyloxy]-2-methylquinoxaline

25 NMR (CDCl₃, δ) : 2.77 (3H, s), 3.02 (3H, d, J=5Hz),
3.28 (3H, s), 3.67 (1H, dd, J=17, 4Hz), 3.94
(1H, dd, J=17, 4Hz), 5.62 (2H, s), 6.20 (1H, br
d, J=5Hz), 6.53 (1H, d, J=16Hz), 6.69 (1H, br t,
J=4Hz), 7.29-7.38 (2H), 7.49-7.80 (8H), 8.74
30 (1H, s)

its hydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 2.89 (3H, s), 2.98 (3H, s),
3.29 (3H, s), 3.19 (1H, d, J=17Hz), 4.00 (1H, d,
J=17Hz), 5.65 (2H, s), 6.62 (1H, d, J=15Hz),
7.44-7.63 (6H), 7.75-7.91 (4H), 8.92 (1H, s)

(23) 8-[2,6-Dichloro-3-[N-[4-(dimethylcarbamoyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoxaline

mp : 109-116°C

5 NMR (CDCl₃, δ) : 2.77 (3H, s), 2.98 (3H, s), 3.11
(3H, s), 3.27 (3H, s), 3.67 (1H, dd, J=16.5,
3.0Hz), 3.95 (1H, dd, J=16.5, 3.0Hz), 5.62 (2H,
s), 6.51 (1H, d, J=15.0Hz), 6.68 (1H, br t,
J=3.0Hz), 7.28-7.36 (2H, m), 7.42 (2H, d,
10 J=8.5Hz), 7.48-7.70 (5H, m), 7.76 (1H, d,
J=8.5Hz), 8.74 (1H, s)

(24) 8-[2,6-Dichloro-3-[N-[4-(ethylcarbamoyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoxaline

mp : 199-202°C

15 NMR (CDCl₃, δ) : 1.26 (3H, t, J=7.5Hz), 2.77 (3H,
s), 3.27 (3H, s), 3.51 (2H, m), 3.66 (1H, dd,
J=16.5, 3.0Hz), 3.95 (1H, dd, J=16.5, 3.0Hz),
20 5.63 (2H, s), 6.15 (1H, br t, J=7.5Hz), 6.53
(1H, d, J=16.0Hz), 6.68 (1H, br t, J=3.0Hz),
7.28-7.36 (2H, m), 7.48-7.79 (8H, m), 8.73 (1H,
s)

(25) 8-[2,6-Dichloro-3-[N-[4-(methoxycarbonyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoxaline

25 NMR (CDCl₃, δ) : 2.77 (3H, s), 3.27 (3H, s), 3.65
(1H, dd, J=16.5, 2.5Hz), 3.90 (3H, s), 3.94 (1H,
30 dd, J=16.5, 2.5Hz), 5.62 (2H, s), 6.56 (1H, d,
J=15.0Hz), 6.69 (1H, br t, J=2.5Hz), 7.28-7.38
(2H, m), 7.47-7.79 (6H, m), 7.98-8.06 (2H, m),
8.73 (1H, s)

(26) 8-[3-[N-[4-(Acetamido)cinnamoylglycyl]-N-

methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoxaline

NMR (CDCl₃, δ) : 2.15 (3H, s), 2.76 (3H, s), 3.26 (3H, s), 3.64 (1H, dd, J=17, 4Hz), 3.92 (1H, dd, J=17, 5Hz), 5.61 (2H, s), 6.39 (1H, d, J=15Hz), 6.61 (1H, br t, J=4Hz), 7.28-7.35 (2H), 7.40-7.58 (6H), 7.62-7.71 (2H), 7.78 (1H, d, J=8Hz), 8.74 (1H, s)

10 (27) 8-[2,6-Dichloro-3-[N-[4-(methoxyacetamido)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoxaline

15 NMR (CDCl₃, δ) : 2.78 (3H, s), 3.28 (3H, s), 3.51 (3H, s), 3.65 (1H, dd, J=17, 4Hz), 3.94 (1H, dd, J=17, 5Hz), 4.02 (2H, s), 5.62 (2H, s), 6.41 (1H, d, J=15Hz), 6.59 (1H, br t, J=4Hz), 7.29-7.37 (2H), 7.44-7.70 (7H), 7.78 (1H, d, J=8Hz), 8.32 (1H, br s), 8.72 (1H, s)

20 (28) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-oxopyrrolidin-1-yl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoxaline

25 NMR (CDCl₃, δ) : 2.12-2.25 (2H), 2.63 (2H, t, J=7.5Hz), 2.78 (3H, s), 3.28 (3H, s), 3.65 (1H, dd, J=17, 4Hz), 3.85-4.00 (3H), 5.62 (2H, s), 6.43 (1H, d, J=15Hz), 6.59 (1H, br t, J=4Hz), 7.29-7.38 (2H), 7.48-7.70 (7H), 7.78 (1H, d, J=8Hz), 8.73 (1H, s)

30 (29) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-cinnamoylglycyl]amino]benzyloxy]cinnoline

35 NMR (CDCl₃, δ) : 3.02 (3H, d, J=5Hz), 3.29 (3H, s), 3.70 (1H, dd, J=17, 4Hz), 3.93 (1H, dd, J=17, 5Hz), 5.64 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.20 (1H, br d, J=5Hz), 6.53 (1H, d,

2122236

J=15Hz), 6.71 (1H, br t, J=4Hz), 7.31-7.39 (2H),
7.45-7.62 (5H), 7.70-7.78 (3H), 7.82 (1H, d,
J=7.5Hz), 9.34 (1H, d, J=6Hz)

5 (30) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinazoline
NMR (CDCl₃, δ) : 2.90 (3H, s), 3.02 (3H, d, J=5Hz),
3.28 (3H, s), 3.67 (1H, dd, J=18, 4Hz), 3.93
10 (1H, dd, J=18, 4Hz), 5.63 (2H, s), 6.20 (1H, br
d, J=5Hz), 6.52 (1H, d, J=16Hz), 6.68 (1H, br t,
J=4Hz), 7.33 (1H, d, J=7.5Hz), 7.41-7.62 (7H),
7.77 (2H, d, J=8Hz), 9.31 (1H, s)

15 (31) 8-[3-[N-Benzyl-N-[4-(methylcarbamoyl)-
cinnamoylglycyl]amino]-2,6-dichlorobenzyloxy]-2-
methylquinoline
NMR (CDCl₃, δ) : 2.74 (3H, s), 3.02 (3H, d, J=5Hz),
3.67 (1H, dd, J=17, 5Hz), 3.92 (1H, dd, J=17,
5Hz), 4.00 (1H, d, J=14Hz), 5.60-5.71 (3H), 6.19
20 (1H, m), 6.53 (1H, d, J=16Hz), 6.69-6.79 (2H),
6.69-6.79 (2H), 7.18-7.62 (13H), 7.75 (2H, d,
J=7.5Hz), 8.03 (1H, d, J=7.5Hz)

its hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 2.98 (3H, s), 3.10 (3H, s),
3.98 (2H, br s), 4.30 (1H, d, J=14Hz), 5.51 (1H,
d, J=14Hz), 5.59 (1H, d, J=10Hz), 5.75 (1H, d,
J=10Hz), 6.68 (1H, d, J=15Hz), 7.04 (1H, d,
J=7.5Hz), 7.21-7.33 (5H), 7.41 (1H, d, J=7.5Hz),
30 7.48 (1H, d, J=15Hz), 7.57 (2H, d, J=7.5Hz),
7.69 (1H, d, J=7.5Hz), 7.79-7.99 (5H), 8.95 (1H,
d, J=7.5Hz)

(32) 5,7-Dibromo-8-[2,6-dichloro-3-[N-methyl-N-[4-(methyl-
35 carbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-

2122236

methylquinoline

mp : 134-139°C

5 NMR (CDCl₃, δ) : 2.81 (3H, s), 3.03 (3H, d, J=5.5Hz), 3.23 (3H, s), 3.56 (1H, dd, J=16.5, 5.5Hz), 3.92 (1H, dd, J=16.5, 5.5Hz), 5.88 (1H, d, J=11.5Hz), 5.95 (1H, d, J=11.5Hz), 6.17 (1H, br q, J=5.5Hz), 6.52 (1H, d, J=16.0Hz), 6.64 (1H, br t, J=5.5Hz), 7.30 (1H, d, J=8.5Hz), 7.40 (1H, d, J=8.5Hz), 7.47 (1H, d, J=8.5Hz), 7.54 (2H, d, J=8.5Hz), 7.60 (1H, d, J=16.0Hz), 7.76 (2H, d, J=8.5Hz), 7.87 (1H, s), 8.33 (1H, d, J=8.5Hz)

15 its hydrochloride

mp : 121-126°C

20 NMR (CDCl₃-CD₃OD) : 2.93-3.07 (6H, m), 3.21 (3H, s), 3.59 (1H, d, J=16.5Hz), 3.96 (1H, d, J=16.5Hz), 5.88 (2H, s), 6.60 (1H, d, J=16.0Hz), 7.37 (1H, d, J=8.5Hz), 7.44-7.64 (6H, m), 7.70-7.80 (3H, m), 8.01 (1H, s), 8.61 (1H, d, J=8.5Hz)

(33) 8-[2,6-Dichloro-3-[N-[4-[N-methoxyacetyl-N-(3-pyridylmethyl)amino]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.75 (3H, s), 3.27 (3H, s), 3.35 (3H, s), 3.66 (1H, dd, J=4, 16Hz), 3.79 (2H, s), 3.95 (1H, dd, J=4, 16Hz), 4.49 (2H, s), 5.65 (2H, s-like), 6.46 (1H, d, J=16Hz), 6.66 (1H, t-like), 6.8 (2H, d, J=8Hz), 7.20-7.35 (4H, m), 7.37-7.58 (6H, m), 7.66 (1H, dd-like, J=8Hz), 8.03 (1H, d, J=8Hz), 8.35 (1H, d, J=2Hz), 8.51 (1H, dd, J=6, 2Hz)

35 its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.15 (3H, s), 3.28 (3H, s),

2122236

3.33 (3H, s), 3.85 (2H, s), 3.89 (1H, d, J=16Hz), 4.10 (1H, d, J=16Hz), 5.06 (2H, s), 5.59 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.67 (1H, d, J=16Hz), 7.10 (2H, d, J=8Hz), 7.43 (1H, d, J=16Hz), 7.51-7.67 (5H, m), 7.79 (1H, d, J=8Hz), 7.83-8.00 (3H, m), 8.53 (1H, d, J=8Hz), 8.70 (1H, s-like), 8.78 (1H, d, J=6Hz), 8.85 (1H, d, J=8Hz)

5

10

(34) 8-[3-[N-[(E)-3-(6-Acetamidopyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dichlorobenzoyloxy]-2-methylquinoline

mp : 133-139°C

15

NMR (CDCl₃, δ) : 2.22 (3H, s), 2.74 (3H, s), 3.27 (3H, s), 3.67 (1H, dd, J=16.5, 5.5Hz), 3.96 (1H, dd, J=16.5, 5.5Hz), 5.62 (1H, d, J=11.0Hz), 5.67 (1H, d, J=11.0Hz), 6.46 (1H, d, J=16.0Hz), 6.73 (1H, br t, J=5.5Hz), 7.21-7.33 (3H, m), 7.38-7.51 (3H, m), 7.52 (1H, d, J=16.0Hz), 7.82 (1H, dd, J=8.5, 1.5Hz), 8.03 (1H, d, J=8.5Hz), 8.13-8.25 (2H, m), 8.33 (1H, d, J=1.5Hz)

20

its dihydrochloride

mp : 153.5-158°C

25

NMR (DMSO-d₆, δ) : 2.12 (3H, s), 2.94 (3H, s), 3.16 (3H, s), 3.59 (1H, dd, J=16.5, 5.5Hz), 3.90 (1H, dd, J=16.5, 5.5Hz), 5.63 (1H, d, J=10.5Hz), 5.67 (1H, d, J=10.5Hz), 6.81 (1H, d, J=16.0Hz), 7.37 (1H, d, J=16.0Hz), 7.79-8.06 (6H, m), 8.10 (1H, d, J=8.5Hz), 8.30-8.40 (1H, m), 8.49 (1H, d, J=1.0Hz), 9.03 (1H, d, J=8.5Hz)

30

Example 53

35

The following compounds were obtained according to a similar manner to that of Example 20.

2122236

(1) 8-[3-[N-(4-Carboxycinnamoylglycyl)-N-methylamino]-
2,6-dichlorobenzyloxy]-2-methylquinoline

mp : 237.8-240.9°C

NMR (DMSO-d₆, δ) : 2.61 (3H, s), 3.15 (3H, s), 3.51
(1H, dd, J=4, 18Hz), 3.81 (1H, dd, J=4, 18Hz),
5.48 (1H, d, J=10Hz), 5.54 (1H, d, J=10Hz), 6.90
(1H, d, J=16Hz), 7.32-7.60 (5H, m), 7.64-7.75
(2H, m), 7.75-7.85 (2H, m), 7.96 (2H, d, J=8Hz),
8.21 (1H, d, J=8Hz), 8.35-8.44 (1H, m)

(2) 8-[3-[N-(3-Carboxycinnamoylglycyl)-N-methylamino]-
2,6-dichlorobenzyloxy]-2-methylquinoline

mp : 161°C

NMR (CDCl₃-CD₃OD, δ) : 2.70 (3H, s), 3.26 (3H, s),
3.65 (1H, d, J=16Hz), 4.00 (1H, d, J=16Hz), 5.58
(2H, s), 6.60 (1H, d, J=16Hz), 7.20-7.68 (9H,
m), 8.00 (1H, d, J=7.5Hz), 8.06 (1H, d, J=8Hz),
8.20 (1H, s-like)

(3) 8-[3-[N-[N'-(4-Carboxyphenyl)ureidoacetyl]-N-
methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

mp : 186-235°C

NMR (CDCl₃-CD₃OD, δ) : 2.70 (3H, s), 3.25 (3H, s),
3.85 (1H, d, J=16Hz), 3.93 (1H, d, J=16Hz), 5.52
(1H, d, J=10Hz), 5.60 (1H, d, J=10Hz), 7.25-7.60
(8H, m), 7.86 (2H, d, J=7.5Hz), 8.13-8.23 (1H,
m)

(4) 8-[3-[N-[(E)-3-(6-Carboxypyridin-3-yl)acryloyl-
glycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-
methylquinoline

NMR (DMSO-d₆, δ) : 2.58 (3H, s), 3.13 (3H, s), 3.50
(1H, dd, J=4, 16Hz), 3.80 (1H, dd, J=4, 16Hz),
5.46 (1H, d, J=10Hz), 5.53 (1H, d, J=10Hz), 6.95
(1H, d, J=16Hz), 7.30-7.57 (5H, m), 7.78 (2H,

2122236

s-like), 8.02 (1H, d, J=8Hz), 8.10 (1H, d, J=7.5Hz), 8.20 (1H, d, J=8Hz), 8.45 (1H, t-like), 8.85 (1H, s-like)

5 (5) 8-[3-[N-(4-Carboxycinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoxaline

10 NMR (CDCl₃, δ) : 2.77 (3H, s), 3.26 (3H, s), 3.62 (1H, dd, J=16.5, 2.5Hz), 3.99 (1H, dd, J=16.5, 2.5Hz), 5.60 (2H, s), 6.51 (1H, d, J=15.0Hz), 6.97 (1H, br s), 7.24-7.80 (8H, m), 7.93-8.07 (2H, m), 8.76 (1H, s)

Example 54

15 To a mixture of 8-[3-[N-(4-carboxycinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (100 mg), ethylamine hydrochloride (16.9 mg) and N,N-dimethylformamide (2 ml) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (32.2 mg) and 1-hydroxybenzotriazole (30.4 mg), and the mixture was
20 stirred for 6 hours at ambient temperature. The mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate solution and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was
25 purified by preparative thin-layer chromatography (methylene chloride - methanol) to give 8-[2,6-dichloro-3-[N-[4-(ethylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline (91 mg).

30 NMR (CDCl₃, δ) : 1.26 (3H, t, J=7.5Hz), 2.72 (3H, s), 3.29 (3H, s), 3.50 (2H, quint, J=7.5Hz), 3.68 (1H, dd, J=4, 18Hz), 3.96 (1H, dd, J=4, 18Hz), 5.58-5.70 (2H, m), 6.15 (1H, t-like), 6.54 (1H, d, J=16Hz), 6.73 (1H, t-like), 7.21-7.35 (2H, m), 7.35-7.62 (7H, m), 7.75 (2H, d, J=8Hz), 8.04 (1H, d, J=8Hz)

35

2122236

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.23 (3H, t, J=7.5Hz), 3.13 (3H, s), 3.30 (3H, s), 3.47 (2H, q, J=7.5Hz), 3.90 (1H, d, J=16Hz), 4.10 (1H, d, J=16Hz), 5.60 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.65 (1H, d, J=16Hz), 7.42 (1H, d, J=16Hz), 7.48-7.58 (4H, m), 7.63 (1H, d, J=7.5Hz), 7.70-7.84 (3H, m), 7.84-7.93 (2H, m), 8.87 (1H, d, J=8Hz)

10 Example 55

The following compounds were obtained according to similar manners to those of Examples 21 or 54.

(1) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

15 NMR (CDCl₃, δ) : 2.73 (3H, s), 3.00 (3H, d, J=5Hz), 3.26 (3H, s), 3.64 (1H, dd, J=4, 17Hz), 3.93 (1H, dd, J=4, 17Hz), 5.66 (2H, s), 6.28 (1H, q-like), 6.53 (1H, d, J=16Hz), 6.69 (1H, t-like), 7.18-7.64 (9H, m), 7.75 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)

its methanesulfonic acid salt

mp : 174.1-182.3°C

25 NMR (DMSO-d₆, δ) : 2.29 (3H, s), 2.78 (3H, d, J=5Hz), 2.85 (3H, br s), 3.15 (3H, s), 3.58 (1H, dd, J=17, 4Hz), 3.88 (1H, dd, J=17, 5Hz), 5.58 (1H, d, J=10Hz), 5.64 (1H, d, J=10Hz), 6.88 (1H, d, J=15Hz), 7.41 (1H, d, J=15Hz), 7.63 (2H, d, J=8Hz), 7.73-7.90 (7H), 8.34 (1H, br t, J=5Hz), 8.49 (1H, br d, J=5Hz), 8.83 (1H, br s)

its maleic acid salt

35 NMR (DMSO-d₆, δ) : 2.64 (3H, s), 2.77 (3H, d, J=6Hz), 3.14 (3H, s), 3.51 (1H, d, J=17 and 6Hz), 3.81 (1H, dd, J=17, 5Hz), 5.49 (1H, d,

J=9Hz), 5.54 (1H, d, J=9Hz), 6.22 (2H, s), 6.86 (1H, d, J=15Hz), 7.35-7.70 (7H, m), 7.72-7.90 (4H, m), 8.23-8.40 (2H, m), 8.42-8.54 (1H, m)

- 5 (2) 8-[3-[N-(4-Carbamoylcinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.72 (3H, s), 3.27 (3H, s), 3.68 (1H, dd, J=4, 18Hz), 3.95 (1H, dd, J=4, 18Hz), 5.57-5.69 (2H, m), 6.54 (1H, d, J=16Hz), 6.77 (1H, t-like), 7.22-7.35 (2H, m), 7.38-7.63 (7H, m), 7.80 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)
- 10

its hydrochloride

- NMR (CDCl₃-CD₃OD, δ) : 3.13 (3H, s), 3.30 (3H, s), 3.90 (1H, d, J=16Hz), 4.07 (1H, d, J=16Hz), 5.59 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.67 (1H, d, J=16Hz), 7.44 (1H, d, J=16Hz), 7.49-7.69 (5H, m), 7.77-7.95 (5H, m), 8.89 (1H, d, J=8Hz)
- 15

- 20 (3) 8-[2,6-Dichloro-3-[N-[4-(N-ethyl-N-methylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 1.06-1.29 (3H, m), 2.73 (3H, s), 2.94 (3/2H, br s), 3.06 (3/2H, br s), 3.26 (3H, s), 3.45-3.73 (3H, m), 3.95 (1H, dd, J=4, 18Hz), 5.64 (2H, s), 6.50 (1H, d, J=16Hz), 6.68 (1H, t-like), 7.20-7.61 (11H, m), 8.03 (1H, d, J=8Hz)
- 25

its hydrochloride

- NMR (CDCl₃-CD₃OD, δ) : 1.10-1.33 (3H, m), 2.93-3.12 (6H, m), 3.50-3.66 (2H, m), 3.90 (1H, d, J=16Hz), 3.99 (1H, d, J=16Hz), 5.65 (1H, d, J=10Hz), 5.83 (1H, d, J=10Hz), 6.70 (1H, d, J=16Hz), 7.35-7.73 (7H, m), 7.76-8.01 (4H, m), 9.01 (1H, d, J=8Hz)
- 30
- 35

2122236

(4) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(1-pyrrolidinyl-carbonyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

5 NMR (CDCl₃, δ) : 1.83-2.03 (4H, m), 2.74 (3H, s),
3.28 (3H, s), 3.43 (2H, t, J=7Hz), 3.60-3.74
(3H, m), 3.95 (1H, dd, J=4, 18Hz), 7.22-7.61
(11H, m), 8.03 (1H, d, J=8Hz)

its hydrochloride

10 NMR (CDCl₃-CD₃OD, δ) : 1.80-2.05 (4H, m), 3.15 (3H,
s), 3.30 (3H, s), 3.30-3.72 (4H, m), 3.88 (1H,
d, J=16Hz), 4.03 (1H, d, J=16Hz), 5.61 (1H, d,
J=10Hz), 5.71 (1H, d, J=10Hz), 6.64 (1H, d,
J=16Hz), 7.40-7.70 (8H, m), 7.73-7.96 (3H, m),
15 8.89 (1H, d, J=8Hz)

(5) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(morpholino-carbonyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

20 NMR (CDCl₃, δ) : 2.75 (3H, s), 3.27 (3H, s), 3.55-
3.85 (9H, m), 3.94 (1H, dd, J=4, 18Hz), 5.60-
5.70 (2H, m), 6.51 (1H, d, J=16Hz), 6.66 (1H, t-
like), 7.21-7.34 (2H, m), 7.37-7.61 (9H, m),
8.03 (1H, d, J=8Hz)

25 its hydrochloride

30 NMR (CDCl₃-CD₃OD, δ) : 3.20 (3H, s), 3.31 (3H, s),
3.56-3.84 (8H, m), 3.90 (1H, d, J=16Hz), 4.03
(1H, d, J=16Hz), 5.63 (1H, d, J=10Hz), 5.70 (1H,
d, J=10Hz), 7.33-7.63 (8H, m), 7.73-7.93 (3H,
m), 8.85 (1H, d, J=8Hz)

(6) 8-[2,6-Dichloro-3-[N-[4-(3-methoxypropylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

35

2122236

NMR (CDCl₃, δ) : 1.81-1.96 (2H, m), 2.74 (3H, s),
3.27 (3H, s), 3.40 (3H, s), 3.51-3.71 (5H, m),
3.88-4.00 (1H, m), 5.65 (2H, s), 6.53 (1H, d,
J=16Hz), 6.60-6.70 (1H, m), 6.90-7.00 (1H, m),
7.20-7.63 (9H, m), 7.74 (2H, d, J=8Hz), 8.03
(1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.90 (2H, quint, J=7Hz), 3.16
(3H, s), 3.29 (3H, s), 3.55 (4H, q-like), 3.90
(1H, d, J=16Hz), 4.08 (1H, d, J=16Hz), 5.61 (1H,
d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.66 (1H, d,
J=16Hz), 7.41-7.93 (11H, m), 8.85 (1H, d, J=8Hz)

(7) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(3-pyridylmethyl)-
carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 2.69 (3H, s), 3.27 (3H, s), 3.67
(1H, dd, J=4, 18Hz), 3.93 (1H, dd, J=4, 18Hz),
4.64 (2H, d, J=6Hz), 5.63 (2H, s), 6.54 (1H, d,
J=16Hz), 6.66-6.77 (1H, m), 7.19-7.33 (5H, m),
7.38-7.63 (6H, m), 7.63-7.82 (3H, m), 8.03 (1H,
d, J=8.4Hz), 8.51-8.59 (2H, m)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.09 (3H, s), 3.28 (3H, s),
3.90 (1H, d, J=16Hz), 4.09 (1H, d, J=16Hz), 4.77
(2H, s), 5.58 (1H, d, J=10Hz), 5.72 (1H, d,
J=10Hz), 6.63 (1H, d, J=16Hz), 7.39 (1H, d,
J=16Hz), 7.48 (2H, d, J=7.5Hz), 7.56 (2H, s-
like), 7.65 (1H, d, J=7.5Hz), 7.77-7.97 (6H, m),
8.65 (2H, d, J=6Hz), 8.89 (1H, d, J=8Hz), 8.95
(1H, s)

(8) 8-[2,6-Dichloro-3-[N-[4-[N-(2-methoxyethyl)-N-

2122236

methylcarbamoyl]cinnamoylglycyl]-N-
methyldamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 2.99-3.15 (3H, m),
3.27 (3H, s), 3.32-3.48 (2H, m), 3.59-3.75 (3H,
5 m), 3.95 (1H, dd, J=4, 18Hz), 5.65 (2H, s), 6.50
(1H, d, J=16Hz), 6.66 (1H, t-like), 7.20-7.61
(11H, m), 8.03 (1H, d, J=8Hz)

its hydrochloride

10 NMR (CDCl₃-CD₃OD, δ) : 3.00-3.13 (3H, m), 3.15 (3H,
s), 3.30 (3H, s), 3.36-3.50 (2H, m), 3.64-3.76
(2H, m), 3.88 (1H, d, J=16Hz), 3.99 (1H, d,
J=16Hz), 5.61 (1H, d, J=10Hz), 5.72 (1H, d,
J=10Hz), 6.62 (1H, d, J=16Hz), 7.39 (2H, d,
15 J=7.5Hz), 7.43-7.68 (6H, m), 7.77-7.93 (3H, m),
8.89 (1H, d, J=8Hz)

(9) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(n-propylcarbamoyl)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

20 NMR (CDCl₃, δ) : 0.92 (3H, t, J=7.5Hz), 1.55-1.70
(2H, m), 2.73 (3H, s), 3.27 (3H, s), 3.43 (2H,
q, J=7.5Hz), 3.66 (1H, dd, J=4, 16Hz), 3.95 (1H,
dd, J=4, 16Hz), 5.66 (2H, s), 6.13 (1H, t-like),
6.55 (1H, d, J=16Hz), 6.69 (1H, t-like), 7.23-
25 7.35 (3H, m), 7.38-7.63 (6H, m), 7.75 (2H, d,
J=7.5Hz), 8.03 (1H, d, J=8Hz)

its hydrochloride

30 NMR (CDCl₃-CD₃OD, δ) : 0.98 (3H, t, J=7.5Hz), 1.57-
1.73 (2H, m), 3.16 (3H, s), 3.29 (3H, s), 3.34-
3.45 (2H, m), 3.89 (1H, d, J=16Hz), 4.11 (1H, d,
J=16Hz), 5.60 (1H, d, J=10Hz), 5.69 (1H, d,
J=10Hz), 6.65 (1H, d, J=16Hz), 7.37-7.65 (6H,
m), 7.65-7.92 (5H, m), 8.84 (1H, d, J=8Hz)

35

(10) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(3-pyridyl-carbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

5 NMR (CDCl₃, δ) : 2.69 (3H, s), 3.23 (3H, s), 3.65
(1H, dd, J=4, 16Hz), 3.93 (1H, dd, J=4, 16Hz),
5.64 (2H, s), 6.55 (1H, d, J=16Hz), 6.73 (1H, t-
like), 7.23-7.39 (4H, m), 7.39-7.51 (3H, m),
7.51-7.65 (3H, m), 7.92 (2H, d, J=7.5Hz), 8.05
10 (1H, d, J=8Hz), 8.32 (1H, d, J=8Hz), 8.39 (1H,
d, J=6Hz), 8.45 (1H, s), 8.72 (1H, s-like)

its dihydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 3.13 (3H, s), 3.30 (3H, s),
3.91 (1H, d, J=16Hz), 4.15 (1H, d, J=16Hz), 5.59
(1H, d, J=10Hz), 5.74 (1H, d, J=10Hz), 6.66 (1H,
d, J=16Hz), 7.32 (1H, d, J=16Hz), 7.48 (2H, d,
J=7.5Hz), 7.53-7.70 (3H, m), 7.78-7.98 (4H, m),
8.07 (2H, d, J=7.5Hz), 8.47 (6H, d), 8.90 (1H,
d, J=7.5Hz), 9.25 (1H, d, J=7.5Hz), 9.63 (1H, s-
20 like)

(11) 8-[2,6-Dichloro-3-[N-[4-(2-hydroxyethylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.70 (3H, s), 3.26 (3H, s), 3.53-
3.63 (2H, m), 3.65-3.82 (3H, m), 3.97 (1H, dd,
J=4, 16Hz), 5.60 (1H, d, J=10Hz), 5.67 (1H, d,
J=10Hz), 6.51 (1H, d, J=16Hz), 6.75 (1H, t-
like), 6.93 (1H, t-like), 7.20-7.37 (3H, m),
30 7.37-7.56 (6H, m), 7.75 (2H, d, J=8Hz), 8.03
(1H, d, J=8Hz)

its hydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.28 (3H, s),
3.57 (2H, t, J=6Hz), 3.79 (2H, t, J=6Hz), 3.90

2122236

(1H, d, J=16Hz), 4.11 (1H, d, J=16Hz), 5.59 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.60 (1H, d, J=16Hz), 7.35 (1H, d, J=16Hz), 7.43 (2H, d, J=8Hz), 7.49-7.58 (2H, m), 7.63 (1H, d, J=8Hz), 7.75-7.93 (5H, m), 8.87 (1H, d, J=8Hz)

(12) 8-[2,6-Dichloro-3-[N-[4-(2-ethoxyethylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.20 (3H, t, J=7.5Hz), 2.73 (3H, s), 3.25 (3H, s), 3.47-3.71 (7H, m), 3.95 (1H, dd, J=4, 16Hz), 5.60-5.70 (2H, m), 6.49-6.60 (2H, m), 6.67 (1H, t-like), 7.22-7.33 (3H, m), 7.33-7.64 (6H, m), 7.76 (2H, d, J=7.5Hz), 8.03 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.23 (3H, t, J=7.5Hz), 3.15 (3H, s), 3.30 (3H, s), 3.57 (2H, q), 3.63 (4H, s-like), 3.90 (1H, d, J=16Hz), 4.05 (1H, d, J=16Hz), 5.62 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 6.66 (1H, d, J=16Hz), 7.43-7.69 (6H, m), 7.73-7.94 (5H, m), 8.49 (1H, d, J=8Hz)

(13) 8-[3-[N-[4-[N,N-Bis(2-ethoxyethyl)carbamoyl]-cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.11-1.25 (6H, m), 2.73 (3H, s), 3.26 (3H, s), 3.30-3.80 (13H, m), 3.95 (1H, dd, J=4, 16Hz), 5.60-5.70 (2H, m), 6.49 (1H, d, J=16Hz), 6.64 (1H, t-like), 7.23-7.33 (3H, m), 7.33-7.63 (8H, m), 8.01 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.00-1.30 (6H, m), 3.01 (3H,

2122236

s), 3.17-3.82 (15H, m), 3.89 (2H, s), 5.61 (1H, d, J=10Hz), 5.77 (1H, d, J=10Hz), 6.63 (1H, d, J=16Hz), 7.35-7.71 (6H, m), 7.71-8.01 (5H, m), 8.96 (1H, d, J=8Hz)

5

(14) 8-[2,6-Dichloro-3-[N-[4-[2-(dimethylamino)-ethylcarbamoyl]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 2.30 (6H, s), 2.55 (2H, t, J=6Hz),
2.73 (3H, s), 3.28 (3H, s), 3.54 (2H, q, J=6Hz),
3.67 (1H, dd, J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz), 5.65 (2H, s-like), 6.53 (1H, d, J=16Hz),
6.69 (1H, t-like), 6.95 (1H, t-like), 7.22-7.35 (3H, m), 7.35-7.63 (6H, m), 7.80 (2H, d, J=7.5Hz),
15 8.02 (1H, d, J=8Hz)

its dihydrochloride

20 NMR (CD₃OD, δ) : 2.92-3.03 (9H, m), 3.35-3.47 (2H, m), 3.72-3.91 (3H, m), 4.01 (1H, d, J=16Hz),
5.71 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.80 (1H, d, J=16Hz), 7.55 (1H, d, J=16Hz), 7.62-7.75 (4H, m), 7.86-8.00 (6H, m), 9.03 (1H, d, J=8Hz)

25 (15) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(2-pyridylmethyl)-carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.73 (3H, s), 3.27 (3H, s), 3.66 (1H, dd, J=3, 16Hz), 3.95 (1H, dd, J=4, 16Hz),
4.75 (2H, d, J=5Hz), 5.63 (2H, s-like), 6.54 (1H, d, J=16Hz), 6.70-6.77 (1H, m), 7.18-7.36 (5H, m), 7.36-7.75 (8H, m), 7.87 (2H, d, J=7.5Hz), 8.03 (1H, d, J=8Hz), 8.08 (1H, d, J=5Hz)

35

its dihydrochloride

NMR (CD₃OD, δ) : 3.00 (3H, s), 3.27 (3H, s), 3.84
(1H, d, J=16Hz), 4.00 (1H, d, J=16Hz), 4.91 (2H,
s), 5.73 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz),
6.81 (1H, d, J=16Hz), 7.55 (1H, d, J=16Hz),
7.63-7.76 (4H, m), 7.90-8.05 (7H, m), 8.09 (1H,
d, J=7.5Hz), 8.61 (1H, t, J=7.5Hz), 8.79 (1H, d,
J=7.5Hz), 9.04 (1H, d, J=7.5Hz)

(16) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(4-pyridylmethyl)-
carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 2.70 (3H, s), 3.24 (3H, s), 3.66
(1H, dd, J=3, 16Hz), 3.93 (1H, dd, J=4, 16Hz),
4.65 (2H, d, J=6Hz), 5.64 (2H, s-like), 6.54
(1H, d, J=16Hz), 6.66-6.75 (1H, m), 7.19-7.34
(6H, m), 7.34-7.51 (3H, m), 7.51-7.63 (3H, m),
7.81 (2H, d, J=8Hz), 8.01 (1H, d, J=8Hz), 8.50-
8.60 (2H, m)

its dihydrochloride

NMR (CD₃OD, δ) : 3.01 (3H, s), 3.85 (1H, d, J=16Hz),
4.01 (1H, d, J=16Hz), 5.73 (1H, d, J=10Hz), 5.82
(1H, d, J=10Hz), 6.80 (1H, d, J=16Hz), 7.54 (1H,
d, J=16Hz), 7.63-7.75 (4H, m), 7.87-7.99 (6H,
m), 8.06 (2H, d, J=6Hz), 8.80 (2H, d, J=6Hz),
9.04 (1H, d, J=7.5Hz)

(17) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(1,2,3,6-tetrahydro-
pyridin-1-ylcarbonyl)cinnamoylglycyl]amino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.10-2.33 (2H, m), 2.73 (3H, s),
3.26 (3H, s), 3.37-3.53 (1H, m), 3.65 (1H, dd,
J=4, 16Hz), 3.75-4.00 (3H, m), 4.12-4.26 (1H,
m), 5.64 (2H, s), 5.67-5.94 (2H, m), 6.50 (1H,
d, J=16Hz), 6.68 (1H, t-like), 7.20-7.35 (2H,

m), 7.35-7.63 (9H, m), 8.02 (1H, d, J=8Hz)

its hydrochloride

NMR (CD₃OD, δ) : 2.15-2.31 (2H, m), 3.00 (3H, s),
5 3.27 (3H, s), 3.34-3.56 (2H, m), 3.81-4.06 (3H,
m), 4.17 (1H, s-like), 5.54-5.96 (4H, m), 6.76
(1H, d, J=16Hz), 7.41-7.74 (7H, m), 7.88-7.99
(4H, m), 9.03 (1H, d, J=8Hz)

10 (18) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(piperidino-
carbonyl)cinnaoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 1.43-1.73 (6H, m), 2.73 (3H, s),
15 3.26 (3H, s), 3.29-3.43 (2H, m), 3.60-3.75 (3H,
m), 3.95 (1H, dd, J=4, 16Hz), 5.66 (2H, s-like),
6.50 (1H, d, J=16Hz), 6.66 (1H, t-like), 7.20-
7.61 (11H, m), 8.03 (1H, d, J=8Hz)

its hydrochloride

20 NMR (CD₃OD, δ) : 1.48-1.60 (2H, m), 1.60-1.78 (4H,
m), 3.00 (3H, s), 3.33-3.45 (2H, m), 3.64-3.76
(2H, m), 3.85 (1H, d, J=16Hz), 4.01 (1H, d,
J=16Hz), 5.70 (1H, d, J=10Hz), 5.82 (1H, d,
J=10Hz), 6.74 (1H, d, J=16Hz), 7.40 (2H, d,
25 J=8Hz), 7.50 (1H, d, J=16Hz), 7.64 (2H, d,
J=8Hz), 7.72 (2H, s-like), 7.87-7.99 (4H, m),
9.03 (1H, d, J=8Hz)

30 (19) 8-[2,6-Dichloro-3-[N-[4-[(2-furylmethyl)carbamoyl]-
cinnaoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 2.71 (3H, s), 3.26 (3H, s), 3.65
(1H, dd, J=4, 16Hz), 3.94 (1H, dd, J=4, 16Hz),
4.14 (2H, d, J=5Hz), 5.64 (2H, s-like), 6.26-
35 6.30 (1H, m), 6.30-6.35 (1H, m), 6.45-6.58 (2H,

m), 6.69 (1H, t-like), 7.23-7.33 (4H, m), 7.33-7.61 (6H, m), 7.78 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)

5 its hydrochloride

NMR (CD₃OD, δ) : 3.00 (3H, s), 3.85 (1H, d, J=16Hz),
4.00 (1H, d, J=16Hz), 4.56 (2H, s), 5.70 (1H, d, J=10Hz), 5.81 (1H, d, J=10Hz), 6.26-6.32 (1H, m), 6.32-6.39 (1H, m), 6.75 (1H, d, J=16Hz),
10 7.43 (1H, d, J=2Hz), 7.51 (1H, d, J=16Hz), 7.57-7.77 (4H, m), 7.77-8.02 (6H, m), 8.02 (1H, d, J=8Hz)

(20) 8-[3-[N-[4-(Allylcarbamoyl)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

15 NMR (CDCl₃, δ) : 2.73 (3H, s), 3.25 (3H, s), 3.65 (1H, dd, J=4, 16Hz), 3.94 (1H, dd, J=4, 16Hz), 4.09 (2H, t-like), 5.20 (1H, d, J=11Hz), 5.26 (1H, d, J=18Hz), 5.65 (2H, s), 5.85-6.02 (1H, m),
20 6.20 (1H, t-like), 6.53 (1H, d, J=16Hz), 6.69 (1H, t-like), 7.22-7.33 (3H, m), 7.33-7.63 (6H, m), 7.77 (2H, d, J=7.5Hz), 8.03 (1H, d, J=8Hz)

25 its hydrochloride

NMR (CD₃OD, δ) : 2.99 (3H, s), 3.85 (1H, d, J=16Hz),
3.91-4.05 (3H, m), 5.14 (1H, d, J=11Hz), 5.23 (1H, d, J=18Hz), 5.71 (1H, d, J=10Hz), 5.82 (1H, d, J=10Hz), 5.85-6.02 (1H, m), 6.76 (1H, d, J=16Hz),
30 7.47-7.75 (5H, m), 7.80-8.00 (6H, m), 9.03 (1H, d, J=8Hz)

(21) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-propynylcarbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

35

2122236

NMR (CDCl₃, δ) : 2.27 (1H, s), 2.72 (3H, s), 3.25 (3H, s), 3.66 (1H, dd, J=4, 16Hz), 3.93 (1H, dd, J=4, 16Hz), 4.25 (2H, t-like), 5.60-5.69 (2H, m), 6.40 (1H, t-like), 6.55 (1H, d, J=16Hz), 6.70 (1H, t-like) 7.23-7.34 (3H, m), 7.37-7.63 (6H, m), 7.78 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.28 (1H, t-like), 3.15 (3H, s), 3.29 (3H, s), 3.90 (1H, d, J=16Hz), 4.12 (1H, d, J=16Hz), 4.21 (2H, d-like), 5.60 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.67 (1H, d, J=16Hz), 7.36-7.65 (6H, m), 7.70-7.92 (5H, m), 8.85 (1H, d, J=7.5Hz)

(22) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(2-thienylmethyl)-carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.27 (3H, s), 3.65 (1H, dd, J=4, 16Hz), 3.94 (1H, dd, J=4, 16Hz), 4.83 (2H, d, J=6Hz), 5.66 (2H, s-like), 6.46-6.58 (2H, m), 6.70 (1H, t-like), 6.98 (1H, t, J=5Hz), 7.00-7.06 (1H, m), 7.20-7.34 (4H, m), 7.34-7.62 (6H, m), 7.79 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.13 (3H, s), 3.28 (3H, s), 3.89 (1H, d, J=16Hz), 4.09 (1H, d, J=16Hz), 4.77 (2H, s), 5.59 (1H, d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.66 (1H, d, J=16Hz), 6.96 (1H, t, J=5Hz), 7.06 (1H, d-like), 7.23 (1H, d, J=5Hz), 7.43 (1H, d, J=16Hz), 7.48-7.57 (4H, m), 7.63 (1H, d, J=7.5Hz), 7.71-7.82 (3H, m), 7.82-7.92

2122236

(2H, m), 8.84 (1H, d, J=8Hz)

(23) 8-[2,6-Dichloro-3-[N-methyl-N-[3-(methylcarbamoyl)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

5 NMR (CDCl₃, δ) : 2.70 (3H, s), 2.99 (3H, d-like),
3.25 (3H, s), 3.66 (1H, dif.-dd, J=16Hz), 3.95
(1H, dif.-dd, J=16Hz), 5.65 (2H, s), 6.45-6.60
(2H, m), 6.81-6.90 (1H, m), 7.21-7.69 (9H, m),
7.75 (1H, d, J=8Hz), 7.87 (1H, s-like), 8.04
10 (1H, d, J=7.5Hz)

its hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 3.00 (3H, s), 3.19 (3H, s),
3.28 (3H, s), 3.86 (1H, d, J=16Hz), 4.28 (1H, d,
J=16Hz), 5.55 (1H, d, J=10Hz), 5.72 (1H, d,
J=10Hz), 6.72 (1H, d, J=16Hz), 7.32-7.48 (3H,
m), 7.48-7.69 (3H, m), 7.73-7.96 (4H, m), 8.18
(1H, s-like) 8.87 (8H, d)

20 (24) 8-[3-[N-[N'-(3-Carbamoylphenyl)ureidoacetyl]-N-
methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.70 (3H, s), 3.28 (3H, s), 3.65
(1H, d, J=17Hz), 3.90 (1H, d, J=17Hz), 5.59 (2H,
s), 7.21-7.61 (9H), 7.81 (1H, br s), 8.10 (1H,
d, J=9Hz)

its hydrochloride

30 NMR (CDCl₃-CD₃OD, δ) : 2.94 (3H, s), 3.29 (3H, s),
3.80-4.10 (2H, overlapped with H₂O), 5.59 (1H,
d, J=10Hz), 5.79 (1H, d, J=10Hz), 7.20 (1H, t,
J=8Hz), 7.31-7.98 (9H), 8.89 (1H, d, J=9Hz)

(25) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(3-
propylcarbamoylphenyl)ureidoacetyl]amino]benzyloxy]-
2-methylquinoline

35

2122236

NMR (CDCl₃, δ) : 0.86 (3H, t, J=7.5Hz), 1.42-1.55
(2H, m), 2.56 (3H, s), 3.18 (3H, s), 3.21-3.35
(2H, m), 3.80 (1H, dd, J=4, 16Hz), 4.16 (1H, dd,
J=7, 16Hz), 5.45 (1H, d, J=9Hz), 5.61 (1H, d,
J=9Hz), 5.64-5.72 (1H, m), 6.29 (1H, t-like),
7.10 (1H, t, J=7.5Hz), 7.17-7.40 (6H, m), 7.42-
7.49 (2H, m), 7.54-7.59 (1H, m), 8.05 (1H, d,
J=8Hz), 8.44 (1H, s)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 0.92 (3H, t, J=7.5Hz), 1.50-
1.64 (2H, m), 2.81 (3H, s), 3.15-3.29 (5H, m),
3.85 (1H, d, J=16Hz), 4.28 (1H, d, J=16Hz), 5.59
(1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 7.02 (1H,
t, J=7.5Hz), 7.26-7.39 (2H, m), 7.51 (1H, d,
J=7.5Hz), 7.55-7.65 (3H, m), 7.65-7.78 (2H, m),
7.78 (1H, t, J=7.5Hz), 8.75 (1H, d, J=7.5Hz)

(26) 8-[2,6-Dichloro-3-[N-[N'-[3-(2-
hydroxyethylcarbamoyl)phenyl]ureidoacetyl]-N-
methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.67 (3H, s), 3.23 (3H, s), 3.47-
3.56 (2H, m), 3.69-3.82 (3H, m), 3.83-3.93 (2H,
m), 5.56 (1H, d, J=10Hz), 5.65 (1H, d, J=10Hz),
6.04-6.16 (1H, m), 7.06-7.17 (2H, m), 7.17-7.54
(9H, m), 8.05 (1H, d, J=8Hz), 8.03 (1H, s)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.25 (3H, s), 3.42-3.51 (2H,
m), 3.72 (2H, t, J=6Hz), 3.88 (1H, d, J=16Hz),
4.19 (1H, d, J=16Hz), 5.58 (1H, d, J=10Hz), 5.74
(1H, d, J=10Hz), 7.04 (1H, t, J=7.5Hz), 7.28-
7.44 (3H, m), 7.48-7.82 (5H, m), 7.87 (1H, t,
J=7.5Hz), 8.79 (1H, d, J=8Hz)

2122236

(27) 8-[2,6-Dichloro-3-[N-[N'-[3-(2-ethoxyethylcarbamoyl)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

5 NMR (CDCl₃, δ) : 1.20 (3H, t, J=7.5Hz), 2.61 (3H, s), 3.24 (3H, s), 3.43-3.62 (6H, m), 3.81 (1H, dd, J=4, 16Hz), 4.25 (1H, dd, J=7.5, 16Hz), 5.47 (1H, d, J=10Hz), 5.58-5.70 (2H, m), 6.60 (1H, br s), 7.17 (1H, t, J=7.5Hz), 7.21-7.38 (6H, m), 7.41-7.50 (2H, m), 7.64-7.70 (1H, m), 8.08 (1H, d, J=7.5Hz), 8.48 (1H, s)

10

its hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 1.19 (3H, t, J=7.5Hz), 2.84 (3H, s), 3.26 (3H, s), 3.30-3.61 (6H, m), 3.85 (1H, d, J=16Hz), 4.26 (1H, d, J=16Hz), 5.58 (1H, d, J=10Hz), 5.73 (1H, d, J=10Hz), 7.09 (1H, t, J=7.5Hz), 7.25-7.33 (1H, m), 7.39 (1H, d, J=7.5Hz), 7.53 (1H, d, J=8Hz), 7.57-7.70 (3H, m), 7.70-7.80 (2H, m), 7.87 (1H, t, J=8Hz), 8.78 (1H, d, J=8Hz)

20

(28) 8-[2,6-Dichloro-3-[N-[N'-[4-(dimethylcarbamoyl)-phenyl]ureidoacetyl]-N-methylamino]benzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.59 (3H, s), 3.01 (6H, br s), 3.22 (3H, s), 3.78 (1H, dd, J=4, 16Hz), 4.37 (1H, dd, J=7.5, 16Hz), 5.42 (1H, d, J=10Hz), 5.47-5.55 (1H, m), 5.62 (1H, d, J=10Hz), 7.16-7.37 (8H, m), 7.44-7.54 (2H, m), 8.10 (1H, d, J=8Hz), 7.71 (1H, s)

30

its hydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 2.92 (3H, s), 3.25 (3H, s), 3.85 (1H, d, J=16Hz), 4.13 (1H, d, J=16Hz), 5.60 (1H, d, J=10Hz), 5.75 (1H, d, J=10Hz), 7.19 (2H,

2122236

d, J=8Hz), 7.28-7.42 (2H, m), 7.48-7.70 (3H, m),
7.70-7.95 (3H, m), 8.83 (1H, d, J=8Hz)

(29) 8-[3-[N-[N'-(3-Ethylcarbamoylphenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.16 (3H, t, J=7.5Hz), 2.63 (3H, s), 3.20 (3H, s), 3.38 (2H, dq, J=7.5, 5Hz), 3.81 (1H, dd, J=17, 5Hz), 4.00 (1H, dd, J=17, 6Hz), 5.51 (1H, d, J=9Hz), 5.63 (1H, d, J=9Hz), 5.95 (1H, br t, J=5Hz), 6.57 (1H, br t, J=5Hz), 7.13 (1H, t, J=8Hz), 7.20-7.41 (6H, m), 7.45 (2H, d, J=5Hz), 7.55 (1H, br s), 8.06 (1H, d, J=9Hz), 8.48 (1H, br s)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.22 (3H, t, J=7.5Hz), 2.97 (3H, s), 3.30 (3H, s), 3.40 (2H, q, J=7.5Hz), 3.86 (2H, s), 5.60 (1H, d, J=9Hz), 5.82 (1H, d, J=9Hz), 7.24 (1H, t, J=8Hz), 7.30-7.46 (2H, m), 7.58 (1H, d, J=7Hz), 7.65 (1H, d, J=7Hz), 7.70-7.81 (2H, m), 7.81-8.01 (3H, m), 8.91 (1H, d, J=8Hz)

(30) 8-[2,6-Dichloro-3-[N-[4-[N-(2-ethoxyethyl)-N-methylcarbamoyl]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.11-1.26 (3H, m), 2.74 (3H, s), 3.03 (1.5H, br s), 3.10 (1.5H, br s), 3.28 (3H, s), 3.33-3.60 (4H, m), 3.60-3.75 (3H, m), 3.96 (1H, dd, J=4, 16Hz), 5.65 (2H, s-like), 6.50 (1H, d, J=16Hz), 6.65 (1H, t-like), 7.22-7.35 (3H, m), 7.35-7.46 (3H, m), 7.48 (1H, d, J=16Hz), 8.03 (1H, d, J=8Hz)

its hydrochloride

2122236

NMR (CDCl₃-CD₃OD, δ) : 1.13-1.27 (3H, m), 3.03
(1.5H, br s), 3.10 (1.5H, br s), 3.20 (3H, s),
3.30 (3H, s), 3.36-3.58 (4H, m), 3.71 (2H, br),
3.90 (1H, d, J=16Hz), 4.03 (1H, d, J=16Hz), 5.63
(1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.62 (1H,
d, J=16Hz), 7.36 (2H, d, J=8Hz), 7.40-7.57 (5H,
m), 7.61 (1H, d, J=8Hz), 7.76 (1H, d, J=8Hz),
7.80-7.90 (2H, m), 8.81 (1H, d, J=8Hz)

(31) 8-[2,6-Dichloro-3-[N-[4-[N-methyl-N-(2-
pyridylmethyl)carbamoyl]cinnamoylglycyl]-N-
methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.00 (1.5H, br s),
3.09 (1.5H, br s), 3.65 (1H, br d, J=16Hz), 3.94
(1H, br d, J=16Hz), 4.60 (1H, s), 4.87 (1H, s),
5.64 (1H, s-like), 6.41-6.59 (1H, m), 6.59-6.76
(1H, m), 7.14-7.36 (5H, m), 7.36-7.65 (8H, m),
7.71 (1H, td, J=8, 2Hz), 8.03 (1H, d, J=8Hz),
8.57 (1H, d, J=6Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.18 (3H, s), 3.25 (3H, s),
3.29 (3H, s), 3.90 (1H, d, J=16Hz), 4.06 (1H, d,
J=16Hz), 5.20 (2H, s), 5.61 (1H, d, J=10Hz),
5.70 (1H, d, J=10Hz), 6.67 (1H, d, J=16Hz),
7.41-7.59 (7H, m), 7.63 (1H, d, J=8Hz), 7.79
(1H, d, J=8Hz), 7.83-7.93 (3H, m), 8.01-8.11
(1H, m), 8.40-8.52 (1H, m), 8.81 (1H, d, J=6Hz),
8.85 (1H, d, J=8Hz)

(32) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-methylallyl-
carbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 1.80 (3H, s), 2.71 (3H, s), 3.25
(3H, s), 3.65 (1H, dd, J=4, 16Hz), 3.94 (1H, dd,

2122236

J=4, 16Hz), 4.02 (2H, d, J=6Hz), 4.85-4.93 (2H, m), 5.60-5.70 (2H, m), 6.21 (1H, t-like), 6.54 (1H, d, J=16Hz), 6.69 (1H, t-like), 7.22-7.36 (3H, m), 7.36-7.65 (6H, m), 7.79 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.78 (3H, s), 3.14 (3H, s), 3.29 (3H, s), 3.89 (1H, d, J=16Hz), 3.99 (2H, s), 4.10 (1H, d, J=16Hz), 4.90 (2H, d-like), 5.60 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.66 (1H, d, J=16Hz), 7.45 (1H, d, J=16Hz), 7.49-7.67 (5H, m), 7.67-7.94 (5H, m), 8.86 (1H, d, J=8Hz)

(33) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(methylcarbamoyl)pyridin-3-yl]acryloylglycyl]-amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.04 (3H, d, J=6Hz), 3.28 (3H, s), 3.61-3.75 (1H, m), 3.95 (1H, dd, J=4, 16Hz), 5.64 (2H, s), 6.64 (1H, d, J=16Hz), 6.76 (1H, br), 7.21-7.37 (3H, m), 7.37-7.54 (3H, m), 7.60 (1H, d, J=16Hz), 7.88-8.09 (3H, m), 8.19 (1H, d, J=8Hz), 8.62 (1H, d-like)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.00 (3H, s), 3.13 (3H, s), 3.25 (3H, s), 3.85 (1H, d, J=16Hz), 4.21 (1H, d, J=16Hz), 5.53 (1H, d, J=10Hz), 5.64 (1H, d, J=10Hz), 6.85 (1H, d, J=16Hz), 7.41-7.62 (4H, m), 7.73 (1H, d, J=8Hz), 7.78-7.88 (2H, m), 8.33 (2H, s-like), 8.80 (1H, d, J=8Hz), 9.00 (1H, br s)

(34) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(dimethylcarbamoyl)-pyridin-3-yl]acryloylglycyl]-N-methylamino]-

2122236

benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.09 (3H, s), 3.14 (3H, s), 3.28 (3H, s), 3.68 (1H, dd, J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz), 5.60-5.71 (2H, m), 6.60 (1H, d, J=16Hz), 6.75 (1H, t-like), 7.23-7.35 (3H, m), 7.35-7.68 (5H, m), 7.89 (1H, dd, J=8, 2Hz), 8.03 (1H, d, J=8Hz), 8.66 (1H, d-like)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.06 (3H, s), 3.08-3.16 (6H, m), 3.26 (3H, s), 3.85 (1H, d, J=16Hz), 4.35 (1H, d, J=16Hz), 5.51 (1H, d, J=10Hz), 5.65 (1H, d, J=10Hz), 6.97 (1H, d, J=16Hz), 6.44 (1H, d, J=16Hz), 7.50-7.66 (3H, m), 7.73 (1H, d, J=8Hz), 7.78-7.91 (3H, m), 8.70 (1H, br d, J=8Hz), 8.79 (1H, d, J=8Hz), 9.04 (1H, br s)

(35) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(ethylcarbamoyl)-pyridin-3-yl]acryloylglycyl]-N-methylamino]-benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.28 (3H, t, J=7.5Hz), 2.74 (3H, s), 3.28 (3H, s), 3.52 (2H, quint, J=7.5Hz), 3.70 (1H, dd, J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz), 5.65 (2H, s), 6.63 (1H, d, J=16Hz), 6.77 (1H, br), 7.20-7.36 (3H, m), 7.36-7.54 (3H, m), 7.61 (1H, d, J=16Hz), 7.88-8.00 (2H, m), 8.04 (1H, d, J=8Hz), 8.18 (1H, d, J=8Hz), 8.62 (1H, br)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.29 (3H, t, J=7.5Hz), 3.18 (3H, s), 3.30 (3H, s), 3.50 (2H, q, J=7.5Hz), 3.90 (1H, d, J=16Hz), 4.07 (1H, d, J=16Hz), 5.60 (1H, d, J=10Hz), 5.20 (1H, d, J=10Hz), 6.81 (1H, d, J=16Hz), 7.49-7.60 (3H, m), 7.64 (1H, d,

2122236

J=8Hz), 7.79 (1H, d, J=8Hz), 7.83-7.93 (2H, m),
8.09 (1H, d, J=8Hz), 8.17 (1H, d, J=8Hz), 8.74
(1H, br s), 8.86 (1H, d, J=8Hz)

- 5 (36) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(N-ethyl-N-
methylcarbamoyl)pyridin-3-yl]acryloylglycyl]-N-
methylamino]benzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 1.17 (3/2H, t, J=7.5Hz), 1.25
(3/2H, t, J=7.5Hz), 2.73 (3H, s), 3.03 (3/2H,
s), 3.10 (3/2H, s), 3.27 (3H, s), 3.41 (1H, q,
J=7.5Hz), 3.60 (1H, q, J=7.5Hz), 3.69 (1H, dd,
J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz), 5.60-5.67
15 (2H, m), 6.58 (1H, d, J=16Hz), 6.73 (1H, br),
7.19-7.35 (3H, m), 7.35-7.65 (5H, m), 7.88 (1H,
d, J=8Hz), 8.03 (1H, d, J=8Hz), 8.66 (1H, br s)

its dihydrochloride

20 NMR (CDCl₃-CD₃OD, δ) : 1.22 (1.5H, t, J=7.5Hz), 1.27
(1.5H, t, J=7.5Hz), 3.05 (1.5H, s), 3.11 (1.5H,
s), 3.15 (3H, s), 3.29 (3H, s), 3.33-3.46 (1H,
m), 3.60 (1H, q, J=7.5Hz), 3.87 (1H, d, J=16Hz),
4.32 (0.5H, d, J=16Hz), 4.39 (0.5H, d, J=16Hz),
5.01-5.10 (1H, m), 5.69 (1H, d, J=10Hz), 6.94
25 (0.5H, d, J=16Hz), 7.00 (0.5H, d, J=16Hz), 7.50
(1H, d, J=16Hz), 7.55-7.69 (3H, m), 7.78 (1H, d,
J=8Hz), 7.81-7.95 (3H, m), 8.56 (0.5H, br), 8.75
(0.5H, br), 8.82 (1H, d, J=8Hz), 9.00 (0.5H, br
s), 9.09 (0.5H, br s)

- 30 (37) 8-[3-[N-[(E)-3-[6-(Allylcarbamoyl)pyridin-3-
yl]acryloylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

35 NMR (CDCl₃, δ) : 2.73 (3H, s), 3.28 (3H, s), 3.70
(1H, dd, J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz),
4.10 (2H, t-like), 5.18 (1H, d, J=11Hz), 5.26

5 (1H, d, J=18Hz), 5.59-5.70 (2H, m), 5.86-6.03
(1H, m), 6.63 (1H, d, J=16Hz), 6.75 (1H,
t-like), 7.20-7.34 (3H, m), 7.36-7.52 (3H, m),
7.60 (1H, d, J=16Hz), 7.93 (1H, dd, J=2, 8Hz),
8.03 (1H, d, J=8Hz), 8.07 (1H, t-like), 8.18
(1H, d, J=8Hz), 8.63 (1H, d, J=2Hz)

its dihydrochloride

10 NMR (CDCl₃-CD₃OD, δ) : 3.13 (3H, s), 3.25 (3H, s),
3.86 (1H, d, J=16Hz), 4.06 (2H, d-like), 4.23
(1H, d, J=16Hz), 5.17 (1H, d, J=11Hz), 5.26 (1H,
d, J=18Hz), 5.55 (1H, d, J=10Hz), 5.64 (1H, d,
J=10Hz), 5.82-6.00 (1H, m), 6.88 (1H, d,
J=16Hz), 7.43-7.63 (4H, m), 7.73 (1H, d, J=8Hz),
15 7.78-7.89 (2H, m), 8.25-8.41 (2H, m), 8.78 (1H,
d, J=8Hz), 8.97 (1H, br s)

(38) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(2-
propynylcarbamoyl)pyridin-3-yl]acryloylglycyl]-
20 amino]benzyloxy]-2-methylquinoline

25 NMR (CDCl₃, δ) : 2.27 (1H, t-like), 2.73 (3H, s),
3.26 (3H, s), 3.70 (1H, dd, J=4, 16Hz), 3.95
(1H, dd, J=4, 16Hz), 4.23-4.30 (2H, m), 5.65
(2H, s-like), 6.13 (1H, d, J=16Hz), 6.77 (1H,
t-like), 7.20-7.35 (3H, m), 7.35-7.53 (3H, m),
7.60 (1H, d, J=16Hz), 7.94 (1H, dd, J=2, 8Hz),
8.03 (1H, d, J=8Hz), 8.16 (1H, d, J=8Hz), 8.62
(1H, d, J=2Hz)

30 its dihydrochloride

35 NMR (CDCl₃-CD₃OD, δ) : 2.27 (1H, t-like), 3.17 (3H,
s), 3.27 (3H, s), 3.88 (1H, d, J=16Hz), 4.18-
4.32 (3H, m), 5.55 (1H, d, J=10Hz), 5.64 (1H, d,
J=10Hz), 6.90 (1H, d, J=16Hz), 7.41-7.63 (4H,
m), 7.73 (1H, d, J=8Hz), 7.78-7.88 (2H, m), 8.30

2122236

(1H, d, J=8Hz), 8.37 (1H, d, J=8Hz), 8.79 (1H, d, J=8Hz), 9.00 (1H, br s)

(39) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(1-pyrrolidinylcarbonyl)pyridin-3-yl]acryloylglycyl]-amino]benzyloxy]-2-methylquinoline dihydrochloride
NMR (CDCl₃-CD₃OD, δ) : 1.93-2.05 (4H, m), 3.13 (3H, s), 3.30 (3H, s), 3.63-3.75 (4H, m), 3.86 (1H, d, J=16Hz), 4.40 (1H, d, J=16Hz), 5.53 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.99 (1H, d, J=16Hz), 7.49 (1H, d, J=16Hz), 7.55-7.70 (3H, m), 7.77 (1H, d, J=8Hz), 7.81-7.93 (2H, m), 8.06-8.15 (1H, m), 8.74-8.87 (2H, m), 9.20 (1H, br s)

(40) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(2-methoxyethylcarbonyl)pyridin-3-yl]acryloylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.72 (3H, s), 3.26 (3H, s), 3.40 (3H, s), 3.57 (2H, t, J=6Hz), 3.66 (2H, t, J=6Hz), 3.70 (1H, dd, J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz), 5.63 (1H, d, J=10Hz), 5.67 (1H, d, J=10Hz), 6.63 (1H, d, J=16Hz), 6.76 (1H, t-like), 7.22-7.35 (3H, m), 7.37-7.53 (3H, m), 7.60 (1H, d, J=16Hz), 7.93 (1H, dd, J=2, 8Hz), 8.03 (1H, d, J=8Hz), 8.16 (1H, d, J=8Hz), 8.26 (1H, t-like), 8.63 (1H, d, J=2Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.17 (3H, s), 3.30 (3H, s), 3.40 (3H, s), 3.57-3.63 (2H, m), 3.63-3.70 (2H, m), 3.89 (1H, d, J=16Hz), 4.24 (1H, d, J=16Hz), 5.58 (1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 6.90 (1H, d, J=16Hz), 7.45-7.67 (4H, m), 7.77 (1H, d, J=8Hz), 7.81-7.92 (2H, m), 8.26-8.43 (2H, m),

2122236

8.83 (1H, d, J=8Hz), 8.99 (1H, br s)

(41) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(2-ethoxyethylcarbamoyl)pyridin-3-yl]acryloylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.23 (3H, t, J=7.5Hz), 2.73 (3H, s), 3.27 (3H, s), 3.55 (2H, q, J=7.5Hz), 3.57-3.75 (5H, m), 3.94 (1H, dd, J=4, 16Hz), 5.62 (1H, d, J=10Hz), 5.67 (1H, d, J=10Hz), 6.61 (1H, d, J=16Hz), 6.75 (1H, t-like), 7.23-7.35 (3H, m), 7.35-7.53 (3H, m), 7.60 (1H, d, J=16Hz), 7.93 (1H, dd, J=2, 8Hz), 8.03 (1H, d, J=8Hz), 8.16 (1H, d, J=8Hz), 8.29 (1H, t-like), 8.63 (1H, d, J=2Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.21 (3H, t, J=7.5Hz), 3.17 (3H, s), 3.30 (3H, s), 3.55 (2H, q, J=7.5Hz), 3.60-3.70 (4H, m), 3.86 (1H, d, J=16Hz), 4.30 (1H, d, J=16Hz), 5.57 (1H, d, J=10Hz), 5.67 (1H, d, J=10Hz), 6.93 (1H, d, J=16Hz), 7.50 (1H, d, J=16Hz), 7.56-7.64 (3H, m), 7.78 (1H, d, J=8Hz), 7.82-7.92 (2H, m), 8.36 (1H, d, J=8Hz), 8.47 (1H, d, J=8Hz), 8.83 (1H, d, J=8Hz), 9.07 (1H, br s)

(42) 8-[3-[N-[(E)-3-[6-[N,N-Bis(2-methoxyethyl)carbamoyl]pyridin-3-yl]acryloylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.23 (3H, s), 3.27 (3H, s), 3.38 (3H, s), 3.54 (2H, t, J=6Hz), 3.61-3.83 (7H, m), 3.94 (1H, dd, J=4, 16Hz), 5.65 (1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 6.60 (1H, d, J=16Hz), 6.72 (1H, t-like), 7.24-7.36 (3H, m), 7.36-7.70 (5H, m), 7.88 (1H, dd, J=2,

2122236

8Hz), 8.03 (1H, d, J=8Hz), 8.65 (1H, d, J=2Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.13 (3H, s), 3.21-3.80 (17H, m), 3.85 (1H, d, J=16Hz), 4.51 (1H, d, J=16Hz), 5.50 (1H, d, J=10Hz), 5.67 (1H, d, J=10Hz), 7.05 (1H, d, J=16Hz), 7.47 (1H, d, J=16Hz), 7.53-7.64 (2H, m), 7.70 (1H, d, J=8Hz), 7.76 (1H, d, J=8Hz), 7.84 (1H, d, J=8Hz), 7.89 (1H, d, J=8Hz), 8.00-8.06 (1H, m), 8.81 (1H, d, J=8Hz), 8.87-8.96 (1H, m), 9.29 (1H, br s)

(43) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(morpholinocarbonyl)pyridin-3-yl]acryloylglycyl]-amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.25 (3H, s), 3.63-3.74 (5H, m), 3.80 (4H, s-like), 3.95 (1H, dd, J=4, 16Hz), 5.63 (1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 6.60 (1H, d, J=16Hz), 6.73 (1H, t-like), 7.23-7.35 (3H, m), 7.35-7.53 (3H, m), 7.59 (1H, d, J=16Hz), 7.71 (1H, d, J=8Hz), 7.91 (1H, dd, J=2, 8Hz), 8.03 (1H, d, J=8Hz), 8.66 (1H, d, J=2Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.15 (3H, s), 3.29 (3H, s), 3.61 (2H, br), 3.73 (2H, br), 3.82 (4H, br), 3.90 (1H, d, J=16Hz), 4.27 (1H, d, J=16Hz), 5.67 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.93 (1H, d, J=16Hz), 7.49 (1H, d, J=16Hz), 7.53-7.65 (3H, m), 7.76 (1H, d, J=8Hz), 7.80-7.92 (3H, m), 8.47-8.57 (1H, m), 8.82 (1H, d, J=8Hz), 8.94 (1H, br)

(44) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-[(2-

2122236

pyridylmethyl)carbamoyl]pyridin-3-yl]acryloylglycyl]-
amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.27 (3H, s), 3.70
(1H, dd, J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz),
5 4.80 (2H, d, J=6Hz), 5.65 (2H, s), 6.63 (1H, d,
J=16Hz), 6.76 (1H, t-like), 7.17-7.38 (5H, m),
7.37-7.54 (3H, m), 7.61 (1H, d, J=16Hz), 7.67
(1H, td, J=8, 2Hz), 7.95 (1H, d, J=8Hz), 8.03
(1H, d, J=8Hz), 8.20 (1H, d, J=8Hz), 8.61 (1H,
10 d, J=6Hz), 8.67 (1H, s-like), 8.90 (1H, t-like)

its trihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.19 (3H, s), 3.30 (3H, s),
3.90 (1H, d, J=16Hz), 4.17 (1H, d, J=16Hz), 5.13
15 (2H, s), 5.60 (1H, d, J=10Hz), 5.70 (1H, d,
J=10Hz), 6.90 (1H, d, J=16Hz), 7.45-7.70 (4H,
m), 7.77-7.98 (4H, m), 8.12 (1H, d, J=8Hz),
8.16-8.30 (2H, m), 8.43 (1H, t, J=8Hz), 8.77
(1H, d, J=6Hz), 8.81-8.93 (2H, m)

(45) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(morpholino-
carbonyl)cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoxaline

mp : 118-130°C

NMR (CDCl₃, δ) : 2.78 (3H, s), 3.28 (3H, s), 3.37-
3.55 (2H, m), 3.67 (1H, dd, J=16.5, 3.0Hz),
3.59-3.88 (6H, m), 3.96 (1H, dd, J=16.5, 3.0Hz),
5.62 (2H, s), 6.52 (1H, d, J=15.0Hz), 6.66 (1H,
t, J=3.0Hz), 7.29-7.38 (2H, m), 7.42 (2H, d,
J=8.5Hz), 7.49-7.70 (5H, m), 7.77 (1H, d,
J=8.5Hz), 8.73 (1H, s)

(46) 8-[2,6-Dichloro-3-[N-[4-[(2-pyridylmethyl)carbamoyl]-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoxaline

mp : 111-124°C

NMR (CDCl₃, δ) : 2.78 (3H, s), 3.28 (3H, s), 3.67 (1H, dd, J=16.5, 3.0Hz), 3.96 (1H, dd, J=16.5, 3.0Hz), 4.77 (2H, d, J=3.0Hz), 5.62 (2H, s), 6.53 (1H, d, J=16.0Hz), 6.72 (1H, t, J=3.0Hz), 7.20-7.38 (4H, m), 7.49-7.71 (7H, m), 7.75 (1H, t, J=8.5Hz), 7.89 (2H, d, J=8.5Hz), 8.57 (1H, d, J=4.5Hz), 8.73 (1H, s)

10 (47) 8-[3-[N-[4-(Allylcarbamoyl)cinnamoylglycyl]-N-methyl-amino]-2,6-dichlorobenzyloxy]-2-methylquinoxaline

mp : 117-123°C

15 NMR (CDCl₃, δ) : 2.76 (3H, s), 3.27 (3H, s), 3.65 (1H, dd, J=16.5, 3.0Hz), 3.94 (1H, dd, J=16.5, 3.0Hz), 4.09 (2H, m), 5.19 (1H, d, J=11.5Hz), 5.27 (1H, d, J=16.5Hz), 5.62 (2H, s), 5.86-6.00 (1H, m), 6.25 (1H, t, J=7.0Hz), 6.53 (1H, d, J=15.0Hz), 6.70 (1H, t, J=3.0Hz), 7.29-7.36 (2H, m), 7.48-7.82 (8H, m), 8.73 (1H, s)

20 (48) 8-[2,6-Dichloro-3-[N-[4-(2-ethoxyethylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoxaline

mp : 97-111°C

25 NMR (CDCl₃, δ) : 1.23 (3H, t, J=7.0Hz), 2.77 (3H, s), 3.27 (3H, s), 3.54 (2H, q, J=7.0Hz), 3.57-3.71 (5H, m), 3.94 (1H, dd, J=16.5, 3.0Hz), 5.63 (2H, s), 6.53 (1H, d, J=15.0Hz), 6.58 (1H, t, J=6.0Hz), 6.69 (1H, t, J=3.0Hz), 7.29-7.37 (2H, m), 7.49-7.82 (8H, m), 8.74 (1H, s)

30 (49) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(phenylcarbamoyl)phenyl]ureidoacetyl]amino]benzyloxy]-2-methylquinoline

35 NMR (CDCl₃, δ) : 2.69 (3H, s), 3.24 (3H, s), 3.88

2122236

(1H, dd, J=17, 4Hz), 4.02 (1H, dd, J=17, 5Hz),
5.51 (2H, s), 6.35 (1H, br s), 7.00-7.51 (13H),
7.88 (2H, d, J=8Hz), 8.06 (1H, d, J=8Hz), 8.39
(1H, s), 9.17 (1H, br s)

5

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.84 (3H, s), 3.25 (3H, s),
3.87 (1H, br d, J=17Hz), 4.31 (1H, br d,
J=17Hz), 5.59 (1H, d, J=10Hz), 5.68 (1H, d,
J=10Hz), 7.05-7.13 (2H), 7.28-7.71 (11H), 7.76-
7.86 (2H), 8.70 (1H, d, J=8Hz)

10

(50) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(phenylcarbamoyl)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.69 (3H, s), 3.24 (3H, s), 3.65
(1H, dd, J=17, 4Hz), 3.92 (1H, dd, J=17, 5Hz),
5.63 (2H, s), 6.53 (1H, d, J=15Hz), 6.76 (1H, br
t, J=4Hz), 7.13 (1H, t, J=8Hz), 7.23-7.61 (11H),
7.67 (2H, d, J=8Hz), 7.88 (2H, d, J=8Hz), 8.03
(1H, d, J=8Hz), 8.18 (1H, br s)

15

20

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.12 (3H, s), 3.29 (3H, s),
3.89 (1H, d, J=17Hz), 4.13 (1H, d, J=17Hz), 5.59
(1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.69 (1H,
d, J=15Hz), 7.15 (1H, t, J=8Hz), 7.32-7.40 (2H),
7.42 (1H, d, J=15Hz), 7.62 (1H, d, J=8Hz), 7.70-
7.92 (8H), 8.85 (1H, d, J=8Hz)

25

30

(51) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[2-(
(methylcarbamoyloxy)ethylcarbamoyl]cinnamoylglycyl]-
amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 2.80 (3H, d, J=6Hz),
3.27 (3H, s), 3.61-3.77 (2H, m), 3.66 (1H, d,
J=17, 4Hz), 3.94 (1H, d, J=17, 5Hz),

35

2122236

4.25-4.37 (2H, m), 5.61 (1H, d, J=9Hz), 5.66
(1H, d, J=9Hz), 6.53 (1H, d, J=16Hz), 6.71 (1H,
br t, J=6Hz), 7.01 (1H, m), 7.22-7.35 (3H, m),
7.38-7.64 (6H, m), 7.74-7.85 (2H, m), 8.02 (1H,
d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.74 (3H, s), 3.10 (3H, s),
3.30 (3H, s), 3.66 (2H, br t, J=7Hz), 3.91 (1H,
d, J=17Hz), 4.02 (1H, d, J=17Hz), 4.26 (2H, br
t, J=7Hz), 5.60 (1H, d, J=9Hz), 5.76 (1H, d,
J=9Hz), 6.66 (1H, d, J=15Hz), 7.45 (1H, d,
J=15Hz), 7.50-7.74 (5H, m), 7.77-8.00 (5H, m),
8.94 (1H, d, J=9Hz)

(52) 8-[2,6-Dichloro-3-[N-[4-[(ethoxycarbonylmethyl)-
carbamoyl]cinnamoylglycyl]-N-methylamino]benzyloxy]-
2-methylquinoline

NMR (CDCl₃, δ) : 1.31 (3H, t, J=7.5Hz), 2.74 (3H,
s), 3.27 (3H, s), 3.64 (1H, dd, J=4, 16Hz), 3.95
(1H, dd, J=4, 16Hz), 4.15-4.33 (4H, m), 5.60-
5.71 (2H, m), 6.55 (1H, d, J=16Hz), 6.65-6.77
(2H, m), 7.17-7.35 (3H, m), 7.35-7.65 (6H, m),
7.80 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)

(53) 8-[2,6-Dichloro-3-[N-[4-[N-(methoxycarbonylmethyl)-N-
methylcarbamoyl]cinnamoylglycyl]-N-
methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.05 (2H, s), 3.10
(1H, s), 3.26 (3H, s), 3.64 (1H, dd, J=4, 16Hz),
3.70-3.83 (3H, m), 3.86-4.02 (1.7H, m), 4.27
(1.3H, br s), 5.60-5.71 (2H, m), 6.50 (1H, br d,
J=16Hz), 6.65 (1H, br), 7.17-7.33 (3H, m),
7.33-7.63 (8H, m), 8.02 (1H, d, J=8Hz)

2122236

(54) 8-[2,6-Dichloro-3-[N-[4-[(2-methoxycarbonyl)ethyl)-
carbamoyl]cinnamoylglycyl]-N-methylamino]benzyloxy]-
2-methylquinoline

NMR (CDCl₃, δ) : 2.65 (2H, t, J=6Hz), 2.73 (3H, s),
3.25 (3H, s), 3.58-3.77 (6H, m), 3.94 (1H, dd,
J=4, 16Hz), 5.90-5.70 (2H, m), 6.52 (1H, d,
J=16Hz), 6.63-6.70 (1H, m), 6.85 (1H, t-like),
7.20-7.35 (3H, m), 7.35-7.62 (6H, m), 7.75 (2H,
d, J=8Hz), 8.01 (1H, d, J=8Hz)

(55) 8-[2,6-Dichloro-3-[N-[4-[(R)-1-
methoxycarbonyl)ethyl)carbamoyl]cinnamoylglycyl]-N-
methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.52 (3H, d, J=7.5Hz), 2.72 (3H,
s), 3.25 (3H, s), 3.65 (1H, dt, J=16, 4Hz), 3.80
(3H, s), 3.95 (1H, dt, J=16, 4Hz), 4.80 (1H,
quint, J=7.5Hz), 5.59-5.70 (2H, m), 6.54 (1H,
dd, J=4, 16Hz), 6.64-6.81 (2H, m), 7.20-7.35
(3H, m), 7.35-7.65 (6H, m), 7.80 (2H, d, J=8Hz),
8.03 (1H, d, J=8Hz),

[α]_D²⁰ : -22.7° (C=20 mg/2 ml, CDCl₃)

(56) 8-[2,6-Dichloro-3-[N-[4-[(R)-1-methoxycarbonyl-2-
phenylethyl)carbamoyl]cinnamoylglycyl]-N-
methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.74 (3H, s), 3.16-3.37 (5H, m),
3.65 (1H, dd, J=4, 16Hz), 3.78 (3H, s), 3.94
(1H, dd, J=4, 16Hz), 5.09 (1H, q, J=7.5Hz),
5.60-5.71 (2H, m), 6.49-6.60 (2H, m), 6.63-6.72
(1H, m), 7.12 (2H, d, J=8Hz), 7.20-7.36 (6H, m),
7.36-7.63 (6H, m), 7.70 (2H, d, J=8Hz), 8.02
(1H, d, J=8Hz)

[α]_D²⁰ : +49.5° (C=20 mg/2 ml, MeOH)

(57) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(4-

2122236

pyridylcarbamoyl)pyridin-3-yl]acryloylglycyl]amino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.28 (3H, s), 3.71
(1H, dd, J=17, 4Hz), 3.97 (1H, dd, J=17, 5Hz),
5.66 (2H, s), 6.69 (1H, d, J=15Hz), 6.83 (1H, br
t, J=4Hz), 7.21-7.36 (4H), 7.39-7.52 (3H), 7.62
(1H, d, J=15Hz), 7.71 (1H, d, J=6Hz), 7.98-8.07
(2H), 8.27 (1H, d, J=7.5Hz), 8.58 (2H, d,
J=6Hz), 8.69 (1H, d, J=2Hz)

its trihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.20 (3H, s), 3.30 (3H, s),
3.92 (1H, d, J=17Hz), 4.26 (1H, d, J=17Hz), 5.60
(1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.98 (1H,
d, J=15Hz), 7.49-7.69 (4H), 7.79 (1H, d,
J=7.5Hz), 7.85-7.93 (2H), 8.17 (1H, br d,
J=7.5Hz), 8.33 (1H, br d, J=7.5Hz), 8.46 (2H, d,
J=6Hz), 8.67 (2H, d, J=6Hz), 8.87 (1H, d,
J=7.5Hz), 8.99 (1H, br s)

(58) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(3-
pyridylmethylcarbamoyl)pyridin-3-yl]acryloylglycyl]-
amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.71 (3H, s), 3.27 (3H, s), 3.69
(1H, dd, J=17, 4Hz), 3.93 (1H, dd, J=17, 5Hz),
4.69 (2H, d, J=5Hz), 5.65 (2H, s), 6.62 (1H, d,
J=15Hz), 6.79 (1H, br t, J=4Hz), 7.20-7.33 (4H),
7.37-7.52 (4H), 7.59 (1H, d, J=15Hz), 7.71 (1H,
br d, J=7.5Hz), 7.95 (1H, dd, J=7.5, 2Hz), 8.02
(1H, d, J=7.5Hz), 8.20 (1H, d, J=7.5Hz), 8.37
(1H, br t, J=5Hz), 8.53 (1H, d, J=2Hz), 8.62
(2H, dd, J=7.5, 2Hz)

its trihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.13 (3H, s), 3.29 (3H, s),

2122236

3.90 (1H, d, J=17Hz), 4.28 (1H, d, J=17Hz), 4.88 (2H, br s), 5.56 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 7.04 (1H, br d, J=15Hz), 7.46-7.69 (4H), 7.81 (1H, d, J=7.5Hz), 7.87-8.02 (3H), 8.56 (1H, br d, J=7.5Hz), 8.69-8.81 (3H), 8.89 (1H, br d, J=7.5Hz), 8.99 (1H, br s), 9.33 (1H, br s)

(59) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(4-pyridylmethylcarbamoyl)pyridin-3-yl]acryloylglycyl]-amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.28 (3H, s), 3.70 (1H, dd, J=17, 4Hz), 3.96 (1H, dd, J=17, 5Hz), 4.69 (2H, d, J=5Hz), 5.66 (2H, s), 6.64 (1H, d, J=15Hz), 6.79 (1H, br t, J=4Hz), 7.23-7.33 (5H), 7.38-7.52 (3H), 7.61 (1H, d, J=15Hz), 7.98 (1H, dd, J=7.5, 2Hz), 8.02 (1H, d, J=7.5Hz), 8.20 (1H, d, J=7.5Hz), 8.42 (1H, br t, J=5Hz), 8.57 (2H, d, J=6Hz), 8.62 (1H, d, J=2Hz)

its trihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.15 (3H, br s), 3.29 (3H, s), 3.90 (1H, d, J=17Hz), 4.30 (1H, d, J=17Hz), 4.92 (2H, br s), 5.56 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 7.07 (1H, br s), 7.45-7.68 (4H), 7.60 (1H, d, J=7.5Hz), 7.85-7.98 (2H), 8.03-8.12 (2H), 8.58 (1H, br s), 8.70-8.91 (4H), 9.40 (1H, br s)

(60) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(2-pyridyl)-carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.71 (3H, s), 3.26 (3H, s), 3.67 (1H, dd, J=4, 16Hz), 3.95 (1H, dd, J=4, 16Hz), 5.64 (2H, s-like), 6.58 (1H, d, J=16Hz),

2122236

6.86 (1H, t-like), 7.08 (1H, dd, J=5, 8Hz),
7.18-7.35 (4H, m), 7.35-7.52 (3H, m), 7.52-7.67
(3H, m), 7.76 (1H, ddd, J=8, 8, 2Hz), 7.91 (2H,
d, J=8Hz), 8.03 (1H, d, J=8Hz), 8.29 (1H, dd,
J=2, 5Hz), 8.38 (1H, d, J=8Hz), 8.75 (1H, s)

(61) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(5-tetrazolyl)-
carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.69 (3H, s), 3.27 (3H, s),
3.51-3.78 (1H, m), 4.01 (1H, d, J=17Hz), 5.58
(2H, s), 6.67 (1H, d, J=15Hz), 7.20-7.80 (8H,
m), 7.90-8.20 (4H, m)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.11 (3H, br s), 3.32 (3H, s),
3.92 (1H, d, J=17Hz), 4.00 (1H, d, J=17Hz), 5.63
(1H, d, J=9Hz), 5.80 (1H, d, J=9Hz), 6.77 (1H,
d, J=15Hz), 7.44-8.15 (11H, m), 8.98 (1H, m)

Example 56

8-[2,6-Dichloro-3-[N-[4-(ethoxycarbonylacetamido)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methyl-
quinoline was obtained by reacting 8-[3-[N-(4-amino-
cinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-
methylquinoline with ethoxycarbonylacetyl chloride
according to a similar manner to that of Example 15.

NMR (CDCl₃, δ) : 1.33 (3H, t, J=7.5Hz), 2.73 (3H,
s), 3.25 (3H, s), 3.46 (2H, s), 3.63 (1H, dd,
J=4, 18Hz), 3.93 (1H, dd, J=4, 18Hz), 4.25 (2H,
q, J=7.5Hz), 5.63 (2H, s), 6.40 (1H, d, J=16Hz),
6.60 (1H, t-like), 7.20-7.34 (3H, m), 7.34-7.53
(6H, m), 7.53-7.62 (2H, m), 8.02 (1H, d, J=8Hz),
9.46 (1H, s)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.31 (3H, t, J=7.5Hz), 3.07 (3H, s), 3.27 (3H, s), 3.51 (2H, s), 3.87 (1H, d, J=10Hz), 4.01 (1H, d, J=10Hz), 4.25 (2H, q, J=7.5Hz), 5.60 (1H, d, J=10Hz), 5.20 (1H, d, J=10Hz), 6.47 (1H, d, J=16Hz), 7.32-7.43 (3H, m), 7.49-7.65 (5H, m), 7.71-7.90 (3H, m), 8.76-8.88 (1H, m)

10 Example 57

8-[2,6-Dichloro-3-[N-methyl-N-[N'-(3-propionamidophenyl)ureidoacetyl]amino]benzyloxy]-2-methylquinoline was obtained by reacting 8-[3-[N-[N'-(3-aminophenyl)ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline with propionyl chloride according to a similar manner to that of Example 56.

NMR (CDCl₃, δ) : 1.13 (3H, t, J=7.5Hz), 2.27 (2H, q, J=7.5Hz), 2.60 (3H, s), 3.18 (3H, s), 3.78-3.90 (1H, m), 3.93-4.06 (1H, m), 5.50 (1H, d, J=10Hz), 5.60 (1H, d, J=10Hz), 5.75-7.85 (1H, m), 6.78-6.88 (1H, m), 7.04 (1H, t, J=7.5Hz), 7.21-7.50 (8H, m), 7.91 (1H, br s), 8.07 (1H, d, J=8Hz), 8.26 (1H, br s)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.11 (3H, t, J=7.5Hz), 2.29 (2H, q, J=7.5Hz), 2.73 (3H, s), 3.25 (3H, s), 3.84 (1H, d, J=16Hz), 4.24 (1H, d, J=16Hz), 5.58 (1H, d, J=10Hz), 5.73 (1H, d, J=10Hz), 6.78 (1H, t, J=8Hz), 6.90 (1H, d, J=7.5Hz), 7.14 (1H, s-like), 7.36 (1H, d, J=7.5Hz), 7.50 (1H, d, J=8Hz), 7.54-7.65 (2H, m), 7.65-7.80 (2H, m), 7.86 (1H, t, J=8Hz), 8.76 (1H, d, J=8Hz)

Example 58

The following compounds were obtained according to similar manners to those of Examples 36, 56 or 57.

- 5 (1) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[2-(1-methyl-1H-pyrrol-2-yl)acetamido]cinnamoylglycyl]-amino]benzyloxy]-2-methylquinoline
- 10 NMR (CDCl₃, δ) : 2.74 (3H, s), 3.27 (3H, s), 3.55 (3H, s), 3.64 (1H, dd, J=4, 16Hz), 3.71 (2H, s), 3.94 (1H, dd, J=4, 16Hz), 5.65 (2H, s-like), 6.11-6.29 (2H, m), 6.40 (1H, d, J=16Hz), 6.10 (1H, t-like), 6.64-6.70 (1H, m), 7.23-7.33 (3H, m), 7.37-7.55 (9H, m), 8.03 (1H, d, J=8Hz)
- 15 its hydrochloride
- NMR (CDCl₃-CD₃OD, δ) : 3.13 (3H, s), 3.30 (3H, s), 3.59 (3H, s), 3.74 (2H, s), 3.88 (1H, d, J=16Hz), 4.00 (1H, d, J=16Hz), 5.59 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.47 (1H, d, J=16Hz), 7.32-7.63 (10H, m), 7.75-7.90 (4H, m), 8.86 (1H, d, J=8Hz)
- 20
- (2) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(3-thienyl-carbonyl)amino]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline
- 25 NMR (CDCl₃, δ) : 2.67 (3H, s), 3.21 (3H, s), 3.62 (1H, dd, J=4, 16Hz), 3.90 (1H, dd, J=4, 16Hz), 5.62 (2H, s), 6.40 (1H, d, J=16Hz), 6.60 (1H, t-like), 7.20-7.56 (11H, m), 7.65 (2H, d, J=8Hz), 8.00-8.09 (2H, m), 8.35 (1H, s)
- 30
- its hydrochloride
- NMR (CDCl₃-CD₃OD, δ) : 3.08 (3H, s), 3.29 (3H, s), 3.91 (1H, d, J=17Hz), 4.06 (1H, d, J=17Hz), 5.59 (1H, d, J=10Hz), 5.74 (1H, d, J=10Hz), 6.49 (1H,
- 35

2122236

d, J=16Hz), 7.30-7.97 (13H, m), 8.25 (1H, d, J=2Hz), 8.92 (1H, d, J=8Hz)

(3) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(2-thienylcarbonyl)amino]cinnamoylglycyl]amino]-benzyloxy]-2-methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.60 (3H, s), 3.19 (3H, s), 3.60 (1H, d, J=16Hz), 3.90 (1H, d, J=16Hz), 5.53 (2H, s), 6.40 (1H, d, J=16Hz), 7.01 (1H, t-like, J=4.5Hz), 7.19-7.41 (6H, m), 7.41-7.55 (4H, m), 7.64 (2H, d, J=8Hz), 7.80 (1H, d, J=4.5Hz), 8.06 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.10 (3H, s), 3.30 (3H, s), 3.83-4.18 (2H, m), 5.59 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.49 (1H, d, J=16Hz), 7.11-7.18 (1H, m), 7.25-7.46 (3H, m), 7.46-7.98 (10H, m), 8.90 (1H, d, J=7.5Hz)

(4) 8-[2,6-Dichloro-3-[N-[4-[(2-furylcarbonyl)amino]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.26 (3H, s), 3.65 (1H, dd, J=4, 16Hz), 3.94 (1H, dd, J=4, 16Hz), 5.64 (2H, s), 6.43 (1H, d, J=16Hz), 6.54-6.58 (1H, m), 6.61 (1H, t-like), 7.20-7.34 (4H, m), 7.37-7.60 (7H, m), 7.68 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz), 8.20 (1H, s)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.16 (3H, s), 3.30 (3H, s), 3.90 (1H, d, J=16Hz), 4.05 (1H, d, J=16Hz), 5.61 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 6.48-6.61 (2H, m), 7.24-7.37 (1H, m), 7.37-7.50 (3H, m),

7.50-7.60 (3H, m), 7.60-7.70 (3H, m), 7.76-7.94
(3H, m), 8.89 (1H, d, J=8Hz)

- (5) 8-[2,6-Dichloro-3-[N-[4-[(3-furylcarbonyl)-
5 amino]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.63 (3H, s), 3.20 (3H, s),
3.60 (1H, d, J=16Hz), 3.93 (1H, d, J=16Hz), 5.55
10 (2H, s), 6.40 (1H, d, J=16Hz), 6.85 (1H,
d-like), 7.20-7.50 (10H, m), 7.63 (2H, d,
J=8Hz), 8.06 (1H, d, J=8Hz), 8.13 (1H, s)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.09 (3H, s), 3.29 (3H, s),
15 3.90 (1H, d, J=16Hz), 4.08 (1H, d, J=16Hz), 5.58
(1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.46 (1H,
d, J=16Hz), 6.95 (1H, s-like), 7.49 (2H, d,
J=7.5Hz), 7.45-7.48 (1H, m), 7.55 (1H, s-like),
20 7.60-7.75 (4H, m), 7.75-7.93 (4H, m), 8.25 (1H,
s-like), 8.90 (1H, d, J=8Hz)

- (6) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(3-thienyl)-
acetamido]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃-CD₃OD, δ) : 2.70 (3H, s), 3.25 (3H, s),
25 3.63 (1H, dd-like, J=16Hz), 3.76 (2H, s), 3.93
(1H, dd, J=4, 16Hz), 5.65 (2H, s), 6.40 (1H, d,
J=16Hz), 6.55-6.64 (1H, m), 7.03-7.09 (1H, m),
30 7.16-7.34 (4H, m), 7.34-7.57 (10H, m), 8.04 (1H,
d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.07 (3H, s), 3.27 (3H, s),
3.76 (2H, s), 3.90 (1H, d, J=16Hz), 4.04 (1H, d,
35 J=16Hz), 5.58 (1H, d, J=10Hz), 5.70 (1H, d,

J=10Hz), 6.45 (1H, d, J=16Hz), 7.13 (1H, d, J=5Hz), 7.21-7.70 (9H, m), 7.70-7.92 (4H, m), 8.88 (1H, d, J=8Hz)

5 (7) 8-[3-[N-(4-Acryloylamino-cinnamoyl-glycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.66 (3H, s), 3.23 (3H, s), 3.62 (1H, dd, J=4, 16Hz), 3.89 (1H, dd, J=4, 16Hz), 5.70 (1H, d, J=10Hz), 6.23 (1H, d, J=16Hz), 10 6.35-6.45 (2H, m), 6.62 (1H, t-like), 7.21-7.56 (9H, m), 7.61 (2H, d, J=8Hz), 8.05 (1H, d, J=8Hz), 8.30 (1H, s)

its hydrochloride

15 NMR (CDCl₃-CD₃OD, δ) : 3.08 (3H, s), 3.30 (3H, s), 3.91 (1H, d, J=16Hz), 4.07 (1H, d, J=16Hz), 5.57 (1H, d, J=10Hz), 5.65-5.80 (2H, m), 6.35-6.55 (2H, m), 7.24-7.35 (4H, m), 7.53 (2H, s-like), 7.58-7.70 (3H, m), 7.75-7.91 (3H, m), 8.90 (1H, 20 d, J=8Hz)

(8) 8-[2,6-Dichloro-3-[N-methyl-N-(4-trifluoroacetamido-cinnamoyl-glycyl)amino]benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 2.60 (3H, s), 3.17 (3H, s), 3.58 (1H, dd, J=4, 16Hz), 3.83 (1H, dd, J=4, 16Hz), 25 5.54 (2H, s-like), 6.41 (1H, d, J=16Hz), 6.79 (1H, t-like), 7.14 (1H, d, J=8Hz), 7.20-7.33 (3H, m), 7.33-7.55 (5H, m), 7.71 (2H, d, J=8Hz), 8.07 (1H, d, J=8Hz)

30 its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.15 (3H, s), 3.30 (3H, s), 3.90 (1H, d, J=16Hz), 4.12 (1H, d, J=16Hz), 5.60 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.56 (1H, 35 d, J=16Hz), 7.31-7.50 (3H, m), 7.55 (2H,

s-like), 7.58-7.66 (3H, m), 7.77-7.94 (3H, m),
8.87 (1H, d, J=8Hz)

(9) 8-[2,6-Dichloro-3-[N-[4-(ethoxycarbonylamino)-
5 cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoline

NMR (CDCl₃, δ) : 1.30 (3H, t, J=7.5Hz), 2.72 (3H,
s), 3.25 (3H, s), 3.63 (1H, dd, J=4, 18Hz), 3.93
10 (1H, dd, J=4, 18Hz), 4.23 (2H, q, J=7.5Hz), 5.63
(2H, s), 6.39 (1H, d, J=16Hz), 6.61 (1H,
t-like), 6.79 (1H, s), 7.20-7.59 (11H, m), 8.02
(1H, d, J=8Hz)

its hydrochloride

15 NMR (CDCl₃-CD₃OD) : 1.27 (3H, t, J=7.5Hz), 3.07 (3H,
s), 3.26 (3H, s), 3.83 (1H, d, J=16Hz), 3.95
(1H, d, J=16Hz), 4.18 (2H, q, J=7.5Hz), 5.54
(1H, d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.40 (1H,
d, J=16Hz), 7.29-7.45 (5H, m), 7.45-7.65 (3H,
20 m), 7.70-7.91 (3H, m), 8.86 (1H, d, J=8Hz)

(10) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(nicotinoylamino)-
cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.56 (3H, s), 3.16 (3H, s), 3.60
25 (1H, dd, J=4, 17.5Hz), 3.88 (1H, dd, J=4,
17.5Hz), 5.55 (2H, s), 6.38 (1H, d, J=16Hz),
6.72 (1H, t-like), 7.10-7.35 (5H, m), 7.35-7.60
(5H, m), 7.70 (2H, d, J=8Hz), 8.05 (1H, d,
J=8Hz), 8.24 (1H, dif.-dd, J=8Hz), 8.66 (1H, d,
30 J=5Hz), 9.11 (1H, d, J=1Hz), 9.29 (1H, s)

its dihydrochloride

NMR (DMSO-d₆, δ) : 2.91 (3H, s), 3.15 (3H, s), 3.90
(1H, dd, J=4, 17Hz), 5.91 (1H, d, J=10Hz), 5.67
35 (1H, d, J=10Hz), 6.75 (1H, d, J=16Hz), 7.38 (1H,

2122236

d, J=16Hz), 7.59 (2H, d, J=8Hz), 7.74 (1H, dd, J=5, 8Hz), 7.79-7.99 (7H, m), 8.31 (1H, t, J=5Hz), 8.51 (1H, d, J=8Hz), 8.86 (1H, d, J=5Hz), 8.98 (1H, dif.-d), 9.23 (1H, s-like)

5

(11) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-pyridine-carboxamido)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 2.74 (3H, s), 3.26 (3H, s), 3.65 (1H, dd, J=4, 18Hz), 3.96 (1H, dd, J=4, 18Hz), 5.65 (2H, s), 6.45 (1H, d, J=16Hz), 6.60 (1H, t-like), 7.21-7.40 (3H, m), 7.40-7.65 (7H, m), 7.81 (2H, d, J=8Hz), 7.93 (1H, td, J=8Hz, 1Hz), 8.03 (1H, d, J=8Hz), 8.30 (1H, d, J=8Hz), 8.63
15 (1H, d, J=5Hz), 10.13 (1H, s)

its dihydrochloride

20 NMR (CMSO-d₆, δ) : 2.90 (3H, s), 3.15 (3H, s), 3.90 (1H, dd, J=4, 18Hz), 5.60 (1H, d, J=10Hz), 5.66 (1H, d, J=10Hz), 6.74 (1H, d, J=16Hz), 7.38 (1H, d, J=16Hz), 7.58 (2H, d, J=8Hz), 7.66-7.75 (1H, m), 7.78-8.04 (8H, m), 8.09 (1H, t, J=7.5Hz), 8.19 (1H, d, J=7.5Hz), 8.30 (1H, t, J=5Hz), 8.76 (1H, d, J=5Hz), 8.90 (1H, br)

25

(12) 8-[2,6-Dichloro-3-[N-(4-isobutyramidocinnamoylglycyl)-N-methylamino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 1.24 (6H, d, J=7.5Hz), 2.50 (1H, m, J=7.5Hz), 2.73 (3H, s), 3.27 (3H, s), 3.64 (1H, dd, J=18, 4Hz), 3.94 (1H, dd, J=18, 4Hz), 5.63 (1H, d, J=10Hz), 5.64 (1H, d, J=10Hz), 6.41 (1H, d, J=15Hz), 6.60 (1H, t-like), 7.23-7.36 (2H, m), 7.36-7.60 (9H, m), 8.03 (1H, d, J=8Hz)

35

its hydrochloride

2122236

NMR (DMSO-d₆, δ) : 1.09 (6H, d, J=7.5Hz), 2.60 (1H, m), 2.85 (3H, s), 3.13 (3H, s), 3.86 (1H, dd, J=4, 17Hz), 5.51-5.78 (2H, m), 6.66 (1H, d, J=16Hz), 7.31 (1H, d, J=16Hz), 7.49 (2H, d, J=8Hz), 7.66 (2H, d, J=8Hz), 7.73-7.93 (6H, m), 8.25 (1H, t, J=5Hz)

(13) 8-[3-[N-[4-(Acetylglycylamino)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.94 (3H, s), 2.66 (3H, s), 3.20 (3H, s), 3.60 (1H, dd, J=4, 18Hz), 3.80-4.04 (3H, m), 5.55 (2H, s), 6.37 (1H, d, J=16Hz), 7.10-7.60 (11H, m), 8.03 (1H, d, J=8Hz)

its hydrochloride

NMR (DMSO-d₆, δ) : 1.87 (3H, s), 2.87 (3H, s), 3.11 (3H, s), 3.80-3.91 (3H, m), 5.55-5.68 (2H, m), 6.66 (1H, d, J=16Hz), 7.31 (1H, d, J=16Hz), 7.50 (2H, d, J=8Hz), 7.64 (2H, d, J=8Hz), 7.75-7.97 (5H, m), 8.19-8.32 (2H, m)

(14) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(dimethylamino)-acetamido]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.35 (6H, s), 2.70 (3H, s), 3.07 (2H, s), 3.25 (3H, s), 3.63 (1H, dd, J=4, 18Hz), 3.90 (1H, dd, J=4, 18Hz), 5.60 (2H, s), 6.41 (1H, d, J=16Hz), 6.69 (1H, t-like), 7.20-7.35 (3H, m), 7.36-7.49 (5H, m), 7.52 (1H, d, J=16Hz), 7.60 (2H, d, J=8Hz), 8.04 (1H, d, J=8Hz), 9.22 (1H, s)

its dihydrochloride

NMR (DMSO-d₆, δ) : 2.76-2.93 (9H, m), 3.12 (3H, s), 3.86 (1H, dif.-dd, J=16Hz), 4.11-4.21 (2H, m),

5.52-5.63 (2H, m), 6.70 (1H, d, J=16Hz), 7.35 (1H, d, J=16Hz), 7.55 (2H, d, J=8Hz), 7.66 (2H, d, J=8Hz), 7.70-7.94 (6H, m), 8.25-8.34 (1H, m)

5 (15) 8-[2,6-Dichloro-3-[N-[4-(3-methoxypropionamido)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

10 NMR (CDCl₃, δ) : 2.57 (2H, t, J=6Hz), 2.68 (3H, s), 3.24 (3H, s), 3.40 (3H, s), 3.54-3.75 (3H, m), 3.90 (1H, dd, J=17.5, 4Hz), 5.60 (2H, s), 6.69 (1H, t-like), 7.17-7.33 (3H, m), 7.33-7.48 (5H, m), 7.48-7.60 (3H, m), 8.03 (1H, d, J=8Hz), 8.89 (1H, s)

15 its hydrochloride

20 NMR (CDCl₃-CD₃OD, δ) : 2.63 (2H, t, J=6Hz), 3.09 (3H, s), 3.30 (3H, s), 3.40 (3H, s), 3.74 (2H, t, J=6Hz), 3.93 (2H, s), 5.59 (1H, d, J=10Hz), 5.77 (1H, d, J=10Hz), 6.46 (1H, d, J=16Hz), 7.28-7.40 (1H, m), 7.43 (2H, d, J=8Hz), 7.48-7.76 (5H, m), 7.80-7.99 (3H, m), 8.95 (1H, d, J=8Hz)

25 (16) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(2-thienyl)-acetamido]cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 2.70 (3H, s), 3.24 (3H, s), 3.62 (1H, dd, J=4, 16Hz), 3.85-3.97 (3H, m), 5.58-5.68 (2H, m), 6.38 (1H, d, J=16Hz), 6.59 (1H, t-like), 6.93-7.00 (1H, m), 7.00-7.05 (1H, m), 7.22-7.32 (2H, m), 7.36-7.54 (8H, m), 7.74 (1H, s), 8.03 (1H, d, J=8Hz)

its hydrochloride

35 NMR (CD₃OD, δ) : 2.99 (3H, s), 3.76-3.94 (3H, m),

2122236

4.00 (1H, d, J=16Hz), 5.70 (1H, d, J=10Hz), 5.80
(1H, d, J=10Hz), 6.60 (1H, d, J=16Hz), 6.92-7.07
(2H, m), 7.23-7.35 (1H, m), 7.35-7.80 (7H, m),
7.80-8.04 (4H, m), 9.02 (1H, d, J=8Hz)

5

(17) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(4-pyridyl-
acetamido)phenyl]ureidoacetyl]amino]benzyloxy]-2-
methylquinoline

10

NMR (CDCl₃, δ) : 2.51 (3H, s), 3.13 (3H, s), 3.53
(2H, s), 3.85 (1H, br s), 5.51 (2H, s), 5.59
(1H, br s), 6.88-7.38 (8H, m), 7.38-7.56 (4H,
m), 8.07 (1H, d, J=8Hz), 8.40-8.50 (3H, m)

its dihydrochloride

15

NMR (CDCl₃-CD₃OD, δ) : 2.78 (3H, s), 3.21 (3H, s),
3.80 (1H, d, J=16Hz), 3.98 (1H, d, J=16Hz), 4.07
(2H, s), 5.53 (1H, d, J=10Hz), 5.67 (1H, d,
J=10Hz), 6.74-6.86 (2H, m), 7.29-7.38 (1H, m),
7.43-7.53 (3H, m), 7.66-7.89 (3H, m), 8.04 (2H,
20 d, J=6Hz), 8.60 (2H, d, J=6Hz), 8.79 (1H, d,
J=8Hz)

(18) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-[3-(isonicotinoyl-
amino)phenyl]ureidoacetyl]amino]benzyloxy]-2-
25 methylquinoline

25

NMR (CDCl₃-CD₃OD, δ) : 2.64 (3H, s), 3.22 (3H, s),
3.77-3.95 (2H, m), 5.53 (1H, d, J=10Hz), 5.60
(1H, d, J=10Hz), 5.88-5.96 (1H, m), 6.78-6.86
(1H, m), 7.15 (1H, t, J=7.5Hz), 7.21-7.50 (6H,
30 m), 7.55-7.66 (2H, m), 7.71-7.80 (2H, m), 8.07
(1H, d, J=8Hz), 8.70 (2H, d, J=6Hz)

its dihydrochloride

35

NMR (CDCl₃-CD₃OD, δ) : 2.92 (3H, s), 3.24 (3H, s),
3.85 (1H, d, J=16Hz), 4.05 (1H, d, J=16Hz), 5.56

2122236

(1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.90-7.07
(2H, m), 7.38-7.67 (5H, m), 7.67-7.89 (3H, m),
8.42-8.60 (2H, m), 8.75-8.99 (3H, m)

5 (19) 8-[2,6-Dichloro-3-[N-methyl-N-[N'-(3-methoxyacetamidophenyl)ureidoacetyl]amino]benzyloxy]-
2-methylquinoline

10 NMR (CDCl₃, δ) : 2.60 (3H, s), 3.23 (3H, s), 3.46
(3H, s), 3.80 (1H, dd, J=4, 16Hz), 3.96 (2H, s),
4.27 (1H, dd, J=7.5, 16Hz), 5.48 (1H, d,
J=10Hz), 5.54 (1H, t-like), 5.66 (1H, d,
J=10Hz), 6.70 (1H, d, J=8Hz), 7.05 (1H, t,
J=7.5Hz), 7.22-7.38 (4H, m), 7.38-7.50 (3H, m),
7.58 (1H, t-like), 8.08 (1H, d, J=8Hz), 8.19
15 (1H, s), 8.28 (1H, s)

its hydrochloride

20 NMR (CDCl₃-CD₃OD, δ) : 2.78 (3H, s), 3.25 (3H, s),
3.41 (3H, s), 3.63 (1H, d, J=16Hz), 3.73-3.91
(2H, m), 4.32 (1H, d, J=16Hz), 5.60 (1H, d,
J=10Hz), 5.74 (1H, d, J=10Hz), 6.97 (2H, d,
J=5Hz), 7.20-7.27 (1H, m), 7.31 (1H, s-like),
7.50 (1H, d, J=8Hz), 7.58-7.65 (2H, m), 7.65-
7.80 (2H, m), 7.86 (1H, t, J=7.5Hz), 8.77 (1H,
25 d, J=8Hz)

30 (20) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(propionamido)pyridin-3-yl]acryloylglycyl]amino]-
benzyloxy]-2-methylquinoline
NMR (CDCl₃, δ) : 1.26 (3H, t, J=7.5Hz), 2.45 (2H, q,
J=7.5Hz), 2.72 (3H, s), 3.28 (3H, s), 3.68 (1H,
dd, J=17, 4Hz), 3.94 (1H, dd, J=17, 5Hz), 5.62
(1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 6.48 (1H,
d, J=15Hz), 6.69 (1H, br t, J=4Hz), 7.21-7.32
35 (3H), 7.39-7.57 (4H), 7.82 (1H, dd, J=7.5, 2Hz),

2122236

7.99 (1H, br s), 8.02 (1H, d, J=7.5Hz), 8.21
(1H, d, J=7.5Hz), 8.34 (1H, d, J=2Hz)

its dihydrochloride

5 NMR (CDCl₃-CD₃OD, δ) : 1.27 (3H, t, J=7.5Hz), 2.78
(2H, q, J=7.5Hz), 3.22 (3H, s), 3.28 (3H, s),
3.93 (1H, d, J=17Hz), 4.27 (1H, d, J=17Hz), 5.59
(1H, d, J=10Hz), 5.64 (1H, d, J=10Hz), 6.95 (1H,
10 d, J=15Hz), 7.52 (2H, s), 7.57-7.70 (2H), 7.85-
8.12 (5H), 8.97-9.02 (2H)

(21) 8-[3-[N-[(E)-3-[6-(Acrylamido)pyridin-3-
yl]acryloylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

15 NMR (CDCl₃, δ) : 2.72 (3H, s), 3.28 (3H, s), 3.68
(1H, dd, J=17, 4Hz), 3.94 (1H, dd, J=17, 5Hz),
5.62 (1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 5.84
(1H, d, J=10Hz), 6.29 (1H, dd, J=15, 10Hz), 6.49
(1H, d, J=15Hz), 6.70 (1H, br t, J=4Hz), 7.22-
20 7.58 (7H), 7.87 (1H, dd, J=7.5, 2Hz), 8.02 (1H,
d, J=7.5Hz), 8.21 (1H, br s), 8.30 (1H, d,
J=7.5Hz), 8.38 (1H, d, J=2Hz)

its dihydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 3.21 (3H, s), 3.26 (3H, s),
3.92 (1H, d, J=17Hz), 4.32 (1H, d, J=17Hz), 5.58
(1H, d, J=10Hz), 5.63 (1H, d, J=10Hz), 5.84 (1H,
dd, J=10, 2Hz), 6.70-6.78 (2H), 6.94 (1H, d,
J=15Hz), 7.48-7.64 (4H), 7.80-7.94 (3H), 8.10
30 (1H, br d, J=7.5Hz), 8.31 (1H, br d, J=7.5Hz),
8.92 (1H, d, J=7.5Hz), 8.99 (1H, br s)

(22) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-
(isonicotinoylamino)pyridin-3-yl]acryloylglycyl]-
35 amino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.28 (3H, s), 3.69 (1H, dd, J=17, 4Hz), 3.95 (1H, dd, J=17, 5Hz), 5.66 (2H, s), 6.52 (1H, d, J=15Hz), 6.72 (1H, br s), 7.24-7.34 (3H), 7.39-7.52 (3H), 7.57 (1H, d, J=15Hz), 7.77 (2H, d, J=6Hz), 7.92 (1H, dd, J=7.5, 2Hz), 8.03 (1H, d, J=7.5Hz), 8.42 (1H, d, J=2Hz), 8.71 (1H, s), 8.84 (2H, d, J=6Hz)

its trihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.18 (3H, s), 3.29 (3H, s), 3.92 (1H, d, J=17Hz), 4.24 (1H, d, J=17Hz), 5.57 (1H, d, J=10Hz), 5.73 (1H, d, J=10Hz), 7.06 (1H, br d, J=15Hz), 7.47 (1H, d, J=15Hz), 7.56-7.69 (3H), 7.81 (1H, d, J=7.5Hz), 7.90 (1H, t, J=7.5Hz), 7.98 (1H, d, J=7.5Hz), 8.67 (2H, s), 8.89 (1H, d, J=7.5Hz), 8.91-8.99 (2H), 9.05-9.14 (3H)

(23) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(ethoxycarbonyl-acetamido)pyridin-3-yl]acryloyl]glycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.32 (3H, t, J=7.5Hz), 2.73 (3H, s), 3.28 (3H, s), 3.50 (2H, s), 3.68 (1H, dd, J=17, 4Hz), 3.95 (1H, dd, J=17, 5Hz), 4.28 (2H, q, J=7.5Hz), 5.62 (1H, d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.49 (1H, d, J=15Hz), 6.69 (1H, br s), 7.22-7.33 (3H), 7.39-7.49 (3H), 7.52 (1H, d, J=15Hz), 7.82 (1H, dd, J=7.5, 2Hz), 8.02 (1H, d, J=7.5Hz), 8.18 (1H, br d, J=7.5Hz), 8.40 (1H, d, J=2Hz), 9.59 (1H, s)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.30 (3H, t, J=7.5Hz), 3.21 (3H, br s), 3.28 (3H, s), 3.79 (1H, d, J=8Hz), 3.91 (1H, d, J=17Hz), 4.18-4.28 (3H), 4.32 (1H,

2122236

d, J=17Hz), 5.59 (1H, d, J=10Hz), 5.64 (1H, d, J=10Hz), 6.96 (1H, br d, J=15Hz), 7.42-7.64 (4H), 7.79-7.93 (3H), 8.05 (1H, m), 8.35 (1H, m), 8.88-8.96 (2H)

5

(24) 8-[3-[N-[N'-[3-(Benzamido)phenyl]ureidoacetyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.60 (3H, s), 3.15 (3H, s), 3.81 (1H, dd, J=17, 5Hz), 3.99 (1H, br dd, J=17, 5Hz), 5.49 (1H, d, J=10Hz), 5.60 (1H, d, J=10Hz), 5.85 (1H, br s), 6.82 (1H, br d, J=8Hz), 7.09 (1H, t, J=8Hz), 7.23-7.59 (10H), 7.62 (1H, br s), 7.83 (2H, d, J=8Hz), 8.06 (1H, d, J=8Hz), 8.30-8.41 (2H)

10

15

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.66 (3H, br s), 3.26 (3H, s), 3.85 (1H, br d, J=17Hz), 4.36 (1H, br d, J=17Hz), 5.59 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.91 (1H, t, J=8Hz), 6.99 (1H, br d, J=8Hz), 7.37 (1H, br s), 7.39-7.58 (6H), 7.62 (1H, d, J=8Hz), 7.68 (2H, d, J=8Hz), 7.72-7.82 (3H), 8.71 (1H, d, J=8Hz)

20

25

(25) 8-[3-[N-[4-(Cyclohexanecarboxamido)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.18-1.99 (10H), 2.20 (1H, m), 2.72 (3H, s), 3.26 (3H, s), 3.64 (1H, dd, J=17, 4Hz), 3.93 (1H, dd, J=17, 5Hz), 5.61 (1H, d, J=10Hz), 5.67 (1H, d, J=10Hz), 6.39 (1H, d, J=15Hz), 6.61 (1H, br t, J=4Hz), 7.22-7.59 (12H), 8.02 (1H, d, J=8Hz)

30

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.20-1.98 (10H), 2.38 (1H,

35

2122236

m), 3.12 (3H, br s), 3.29 (3H, s), 3.91 (1H, br
d, J=17Hz), 4.10 (1H, br d, J=17Hz), 5.59 (1H,
d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.48 (1H, d,
J=15Hz), 7.26-7.38 (3H), 7.50-7.65 (5H), 7.77-
7.90 (3H), 8.90 (1H, d, J=8Hz)

(26) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(4-methyl-5-
oxazolylcarbonyl)amino]cinnamoylglycyl]amino]-
benzyloxy]-2-methylquinoline

mp : 141-148°C

NMR (CDCl₃, δ) : 2.58 (3H, s), 2.70 (3H, s), 3.24
(3H, s), 3.63 (1H, dd, J=16.5, 4.5Hz), 3.93 (1H,
dd, J=16.5, 4.5Hz), 5.61 (1H, d, J=11.0Hz), 5.66
(1H, d, J=11.0Hz), 6.43 (1H, d, J=15.0Hz), 6.62
(1H, br t, J=4.5Hz), 7.23-7.32 (3H, m), 7.37-
7.54 (5H, m), 7.54 (1H, d, J=15.0Hz), 7.65 (2H,
d, J=8.5Hz), 7.77 (1H, s), 8.03 (1H, d,
J=8.5Hz), 8.16 (1H, s)

its dihydrochloride

mp : 160.5-164.5°C

NMR (CDCl₃-CD₃OD, δ) : 2.57 (3H, s), 3.11 (3H, s),
3.30 (3H, s), 3.89 (1H, d, J=16.0Hz), 4.04 (1H,
d, J=16.0Hz), 5.60 (1H, d, J=9.0Hz), 5.73 (1H,
d, J=9.0Hz), 6.53 (1H, d, J=16.0Hz), 7.41 (1H,
d, J=16.0Hz), 7.47 (2H, d, J=8.5Hz), 7.55 (2H,
s), 7.63-7.72 (3H, m), 7.79-7.95 (3H, m), 7.97
(1H, s), 8.93 (1H, d, J=8.5Hz)

(27) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(2-methyl-4-
oxazolylcarbonyl)amino]cinnamoylglycyl]amino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.52 (3H, s), 2.73 (3H, s), 3.26
(3H, s), 3.63 (1H, dd, J=17, 4Hz), 3.94 (1H, dd,
J=17, 5Hz), 5.62 (1H, d, J=10Hz), 5.68 (1H, d,

J=10Hz), 6.42 (1H, d, J=15Hz), 6.60 (1H, br t, J=4Hz), 7.23-7.33 (3H), 7.39-7.59 (6H), 7.69 (2H, d, J=8Hz), 8.02 (1H, d, J=8Hz), 8.18 (1H, s), 8.73 (1H, s)

5

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.54 (3H, s), 3.16 (3H, s), 3.31 (3H, s), 3.90 (1H, d, J=17Hz), 4.01 (1H, d, J=17Hz), 5.61 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 6.53 (1H, d, J=15Hz), 7.41-7.51 (3H), 7.54 (1H, d, J=8Hz), 7.59 (1H, d, J=8Hz), 7.63-7.71 (3H), 7.79-7.93 (3H), 8.25 (1H, s), 8.91 (1H, d, J=8Hz)

10

15 (28) 8-[2,6-Dichloro-3-[N-[4-[(3,5-dimethyl-4-isoxazolylcarbonyl)amino]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.50 (3H, s), 2.69 (3H, s), 2.74 (3H, s), 3.28 (3H, s), 3.67 (1H, dd, J=17, 4Hz), 3.94 (1H, dd, J=17, 5Hz), 5.63 (1H, d, J=10Hz), 5.68 (1H, d, J=10Hz), 6.44 (1H, d, J=15Hz), 6.65 (1H, br t, J=4Hz), 7.23-7.61 (12H), 8.04 (1H, d, J=8Hz)

20

25 its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.47 (3H, s), 2.64 (3H, s), 3.17 (3H, br s), 3.30 (3H, s), 3.91 (1H, d, J=17Hz), 4.10 (1H, d, J=17Hz), 5.60 (1H, d, J=10Hz), 5.71 (1H, d, J=10Hz), 6.52 (1H, d, J=15Hz), 7.34-7.48 (3H), 7.53 (2H, s), 7.62 (3H, d, J=8Hz), 7.79 (1H, d, J=8Hz), 7.83-7.91 (2H), 8.88 (1H, d, J=8Hz)

30

(29) 8-[3-[N-[4-[(N-tert-Butoxycarbonyl-L-prolyl)amino]cinnamoylglycyl]-N-methylamino]-2,6-

35

dichlorobenzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.49 (9H, br s), 1.83-2.03 (4H),
2.70 (3H, s), 3.26 (3H, s), 3.29-3.69 (3H), 3.93
(1H, dt, J=17, 5Hz), 4.46 (1H, m), 5.63 (2H, s),
5 6.39 (1H, d, J=15Hz), 6.62 (1H, m), 7.20-7.57
(12H), 8.02 (1H, d, J=8Hz)

(30) 8-[2,6-Dichloro-3-[N-[4-[(1-ethylpiperidine-4-
carbonyl)amino]cinnamoylglycyl]-N-methylamino]-
10 benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 1.11-1.22 (3H), 1.62-2.10 (9H),
2.72 (3H, s), 3.04-3.17 (2H), 3.27 (3H, s), 3.64
(1H, dd, J=17, 4Hz), 3.94 (1H, dd, J=17, 5Hz),
5.65 (2H, br s), 6.40 (1H, d, J=15Hz), 6.61 (1H,
15 m), 7.21-7.61 (12H), 8.03 (1H, d, J=8Hz)

its dihydrochloride

NMR (CDCl₃-CD₃OD, δ) : 1.42 (3H, t, J=7.5Hz), 2.10-
2.47 (4H), 2.98-3.19 (8H), 3.28 (3H, s), 3.49-
20 3.59 (2H), 3.92 (1H, d, J=17Hz), 4.08 (1H, d,
J=17Hz), 5.58 (1H, d, J=10Hz), 5.71 (1H, d,
J=10Hz), 6.43 (1H, d, J=15Hz), 7.24 (2H, d,
J=8Hz), 7.38 (1H, m), 7.52-7.69 (5H), 7.80-7.95
(3H), 8.95 (1H, d, J=8Hz)

(31) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(methoxyacetamido)-
pyridin-3-yl]acryloylglycyl]-N-methylamino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.26 (3H, s), 3.51
30 (3H, s), 3.67 (1H, dd, J=16.5, 5.5Hz), 3.93 (1H,
dd, J=16.5, 5.5Hz), 4.03 (2H, s), 5.63 (1H, d,
J=11.0Hz), 5.68 (1H, d, J=11.0Hz), 6.49 (1H, d,
J=16.0Hz), 6.67 (1H, br t, J=5.5Hz), 7.22-7.35
(3H, m), 7.38-7.53 (3H, m), 7.53 (1H, d,
35 J=16.0Hz), 7.85 (1H, dd, J=8.5, 1.5Hz), 8.03

(1H, d, J=8.5Hz), 8.25 (1H, d, J=8.5Hz), 8.40
(1H, d, J=1.5Hz), 8.93 (1H, s)

its dihydrochloride

5

mp : 142-146°C

NMR (DMSO-d₆, δ) : 2.91 (3H, s), 3.13 (3H, s), 3.36
(3H, s), 3.59 (1H, dd, J=16.0, 5.5Hz), 3.90 (1H,
dd, J=16.0, 5.5Hz), 4.09 (2H, s), 5.62 (1H, d,
J=10.5Hz), 5.67 (1H, d, J=10.5Hz), 6.81 (1H, d,
10 J=16.0Hz), 7.38 (1H, d, J=16.0Hz), 7.77-8.07
(6H, m), 8.11 (1H, d, J=8.5Hz), 8.30-8.40 (1H,
m), 8.50 (1H, s), 8.99 (1H, m)

(32) 8-[3-[N-[(E)-3-[6-(Acetylglycylamino)pyridin-3-yl]-
15 acryloylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

mp : 128-136.5°C

NMR (CDCl₃, δ) : 2.07 (3H, s), 2.73 (3H, s), 3.27
(3H, s), 3.67 (1H, dd, J=16.0, 4.5Hz), 3.99 (1H,
20 dd, J=16.0, 4.5Hz), 4.03 (2H, d, J=6.0Hz), 5.64
(2H, s), 6.45 (1H, d, J=16.0Hz), 6.83-6.96 (2H,
m), 7.22-7.67 (7H, m), 7.78 (1H, dd, J=8.5,
1.5Hz), 8.02 (1H, d, J=8.5Hz), 8.09-8.24 (1H,
m), 8.35 (1H, d, J=1.5Hz), 9.04 (1H, s)

25

its dihydrochloride

mp : 150-157°C

NMR (CDCl₃-CD₃OD, δ) : 2.10 (3H, s), 3.15 (3H, s),
3.28 (3H, s), 3.89 (1H, d, J=16.0Hz), 4.10-4.31
30 (1H, m), 4.19 (2H, s), 5.57 (1H, d, J=8.5Hz),
5.70 (1H, d, J=8.5Hz), 6.83 (1H, m), 7.44-7.68
(4H, m), 7.71-7.98 (3H, m), 8.10 (1H, m), 8.38
(1H, m), 8.70 (1H, m), 8.88 (1H, m)

35

(33) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[(1-methyl-1H-

imidazole-2-carbonyl)amino]cinnamoylglycyl]amino]-
benzyloxy]-2-methylquinoline

mp : 106.5-115°C

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.26 (3H, s), 3.64
(1H, dd, J=16.5, 4.5Hz), 3.94 (1H, dd, J=16.5,
4.5Hz), 4.12 (3H, s), 5.63 (1H, d, J=11.0Hz),
5.68 (1H, d, J=11.0Hz), 6.43 (1H, d, J=16.0Hz),
6.63 (1H, br t, J=4.5Hz), 7.03 (1H, s), 7.07
(1H, s), 7.23-7.34 (3H, m), 7.39-7.54 (5H, m),
7.54 (1H, d, J=16.0Hz), 7.67 (2H, d, J=8.5Hz),
8.02 (1H, s), 9.32 (1H, s)

its dihydrochloride

mp : 132.5-140°C

NMR (CDCl₃-CD₃OD, δ) : 3.12 (3H, s), 3.29 (3H, s),
3.90 (1H, d, J=16.0Hz), 3.99 (1H, d, J=16.0Hz),
4.29 (3H, s), 5.61 (1H, d, J=8.5Hz), 5.73 (1H,
d, J=8.5Hz), 6.54 (1H, d, J=16.0Hz), 7.39-7.50
(3H, m), 7.52-7.62 (4H, m), 7.69 (1H, d,
J=8.5Hz), 7.82-8.00 (5H, m), 8.97 (1H, d,
J=8.5Hz)

(34) 8-[2,6-Dichloro-3-[N-[(E)-3-[6-(2-
furancarboxamido)pyridin-3-yl]acryloylglycyl]-N-
methylamino]benzyloxy]-2-methylquinoline

mp : 208-212°C

NMR (CDCl₃, δ) : 2.73 (3H, s), 3.27 (3H, s), 3.67
(1H, dd, J=16.5, 5.5Hz), 3.96 (1H, dd, J=16.5,
5.5Hz), 5.63 (1H, d, J=10.5Hz), 5.68 (1H, d,
J=10.5Hz), 6.51 (1H, d, J=16.0Hz), 6.57-6.61
(1H, m), 6.68 (1H, br t, J=5.5Hz), 7.23-7.34
(4H, m), 7.39-7.58 (5H, m), 7.88 (1H, dd, J=8.5,
1.5Hz), 8.03 (1H, d, J=8.5Hz), 8.33 (1H, d,
J=8.5Hz), 8.41 (1H, d, J=1.5Hz), 8.80 (1H, s)

2122236

its dihydrochloride

mp : 154.5-158°C

NMR (CDCl₃-CD₃OD, δ) : 3.19 (3H, s), 3.28 (3H, s),
3.90 (1H, d, J=16.0Hz), 4.29 (1H, d, J=16.0Hz),
5.57 (1H, d, J=9.0Hz), 5.69 (1H, d, J=9.0Hz),
6.63 (1H, m), 6.89 (1H, d, J=16.0Hz), 7.42 (1H,
d, J=16.0Hz), 7.52-7.64 (3H, m), 7.72 (1H, s),
7.77-7.95 (4H, m), 8.42-8.58 (2H, m), 8.72 (1H,
br s), 8.87 (1H, d, J=8.5Hz)

(35) 8-[2,6-Dichloro-3-[N-methyl-N-[(E)-3-[6-(4-pyridylacetamido)pyridin-3-yl]acryloylglycyl]-amino]benzyloxy]-2-methylquinoline

mp : 126.5-132°C

NMR (CDCl₃, δ) : 2.72 (3H, s), 3.26 (3H, s), 3.65
(1H, dd, J=16.5, 5.5Hz), 3.75 (2H, s), 3.95 (1H,
dd, J=16.5, 5.5Hz), 5.62 (1H, d, J=10.5Hz), 5.68
(1H, d, J=10.5Hz), 6.47 (1H, d, J=16.0Hz), 6.77
(1H, br t, J=5.5Hz), 7.21-7.33 (5H, m), 7.39-
7.49 (3H, m), 7.51 (1H, d, J=16.0Hz), 7.82 (1H,
dd, J=8.5, 1.5Hz), 8.03 (1H, d, J=8.5Hz), 8.19
(1H, d, J=8.5Hz), 8.28 (1H, s), 8.33 (1H, d,
J=1.5Hz), 8.57-8.65 (2H, m)

its trihydrochloride

mp : 156-158°C

NMR (CDCl₃-CD₃OD, δ) : 2.80-3.24 (2H, m), 3.13 (3H,
s), 3.28 (3H, s), 3.89 (1H, d, J=16.5Hz), 4.19
(1H, d, J=16.5Hz), 5.55 (1H, d, J=9.0Hz), 5.72
(1H, d, J=9.0Hz), 6.90 (1H, d, J=16.5Hz), 7.40
(1H, d, J=16.5Hz), 7.53-7.69 (3H, m), 7.79-8.07
(4H, m), 8.17-8.28 (2H, m), 8.39 (1H, m), 8.76-
8.94 (4H, m)

(36) 8-[3-[N-[4-(1-Adamantylacetamido)cinnamoylglycyl]-N-

methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline
mp : 147-154°C

NMR (CDCl₃, δ) : 1.56-1.77 (12H, m), 1.92-2.01 (3H, m), 2.07 (2H, s), 2.73 (3H, s), 3.25 (3H, s), 3.63 (1H, dd, J=16.5, 5.5Hz), 3.93 (1H, dd, J=16.5, 5.5Hz), 5.62 (1H, d, J=11.5Hz), 5.66 (1H, d, J=11.5Hz), 6.40 (1H, d, J=16.0Hz), 6.60-6.68 (1H, m), 7.21-7.35 (5H, m), 7.39-7.59 (7H, m), 8.04 (1H, d, J=8.5Hz)

(37) 8-[3-[N-[4-[(1-Acetylpiperidin-4-yl)carbonylamino]-cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline
mp : 146.5-153°C

NMR (CDCl₃, δ) : 1.62-1.91 (4H, m), 2.07 (3H, s), 2.24-2.50 (2H, m), 2.69 (3H, s), 2.85-2.97 (1H, m), 3.20 (3H, s), 3.61 (1H, dd, J=16.5, 5.5Hz), 3.77-3.87 (1H, m), 3.90 (1H, dd, J=16.5, 5.5Hz), 4.47-4.58 (1H, m), 5.58 (1H, d, J=11.5Hz), 5.62 (1H, d, J=11.5Hz), 6.40 (1H, d, J=16.0Hz), 6.69 (1H, br t, J=5.5Hz), 7.18-7.62 (11H, m), 8.05 (1H, d, J=8.5Hz), 8.23 (1H, s)

its hydrochloride

mp : 155-161°C

NMR (CDCl₃-CD₃OD, δ) : 1.63-1.84 (2H, m), 1.88-2.03 (2H, m), 2.14 (3H, s), 2.71-3.33 (3H, m), 3.08 (3H, s), 3.29 (3H, s), 3.82-3.98 (1H, m), 3.91 (1H, d, J=16.0Hz), 4.06 (1H, d, J=16.0Hz), 4.49-4.61 (1H, m), 5.59 (1H, d, J=9.0Hz), 5.73 (1H, d, J=9.0Hz), 6.43 (1H, d, J=16.0Hz), 7.26-7.38 (3H, m), 7.55 (2H, s), 7.60-7.71 (3H, m), 7.79-7.95 (3H, m), 8.92 (1H, d, J=8.5Hz)

(38) 8-[3-[N-[4-(Cyclopropylcarbonylamino)cinnamoyl-

glycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline

mp : 129-133°C

NMR (CDCl₃, δ) : 0.69-0.82 (2H, m), 0.97-1.08 (2H, m), 1.46-1.57 (1H, m), 2.69 (3H, s), 3.21 (3H, s), 3.61 (1H, dd, J=16.5, 5.5Hz), 3.88 (1H, dd, J=16.5, 5.5Hz), 5.60 (2H, s), 6.38 (1H, d, J=16.0Hz), 6.61 (1H, br t, J=5.5Hz), 7.19-7.49 (9H, m), 7.54 (2H, d, J=8.5Hz), 8.06 (1H, d, J=8.5Hz), 8.71 (1H, br s)

its hydrochloride

mp : 160-165°C

NMR (CDCl₃-CD₃OD, δ) : 0.79-0.87 (2H, m), 0.97-1.04 (2H, m), 1.81-1.93 (1H, m), 3.08 (3H, s), 3.28 (3H, s), 3.90 (1H, d, J=16.5Hz), 4.08 (1H, d, J=16.5Hz), 5.58 (1H, d, J=9.0Hz), 5.70 (1H, d, J=9.0Hz), 6.42 (1H, d, J=16.0Hz), 7.23-7.34 (3H, m), 7.50-7.67 (5H, m), 7.78-7.92 (3H, m), 8.91 (1H, d, J=8.5Hz)

Example 59

8-[3-[N-[4-[(Carboxymethyl)carbamoyl]-cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline was obtained from 8-[3-[N-[4-[(ethoxycarbonylmethyl)carbamoyl]cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline according to a similar manner to that of Example 20.

NMR (DMSO-d₆, δ) : 2.63 (3H, s), 3.15 (3H, s), 3.53 (1H, d, J=16Hz), 3.82 (1H, d, J=16Hz), 3.92 (2H, d, J=6Hz), 5.44-5.60 (2H, m), 6.90 (1H, d, J=16Hz), 7.35-7.63 (4H, m), 7.63-7.73 (2H, m), 7.79 (2H, s-like), 7.90 (2H, d, J=8Hz), 8.30-8.41 (1H, m), 8.85-8.94 (1H, m)

Example 60

The following compounds were obtained according to a similar manner to that of Example 59.

- 5 (1) 8-[3-[N-[4-(N-Carboxymethyl-N-methylcarbamoyl)-
cinnamoylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

10 NMR (DMSO-d₆, δ) : 2.60 (3H, s), 2.95 (1.8H, s),
2.97 (1.2H, s), 3.15 (3H, s), 3.51 (1H, dd-like,
J=16Hz), 3.81 (1H, dd, J=16, 4Hz), 3.93 (0.8H,
s), 4.14 (1.2H, s), 5.46 (1H, d, J=11Hz), 5.53
(1H, d, J=11Hz), 6.83 (1H, d, J=16Hz), 7.29-7.57
(7H, m), 7.57-7.70 (2H, m), 7.85 (2H, s-like),
8.20 (1H, d, J=8Hz), 8.26-8.40 (1H, m)

- 15 (2) 8-[3-[N-[4-[(2-Carboxyethyl)carbamoyl]-
cinnamoylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

20 NMR (DMSO-d₆, δ) : 2.70 (3H, br s), 3.15 (3H, s),
3.27-3.60 (5H, m), 3.84 (1H, dd, J=4, 16Hz),
5.56-5.61 (2H, m), 6.88 (1H, d, J=16Hz), 7.43
(1H, d, J=16Hz), 7.49-7.73 (5H, m), 7.80 (2H,
s-like), 7.85 (2H, d, J=8Hz), 8.29-8.43 (2H, m),
8.59 (1H, t-like)

- 25 (3) 8-[3-[N-[4-[(R)-1-Carboxyethyl)carbamoyl]-
cinnamoylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

30 NMR (CDCl₃, δ) : 1.40 (3H, d, J=7.5Hz), 2.63 (3H,
s), 3.16 (3H, s), 3.53 (1H, dd-like, J=16Hz),
3.83 (1H, dd-like, J=16Hz), 4.41 (1H, quint,
J=7.5Hz), 5.43-5.60 (2H, m), 6.90 (1H, d,
J=16Hz), 7.31-7.61 (5H, m), 7.61-7.71 (2H, m),
7.80 (2H, s-like), 7.92 (2H, d, J=8Hz), 8.16-
35 8.43 (2H, m), 8.71 (1H, d, J=7.5Hz)

$[\alpha]_D^{20}$: -6.7° (C=20 mg/2 ml, MeOH)

(4) 8-[3-[N-[4-[(R)-1-Carboxy-2-phenylethyl)carbamoyl]-
cinnamoylglycyl]-N-methylamino]-2,6-
dichlorobenzyloxy]-2-methylquinoline

NMR (DMSO-d₆, δ) : 2.65 (3H, s), 3.00-3.26 (5H, m),
3.53 (1H, dd-like, J=16Hz), 3.83 (1H, dd-like,
J=16Hz), 4.56-4.69 (1H, m), 5.45-5.60 (2H, m),
6.87 (1H, d, J=16Hz), 7.13-7.21 (1H, m), 7.21-
7.35 (4H, m), 7.35-7.75 (7H, m), 7.75-7.88 (4H,
m), 8.26-8.42 (2H, m), 8.77 (1H, d, J=7.5Hz)

$[\alpha]_D^{20}$: +38.5° (C=20 mg/2 ml, MeOH)

Example 61

8-[2,6-Dichloro-3-[N-methyl-N-[4-[(methylcarbamoyl-
methyl)carbamoyl]cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoline was obtained by reacting 8-[3-[N-[4-
[(carboxymethyl)carbamoyl]cinnamoylglycyl]-N-methylamino]-
2,6-dichlorobenzyloxy]-2-methylquinoline with methylamine
hydrochloride according to a similar manner to that of
Example 54.

NMR (CDCl₃, δ) : 2.73 (3H, s), 2.85 (3H, d, J=5Hz),
3.27 (3H, s), 3.64 (1H, dd-like, J=16Hz), 3.96
(1H, dd, J=16, 4Hz), 4.09 (2H, d, J=5Hz), 5.58-
5.71 (2H, m), 6.19-6.29 (1H, m), 6.55 (1H, d,
J=16Hz), 6.80-6.88 (1H, m), 7.15-7.37 (3H, m),
7.37-7.62 (6H, m), 7.80 (2H, d, J=8Hz), 8.03
(1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.79 (3H, s), 3.13 (3H, s),
3.30 (3H, s), 3.89 (1H, d, J=16Hz), 4.05 (2H,
s), 4.07 (1H, d, J=16Hz), 5.61 (1H, d, J=10Hz),
5.70 (1H, d, J=10Hz), 6.63 (1H, d, J=16Hz), 7.40
(1H, d, J=16Hz), 7.50 (2H, d, J=8Hz), 7.50 (2H,

s-like), 7.64 (1H, d, J=8Hz), 7.75-7.93 (5H, m),
8.38 (1H, d, J=8Hz)

Example 62

5 The following compounds were obtained according to a
similar manner to that of Example 61.

(1) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[N-(methylcarbamoyl-
methyl)-N-methylcarbamoyl]cinnamoylglycyl]amino]-
10 benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.70 (3H, s), 2.85 (3H, d, J=5Hz),
3.10 (3H, s), 3.26 (3H, s); 3.65 (1H, dd, J=4,
16Hz), 3.83-4.03 (1.5H, m), 4.03-4.13 (1.5H, m),
5.60-5.72 (2H, m), 6.43-6.60 (2H, m), 6.70 (1H,
15 br s), 7.22-7.36 (3H, m), 7.36-7.65 (8H, m),
8.03 (1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.82 (3H, br s), 3.09 (3H,
20 s), 3.29 (3H, s), 3.82-4.20 (4H, m), 5.60 (1H,
d, J=10Hz), 5.73 (1H, d, J=10Hz), 6.54-6.71 (1H,
m), 7.36-7.63 (7H, m), 7.66 (1H, d, J=8Hz),
7.79-7.98 (3H, m), 8.90 (1H, d, J=8Hz)

25 (2) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[[2-(methyl-
carbamoyl)ethyl]carbamoyl]cinnamoylglycyl]amino]-
benzyloxy]-2-methylquinoline

NMR (CDCl₃, δ) : 2.50 (2H, t, J=6Hz), 2.73 (3H, s),
2.83 (3H, d, J=5Hz), 3.27 (3H, s), 3.65 (1H, dd,
30 J=4, 16Hz), 3.73 (2H, q, J=6Hz), 3.95 (1H, dd,
J=4, 16Hz), 5.60-5.76 (3H, m), 6.54 (1H, d,
J=16Hz), 6.70 (1H, t-like), 7.23-7.36 (3H, m),
7.36-7.63 (6H, m), 7.78 (2H, d, J=8Hz), 8.03
(1H, d, J=8Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.70 (2H, t, J=7Hz), 2.73 (3H, s), 3.15 (3H, s), 3.30 (3H, s), 3.68 (2H, t, J=7Hz), 3.90 (1H, d, J=16Hz), 4.06 (1H, d, J=16Hz), 5.60 (1H, d, J=10Hz), 5.60 (1H, d, J=10Hz), 6.65 (1H, d, J=16Hz), 7.45 (1H, d, J=16Hz), 7.49-7.57 (4H, m), 7.63 (1H, d, J=8Hz), 7.77-7.93 (5H, m), 8.88 (1H, d, J=8Hz)

10 (3) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[[*(R)*-1-(methylcarbamoyl)ethyl]carbamoyl]cinnamoylglycyl]-amino]benzyloxy]-2-methylquinoline

15 NMR (CDCl₃, δ) : 1.47 (3H, d, J=7.5Hz), 2.73 (3H, s), 2.85 (3H, d, J=5Hz), 3.65 (1H, dt, J=16, 4Hz), 3.95 (1H, dt, J=16, 4Hz), 4.65 (1H, quint, J=7.5Hz), 5.58-5.70 (2H, m), 6.19 (1H, br), 6.55 (1H, dd-like, J=16Hz), 6.68-6.80 (1H, m), 6.87 (1H, t-like), 7.20-7.37 (3H, m), 7.37-7.64 (6H, m), 7.79 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)

20 $[\alpha]_D^{20}$: -6.2° (C=20 mg/2 ml, CHCl₃)

its hydrochloride

25 NMR (CDCl₃-CD₃OD, δ) : 1.45 (3H, d, J=7.5Hz), 2.81 (3H, s), 3.14 (3H, s), 3.30 (3H, s), 3.90 (1H, d, J=16Hz), 4.04 (1H, d, J=16Hz), 4.61 (1H, q, J=7.5Hz), 5.60 (1H, d, J=10Hz), 5.73 (1H, d, J=10Hz), 6.66 (1H, d, J=16Hz), 7.47 (1H, d, J=16Hz), 7.50-7.69 (5H, m), 7.79-7.95 (5H, m), 8.90 (1H, d, J=8Hz)

30 $[\alpha]_D^{25}$: -13.0° (C=20 mg/2 mg, MeOH)

(4) 8-[2,6-Dichloro-3-[N-methyl-N-[4-[[*(R)*-1-(methylcarbamoyl)-2-phenylethyl]carbamoyl]cinnamoylglycyl]-amino]benzyloxy]-2-methylquinoline

35 NMR (CDCl₃, δ) : 2.68-2.77 (6H, m), 3.09 (1H, dd,

J=7.5, 13Hz), 3.20-3.35 (4H, m), 3.67 (1H, dt, J=16, 4Hz), 3.96 (1H, dt, J=16, 4Hz), 4.78 (1H, q, J=7.5Hz), 5.60-5.78 (3H, m), 6.55 (1H, dd-like, J=16Hz), 6.73-6.84 (1H, m), 6.94 (1H, t-like), 7.20-7.38 (3H, m), 7.38-7.63 (6H, m), 7.72 (2H, d, J=8Hz), 8.03 (1H, d, J=8Hz)
 $[\alpha]_D^{20}$: -0.5° (C=20 mg/2 ml, CHCl₃)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.73 (3H, s), 3.09-3.21 (5H, m), 3.30 (3H, s), 3.89 (1H, d, J=16Hz), 4.03 (1H, d, J=16Hz), 4.77 (1H, t, J=7.5Hz), 5.60 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.65 (1H, d, J=16Hz), 7.18-7.33 (4H, m), 7.40-7.93 (12H, m), 8.88 (1H, d, J=8Hz)
 $[\alpha]_D^{25}$: +13.3° (C=20 mg/2 ml, MeOH)

Example 63

To a solution of 8-tert-butoxycarbonylamino-2-methylquinoline (258 mg) in N,N-dimethylformamide (3 ml) was added sodium hydride (44 mg) in an ice-water bath cooling, and the mixture was stirred for 20 minutes at the same temperature. To the reaction mixture was added 2,6-dichloro-3-nitrobenzyl methanesulfonate (300 mg) in an ice water bath cooling, and the mixture was stirred for 80 minutes at the same temperature and then for 15 minutes at ambient temperature. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by flash chromatography eluting with methylene chloride, and crystallized with n-hexane to give 8-[N-tert-butoxycarbonyl-N-(2,6-dichloro-3-nitrobenzyl)amino]-2-methylquinoline (352 mg).

mp : 130-131°C

NMR (CDCl₃, δ) : 1.21 (6H, s), 1.60 (3H, s), 2.72

(3H, s), 5.20 (1H, d, J=15Hz), 5.67 (1H, d, J=15Hz), 6.91 (1H, d, J=8Hz), 7.11-7.31 (3H), 7.53 (1H, d, J=8Hz), 7.65 (1H, d, J=8Hz), 8.00 (1H, d, J=8Hz)

5

Example 64

8-[N-tert-Butoxycarbonyl-N-(2,6-dichloro-3-nitrobenzyl)amino]-2-methylquinoline (100 mg) was treated with 4M hydrogen chloride - ethyl acetate (2 ml) at ambient temperature for 40 minutes. The precipitate was collected by vacuum filtration and washed with ethyl acetate to give 8-[(2,6-dichloro-3-nitrobenzyl)amino]-2-methylquinoline dihydrochloride (88 mg) as pale yellow crystals.

10

15

mp : 230-232°C

NMR (DMSO-d₆, δ) : 2.80 (3H, s), 4.76 (2H, s), 7.10 (1H, d, J=8Hz), 7.31 (1H, d, J=8Hz), 7.48-7.69 (2H), 7.84 (1H, d, J=8Hz), 8.10 (1H, d, J=8Hz), 8.52 (1H, d, J=8Hz)

20

Example 65

To a suspension of 8-[2,6-dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline (149.7 mg) in ethanol (1.5 ml) was added 1M sulfuric acid - ethanol solution (253.1 μl) at ambient temperature, and the mixture was warmed at 90°C and then stirred for 1 hour at ambient temperature. The solvent was removed in vacuo to give sulfuric acid salt of 8-[2,6-dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)-cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline (144.5 mg).

25

30

mp : 219-226°C

NMR (DMSO-d₆, δ) : 2.77 (3H, d, J=4.5Hz), 2.86 (3H, s), 3.14 (3H, s), 3.58 (1H, dd, J=4.5, 16.5Hz), 3.89 (1H, dd, J=4.5, 16.5Hz), 5.59 (1H, d, J=11.5Hz), 5.64 (1H, d, J=11.5Hz), 6.87 (1H, d, J=16Hz), 7.40 (1H, d, J=16Hz), 7.63 (2H, d,

35

J=8.5Hz), 7.73-7.93 (8H, m), 8.33 (1H, t,
J=4.5Hz), 8.47 (1H, q, J=4.5Hz), 8.87 (1H, br s)

Example 66

5 To a suspension of 8-[2,6-dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline (225 mg) in ethanol (2.3 ml) was added 1N sulfuric acid - ethanol solution (0.38 ml) at ambient temperature, and the mixture was warmed at 90°C and then
10 stirred for 1 hour at ambient temperature. The resulting precipitate was collected by filtration, and the residue was dissolved in methylene chloride - methanol (10:1). The solvent was removed in vacuo to give 1/2 sulfuric acid salt of 8-[2,6-dichloro-3-[N-methyl-N-[4-(methylcarbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-methylquinoline (210 mg).

15 NMR (DMSO-d₆, δ) : 2.63-2.84 (6H, m), 3.15 (3H, s),
3.55 (1H, dd, J=4, 16Hz), 3.85 (1H, dd, J=5, 16Hz), 5.47-5.65 (2H, m), 6.86 (1H, d, J=16Hz),
20 7.41 (1H, d, J=16Hz), 7.48-7.90 (11H, m), 8.33 (1H, t-like), 8.48 (1H, q-like)

Example 67

25 To a solution of 8-[3-[N-[4-(N-acetyl-N-tert-butoxycarbonylmethylamino)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (143 mg) in dichloromethane (1.4 ml) was added trifluoroacetic acid (0.05 ml) at ambient temperature and the mixture was stirred at the same temperature. After 1 hour, to the
30 solution was added trifluoroacetic acid (1 ml). After 5 hours the solvent was removed in vacuo to give 8-[3-[N-[4-(N-acetyl-N-carboxymethylamino)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (124 mg) as amorphous solid.

35 NMR (CDCl₃-CD₃OD, δ) : 1.98 (3H, s), 3.04 (3H, s),

2122236

3.31 (3H, s), 3.91 (2H, s), 4.21-4.50 (2H, overlapped with H₂O), 5.62 (1H, d, J=10Hz), 5.80 (1H, d, J=10Hz), 6.63 (1H, d, J=16Hz), 7.32-8.00 (11H), 8.91 (1H, d, J=8Hz)

5

Example 68

To a solution of 8-[3-[N-[4-(N-acetyl-N-carboxymethylamino)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (120 mg) in ethanol (1 ml) was added 0.1 N aqueous sodium hydroxide (1.85 ml) at ambient temperature and the mixture was stirred at the same temperature. After 3 minutes the solvent was removed in vacuo. The residue was dissolved in a mixture of ethanol and water (1:2 V/V, 1 ml) and was filtered. The filtrate was lyophilized to give sodium salt of 8-[3-[N-[4-(N-acetyl-N-carboxymethylamino)cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (124 mg) as amorphous solid.

10

15

NMR (CDCl₃-CD₃OD, δ) : 1.95 (3H, s), 2.99 (3H, s), 3.30 (3H, s), 3.82 (1H, d, J=17Hz), 3.97 (1H, d, J=17Hz), 4.33 (2H, s), 5.61 (1H, d, J=10Hz), 5.77 (1H, d, J=10Hz), 6.61 (1H, d, J=16Hz), 7.30-7.90 (11H), 8.75 (1H, d, J=8Hz)

20

25

Example 69

8-[2,6-Dichloro-3-[N-methyl-N-[[2-[4-(4-pyridyl)-1-piperazinyl]acetyl]glycyl]amino]benzyloxy]-4-methoxy-2-methylquinoline was obtained from 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-4-methoxy-2-methylquinoline, bromoacetyl chloride and 1-(4-pyridyl)piperazine according to a similar manner to that of Example 23.

30

NMR (CDCl₃, δ) : 2.60-2.79 (7H), 3.09 (2H, s), 3.23 (3H, s), 3.30-3.61 (5H), 3.90 (1H, dd, J=18, 5Hz), 4.01 (3H, s), 5.62 (2H, s), 6.60-6.72

35

(3H), 7.20-7.42 (3H), 7.50 (1H, d, J=8Hz), 7.78-7.94 (2H), 8.29 (2H, d, J=7Hz)

its tetrahydrochloride

NMR (CDCl₃-CD₃OD, δ) : 3.01 (3H, s), 3.27 (3H, s), 3.08-4.24 (12H), 4.35 (3H, s), 5.57 (1H, d, J=10Hz), 5.72 (1H, d, J=10Hz), 7.19-7.40 (3H), 7.52-7.69 (3H), 7.79 (1H, t, J=8Hz), 7.99 (1H, d, J=8Hz), 8.20 (2H, br d, J=7Hz)

Example 70

A mixture of 8-[3-[N-(4-cyanocinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (76 mg) and trimethyltin azide (109 mg) in xylene (1 ml) was heated at 125°C for 20 hours. After cooled, methanol - chloroform (1:4 V/V, 10 ml) and silica gel (296 mg) was added to the reaction mixture. The resulting suspension was stirred at ambient temperature for one hour. The silica gel was filtered off, and the filtrate was concentrated in vacuo. The residue was purified by preparative thin-layer chromatography eluting with methanol - chloroform (1:6) to afford 8-[2,6-dichloro-3-[N-methyl-N-[4-(5-tetrazolyl)cinnamoylglycyl]amino]-benzyloxy]-2-methylquinoline (40 mg) as a pale yellow glass.

mp : 196-208°C

NMR (CDCl₃-CD₃OD, δ) : 2.70 (3H, s), 3.26 (3H, s), 3.68 (1H, d, J=18Hz), 4.01 (1H, d, J=18Hz), 5.58 (2H, s), 6.60 (1H, d, J=15Hz), 7.20-7.69 (10H, m), 8.00 (1H, d, J=9Hz), 8.10 (1H, d, J=10Hz)

Example 71

8-[2,6-Dichloro-3-[N-[4-[(N-tert-butoxycarbonyl-L-prolyl)amino]cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline (170 mg) was treated with 4M hydrogen

chloride-ethyl acetate (2 ml) at ambient temperature for 30 minutes. The reaction mixture was concentrated to give 8-[2,6-dichloro-3-[N-[4-(L-prolylamino)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride (152 mg).

NMR (CDCl₃-CD₃OD, δ) : 2.05-2.19 (4H), 3.12 (3H, br s), 3.29 (3H, s), 3.44-3.53 (2H), 3.91 (1H, d, J=17Hz), 4.06 (1H, d, J=17Hz), 4.68 (1H, m), 5.59 (1H, d, J=10Hz), 5.70 (1H, d, J=10Hz), 6.49 (1H, d, J=15Hz), 7.25-7.38 (3H), 7.50-7.59 (4H), 7.64 (1H, br d, J=7.5Hz), 7.78-7.96 (3H), 8.95 (1H, d, J=8Hz)

Example 72

8-[3-[N-[4-[(N-Acetyl-L-prolyl)amino]cinnamoylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline was obtained by reacting 8-[2,6-dichloro-3-[N-[4-(L-prolylamino)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline dihydrochloride with acetic anhydride according to a similar manner to that of Example 49.

NMR (CDCl₃, δ) : 1.74-2.25 (6H), 2.60 (1H, m), 2.72 (3H, s), 3.25 (3H, s), 3.35-3.70 (3H), 3.93 (1H, m), 4.78 (1H, t, J=5Hz), 5.63 (2H, s), 6.38 (1H, dd, J=15, 7.5Hz), 6.60 (0.3H, br t, J=4Hz), 6.78 (0.3H, br t, J=4Hz), 7.12-7.57 (10H), 8.02 (1H, d, J=8Hz), 9.93 (1H, br d, J=5Hz)

its hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.00-2.27 (6H), 2.40 (1H, m), 3.15 (3H, br s), 3.30 (3H, s), 3.53 (1H, m), 3.69 (1H, m), 3.91 (1H, br d, J=17Hz), 4.04 (1H, br d, J=17Hz), 4.77 (1H, m), 5.61 (1H, d, J=10Hz), 5.69 (1H, d, J=10Hz), 6.48 (1H, d, J=15Hz), 7.29-7.68 (8H), 7.78-7.91 (3H), 8.90 (1H, br d, J=8Hz)

Example 73

The following compounds were obtained according to a similar manner to that of Example 28.

- 5 (1) 8-[2,6-Dichloro-3-[N-[4-[(2-pyridylmethyl)carbamoyl]-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoxaline dihydrochloride
mp : 181-186°C
NMR (CDCl₃-CD₃OD, δ) : 2.85 (3H, s), 3.27 (3H, s),
10 3.67 (1H, d, J=17.5Hz), 3.98 (1H, d,
J=17.5Hz), 4.99 (2H, s), 5.63 (2H, s), 6.63 (1H,
d, J=16.0Hz), 7.43 (1H, d, J=8.5Hz), 7.48 (1H,
d, J=8.5Hz), 7.52-7.63 (4H, m), 7.80 (1H, t,
J=8.5Hz), 7.84-7.93 (2H, m), 7.98 (2H, d,
15 J=8.5Hz), 8.15 (1H, d, J=8.5Hz), 8.45 (1H, t,
J=8.5Hz), 8.72 (1H, d, J=6.0Hz), 8.85 (1H, s)
- (2) 8-[2,6-Dichloro-3-[N-[4-(dimethylcarbamoyl)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
20 methylquinoxaline hydrochloride
mp : 173-180°C
NMR (CDCl₃-CD₃OD, δ) : 2.90 (3H, s), 2.99 (3H, br
s), 3.11 (3H, br s), 3.28 (3H, s), 3.69 (1H, d,
J=17.5Hz), 3.98 (1H, d, J=17.5Hz), 5.63 (2H, s),
25 6.58 (1H, d, J=15.0Hz), 7.37-7.49 (4H, m), 7.51-
7.62 (4H, m), 7.85 (1H, t, J=8.5Hz), 7.93 (1H,
d, J=8.5Hz), 8.90 (1H, s)
- (3) 8-[3-[N-[4-(Acetamido)cinnamoylglycyl]-N-
30 methylamino]-2,6-dichlorobenzyloxy]-2-
methylquinoxaline hydrochloride
NMR (CDCl₃-CD₃OD, δ) : 2.17 (3H, s), 2.91 (3H, s),
3.29 (3H, s), 3.69 (1H, d, J=17Hz), 3.98 (1H, d,
J=17Hz), 5.62 (2H, s), 6.43 (1H, d, J=15Hz),
35 7.40-7.59 (8H), 7.87 (1H, br t, J=8Hz), 7.95

(1H, br d, J=8Hz), 8.90 (1H, s)

- (4) 8-[2,6-Dichloro-3-[N-[4-(methoxyacetamido)-
cinnamoylglycyl]-N-methylamino]benzyloxy]-2-
methylquinoxaline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.92 (3H, br s), 3.28 (3H, s), 3.51 (3H, s), 3.69 (1H, d, J=17Hz), 3.96 (1H, d, J=17Hz), 4.02 (2H, s), 5.63 (2H, s), 6.47 (1H, d, J=15Hz), 7.41-7.62 (8H), 7.87 (1H, br t, J=8Hz), 7.99 (1H, br d, J=8Hz), 8.90 (1H, s)


- (5) 8-[2,6-Dichloro-3-[N-methyl-N-[4-(2-oxopyrrolidin-1-yl)cinnamoylglycyl]amino]benzyloxy]-2-
methylquinoxaline hydrochloride

NMR (CDCl₃-CD₃OD, δ) : 2.13-2.25 (2H), 2.59-2.72 (2H, overlapped with H₂O), 2.91 (3H, br s), 3.29 (3H, s), 3.69 (1H, d, J=17Hz), 3.89 (2H, t, J=7Hz), 3.96 (1H, d, J=17Hz), 5.63 (2H, s), 6.48 (1H, d, J=15Hz), 7.41-7.38 (2H), 7.85 (1H, br t, J=8Hz), 7.98 (1H, br d, J=8Hz), 8.90 (1H, s)

- 1 -

What we claim is :

1. A compound of the formula :



wherein

X^1 is N or C- R^6 ,


X^2 is N or C- R^7 ,

X^3 is N or C- R^8 ,

R^1 is hydrogen or halogen,

R^2 is halogen,

R^3 is hydrogen; nitro; amino; a group of the formula:



R^{10} is hydrogen or lower alkyl, and

R^{11} is glycyl or glycyl substituted with a substituent selected from the group consisting of lower alkyl, halo(lower)alkanoyl, phenyl(lower)alkanoyl, naphthyl- (lower)alkanoyl, benzoyl, naphthoyl, pyridylpiperazinyl(lower)alkanoyl, lower alkenoyl, tolyl(lower)alkanoyl, phenyl(lower)alkanoyl, lower alkoxy-phenyl(lower)alkanoyl, lower alkylenedioxy-phenyl(lower)alkanoyl, nitro- phenyl(lower)alkanoyl, cyano-phenyl(lower)alkanoyl, halo-phenyl(lower) alkenoyl, hydroxy-phenyl(lower)alkanoyl, hydroxy(lower)alkoxy- phenyl(lower)alkanoyl, amino(lower)alkoxy-phenyl(lower)alkanoyl, lower alkylamino(lower)alkoxy-phenyl(lower)alkanoyl, pyridyl(lower)alkoxy-phenyl(lower)alkanoyl, tetrazolyl- phenyl(lower)alkanoyl, oxopyrrolidinyl-phenyl(lower)alkanoyl, amino-phenyl(lower)alkanoyl, lower alkylamino-

-2-

phenyl(lower)alkenoyl, lower alkanoylamino-phenyl(lower)alkenoyl, N-(lower
 alkanoyl)-N-(lower alkyl)amino-phenyl(lower)alkenoyl, adamantyl(lower)
 alkanoylamino-phenyl(lower)alkenoyl,
 cyclopropylcarbonylamino-phenyl(lower)alkenoyl,
 5 cyclohexylcarbonylamino-phenyl(lower)alkenoyl,
 lower alkenoylamino-phenyl(lower)alkenoyl,
 lower alkoxycarbonylamino-phenyl(lower)alkenoyl,
 hydroxy(lower)alkanoylamino-phenyl(lower)alkenoyl,
 lower alkoxy(lower)alkanoylamino-phenyl(lower)alkenoyl,
 10 halo(lower)alkanoylamino-phenyl(lower)alkenoyl,
 amino(lower)alkanoylamino-phenyl(lower)alkenoyl, lower alkylamino(lower)
 alkanoylamino-phenyl(lower)alkenoyl,
 lower alkanoylamino(lower)alkanoylamino-phenyl(lower)alkenoyl,
 carboxy(lower)alkanoylamino-phenyl(lower)alkenoyl, lower alkoxycarbonyl(lower)-
 15 alkanoylamino-phenyl(lower)alkenoyl,
 lower alkoxycarbonyl(lower)alkenoylamino-phenyl(lower)alkenoyl,
 halo(lower)alkoxycarbonylamino-phenyl(lower)alkenoyl,
 pyridyl(lower)alkanoylamino-phenyl(lower)alkenoyl, thienyl(lower)
 alkanoylamino-phenyl(lower)alkenoyl,
 20 methylpyrrolyl(lower)alkanoylamino-phenyl(lower)alkenoyl,
 benzoylamino-phenyl(lower)alkenoyl, pyridylcarbonylamino-phenyl(lower)alkenoyl,
 morpholinocarbonylamino-phenyl(lower)alkenoyl, furylcarbonylamino-
 phenyl(lower)alkenoyl, thienylcarbonylamino-phenyl(lower)alkenoyl,
 oxazolylcarbonylamino-phenyl(lower)alkenoyl,
 25 methyloxazolylcarbonylamino-phenyl(lower)alkenoyl,
 dimethylisoxazolylcarbonylamino-phenyl(lower)alkenoyl,
 imidazolylcarbonylamino-phenyl(lower)alkenoyl,
 methylimidazolylcarbonylamino-phenyl(lower)alkenoyl,
 piperidylcarbonylamino-phenyl(lower)alkenoyl, ethylpiperidylcarbonylamino-
 30 phenyl(lower)alkenoyl, acetyl piperidylcarbonylamino-phenyl(lower)alkenoyl,
 pyrrolidinylcarbonylamino-phenyl(lower)alkenoyl,
 acetylpyrrolidinylcarbonylamino-phenyl(lower)alkenoyl,
 tert-butoxycarbonylpyrrolidinylcarbonylamino-phenyl(lower)alkenoyl,
 lower alkylsulfonylamino-phenyl(lower)alkenoyl,
 35 N- [lower alkoxy(lower)alkanoyl]-N-[(lower) alkyl]amino-phenyl(lower)alkenoyl,

-3-

- N-(lower alkanoyl)-N-[pyridyl(lower)alkyl] amino-phenyl(lower)alkenoyl,
 N-(lower alkanoyl)-N-[lower alkoxy(lower)alkyl] amino-phenyl(lower)alkenoyl,
 N-(lower alkanoyl)-N-[lower alkoxycarbonyl-(lower)alkyl] amino-phenyl(lower)alkenoyl,
 N-(lower alkanoyl)-N-[carboxy(lower)alkyl] amino-phenyl(lower)alkenoyl,
 5 N-[lower alkoxy(lower)alkanoyl]-N-[pyridyl(lower)alkyl] amino-phenyl(lower)alkenoyl,
 N-(pyridylcarbonyl)-N-[lower alkoxy(lower)alkyl] amino-phenyl(lower)alkenoyl,
 ureido-phenyl(lower)alkenoyl, lower alkylureido-phenyl(lower)alkenoyl, pyridylureido-
 phenyl(lower)alkenoyl, lower alkanoyl-phenyl(lower)alkenoyl,
 carboxy-phenyl(lower)alkenoyl, lower alkoxy-carbonyl-phenyl(lower)alkenoyl,
 10 carbamoyl-phenyl(lower)alkenoyl, lower alkylcarbamoyl-phenyl(lower)alkenoyl,
 hydroxy(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 N-[hydroxy(lower)alkyl]-N-(lower alkyl)carbamoyl-phenyl(lower)alkenoyl,
 lower alkoxy(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 N-[lower alkoxy(lower)alkyl]-N-(lower alkyl)carbamoyl-phenyl(lower)alkenoyl,
 15 pyridyl(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 furyl(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 thienyl(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 N-[pyridyl(lower)alkyl]-N-(lower alkyl)carbamoyl-phenyl(lower)alkenoyl,
 pyridylcarbamoyl-phenyl(lower)alkenoyl, tetrazolylcarbamoyl-phenyl(lower)alkenoyl,
 20 morpholinocarbonyl-phenyl(lower)alkenoyl, pyrrolidinylcarbonyl-phenyl(lower)alkenoyl,
 piperidinocarbonyl-phenyl(lower)alkenoyl,
 tetrahydropyridylcarbonyl-phenyl(lower)alkenoyl,
 methylpiperazinylcarbonyl-phenyl(lower)alkenoyl,
 lower alkenylcarbamoyl-phenyl(lower)alkenoyl,
 25 lower alkynylcarbamoyl-phenyl(lower)alkenoyl,
 amino(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 lower alkylamino(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 lower alkylcarbamoyloxy-(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 lower alkylcarbamoyl(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 30 lower alkoxycarbonyl(lower)alkylcarbamoyl-phenyl(lower)alkenoyl,
 carboxy(lower)alkylcarbamoyl-phenyl(lower)alkenoyl, (lower alkylcarbamoyl-
 phenyl(lower)alkyl]carbamoyl-phenyl(lower)alkenoyl,
 [lower alkoxycarbonyl-phenyl(lower)alkyl]carbamoyl-phenyl(lower)alkenoyl,
 [carboxy-phenyl(lower)alkyl]carbamoyl-phenyl(lower)alkenoyl, N-(lower
 35 alkylcarbamoyl(lower)alkyl)-N-(lower alkyl)carbamoyl-phenyl(lower)alkenoyl, N-(lower

- alkoxycarbonyl(lower)alkyl]-N-(lower alkyl)carbamoyl-phenyl(lower)alkenoyl,
 N-[carboxy(lower)alkyl]-N-(lower alkyl)carbamoyl-phenyl(lower)alkenoyl,
 phenylcarbamoyl-phenyl(lower)alkenoyl, phenyl(lower)alkynoyl, pyridyl(lower)alkenoyl,
 thienyl(lower)alkenoyl, pyridylthio(lower)alkanoyl, amino-pyridyl(lower)alkenoyl,
 5 lower alkylamino-pyridyl(lower)alkenoyl, lower alkanoylamino-pyridyl(lower)alkenoyl,
 lower alkenoylamino-pyridyl(lower)alkenoyl, pyridyl(lower)alkanoylamino-
 pyridyl(lower)alkenoyl, pyridylcarbonylamino-pyridyl(lower)alkenoyl,
 furylcarbonylamino-pyridyl(lower)alkenoyl, lower alkanoylamino(lower)alkanoylamino-
 pyridyl(lower)alkenoyl, lower
- 10 alkoxycarbonyl(lower)alkanoylamino-pyridyl(lower)alkenoyl, lower
 alkoxy(lower)alkanoylamino-pyridyl(lower)alkenoyl, lower alkylureido-
 pyridyl(lower)alkenoyl, carboxy-pyridyl(lower)alkenoyl, lower
 alkoxycarbonyl-pyridyl(lower)alkenoyl, lower alkylcarbamoyl-pyridyl(lower)alkenoyl,
 lower alkoxy(lower)alkylcarbamoyl-pyridyl(lower)alkenoyl,
- 15 hydroxy(lower)alkylcarbamoyl-pyridyl(lower)alkenoyl,
 pyridylcarbamoyl-pyridyl(lower)alkenoyl,
 pyridyl(lower)alkylcarbamoyl-pyridyl(lower)alkenoyl,
 pyrrolidinylcarbonyl-pyridyl(lower)alkenoyl,
 morpholinocarbonyl-pyridyl(lower)alkenoyl, lower
- 20 alkenylcarbamoyl-pyridyl(lower)alkenoyl, lower alkynylcarbamoyl-
 pyridyl(lower)alkenoyl, cyclo(lower)alkylcarbonyl, lower alkoxycarbonyl,
 phenyloxycarbonyl, benzoyl(lower)alkanoyl, nitrophenyloxycarbonyl, carbamoyl, lower
 alkylcarbamoyl, lower alkoxycarbonyl(lower)alkylcarbamoyl, lower alkenylcarbamoyl,
 cyclo(lower)alkylcarbamoyl, phenylcarbamoyl, naphthylcarbamoyl, lower alkoxy-
- 25 phenylcarbamoyl, halo(lower)alkyl-phenylcarbamoyl, halo-phenylcarbamoyl, lower
 alkanoyl-phenylcarbamoyl, hydroxy(lower)alkyl-phenylcarbamoyl,
 morpholinocarbonyl-phenylcarbamoyl, piperidinocarbonyl-phenylcarbamoyl,
 thiomorpholinocarbonyl-phenylcarbamoyl, piperazinylcarbonyl-phenylcarbonyl,
 pyrrolidinylcarbonyl-phenylcarbamoyl,
- 30 1,2,3,6-tetrahydropyridylcarbonyl-phenylcarbamoyl, carboxy-phenylcarbamoyl, lower
 alkoxycarbonyl-phenylcarbamoyl, carbamoyl-phenylcarbamoyl, lower
 alkylcarbamoyl-phenylcarbamoyl, nitro-phenylcarbamoyl, cyano-phenylcarbamoyl,
 amino-phenylcarbamoyl, lower alkylamino-phenylcarbamoyl, lower alkanoylamino-
 phenylcarbamoyl, N-(lower alkanoyl)-N-(lower alkyl)amino-phenylcarbamoyl, lower
- 35 alkoxy(lower)alkanoylamino-phenylcarbamoyl, lower

-5-

5 alkoxy carbonyl(lower)alkanoylamino-phenylcarbamoyl,
 carboxyamino-phenylcarbamoyl, lower alkoxy carbonylamino-phenylcarbamoyl,
 benzoylamino-phenylcarbamoyl, pyridyl carbonylamino-phenylcarbamoyl,
 pyridyl(lower)alkanoylamino-phenylcarbamoyl, ureido-phenylcarbamoyl, lower
 alkylureido-phenylcarbamoyl, hydroxyimino(lower)alkyl-phenylcarbamoyl, lower
 alkoxyimino(lower)alkyl-phenylcarbamoyl,
 lower alkylhydrazono(lower)alkyl-phenylcarbamoyl, oxopyrrolidinyl-phenylcarbamoyl,
 oxopiperidino-phenylcarbamoyl, dioxopyrrolidinyl-phenylcarbamoyl,
 oxooxazolidinyl-phenylcarbamoyl, pyrrolyl-phenylcarbamoyl,
 10 methylpiperazinyl carbonyl-phenylcarbamoyl,
 ethylpiperazinyl carbonyl-phenylcarbamoyl,
 phenylpiperazinyl carbonyl-phenylcarbamoyl,
 pyridylpiperazinyl carbonyl-phenylcarbamoyl,
 acetyl piperazinyl carbonyl-phenylcarbamoyl,
 15 ethoxycarbonylpiperazinyl carbonyl-phenylcarbamoyl,
 methylaminopiperazinyl carbonyl-phenylcarbamoyl,
 dimethylaminopiperidinocarbonyl-phenylcarbamoyl,
 methylcarbamoylpiperazinyl carbonyl-phenylcarbamoyl,
 hydroxy(lower)alkylcarbamoyl-phenylcarbamoyl, N-(hydroxy(lower)alkyl)-N-(lower
 20 alkyl)carbamoyl-phenylcarbamoyl,
 (lower)-alkoxy(lower)alkylcarbamoyl-phenylcarbamoyl, N-(lower
 alkoxy(lower)alkyl)-N-(lower alkyl)carbamoyl-phenylcarbamoyl, lower
 alkylamino(lower)alkylcarbamoyl-phenylcarbamoyl, N-(lower
 alkylamino(lower)alkyl)-N-(lower alkyl)carbamoyl-phenylcarbamoyl,
 25 pyridylcarbamoyl-phenylcarbamoyl, pyrimidinylcarbamoyl-phenylcarbamoyl,
 morpholinylcarbamoyl-phenylcarbamoyl, thienylcarbamoyl-phenylcarbamoyl,
 N-(pyridyl)-N-(lower alkyl)carbamoyl-phenylcarbamoyl,
 pyridyl(lower)alkylcarbamoyl-phenylcarbamoyl, N-[pyridyl(lower)alkyl]-N-(lower
 alkyl)carbamoyl-phenylcarbamoyl, N-[pyridyl(lower)alkyl]-N-(lower
 30 alkoxy(lower)alkyl) carbamoyl-phenylcarbamoyl, phenylcarbamoyl-phenylcarbamoyl,
 lower alkylaminophenylcarbamoyl-phenylcarbamoyl, phenylthiocarbamoyl,
 phenyl(lower)alkylcarbamoyl, benzoylcarbamoyl, pyridylcarbamoyl, pyridyl(lower)
 alkylcarbamoyl, phenylaminocarbamoyl, phenyl(lower)alkenylsulfonyl, lower
 alkylsulfonyl, phthaloyl, glycy, glycy substituted with lower alkyl and cycloheptyl,
 35 glycy substituted with phenyl and glycy substituted with phthaloyl; or piperazinyl
 optionally substituted with substituent(s) selected from the group consisting of oxo,
 phenyl(lower)alkyl and (lower)alkoxy carbonyl-(lower)alkyl;

-6-

R^4 and R^5 are each hydrogen or halogen,
 R^6 and R^8 are each hydrogen, halogen, lower
 alkyl, hydroxy, lower alkylthio, amino
 optionally substituted with lower
 alkyl, or lower alkoxy optionally
 substituted with a substituent selected
 from the group consisting of hydroxy,
 lower alkoxy, amino, lower alkylamino
 and phenyl optionally substituted with
 lower alkoxy,

R^7 is hydrogen or lower alkyl,


A is lower alkylene, and

Q is O or $N-R^9$, in which R^9 is hydrogen or
 acyl,

provided that R^3 is not hydrogen when X^1 is
 $C-R^6$, in which R^6 is hydrogen,

and pharmaceutically acceptable salts thereof.

2. A compound of claim 1, wherein
 a group of the formula : $-X^3=X^2-X^1=N-$ is a group of
 the formula :



-7-

Q is O or NH.

3. A compound of claim 2, wherein
 x^1 is C-R⁶, in which R⁶ is lower alkyl, and
 A is methylene.
4. A pharmaceutical composition comprising a compound of
 claim 1, as the active ingredient, in association with
 a pharmaceutically acceptable carrier or excipient.
5. A compound of claim 1 for use as a medicament.
6. Use of a compound of claim 1 for manufacture of a
 medicament for the prevention and/or the treatment of
 bradykinin or its analogues mediated diseases.
7. A compound of claim 3, wherein
 R³ is a group of the formula:

$$\begin{array}{c} \text{R}^{10} \\ \diagup \\ \text{---N} \\ \diagdown \\ \text{R}^{11} \end{array}$$

R¹⁰ is lower alkyl, and
 R¹¹ is glycyI substituted with lower alkanoylamino, pyridyl, (lower) alkenoyl.
8. A compound of claim 7, which is 8-[3-[N-[(E)-3-(6-acetamidopyridin-3-yl)acryloyl]glycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline and its acid addition salt.
9. Use of a compound of claim 1 for the prevention or treatment of diseases mediated by bradykinin or its analogues, in a human or animal.

